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ABSTRACT
The development of medical knowledge has always proceeded along pathways that
relate to questions arising from expert domain specialty knowledge, practice and work
flow. While medical knowledge advances as a whole, there are independent and specific knowledge streams for each specialty.
Radiation Oncology is a specialty domain, therefore one can expect that its ontology will reflect and be defined by its clinical terms and clinical work flow which are
both specific and interconnected.
The assertion of this thesis is that this particular medical domain specialty demonstrates clearly that knowledge derived in the clinical management of a patient, the
processes used in clinical trials to develop and report new knowledge to be used in
the clinical management of the patient, and the recommendations found in clinical
guidelines that inform routine patient management, are all views of the same domain
specific knowledge structure.
The process of Content Analysis was adapted and applied manually to an objective
corpus of Radiation Oncology literature to establish the semantic entities underlying
the knowledge being communicated to specialist radiation oncologists. These semantic entities were grouped in a hierarchy based on the work flow relevant to the expert
domain. The hierarchical structures were then coded into a schema using an XML
format to form a “Clinical Knowledge Mark up Language” (CKML).
The applicability of this CKML schema is subsequently demonstrated as relevant
by its application to four clinical scenarios: description of a normal clinical patient with
locally advanced oropharyngeal cancer, description of a clinical trial protocol for which
patients with locally advanced oropharyngeal cancer may be eligible, specification of a
clinical trial result from this same trial, and lastly as a description of clinical guidelines
describing the management of patients with locally advanced oropharyngeal cancer.

KEYWORDS: ontology, radiation oncology, markup language, clinical trials,
workflow, guideline

Chapter 1
Background
1.1

The Motivation and Academic Course of the
Research

This research was commenced in early 2006 with the intention of assessing the levels
of, and reasons for deficits in, the use of Oncology Information Systems by radiation
oncologists. Studies have documented that some oncologists do not take advantage of
Oncology Information Systems (OIS) to accumulate routine clinical data [157] which
could be used to further knowledge about cancer management. Given the hope that
improving OIS use might result in better oncological knowledge, I decided to describe
and assess the barriers to an oncologist’s use. However this question was not addressed because more fundamental questions arose that indicated that the outcome
of research on levels of and barriers to use would be swamped by confounding variables.

When assessing the use of OIS software, it is important to know whether the software is really “fit for purpose”. In the Australian and international Radiation Oncology
domain there are two widely used products heavily based on USA management pat-
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terns that qualify as Oncology Information Systems Elekta’s MOSAIQ

2
R

(which was

previously supplied as MultiAccess R and resold by Siemens Oncology Care Systems
as LANTIS R ), and Varian Medical Systems ARIA R . Other systems are available
but are not in widespread use [126, 46].

While both software products function well in their primary role as a Record &
Verify System (R&V) that governs linear accelerator use and records radiation exposure [106], their usefulness as an electronic medical record (EMR) is problematic.
Elekta’s system has shown promise [104, 117, 74] but these paradigms of use have
not achieved wide scale acceptance, despite publications suggesting how oncological
knowledge might be stored and re-utilised [105]. The ARIA software from Varian has
had no publications demonstrating that medical data can be stored and then undergo
an automated retrieval to reconstitute medical knowledge.

Furthermore, personal use of both systems in several departments between 2000
and 2011 has led me to the conclusion that these two software offerings were not equal.
As a result it became clear that the different functional capacities of the systems are
a confounding variable for any comparison of oncologist use. How does one compare
a user who scores 50 using software which can provide a score of 100/100, with a user
who scores 50 using software which can provide a score of only 50/100?

As a result, I turned my attention from users to software with a different research
question: how do I first rate the performance of software in achieving the task of storing a radiation oncologist’s knowledge?

Discussion with both vendors about the historical development of their products
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revealed that neither product was based on a specification of oncological knowledge,
although a radiation oncologist was closely involved with the initial development of
the IMPAC software. Given the lack of a formal specification, any assessment of the
OIS capability will first need to include a formal specification of the information types
and relations to be stored in the OIS. With this specification of the performance of
the OIS in storing, retrieving and reconstituting oncological knowledge completed, an
assessment of the performance of end users in entering oncological knowledge can be
undertaken.

This deficit in software design underscores the fundamental need to describe the
nature of the radiation oncologist’s knowledge to form a basis for future software development, and the final research question was refined to: what are the knowledge
structures, i.e., the information components and their domain specific structure, that
are required in an OIS? During the investigation of this question and in discussing
the significance and utility of these informatics structures with fellow informatics researchers, several manuscripts were published (Appendix A - Publications during the
course of the thesis).

1.2. Radiation Oncology as an Expert Domain

1.2
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Radiation Oncology as an Expert Domain

Radiation Oncology is a disease-centred (cancer) and modality-centred (radiotherapy)
tertiary care medical specialty that utilises radiotherapy in the management of cancer
[106], which only occupies a small position in a patient’s lifelong care. The National
Cancer Institute defines the radiation oncologist as “a doctor who specialises in using radiation to treat cancer” [81]. Given that 434,000 people will develop cancer
each year in Australia [24], and 52% of these people should receive radiotherapy in a
properly resourced system [54], many patients will have some contact with a radiation
oncologist.

It is common that the patients treated with radiotherapy for a cancer will start
and end their cancer journey with their primary care physician. Indeed the primary
care physician will often have instigated the diagnostic process that may eventually
lead to referral to Radiation Oncology.

However, in most health systems, patients will be referred to a radiation oncologist by a secondary care medical practitioner, usually medical specialists (surgeons,
internal medicine physicians), who have already obtained a histological diagnosis and
completed preliminary staging investigations. Patients with clinical and imaging features of malignancy without a histological diagnosis are in the minority. Occasionally
benign disease may be managed with radiotherapy, but radiation oncologists rarely
manage benign disease exclusive of the need for radiotherapy.

Following an accurate description of the extent of the disease (known as ‘staging’)
[80], decision making is structured and driven by disease outcomes reported in the Radiation Oncology literature. The prevailing model of care is biomedical with a heavy
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dependence on a detailed understanding of the disease and its response to therapy.
Radiation Oncology and Medical Oncology overlap in their disease focus but differ in
their modality.

Radiation oncologists are of the general opinion that patients with cancer should
have no delay in the provision of their radiotherapy [88, 72]. During the delivery of
radiotherapy, weekly review of patients is a normal routine, and at completion patients
enter an indefinite period of episodic follow up, which typically may terminate after
several years without recurrence [83]. Thus the radiation oncologist’s care is distinctly
episodic, focused and exclusive although undifferentiated by age, gender and organ
system.

A specialised epistemology and ontology of Radiation Oncology has not been developed apart from the standardized DICOM-RT protocol (Digital Imaging and Communications in Medicine - Radiation Therapy)[23] used in the transfer of images and
associated data between CT scanners, radiation planning systems and linear accelerators. This protocol does not seek to represent medical data.

The medical knowledge base of Radiation Oncology is largely explicit and derived
from the published literature reports of the application of radiation to biological systems. There is an overt assumption that clinical judgement must be applied within
the context of the literature’s predicates if optimal outcomes are to ensue. It is also
assumed that end points, such as, improved survival and successful palliation are important to patients. It is also assumed that objective estimates of quality and wise use
of resources are part of society’s expectation. Furthermore, it is assumed that these
end points are more important than a specific patient’s agenda when interacting with
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their doctor. While the specific term for this is “evidence-based medicine”, it also
ensures that treatment without benefit is not offered.

Given that patients with cancer have what is commonly a single and well-classified
problem, decision-making in Radiation Oncology follows a deductive path where verifiable and well documented information is applied to the precise problem of improved
outcomes, while always reflecting the underlying biomedical model. The cancer problem is structured and defined by the disease (instantiated by a diagnosis and stage), a
series of pertinent prognostic factors known to impact on the disease behaviour, and
therapy options that have already been shown to provide an improved outcome. Other
patient factors are considered, such as an assessment of the patient’s ability to realise
the benefits on offer [109]. If a patient has ‘terminal heart failure’ that will lead to
death in 3 months, but also has a cancer which will lead to death in 9 months, no
oncological treatment is indicated.

The patient is then advised of the oncologist’s opinion about therapy and the
potential problems. Patients then reflect their agreement or otherwise back to the
oncologist, although compliance is generally received in the face of a diagnosis of cancer. Typically, most oncology patients will have only one oncological disease requiring
management.

The initial consultation with the radiation oncologist results in a formal characterisation of the extent of the disease using criteria such as the American Joint Committee on Cancer/Union for International Cancer Control Tumour-Node-Metastasis
(AJCC/UICC TNM) Classification [131]. This classification is based on the major
prognostic features affecting patient outcome [80], and follows a comprehensive review
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of the patient’s tests. The radiation oncologist then proceeds to a treatment decision
and advises on therapy selection. This deductive approach is so entrenched that, in
some areas, patients who do not have a malignant disease already defined may be
returned to the referrer.

This pattern of management results in the requirement of an informatics system
with an initial mandatory accurate disease definition summary and subsequent infrequent assessments after treatment to determine the status of the patient. The status
of the patient is assessed with respect to effectiveness (has the cancer returned? ) and
efficacy (has the effectiveness been achieved without the treatment causing problems? ).

While the doctor-patient relationship can be therapeutic, it is unlikely to cure
a cancer. It is therefore understandable that the benefit of the radiation oncologist
involvement is quantified in terms of the objective outcomes that benefit patients (improved survival, fewer side effects).

This tight coupling of cancer work flow with cancer diagnosis and stage followed
by resultant cancer treatment with objective end points indicates a medical specialty
that is well suited to the development of a domain ontology [5].

Chapter 2
Introduction
2.1

What is the problem?

Radiation oncologists, like all clinicians, keep notes describing patient problems, treatments and outcomes. This record forms the basis of all knowledge re-use. The major
purpose of stored clinical knowledge re-use is to discover answers to clinically relevant
questions. These answers are the medical knowledge on which further patient management is based.

To enable an Oncology Information System (OIS) is able to deliver on this promise
of data re-use, issues of implementation, user interface and knowledge representation
must be negotiated.

The combined functionality of the OIS data structures and user interface will set
a ceiling on the success of strategies to implement the software into the real world,
i.e., a functioning Radiation Oncology department. The level of success under this
ceiling will relate to departmental issues of staff and change management. The issue
of software implementation is related to this endeavour as studies have demonstrated
8
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quite clearly that implementation can have just as large an effect on use as database
structure or user interface [157].

The OIS user interface reflects the design of the underlying knowledge structure
and appreciation of the work flow of the domain expert. The user interface is important for adequate knowledge capture as a dysfunctional user interface would make the
fidelity of the knowledge representation irrelevant, for if the user is unable to use the
interface, no data will be accrued. However structure and design of the user interface
are specific to each software program and not independent of the underlying knowledge
structure.

The information systems available to radiation oncologists are not based on any
published a priori determination of the knowledge structures of radiation oncologists
or even on published assessments of the user interface.

As described above, the OIS has two purposes which are directional. These purposes are the accrual of clinical knowledge into stored electronic data within the
database (storage), and the retrieval of stored electronic data from the database to be
processed (knowledge discovery). The OIS has a data structure, usually a relational
database, into which accrued data elements are saved. The detail of the data structure is provided in an entity-relationship diagram (ERD), and should be evident in
the interface for the end user. Thus the evaluation of the knowledge representation
performance of the OIS will assess its ability to store all relevant oncological data, and
its ability to reconstitute oncological knowledge from stored data items.

Which issue is primary? A perfect system can be unused because of a poor im-
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plementation, therefore the assessment of an implementation is an assessment of a
department, not the OIS. A system built on a perfect knowledge representation with
a dysfunctional user interface will also be unused by the individual domain expert.
Conversely, a functional user interface does not guarantee that the underlying knowledge representation is adequate. While inadequate knowledge representation may not
affect data entry via a user interface, the poorly structured stored data will only fulfil
the storage function, hampering the process of knowledge discovery which is based on
data retrieval.

The inadequacy of knowledge representation is a potential confounder for all other
investigations relating to the use of OIS software. It may be that as oncology knowledge is fragmented electronically into storage structures, proper consideration has not
been given to the inherent relationships of knowledge components. So while data has
been stored electronically, there is no guarantee that the included material can be
reliably and routinely reconstituted into the knowledge structures of the radiation oncologist for subsequent analysis and re-use. Therefore before the issues surrounding
implementation and the interactions of the user with the user interface can be assessed, the capabilities of the OIS to store and reconstitute data should be quantified.
In relation to the reuse of retrieved data, the knowledge representation is fundamental.

In summary, the failure of OIS use could exist at the level of implementation, user
interface or knowledge representation. Deficits in implementation are local and can be
detected by departmental comparison [157]. Variations in user interfaces are specific
to each individual software program. However the issue of knowledge representation is
generic to all OISs and has not been established. The primary and fundamental problem therefore is the establishment of a knowledge representation specific to Radiation

2.2. Why is this research important?
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Oncology and the subject of this research.

2.2

Why is this research important?

The importance of formal knowledge structures in this expert domain becomes apparent when viewing the literature that shows that oncologists become more knowledgeable by the manipulation of their prior knowledge through accumulation and formal
statistical analysis. If stored knowledge lacks a structure to permit pertinent retrieval,
construction of new knowledge cannot be undertaken from the OIS. Oncologists increase their knowledge through radiation oncology literature, in fact all published
clinical literature, which takes past data, analyses it and then reports it. Other oncologists read it and so are better informed and hopefully apply the findings [58]. Earlier
literature [153] supports the current position that rational decisions are those that are
based on controlled clinical studies, in contrast to those that are based on deductions
from biological knowledge.

While the information discovered by oncologists in the course of their clinical work
forms a clinical record, it also forms the platform from which retrospective reviews
point to new directions for knowledge and from which trials are conducted to establish
new medical knowledge in routine practice.

Medical knowledge is highly structured, but the expression of most oncological
knowledge in plain English buries knowledge structures in a highly variable swamp of
natural speech which can hide the formalised structure.

Characterisation of oncological knowledge in a formalised structure enables the
development of appropriate information systems which should permit clinicians to

2.3. Who will be interested in this research?
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produce more oncological knowledge and so to undertake more accurate searches for
applicable oncological knowledge for the individual patient’s care.

2.3

Who will be interested in this research?

The discovery of data elements that are used in the construction of the medical literature is relevant to any group seeking to build an information system for oncology,
whether trials software or an OIS. These data elements are also relevant to the users,
who are clinicians seeking to use the data stored within their OIS.

At present there are several producers of domain-specific software for Radiation Oncology departments, such as Elekta (MOSAIQ R & Multi-Access R ; also re-marketed
by Siemens as LANTIS R ), Varian (VARiS R /ARIA R ), Nucletron (OnCentra R ) and
Mirrabooka (CAS R ). OnCentra R is not installed at any site within Australia or New
Zealand. The current use of CAS R is uncommon.

Although there are many open source electronic medical and health systems available, none of the offerings provide specifically targeted functionality for oncology. Likewise, large Hospital Information Systems (e.g., those provided by CERNA, EPIC,
Meditec) have no specific oncology functionality.

By using the process of knowledge management through term recognition, term
classification and finally term mapping [19], it is hoped that the development of a
specialist medical vocabulary can then progress through a convenient classification
structure and finally emerge into an accurate ontology which can be used as a basis
for future commercial and open source development of oncology information systems.

2.4. What is the structure of this thesis?

2.4
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What is the structure of this thesis?

The research hypotheses were that the knowledge structures of medical domain experts
such as radiation oncologists, which were used in knowledge generation, knowledge application and hypothesis generation, can be discovered from the publications in the
domain’s literature which were constructed and submitted by the domain experts.
Furthermore, that these knowledge structures are related to clinical work flow and
decision making since the domain is a practical clinical domain.

The literature review assessed the Oncology Information System literature to establish the inclusion of pre-determined radiation oncology knowledge structures. Various
methods of defining clinical knowledge were assessed for their usefulness as a methodology for defining clinical knowledge. Special focus was given to the ontology as a
method for detailing the specifications of radiation oncology knowledge structures,
critical assessing how well they achieve their aim of knowledge description.

The research methodology undertaken consisted of a modified Content Analysis
approach crafted to discover semantic entities by deconstructing published articles to
discover the semantic entities collected and analysed in their generation. The accumulated semantic entities were then organised according to the clinical work flow to
generate knowledge structures specific to radiation oncology.

2.5

What is achieved by this research?

This research determines a preliminary specification of radiation oncology knowledge
structures, and then applies this specification in four areas of radiation oncology knowl-
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edge manipulation to establish its viability. The knowledge structure is deployed in the
description of a patient with advanced oropharyngeal cancer, a trial protocol investigating advanced oropharyngeal cancer, a trial report on the management of advanced
oropharyngeal cancer and a clinical guideline for the management of advanced oropharyngeal cancer.

This specification can form the basis for the assessment of an oncology information
system as it specifies the entities that must be stored, as well as the relationships
between the entities which determine their use.

Chapter 3
Literature Review
Oncological knowledge is not chaotic. If oncological knowledge is structured, then the
knowledge can be expressed in an ontology. If an Oncology Information System, which
is a device to store oncological knowledge, is not based on an “oncology ontology”, it
is possible that the relationships inherent in the storage will be inadequate.

The historical development of the OIS did not make it likely that an appropriate
ontology would be used. Indeed the appearance of computers in Radiation Oncology
occurred for reasons of radiation safety rather than clinical information. However once
installed, it was inevitable that wider use would result in serving multiple departmental needs.

Currently, the available Oncology Information Systems are sporadically successful
although some of these successes are tantalising in their potential, indicating that some
Oncology Information Systems might be adequate. But with the lack of an underlying
ontology, this might be the result of good fortune rather than good design. These
issues are explored in this literature review.
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Oncology Information Systems

There is no agreed definition for what constitutes an Oncology Information System
(OIS), or whether such a system is required in addition to a general purpose information system [120]. For the purpose of this thesis, the OIS will be defined as an
integrated electronic system available within an Oncology Department which is composed of several components and designed to integrate clinical work, treatment and
data flow across this well-defined organisational structure.

For the radiation oncologist, the OIS contains the following components [106]:
• an electronic therapy record, whether that is an Electronic Radiotherapy
Record with/without an Electronic Chemotherapy Record
• a computerised clinical database which if included within a work flow framework may have the capacity to function as an electronic medical record by recording descriptors of the oncological disease, treatment side effects and outcomes
• an electronic resource manager, including scheduling, resource allocation,
charges and task lists.

3.2

History

The historical aspects of computer implementation in Radiation Oncology warrant
delineation. Very soon after their advent, computers were employed in an attempt to
detect human errors in the delivery of radiation at therapeutic doses. The software is
given the generic name of “Record & Verify” (R&V) System.

The R&V System is now a consistent feature of all Radiation Oncology departments
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in Australia which are all fitted with linear accelerators. As originally constructed,
the software accesses a database containing the machine settings and tolerances that
are expected when the machine is operated. When the patient has been set up on the
treatment couch and the therapist attempts to activate the linear accelerator, hardware intercepts relay the actual positions of linear accelerator components (e.g., jaws)
to the software. A comparison is undertaken between the actual and the expected position of each component reported. If the setting is outside the permitted tolerances,
the linear accelerator will not deliver dose until an authorised staff member over-rides
the message with their password, or alters the linear accelerator to bring the settings
within tolerance (the “Verify” function). The decision to do either is a professional
and clinical decision. Once the authorisation to commence has been given and the
treatment completed, the intercepted, actual measurements and the delivered radiation dose are then recorded into the database (the “Record ” function).

Although early attempts to provide useful R&V software in the mid 1980s were
spectacularly unsuccessful [95], the software has matured into a robust checking environment that performs its duties admirably [26, 156]. Although these new systems
move the man-machine interface further ‘upstream’ and are overall safer [68], humans
continue to make similar but new mistakes at the new interface.

Since errors have not disappeared, vendors have moved to improve the functionality of newer software to actually undertake the automation of machine parameters
and radiation delivery, removing the human from another layer of action. While this
leads to improvements in the staffing ratios of more complex linear accelerators [90],
errors still occur at the man-machine interface, although the quantity and quality of
the errors has decreased in number but increased in severity[68, 77, 114].
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Electronic Resource Management is likewise widely used in Oncology Departments
because of the greatly improved functionality in relation to scheduling. Both Radiation
and Medical Oncology need repeating clinic appointments and coordination of work
flow between several professional groups. Having made a schedule item, the process
of generating revenue items is a minor addition, since there is substantial overlap in
the data elements between appointments and charges. Managers are keen to use the
information collected to justify resource allocation [117].

The variability of functionality in the OIS and the varying data requirements of
the oncological community reflect the lack of an ontological framework for Oncology
[91].

3.3

The Use of OIS

Within the Radiation Oncology literature, the use of the OIS in its roles of computerised clinical database and electronic resource has been reported sparsely. A Korean
report [74] documents the implementation of two OISs in one department, and clearly
identifies the difficulties at the man-software and software-software interfaces, as well
as the benefits possible from implementing electronic methods. This department’s
requirements for two OISs was driven by problems of language. One OIS was implemented in English and the other in Korean.

While Australian centres should not be greatly affected by language differences,
there have been no studies looking at the effect of the semantics of USA-oriented systems on Australian centres. The Australian Radiation Oncology professional group is
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the Royal Australian and New Zealand College of Radiologists (Faculty of Radiation
Oncologists) which mandates a common path for specialty training (curriculum, examinations and regulations) in the region [25] . From within this regional jurisdiction
there is a similar report from New Zealand pointing out the emergent role of the OIS
as an electronic medical record, providing improvements in work flow, reduction in
data duplication and data accuracy that have hitherto been unrealised [117]. This
data ought to be relevant to the Australian setting.

3.4

Medical Data in the OIS

A portion of the OIS can be used by the oncologist to collect and store relevant clinical information relating to a patient’s medical management, this the computerised
clinical database functionality. This information includes oncological parameters such
as diagnosis, stage, prognostic factors (for outcome predictions) and eligibility factors
(for therapy decisions), treatment decisions, therapy specifications and side effects,
and treatment outcomes.

For an OIS to be useful to a clinician, it should ideally fit a functional specification
which includes the capability of acting as the sole repository for data, being widely
available and usable in the clinic because it follows a discernible work flow that mirrors
oncological practice and seeks to achieve timely entry [105]. In addition the data captured by this method should be collected in a structured manner which is consistent
with the nature of the data constructs of the specialty [71].

The format of the data collected has significant impact on its later usefulness. It
has been well demonstrated that data collected within a commercially available OIS
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which is saved in categorical formats within a relational database is useful for the provision of routine reports such as prescriptions and discharge summaries [117]. Reports
from the same site have also demonstrated the usefulness of this data store in the
comparison of treatment outcomes between clinicians [106] and in assisting epidemiological research [104].

The differences in data format and their usefulness have been highlighted [104].
Normal clinical collection which uses a document paradigm, either as text on paper,
text visible in a scanned images or typed letters stored electronically in word processor format files are of less use than categorical data entry with restricted options.
Although Natural Language Processing offers hope that free text documentation will
be useful [65], it is still far from useful in the oncological setting.

One author has highlighted the current practices involved in accumulating clinical
trial data as a more favourable paradigm [104]. Clinical trial data is collected directly
into the required categories, providing excellent quality [8] , and reducing errors [9].
While in the clinical record the oncologist might enter “mild skin reaction” , in
the clinical trial record the oncologist will enter Skin reaction = 1. The categorical
specification of a skin reaction prevents the appearance of ambiguous free text such
as “mild to moderate skin reaction”, or colloquialisms such as “lobster-red
skin”.

However this clinical trial data is usually marshalled at a large expense [59] by
data managers whose sole role is to collect the data from the clinician, transfer it
onto predefined data sheets, and possibly then enter it into a relational database. The
trial data held is not available for clinical use in generating routine reports, arrives

3.4. Medical Data in the OIS

21

in electronic storage at any time after collection on paper and is infrequently quality
assured against the original clinical interaction. Clinical trial data are a small subset
of available clinical data so that efforts to maintain quality are focused on a small
quantity of data [7]. Clinical trials efforts have produced substantial standardisation
of data entry [44].

The storage of medical data in relational database formats may be inappropriate.
The rapid development of the relational database management system (RDBMS) in
the 1980s and 1990s occurred in the business world. The RDBMS was designed for
use in business and fits this role well since it uses an entity-relationship specification
which represents the particular anatomy of the business ontology [62] and so permits
the accrued business data to be re-constructed and then analysed to discover new
knowledge. This is possible because the database’s entity relationship design (ERD)
reflects the ontology of business [132]. The use and re-use of business data stored in
this fashion validates the ontologies and entity relationships deployed [73]. An ontology can then be used by domain experts [73] to govern the ordered disaggregation of
knowledge into the store, and the intelligent re-aggregation of data elements stored.

The business ontology is reflected in the way that business data is collected and
stored via the specific ERD. Likewise the medical ontology should be reflected in the
RDBMS structure through an ERD which describes the way that medical data is to
be collected, disaggregated and stored. The success of this approach will be measured
from the intelligent re-aggregation of the medical data, not just its storage.

Unfortunately, there is no published Oncology ontology [93] and there are few
literature reports detailing successful episodes of intelligent re-aggregation of stored
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medical data elements. As a result an object-oriented approach has been described as
better fitting the model of an electronic patient folder containing various components
(such as Imaging Reports with multiple instances)[63, 71].

Additional problems with oncological data include the disjunction of data where
the result is divorced from the clinical circumstance. For example, the OIS can store
a report of a chest X-ray taken but without including the reason, or indication, for
the test to be undertaken [75]. The significance of such a report varies depending on
whether it was taken as part of routine follow-up for larynx cancer, or during investigation of haemoptysis to preclude the possibility of a new cancer in the lung. The
test cannot be successfully interpreted without knowledge of the circumstance. A similar situation exists for the Prostate Specific Antigen (PSA) blood test which can be
used for screening, case finding, prognostication before and after treatment, diagnosis
and treatment outcome. A PSA level of 2.0 (normal range 0.0-4.0), is pleasing as a
screening result indicating a small probability of prostate cancer. But the same PSA
following a prostatectomy indicates a failure to achieve a cure.

Whether this failure is inherent to the design of the RDBMS or resulting from the
failure to correctly design the data structures to include the contextual information is
not known. While re-use can be undertaken through automated processes that seek
to change the data’s format but not the content [97], the re-use of poorly organised
data is inherently unsafe [14].

3.5

Transforming Discovered Information

The motivation for the description of a specialist medical terminology or specification
of semantic entities in the Radiation Oncology domain is a relevant domain ontology.
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Developing an ontology involves the engineering of knowledge which is heavily based
in formal logic addressed in the area of Artificial Intelligence. During the progress of
this work, several techniques were considered to have some applicability to the process
of extracting and manipulating knowledge structures and they are described together
with reasons why they have been employed as the sole method.

3.5.1

Semantic Networks

Semantic networks is a graphical knowledge representation technique displaying a taxonomic hierarchy of concepts or subjects (nodes) with connecting links or relationships
(edges) [55]. Semantic networks are used to convey things about things. The nodes
and edges are important with their topology reflecting a two way meaning with cardinality (e.g., uses/is used by). These three phenomena of node, edge and cardinality
are distinct [69].

The binary relationship must exist between two specific subjects, with a kind
(e.g., uses, is a) and a semantic direction (e.g., cancer is a disease, rather than
disease is a cancer). Where concepts have multiple relationships, the discovery of
additional facts is permitted through inheritance. If we have two statements with a
common concept, e.g.,

BREAST CANCER is a CANCER
CANCER is a DISEASE

then via the property of inheritance we can state, correctly, that
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BREAST CANCER is a DISEASE.

As a representation method, semantic networks are limited by the single binary
relationships that exist between objects. One object can relate to multiple objects
by single relationships to establish multiple inheritances. This is a useful feature in
medicine as a single disease can have multiple symptoms, and a single symptom can
be caused by multiple diseases.

While the graphical representation embeds logic, it cannot easily represent the logical concepts of negation and disjunction, and more expressive parts of formal logic.
However graphical representation is easier to manipulate than formal written specifications.

Furthermore, the description of events, multiple events, a work sequence and conditional loops is difficult in semantic networks [57]. This is problematic for Radiation
Oncology. Within this expert domain, the clinical work flow contains concepts, relationships, sequence and events, as assumed components of the underlying knowledge
structure. Radiation Oncology knowledge has no reason for existence other than the
treating of cancer patients, therefore any knowledge representation system has to reveal these properties.

There is no published semantic network describing Radiation Oncology, however,
one would expect that such a network would be similar to that described in Figure
3.1, demonstrating that the representation is easy to manipulate even for an ontology
novice.
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Although this semantic network has been devised by a domain expert, the arrangement has buried domain concepts. These concepts will be evident to the domain expert
but as they are not formally defined, it is not clear that they will be apparent to, or
preserved by a domain-ignorant ontologist. This particular example demonstrates such
a circumstance with respect to the interdependence of knowledge and work flow. If two
concepts with link are examined, e.g., “Disease has a decision for Treatment”,
the knowledge inherent in the Disease includes all of the concepts accessed through the
link has a specification. And the nature of the Treatment includes all of the concepts accessed through the links has a trial, has a treatment offer, has an intent, and has an effect. Links in the semantic network are considered to be bidirectional, however in the expert domain, this bi-directionality is altered. When a concept
such as AcuteSideEffect under the arm of Radiotherapy (that is, Radiotherapy
has a Procedure produces a AcuteSideEffect) is selected, the domain expert will
assume that the ‘upstream’ concepts (with respect to work flow) have been completed,
and for the ‘downstream’ (with respect to work flow) concepts to be unfilled. That is,
the domain expert will expect that if Radiotherapy produces an AcuteSideEffect,
there must be a Diagnosis with the specification already completed, and that until Radiotherapy has a Prescription which has been performed by an Oncologist,
there will be no AcuteSideEffect. Furthermore, the oncologist will not expect to see
an entry for SideEffectAfterTherapy occur before all AcuteSideEffects have been
completed for the approved Prescription. This interdependence and directionality
of knowledge and work flow is not trivial in an expert domain.
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Rule-based Systems

The application of rule-based systems to medicine is not new [129, 128]. Rule-based
systems eschew the organization of concepts in a hierarchy as being static and unchangeable, and instead use rules which are a description of condition and outcome.
This structure is commonly seen in ‘IF....THEN’ logic [43]. Some rule-based systems
have expanded to include medical reasoning, that is, the ‘BECAUSE’ [92]. These rules
are useful in the setting of specialist medical decision making, but limited when applied generally [138].

This logic structure is common in medical diagnostics and management, indicating
that the perception of doctors as just ‘pattern matching’ is incorrect. The conclusions
of the medical process are statements of diagnosis and treatment, but the derivation
of these statements from history, examination and tests in a logical process whose arguments are anatomical, psychological, physiological and pathological. The terms if,
then and because are common words in medical speech. It is therefore not possible
to define a medical ontology without recognising these processes.

For example, the presence of rectal bleeding after prostate cancer treatment suggests different diagnoses.
if ... the patient was treated with radiotherapy.
then ... most likely cause is telangiectasia in the rectum
because ... of the blood vessel damaging effects of radiation.
Similarly,
if ... the patient has a swollen tender calf consistent with a deep vein
thrombosis,
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then ... you must examine the chest looking for pulmonary embolus,
because ... a broken piece of clot will follow the anatomy of the vessels
through the heart and lodge in the first vessel reached with a smaller diameter than the clot fragment which will be in the pulmonary vasculature.
Rules-based systems also allow for reasoning that directs clinical decision making, e.g.,

If ... there is a past history of unprovoked deep vein thrombosis
and
if ... there is a diagnosis of cancer,
then ... prescribe anticoagulation.

When designing a system to support clinical decision making, a rule-based approach is useful, however development becomes problematic if each new piece of literature has to be perused to see whether previously established rules require alteration
and to discover unanticipated conflict between existing rules. This makes the production of conflicts quite easy but difficult to recognise because the reasoning is not
particularly specific to clinical reasoning. Manual generation of rules suffers from the
massive amount of published data each year (see below).

There are more rules operating in clinical medicine than those developed from the
published literature. Each clinician has a different approach to the effect of patient
co-morbidities on treatment decisions. Any system of knowledge specification and application has to account for this clinician ‘idiosyncrasy’. Clinical Guidelines are called
‘guidelines’ because they are not mandatory specifications of management. Medical evidence is developed on highly selected homogeneous patient groups and is therefore of
limited applicability in a heterogeneous clinical world. The information systems avail-
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able today do not present guideline recommendations to clinicians for consideration,
so the reasons and consequences of deviation from a guideline are difficult to ascertain.

The rules-based system however is a methodology for the operational application
of pertinent knowledge, so rules that are generated de novo to govern oncological management will have the assertions and context of oncological knowledge embedded. The
rules-based format is useful for the presentation of oncological facts, as illustrated in
this clinical example [155].

If
Diagnosis = ‘C34’ or ‘Larynx’
AND Histopathology = ‘8140/3’ or ‘squamous cell carcinoma’
AND T stage = ‘1’ or ‘1a’ or ‘1b’
AND N stage = ‘0’
AND M stage = ‘0’
then
Radiation field = “Larynx”
AND Radiation dose = “56.25”
AND Radiation fractions = “25”
AND Radiotherapy schedule = “daily”
The source of oncological facts directing patient management is the oncological
literature. The nature of the randomised trial is sympathetic to manipulation into a
clinical rule as in the example above. But this treatment guideline is not oncological
knowledge per se, as no outcome data is included. Rules are not a useful description
method for oncological knowledge, but a knowledge specification might permit the
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automated generation of rules.

Such a specification would permit the integration of published literature into rules
and subsequent argumentation based on these rules. It would also overcome the problem of generating new rules based on the advancing medical literature. Such a specification would provide added utility and impetus to the knowledge structures.

3.5.3

Case-based Rules Systems

Rules systems that manipulate clinical material are called case-based reasoning (CBR)
systems [1]. These systems rely on the manipulation of past events into matching templates for future decision making. Each previous case becomes a rule when catalogued.
The example above which was derived from a literature report [155], could also be
derived from a specific clinical case where a patient with a T1N0M0 squamous cell
carcinoma of the larynx was treated with 56.25 Gy in 25 fractions over 25 consecutive
work days. This application of specific knowledge derived from previous examples is
seductive as it bypasses problems associated with encoding published literature and
describing clinical idiosyncrasy [1].

In Radiation Oncology, CBR has been used in radiation planning to match patient
and tumour geometry from previous radiation therapy plans with the current patient
[31], and also as a similarity estimate to predict acceptability of radiation plans [116].

The CBR rules, which are formed from individual clinical cases, are used to argue
actions for the next similar case. In each case, relevant clinical parameters are defined
and then weighted in an iterative approach. This approach will include clinician ‘id-

3.6. Ontologies

31

iosyncrasy’ in decision making, making the assumption that such idiosyncrasy is stable
across similar cases. In reality, doctors become more conservative with age [99], and
medical knowledge changes. The idea that the clinician can be used as the conduit
through which clinical medicine knowledge is manifested, rather than the published
literature, is a shortcoming. While it is possible to demonstrate that such systems can
produce a close correlation with clinicians [51], the usefulness of the system can be
expected to deteriorate as medical knowledge changes.

Case-based reasoning is therefore best at maintaining consistency of decision making. By addressing the structure of medical knowledge through pattern matching, the
result is the application of yesterday’s knowledge. However the desire and challenge
of evidence-based medicine approaches is to change patient management by applying
up to date medical knowledge [70, 146] and become better.

3.6

Ontologies

Ontology is that field of Informatics which is concerned with the production of ‘controlled vocabularies’ which are “conceived as graph-theoretical structures consisting
on the one hand of terms (which form the nodes of each corresponding graph) linked
together by means of edges called relations” [130]. In this way, the terms/nodes colon
and large intestine can be linked by the relation/edge is part, e.g.,

colon Anatomic Structure is Physical Part of large intestine
or
colon part of large intestine
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just as colon and organ can be linked:

colon is a body part, organ or organ component [93]

One of the constant characteristics of humans is the drive to categorise, and so,
multiple attempts have been undertaken to categorise medical language into schema,
variously called knowledge bases, ontologies, vocabularies or data dictionaries. These
schema are not equivalent and vary in their usefulness. Vocabularies simply list words
peculiar to a domain. Data dictionaries are limited as they define terms and constrain
examples. Ontologies define data relationships and so can be used for reasoning.

3.6.1

Ontology Engineering

Ontology engineering is the process of taking a corpus of domain knowledge, recognising specific concepts and fashioning them into a structure which reflects the domain
knowledge. The process can be undertaken from top down or from bottom up, but either way, the result will be a specification of general concepts such as Events, Time,
Physical Objects, and Beliefs, which will be further described as sub-concepts
that have relevance to the expert domain. For example, the concept of Time will
be further specified by the sub-concepts of Date of Birth, Date of Diagnosis and
Date of Therapy. This thesis makes no attempt to integrate a Radiation Oncology
ontology into a general purpose ontology of Medicine, or even to describe the applicability of this schema to Medical Oncology or Surgical Oncology. That assessment
should be undertaken by the relevant specialties, although the commonality of management should mean a high level of agreement.
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Ontologies should organise knowledge logically; this may prove difficult in an expert domain where generalisations may seem to have as many exceptions as clinicians.
In the clinical circumstance, knowledge that might have be used for one patient, may
be classed as irrelevant for another. Furthermore, different clinicians will have slightly
different knowledge structure developed through their unique clinical experiences.

In an evidence-based environment where knowledge is fluid and developing daily,
‘exceptions’ will be common. It is therefore important that knowledge structures
developed match the knowledge development methods of the expert domain and so
permit the easy integration of new knowledge. In the Radiation Oncology expert domain, knowledge development and knowledge use follow similar patterns. This thesis
will use this interdependence to test the robustness of the organization of information
within the knowledge specification that becomes the Radiation Oncology Ontology.

The well known Artificial Intelligence text by Russell and Norvig [124] describes
four routes for ontology development, and this attempt falls into the last category
of “enticing unskilled amateurs to enter commonsense knowledge” and is necessary
because “trained ontologist/logicians, who architect the ontology and write axioms”
have no domain specific knowledge. While the manipulation of an electronic corpus
will discover terms and information, the structuring of that information cannot be
verified without the domain expert, who is usually ontologically unskilled.

3.6.2

Medical Ontologies

The field of medicine is no different form other expert domains with several knowledge bases being developed including ILIAD [96], Medical Entities Dictionary (MED)
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[48, 76, 78, 86], NCI caCore Thesaurus (NCIT), the National Cancer Institute’s Common Data Entities (CDE) [101] and OpenEHR’s archetypes [27, 28, 39]. These attempts are outnumbered by other classifications including Systematic Nomenclature in
Medicine (SNOMED), International Classification of Disease (ICD), and the Logical
Observation Identifiers, Names, and Codes semantic structure (LOINC) which started
as organised vocabularies, some ending as formal ontologies.

Ontologies are derived for a purpose and so usefulness in the clinical expert domain
of Radiation Oncology must be proved. An ontology can only be successful when ontologists believe it to be well-formed, and experts find that it represents the domain
adequately.

The ILIAD knowledge base underpins a system using a Bayesian probabilistic approach to produce an expert clinical diagnostic system. The knowledge base is a data
dictionary which includes the a priori prevalence of a disease, along with associated
clinical findings. These clinical findings can alter the post priori likelihood of a diagnosis by estimating the impact of the presence of a finding on disease presence (as a
True Positive) and absence (False Positive) [96]. This system has not been extended
into treatment and outcomes.

The NCI CDE dictionary grew out of a desire to provide a standardized databank
of questions to be asked in clinical trials, to permit data from multiple trials to be coalesced without translation [101]. This solution arose from the scenario where one trial
might use a data category called “Eye Colour” rather than “Colour of Eyes”, and
use choices of 1=blue, 2=brown, 3=mixed rather than 1=brown, 2=blue, 3=green,
4=mixed. The dictionary received contributions from clinical trial researchers involved
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with the NCI in the USA to systematise collection rather than document the importance or relationships between data. While this dictionary will probably include most
of the items reported in the literature, trials often accumulate more data than is required to answer the clinical question.

The OpenEHR is an open standard initiative predominantly based in Australia
with ties to European standards [27]. The ‘archetype’ is the ontological variant developed by this group, devised as a prototype on which software can ultimately be
based. The defining of archetypes is seen as a domain expert task that allows re-use
when building a variety of functioning systems. Archetypes can include observations,
work flow and interventions and can be single items such as Pulse or grouped into
templates such as Physical examination. The system is also open and freely available, but includes few archetypes relating to cancer. There is no archetype relating to
radiotherapy.

The International Classification of Diseases (ICD) is widely implemented but relates only to classifying diseases (diagnoses), morphology, procedures and causative
agents. The Systematized Nomenclature of Medicine (SNOMED) is now widely implemented, however the listing of terms is incomplete, many terms are listed several
times, and management of changes is cumbersome.

Another attempt to bring order and provide interconnectivity between these attempts is the United Medical Language System (UMLS) which provides a correlation
index across languages and particular attempts (SNOMED, ICD, LOINC, etc) so that
a consistent vocabulary can be achieved. In this system, no term is retired.
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At a more fundamental level, while all of these broad-based attempts have proposed various medical classifications, the question as to whether there are single or
multiple medical ontologies within Medicine has not been addressed [52]. Descriptions
of ontologies in different areas leads to the belief that there are very distinct areas
where specialised ontologies are applicable, e.g., anatomical pathology [33],surgical
ICU ([94], malaria [141], and ophthalmology [139]. Even internet humour can attest
to great differences in knowledge type between specialities such as psychiatry, orthopaedic surgery and emergency medicine 1 . Whether these efforts should or can be
coalesced is not yet known. Certainly they cannot be coalesced before they are defined.

3.6.3

Oncology Ontologies

My research would be pointless if a satisfactory ontology for cancer, radiotherapy or
Radiation Oncology already existed. A search was undertaken to identify published
ontologies that relate to Cancer, Oncology, Radiotherapy or Radiation Oncology. The
results are discussed below.

3.6.3.1

Cancer

A search of BioPortal found three cancer-related ontologies:
• Breast Cancer Grading Ontology

2

• Cancer Research and Management ACGT Master Ontology
• Neomark Oral Cancer-Centred Ontology
1

4

http://www.youtube.com/watch?v=q0S5EN7-RtI
http://bioportal.bioontology.org/ontologies/1304
3
http://bioportal.bioontology.org/ontologies/1130
4
http://bioportal.bioontology.org/ontologies/1501
2

3
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The Cancer Research and Management ACGT Master Ontology was developed to
resolve problems of integrating technologies, coding, categories and reporting methods
in cancer trials [41, 40, 42, 143]. The ACGT ontology covers many oncology specific
areas, but can be criticised for its organisation and logic which frequently seems devoid
of domain expertise (Appendix H). Of more concern is the apparent lack of correlation
between terms that coincide in the work flow. The ACGT formal knowledge structure presents Diagnosis and Staging as separate knowledge structures, while in reality
and use, they are intimately related in work flow, use and knowledge constructs of Oncology. The ontology must accurately represent this relationships, if it is to be relevant.

The ontology was built using a top-level ontology, the Basic Formal Ontology.
This ontology initially recognises entities with different characteristics of persistence
in time [36]. A search for items relating to Diagnosis and Staging finds Diagnosis
and TumorStage inside the ACGT.

entity
→ continuant
→ dependent continuant
→ generically dependent continuant
→ acgt:InformationObject
→ acgt:Document
→ acgt:Diagnosis
→ specifically dependent continuant
→ quality
→ acgt:TumorClass
→ acgt:TumorStage
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The terms used in this classification are somewhat unfamiliar. An entity that is
wholly persistent and complete when present is called a continuant (or endurant). Examples include the diagnosis (you do or don’t have a whole cancer). These entities
can be subdivided into dependent and independent continuants. The dependent continuant (Diagnosis) requires an independent continuant (a human entity) in much
the same way that another dependent continuant (TumorStage) requires another dependent continuant (Diagnosis) and also an independent continuant (the patient).
The Diagnosis is a generically-dependent continuant because the the independent
continuant (the patient) is not required to have a disease or be restricted to one disease. However the TumorStage is a specifically-dependent continuant because each
Diagnosis must have at least one TumorStage.

While this relationship is correct, it is not complete from the domain expert’s
stance. It is not explicit in the ontology that each Cancer Diagnosis must have
a TumorStage assigned as is dictated by the expert domain. Close examination of
the Diagnosis and TumorStage entities shows that while the entity Diagnosis has a
qualification “Outcome of some Diagnostic Process”, there are no further requirements
that the Diagnosis be subserved by a TumorStage, or that the TumorStage is linked
to a Diagnosis. Within the ontology there is nothing to say that this specificallydependent continuant (TumorStage) is specifically dependent on the generically-dependent continuant (Diagnosis). It is in real life, so it should be in the ontology.

This lack of a direct link is also compounded by misclassifications which are highlighted in Appendix H.
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is a project partially funded by the European Commission that con-

centrates on Head & Neck cancers. Given the time taken for disease to recur, the
project is seeking to identify possible prognostic features that relate to treatment, genomic biomarkers, and imaging analysis [133] variables that will identify a high risk
‘bio-signature’ [100]. The prognostic significance of the high risk bio-signature in predicting reappearance is being investigated. The collected data is to be represented in
an Informatics framework representing human physiology and pathology [145].

Although listed in the BioPortal website, the Breast Cancer Grading Ontology6
was not available.

3.6.3.2

Radiation Oncology

A Web search using the term “Radiation Oncology Ontology” returned no ontologies.
A search of the BioPortal site

7

revealed no specific ontology. The term “Radiation

Oncology” was found within several listed ontologies, namely ICD-10-PCS, Metathesaurus CPT Hierachical Terms, LOINC, SNOMED Clinical Terms, Health Level Seven,
and NCI Metathesaurus.

The International Classification of Diseases v10 Procedure Coding System (ICD10-PCS) categorises Radiation Oncology procedures with a seven character identifier. The identifiers represent in order Section, Body System, Root Type, Body Part,
Modality Qualifier, Isotope and Qualifier. This is a classification of procedures
devoid of any indicator of diagnosis, stage, treatment intent and therapy importance.
The procedure codes also have no specific indication of technique, dose, or fractionation. Examples of procedure coding are provided in Appendix G (ICD-10-PCS codes
5

http://www.neomark.eu/portal/
http://bioportal.bioontology.org/ontologies/1304
7
http://bioportal.bioontology.org/
6
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for radiotherapy procedures).

Different ontologies define the term “Radiation Oncology” differently. The NCI
Thesaurus lists meta-data such as a definition of “The study of the effects of ionizing radiation for treatment of tumors”, a semantic type of “Biomedical Occupation or
Discipline” and a synonym of “oncology, radiation”. The SNOMED Clinical Terms
however does not provide a definition, has the same semantic type of “Biomedical
Occupation or Discipline”, but the synonym list includes “Radiotherapy” and “Therapeutic radiology”. Yet the US National Cancer Institute (NCI) defines radiotherapy
as “the use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and
other sources to kill cancer cells and shrink tumors” [82], which is clearly not an occupation.

3.6.3.3

Radiotherapy

The term Radiotherapy is likely to be an important part of any Radiation Oncology
Ontology being the name given to the preferred modality. Analysis of this term’s
classification reveals severe shortcomings. The Read Codes, Clinical Terms Version
3 lists radiotherapy along with a sub-term called Purpose of radiotherapy 8 . Subclassification of this term gives the options:
• Radiotherapy - intraoperative control
• Radiotherapy - postoperative control
• Radiotherapy - preoperative control
• Radiotherapy for analgesia
8

http://bioportal.bioontology.org/ontologies/42295?p=terms&conceptid=514
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• Radiotherapy for haemopoietic irradiation
• Radiotherapy for immunosuppression
• Radiotherapy for inflammation
• Radiotherapy for lymphatic irradiation
• Radiotherapy for tumour palliation
• Radiotherapy purposeNOS
For the domain expert this classification provides problems. While the purpose of
radiotherapy can be rightly described as control, analgesia or immunosuppression,
the purpose of radiotherapy for irradiation is tautological and inconsistent. Furthermore there is substantial overlap in these groups, and important omissions. Radiotherapy for analgesia is providing Radiotherapy for tumour palliation. Most
radiotherapy is given for the purposes of cure to eradicate the cancer with radiotherapy without surgery, yet there is no category to describe radiotherapy given for the
purpose of cure of the tumour.

The Cancer Research and Management ACGT Master Ontology only lists types
of radiotherapy. The term acgt:Radiotherapy has the sub-term acgt:Teletherapy
with a further sub-term acgt:MultipleFieldIrradiation and a single sub-sub-term
acgt:OpposingField Irradiation9 . Terms to describe common clinical scenarios of
more than 2 fields and more complex coplanar/non-coplanar and co-axial/non co-axial
arrangements are not included in the ontology.

9

http://bioportal.bioontology.org/ontologies/42497?p=terms&conceptid=acgt:
OpposingFieldIrradiation
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The Dermatology Lexicon (DermLex) only provides a radiotherapy list classified
by beam energy (Grenz rays, kilovoltage x-rays, etc) that are applicable to skin treatment

10

.

The Galen Ontology lists radiotherapy as part of the following hierarchy:
Behaviour
→ NAMEDVolitionalACT
→ ClinicalACT
→ TreatmentAct
→ NAMEDTreatmentAct
→ Radiotherapy
Issues that relate to the purpose of radiotherapy are described under the TreatmentAct hierarchy with a sub-term DiseaseProcessModifyingAct

11

. Yet common terms

associated with radiotherapy such as beam energy and fraction number are not present
in the Galen Ontology.

Within the SNOMED Clinical Terms Ontology, radiotherapy is listed under parent
terms - Special concept > Inactive concept > Reason not stated concept >
Radiation therapy (synonym: radiotherapy). The term has been replaced by
Radiation Oncology AND/OR radiotherapy

12

. Sub-terms within this hierarchy in-

clude Radiotherapy of corneal lesion and Radiotherapy by body site. However this second term includes more sub-terms such as Radiotherapy to head. The
reasons for classifying Radiotherapy to the head and Radiotherapy to the cornea
at different levels in the ontology are not described. The Purpose of Radiotherapy13
10

http://bioportal.bioontology.org/ontologies/39815?p=terms&conceptid=RID18821
http://bioportal.bioontology.org/ontologies/4525?p=terms&conceptid=
DiseaseProcessModifyingAct
12
http://bioportal.bioontology.org/ontologies/44777?p=terms&conceptid=108290001
13
http://bioportal.bioontology.org/ontologies/44777?p=terms&conceptid=168519005
11
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is described with the same structure as seen in the Read Codes above, although
the previous term Radiotherapy for tumour palliation has been replaced with
Palliative course of radiotherapy which has a single sub-term, namely Palliative course of deep X-ray therapy14 . This entity is specific to Deep radiation
therapy, 200-300 kVp which is problematic for the domain expert. Palliative radiotherapy will uncommonly involve 200-300 kVp X-rays but most commonly be given
with megavoltage X-rays [67], as most lesions requiring palliative treatment are deep
and require the additional penetrance. Indeed, this treatment paradigm is so common
that large randomised trials of palliative radiotherapy do not actually specify what
energy radiation be used [119].

Another large thesaurus, the NCI Thesaurus, has similar problems of classification.
If one peruses Therapeutic Procedure

15

, there are multiple examples of misclassifi-

cation. For example, Cancer Therapeutic Procedure is not the hierarchical parent
of Chemotherapy or Radiotherapy, but is the parent of Chemoradiotherapy.

Similarly, the NCI’s Physician Data Query ontology has a term radiation therapy
16

, however its daughters brachytherapy, tomotherapy, breast irradiation, ima-

ge-guided radiation therapy, carbon ion radiotherapy, accelerated radiation therapy and palliative radiation therapy, are a non-overlapping mixture
of types that do not seem to follow a discernible classification pattern.

While all of the Classifications, Terminologies and Thesauri are not formally described ontologies, the problems that have been highlighted should not be perpetrated
14

http://bioportal.bioontology.org/ontologies/44777?p=terms&conceptid=314604005
http://bioportal.bioontology.org/ontologies/45400?p=terms&conceptid=Radiation_
Therapy
16
http://bioportal.bioontology.org/ontologies/45074?p=terms&conceptid=
CDR0000038085
15
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in an ontology. Similar terms have to accumulate into similar positions. The position
of terms should be verified by the domain experts who will be using the ontology.
Term coverage has to be complete, or at least be subserved by a co-opted ontology.
All terms used should have meaning to the domain experts served by the ontology.
In this regard, any domain specific ontology should have a ‘plain language’ output
which is accessible to the domain expert uninformed in ontologies. For example, the
grouping of concepts could be explored by asking for similarity of concept:
• The concepts Radiotherapy - preoperative control and Radiotherapy postoperative control are grouped together - are these concepts similar?
• Is the concept Radiotherapy of corneal site more similar to the concept
Radiotherapy to body site or the concept Radiotherapy to the head?
• The concept Palliative course of radiotherapy has a single sub-concept
- Palliative course of deep X-ray therapy, are there other sub-concepts
that should be here?
• The concept radiation therapy has several sub-concepts - brachytherapy,
tomotherapy, breast irradiation, image-guided radiation therapy, palliative radiation therapy, accelerated radiation therapy and carbon
ion radiotherapy. How should these sub-concepts be grouped?

3.7

Summary

The current ontologies and classifications have been demonstrated to fall short in their
specification of Radiation Oncology knowledge structures. As could be expected, the
deficiencies relate to the lack of expert domain knowledge among ontologists, and the
lack of development of devices that translate ontologies into the language of oncologists,
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which would allow ontologists to understand how their developing ontologies fall short.

As has been shown, the concept that certain entities are linked can be appreciated
in some ontologies. This linkage is not as tight and necessary as that required by
the expert domain knowledge. The lack of this link has two outcomes. First, when
developing an information system from the ontology, the only other way to force the
juxtaposition of Diagnosis and TumorStage is to use a business rule to constrain the
user interface. This introduces an opportunity for customisation in the user interface when none may exist in the knowledge representation. Second, this deficiency in
knowledge representation, where the ontology has failed to enforce the collection of
TumorStage with Diagnosis will mean that the data collected will be deficient and
possibly not useful for analysis.

The cause of the problems also lies with the domain expert. When viewing a list of
items related to Radiotherapy as described above, it takes very little time to appreciate the problems which in part result from assumed equivalence of adjectives describing
Radiotherapy in the semantics of speech. In the expert domain, the terms carbon
ion radiotherapy, accelerated radiation therapy and palliative radiation
therapy represent vastly different entities where the differences are type of particle used (carbon ion; alternatives include photons, electrons, or protons), the rate
of dose accumulation each day (accelerated; alternatives include hypofractionated,
hyperfractionated, or conventional) and usefulness/timing of a modality of therapy
(palliative; alternatives include primary/definitive, adjuvant, neoadjuvant, and concurrent).

Clearly there is a need for a greater involvement of domain experts to deliver
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a more comprehensive set of terms and demonstrate more clearly their important
relationships.

Chapter 4
Research Method
When beginning the specification of an ontology, the issue of choice of methodology
can be perplexing. The most recent attempts to produce ontologies have used increasingly sophisticated, highly complex and purpose built specification software such
as the Protégé system [42]. These attempts within the field of Oncology have the
potential to deliver a ‘theoretical’, objective data specification. However there is insufficient involvement of domain experts who can ensure coverage and consistency, and
no paradigms to engage the domain experts to determine that the resultant ontology
is accurate.

Certainly the person undertaking the task should have training, but given that this
is an expert domain the involvement of ontological and oncological domain experts is
required. However if that person is a radiation oncologist, their status as an oncology
domain expert is likely to be balanced by their informatics domain ignorance. Likewise an ontologist, while an informatics domain expert is likely to be ignorant of the
oncology domain. The basis of the deficiencies lie in the fact that both areas require
substantial and lengthy training, rarely undertaken by the same individual.
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When assessing the level of implementation of the capabilities of an OIS in the
real world situation of a functioning Radiation Oncology department, the initial requirement is the determination of the ability of the OIS to store the required OIS data
elements. For maximum applicability, this initial assessment should be an objective
exercise using real elements drawn from unselected material found in a wide crosssection of Radiation Oncology practice. Although few sources fit the description of
being real and ‘objective’, this description does fit the data types used to construct the
manuscripts published within the Radiation Oncology literature. The classification of
this extracted material carries with it the ability to include the nuances of clinical
practice.

Whether all the data specified will be clinically important or even relevant is a
separate question that does not need an answer. All new and significant discoveries
and management paradigms are reported through the peer-reviewed literature, therefore this paradigm will objectively determine the extent of data that needs to fit into
the OIS recording structures based on the assumption that the published literature
contains the required data specifications.

The objective determination of required OIS functionality has not been reported
in the literature. The only publication found that provided a ‘functional specification’
for the OIS did not describe any formal methods used to delineate its specification of
required functionality [105]. Typically commercial vendors consult users initially to
develop a requirements specification, and later respond to user demands for improved
functionality and bug fixes once the program has been released.

The knowledge reconstitution aspect of clinical knowledge capture is less obvi-
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ous but frequently promised by proponents of IT systems in health. The clinical
data recorded describes a patient’s ‘journey’, and is re-used in the production of
manuscripts. Adequate data structures will permit automation of this process while
inadequate data structures will impact on the ability of a user to use retrieved data
in a clinically and professionally useful manner, preventing automated analysis and
knowledge discovery. Therefore the use of manuscripts as an objective source of data
structures serves the objective of discovering the knowledge structures.

Radiation Oncology staff produce data that is important for delineating clinical
patterns of disease, defining research questions, determining patient management and
settling controversies. Whether stored on paper or in electronic formats, this data is
used to construct manuscripts that are submitted for publication. Leaving poor writing and design aside, if the data inside the submitted manuscript relates to a question
that is considered to be relevant by peer review, the manuscript will be published.

4.1

Methodological Options

The process of knowledge gathering and organization used to determine the knowledge structures of Radiation Oncology requires a corpus of text that contains Radiation
Oncology knowledge (clinical text, clinical guidelines, medical textbooks, medical literature)or an interaction with radiation oncologists (interview, speech analysis). The
method used may be automated or manual. Following determination of the corpus is
the application of an analysis method.This research is based on a manual assessment
of one of these data sources, and utilises a method called Content Analysis.

The most appropriate sources for analysis should be easy to access, cover the sub-

4.1. Methodological Options

50

ject area of Radiation Oncology well and from many perspectives, be applicable in
clinical and trial arenas, and always up to date. It should have the possibility of automated processing, and it would be useful if the source enabled the rapid delineation
and introduction of new knowledge structures into clinical practice.

In circumstances where the expert domain is a silo with well confined limits, if
a domain expert cannot define a knowledge structure, then the domain ‘ignorant’ is
unlikely to be successful in producing a model with agreement. For this reason, management of the knowledge should be undertaken initially by an oncology domain expert
using manual techniques on the objective literature corpus.

Using the oncology domain expert as a source is not useful in the long term. Any
investigation undertaken by a domain ‘ignorant’ requires a substantial learning curve
in the domain area. Given that certification as a specialist radiation oncologist in Australia cannot be achieved in less than 11 years (4 years minimum for medical degree, 2
years minimum for residency, 5 years minimum for specialty [25]), this represents a significant effort. Furthermore, convening meetings of domain experts is expensive, time
consuming, prone to internal arguing, and not likely to provide a complete systematic
coverage of the knowledge base. Medical specialists have excessive time demands from
clinical work [38]. Data inadequacy may result from a lack of systematic coverage of
the entire oncology vista by relying on the memory of a small number of oncologists.
Data creep may occur where the knowledge provided reflects what an oncologist would
like to record, rather than what has been determined as important to the oncology
community. Finally, there can be data stasis where the results of the process become
out of date very quickly. These processes have been shown to be at work in the medical
expert domain of Ophthalmology [47, 79].
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Clinical material from the doctor-patient interaction relates to consultation and
follow up, and is unlikely to reveal knowledge in the areas of simulation, planning and
treatment. It is not peer-reviewed. Guidelines and textbooks by their very nature
are outdated sources which lessens their usefulness in the systematic maintenance of
a knowledge base. Furthermore the knowledge in guidelines and textbooks is ‘secondary’, having been derived from the published literature.

The published literature, however, is easily accessible electronically, covers all facets
and processes in the expert domain, introduces new ideas and verifies the usefulness
of treatment paradigms that should be applied to treatment, drives the specialised
vocabulary of the domain and acts as the objective standard for knowledge in the domain. The status of the published literature is clearly seen in the referral of guidelines
to “Levels of Evidence” which detail the type and strengths of published data supporting a particular treatment approach (for example, see Appendix P - Clinical Practice
Guideline for advanced oropharynx cancer - Scottish Intercollegiate Guidelines Network (UK)). As most publications have been peer reviewed by multiple sub-domain
experts, the relevance of each publication has already been attested.

The published body of Radiation Oncology literature is very large. This corpus
has the additional attraction of being the source that constitutes and popularises new
Radiation Oncology knowledge, as well as the source of clinical advice on how to treat
patients. While not totally objective, the literature is only published after a peerreview process has deemed the contained knowledge as worthy of publication. This
approach to the determination of data utility is unique, and presents an opportunity
to place the definition of data requirements on an objective footing.
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The use of automated analysis is currently a popular paradigm relying on the analysis and groupings of words to infer meaning. Words in the literature typically refer
to instances of entities, rather than the entities, and when attempting to define a
knowledge structure, the important components are the entities rather than the instantiation in a particular case.

When some domain experts undertake the process of knowledge management, all
domain experts will not always agree. Often disagreements will revolve around terminology, e.g., whether the most important cancer therapy used is called the “primary”
or the “definitive” therapy. However, such disagreement does not disqualify them from
the process nor make their model wrong, but rather points to the need for more refinement and standardized vocabularies to underlie the developed ontology. The issue is
whether the model can be verified with outputs that other domain experts can agree
properly represents their knowledge.

4.2

Methodology Used

While the following sections explain the process in detail, the research methodology
consisted of the following steps:
1. defining the relevant literature
2. reading the PDF copy of each manuscript
3. using Content Analysis to identify the Semantic Entities contained within each
manuscript
4. compiling a list of all Semantic Entities identified
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5. matching the Semantic Entities to work flow stages
6. presenting the resultant classification in a markup language.
The “assessment unit” is the sentence which ends with a full stop, question mark
or exclamation mark. In the initial phase of training, sentences were numbered and
assessed sequentially starting at the Introduction, and ending at the final sentence
of the Discussion. Within each sentence, all nouns or phrases that relate to data
analysis resulting in the selection of patients for inclusion, stratification of patients
in management, or measurement were identified. In addition to the text, tables and
diagrams were also analysed to itemise the discrete and implicit semantic entities used.
The approach to variability of semantic entities was similar to that of the Common
Data Elements dictionary that promote consistency of data element used in Phase 3
clinical trials [101] in that overlapping entities were given a single name. All articles
were assessed in their original paper format. A classification sheet (Appendix D - Data
Collection Sheet) was completed. After completion, semantic entities were entered into
an electronic spreadsheet for analysis. An example of this methodology is provided in
Appendix B (Sample Extraction of Semantic Entities).

4.3

Content Analysis

The identification of the entities comprising the expert domain knowledge base which
should be stored in any electronic repository requires the delineation of the discovery
method, including the source of the entities, how they are extracted, and finally how
they are organised into knowledge structures. The source of the entities is the published Radiation Oncology literature.

Among the research methodologies, Content Analysis possesses the ability to be
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transformed to suit the task of extracting entities. As Weber [149] states in his introduction (p.13):
“There is no simple right way to do content analysis. Instead, investigators must judge what methods are most appropriate for their substantive
problems.”
This requirement is inevitable as the processes of making valid inferences from any
text is intimately associated with and determined by the specific problems being investigated. While this inevitable subjectivity does not render the technique useless, any
user of this technique must handle the process carefully and explicitly. Using the analogy of a lamp post, one would like to think that the technique can illuminate, rather
than just prop up a point of view. The specifics of Content Analysis are described
in several texts which were used to develop the present methodology [136, 149]. The
stages of the analysis process as described by Wilkinson were followed [152].

While Radiation Oncology is a medical and scientific endeavour, analysis of its
written material is not, and has similarities with research in consumer behaviour.
Consumer research deals with the adoption of specific communication, and some radiation oncology text deals with the adoption of specific treatment paradigms. Content
analysis was used to systematically identify and record the meaningful data elements,
or semantic entities, that describe these treatment paradigms. The quantitative approach using manifest variables is described below. The approach might be described
as a ‘de-construction analysis’.

Several patterns that obfuscate semantic entities from automated analysis were
detected. Semantic entities were not always delineated within the publication. Some
were only explicitly listed in tables, such as Age, Stage, Radiation Dose. Some semantic
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entities were only identifiable as an instance because it is common to the entire sample
size, e.g., “inflammatory and locally advanced breast cancer” [150] rather than a Stage
Grouping or Tumour-Node-Metastasis (TNM) classification. Other literature related
to a specific scenario where the semantic entity and its value were implied. In these
cases authors of the article had truncated their descriptions based on their expectation
that the audience will have the same background knowledge. For example, an article
describing brachytherapy for prostate cancer [135] in the Radiation Oncology literature
is unlikely to overtly specify several issues:
• that brachytherapy is a radiation procedure as the term is highly specific and inclusive of the concept and has a uniform meaning within the Radiation Oncology
profession (Brachytherapy is “radiotherapy in which the source of irradiation is
placed close to the surface of the body or within a body cavity” 1 )
• that the intent of treatment is curative, as brachytherapy for prostate cancer is
never used as a palliative therapy
• given that all patients in a report will have prostate cancer
In this case, the semantic entities, Radiotherapy, Intent and Diagnosis which can
be derived from the publication by de-construction are all implied, but real, entities.

This process of Content Analysis has not been applied to the elucidation of medical knowledge structures. Its importance rests in its objectivity, where requirements
gathering is subjective. The process has not been validated outside this thesis but is
eminently capable of validation by comparison of extracted and recorded entities.

The focus of my Content Analysis was the identification of the semantic entities
that were stored in a clinical database leading to the generation of the publication.
1

http://dictionary.reference.com/search?q=brachytherapy
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After de-construction identified the semantic entity, cataloguing and classification of
information structures were undertaken. Initially, however, no attempt was made to
catalogue the listings relating to each semantic entity in a taxonomy [32].

4.3.1

The unit of analysis

Quantitative content analysis is based on the ‘unit of analysis’ which has been defined
as representing a single idea or unit of meaning and should be explicit [136]. In this
research, the unit of analysis is defined as the “semantic entity”.

Given that it is common for modern trial specifications to identify and collect
more data than is reported, one may need to determine what an important semantic
entity is. The dilemma is however solved as unreported data do not appear in the
corpus and so can be ignored. The authors of reports make this decision from their
knowledge of the expert domain when submitting their manuscript. Either the unreported items were not analysed, and so should not be reported, or the unreported
items were analysed and failed to reach significance, and so are meaningless. In cases
where the non-significance is a false negative, the first report to demonstrate significance will include the item in its manuscript. The literature is therefore self-correcting.

4.3.2

Semantic Entities

The purpose of analysis is to discover the relevant “semantic entities”, which define
clinical knowledge, which should be stored in a clinical data repository, that is, the
OIS. Content analysis of the literature will look for phrases that demonstrate how the
article’s authors
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• selected the patient group reported (selection criteria)
• defined the patient group reported (definition of patient population)
• described the variety of treatments applied to the patient, where a treatment
modality comparison is being undertaken (such as a report comparing radical
mastectomy with lumpectomy in the local management of early breast cancer)
• described the outcomes observed in the patient (recurrence, survival, side effects).
These groupings fit the notion of ‘evidence-based medicine’ (EBM). This is the application of the literature published about a specific health problem to other patients
who have the same problem. For example, in considering a report from Radiotherapy
& Oncology by Mark Gaze, et al which describes a comparative trial of 10 Gy in
1 fraction of radiotherapy and 22.5 Gy in 5 fractions of radiotherapy, where neither
therapy produced a superior palliative benefit or survival, it is reasonable to expect
that similar patients fitting the same profile (“histologically epithelial or cytologically
proven malignancy of origin, and had one or more bone metastases demonstrated by
plain radiography or skeletal scintigraphy which were causing sufficient pain to merit
radiotherapy to one or two areas”) will be offered the shorter, less resource intensive
treatment [67]. This is not a new concept in knowledge acquisition and application,
and is the basis of modern medical practice.

Radiation Oncology knowledge about a patient at the consultation between radiation oncologist and patient is a large encyclopaedic ‘blob’ which is composed of
the entire history, physical examination and results of all imaging and laboratory
tests. Radiation oncologists routinely subdivide and classify the blob according to
their knowledge structure to make it clinically manageable and useful. When the
knowledge has been sufficiently subdivided into sub-blobs and into pieces of infor-
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mation which can be instantiated by discrete data points, it is available for storage.
These pieces of information have a meaning in isolation as well as a position within
the knowledge acquisition flow and the clinical work flow.

To illustrate, a semantic entity such as Radiation Field Size Width will be instantiated by a number, e.g., “10 cm”. This isolated piece of information and its
data,
Radiation Field Size Width = 10 cm
also possesses meta-data implicitly appreciated by domain experts. In terms of the
flow of knowledge acquisition, this particular semantic entity comes after the semantic
entities of Diagnosis, Stage, Intent and Therapy have already been completed [105].
That is, the radiation field dimensions are not determined until a patient with cancer
has been seen (to determine the Diagnosis and Stage), an application of learning
from the literature has resulted in a treatment decision (Intent) and specific modalities (Therapy) have been selected as most appropriate to achieve the Intent. Similarly,
the Radiation Field Size Width is determined in a specific geographical and work
flow position in the expert domain process, i.e., “Planning”. Planning follows the
other processes of Patient Registration, Consultation with a Radiation Oncologist and
Simulation of the treatment position, and occurs in the Planning Room [107]. Planning occurs before Treatment Delivery and Follow up with a Radiation Oncologist.

Furthermore, the instantiated semantic entity also informs the domain expert that
the area where the tumour is or is likely to be, i.e., the area to be treated, and also
that the tumour must be about 6.6 cm across. The nature of radiation dose deposition
through a beam portal [102] and the movement of target areas in a patient [60, 61, 137]
are part of the expert domain knowledge. It is common for the anatomical targeted
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risk area called the Clinical Target Volume (CTV) to undergo physiological movement
of 1 cm during treatment.The CTV with this motion envelope forms another structure called the Planning Treatment Volume (PTV) [112, 113] . The radiation portal,
or ‘field’, placed around this PTV will require a further 7 mm expansion to account
for the physically determined penumbral area of lower dose at the edge of radiation
portals. So the final 10 cm field will have accounted for a right and left expansion
of 0.7 cm of penumbral margin in addition to an estimated movement envelope (say
1 cm) around the targeted area, meaning the original target area can be no bigger
than 6.6 cm 2 . Therefore if the target area is larger than 6.6 cm, there will be a ‘geographic miss’, that is, some part of the tumour will not be treated adequately [15, 89].

In the process of producing a literature report that is designed to answer a clinical
question, semantic entities are selected as being direct or surrogate measures of the
particular variables pertinent to the question. The report’s author collects and analyses instances of the chosen semantic entities. While the semantic entity that relates to
the data used to construct the literature report may not be identified, it can be derived
from the author’s presentation of the data analysed when constructing the submitted
report.

So in a literature report titled “Evaluating predictive factors for determining enteral nutrition in patients receiving radical radiotherapy for head and neck cancer”
[98], the major semantic entities used measure methods of enteral feeding, the degree
of weight loss and measures of nutrition. A more complete example is provided in
Appendix B (Sample Extraction of Semantic Entities).

2

The usable width of a 10 cm radiation field is reduced by penumbra and movement : 10 cm - (1
cm + 1 cm) - (0.7 cm +0.7 cm) = 6.6 cm
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The semantic entities are units of information and constitute the building blocks of
the knowledge structures of oncology, and are used in medical decision making. The
entities have meta-data which derives from the expert domain and includes information that relates to their position within the knowledge structure, information flow
and clinical work flow.

As a first step this research seeks to catalogue the items that need to be stored,
before imposing any organisation of the storage structure. Thus the research requires
that all data elements to be extracted, be identified by their direct or indirect link to
what may be a specific patient’s problem, that is, relevance is determined by its effect
on patient management.

4.3.3

The Body of Literature

Each year many manuscripts are accepted for publication on the topic of cancer.
Within this cancer-related corpus there are journals that inform cancer groups generally as well as sub-specialty cancer groups (e.g., Medical Oncology, Radiation Oncology, Gynaecological Oncology, Surgical Oncology, Experimental Oncology, Chemotherapeutics, Radiotherapeutic Physics, Psycho-Oncology and professional Oncology groups
like the RANZCR). These journals are of differing quality. Such stratification occurs
in all areas of journal publication [125].

A sample of published manuscripts from the first month of thesis enrolment (February 2006) was selected as the corpus. The PubMed website was searched for relevant manuscripts, and the MedLINE entry for each manuscript was downloaded. A
PDF copy of each manuscript was also obtained. The abstracts were read, and only
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manuscripts pertaining to the clinical management of patients were selected. The
selected manuscripts were broadly grouped into clinical trial and systematic review
of patient treatment outcomes for particular cancers, investigations of prognostic features of the patient or tumour milieu, and lastly, technical issues relating to particular
therapies.

A paper copy of each selected manuscript was produced and the text was analysed to discover semantic entities. The semantic entity was defined as any data entity
manipulated to provide the knowledge presented in the manuscript. For example, if
the manuscript contained a table that reported on the patients’ ages, the semantic
entity contained is Date of Birth. If a manuscript reported the outcomes of surgery
in prostate cancer patients, the semantic entities are Diagnosis and Therapy. The
value of the instance of the semantic entity will be prostate cancer and surgery.

It was also found during the content analysis that some manuscripts contain assumed entities. The domain expert perceived that certain entities are assumed when
the clinical circumstance described permitted only one interpretation. For instance,
the terms denoting that the intent of treatment is ‘cure’ will not be found in articles
describing prostate brachytherapy. Within the expert domain, prostate brachytherapy
is only ever used with the intent of cure, and so authors provide no designation.

4.3.3.1

The Impact of Publication Bias

The reality of negative publication bias has been established [134, 111, 56], however
the impact of this negative publication bias on the content analysis methodology was
assesed as minimal. The content analysis sought to delineate required knowledge
structures from the published literature. A particular knowledge component cannot
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be deemed ‘relevant’ to oncological knowledge until a formal analysis has shown that
it had an impact on clinical outcomes, that is, when it is reported in a positive trial.

This can be demonstrated by an example. If an oncologist were to suspect that patients who were Asian, non-smoking females with adenocarcinoma of the lung seemed
to have a better outcome with different chemotherapy regimens [140], he would construct a null hypothesis, specifically
that there is no difference in progression-free survival when Asian, nonsmoking, female cancer patients with adenocarcinoma of the lung are treated
with chemotherapy regimen A (carboplatin–paclitaxel) or chemotherapy
regimen B (gefitinib)
A formal trial protocol would be written to describe the entry of Asian, nonsmoking, female cancer patients with adenocarcinoma of the lung into the process of
random allocation to one of the two chemotherapy regimes. After a time a formal
analysis the results with respect to progression-free survival would be undertaken.

The results might demonstrate either of the two following scenarios:
• Asian, non-smoking, female cancer patients with adenocarcinoma of the lung
receiving carboplatin-paclitaxel had a progression-free survival of 6.7% at 12
months, and those receiving gefitinib had a progression-free survival of 6.7%
at 12 months ...... then I could conclude that the patient group (Asian, nonsmoking, female cancer patient with adenocarcinoma of the lung) does not have
any oncological significance, and so is not something that oncologists need to
know about. It is not in the expert domain knowledge base precisely BECAUSE
its occurrence does not affect patient outcomes.
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• Asian, non-smoking, female cancer patients with adenocarcinoma of the lung
receiving carboplatin-paclitaxel had a progression-free survival of 6.7% at 12
months, and those receiving gefitinib had a progression-free survival of 24.9%
at 12 months ...... then I could conclude that the patient group (Asian, nonsmoking, female cancer patient with adenocarcinoma of the lung) does have any
oncological significance, and so is something that oncologists need to know about.
It is in the expert domain knowledge base precisely BECAUSE its occurrence
does affect patient outcomes.
The trial was undertaken and the second outcome demonstrated [108]. As a result,
the knowledge of the impact of gefitinib on the survival of Asian, non-smoking, female
cancer patients with adenocarcinoma of the lung is widespread. and the treatment of
choice is gefitinib.

This example does not make the case that negative trials are not useful in oncology.
Negative trials are useful demonstrating what is not oncological knowledge. However
when attempting to determine the semantic entities that need to be represented in the
expert domain knowledge structure, those trials do not add useful semantic entities.

The preposition for this research is that the required semantic entities, that is,
those that are positively significant in impacting on clinical management of patients
and therefore which need to be measured and recorded in an OIS, will be published
in the Radiation Oncology literature, and that the semantic entities of negative trials
therefore do not need to be delineated. In this research no differentiation was undertaken to classify trials as ’positive’ or ’negative’.

4.3. Content Analysis

4.3.3.2

64

The Body of Literature for Analysis

Having settled on a research approach, the issue of the sample size became relevant.
Prior knowledge of the published literature from training in Radiation Oncology points
to a range of different clinical publication types covering several categories (such as retrospective review, randomised trial, prognostication, Quality of Life) but with broadly
similar reporting criteria in each. Therefore the initial expectation was that commonly used semantic entities would be quickly recognised, and that these entities
might already be adequately dealt with by an existing OIS. Uncommonly used semantic entities were of more interest, as these semantic entities are likely to reveal
deficiencies of the data structures incorporated into a current OIS. Where new semantic entities are found, the expansion of the OIS to include these new entities can be
assessed. Infrequent semantic entities are more likely to point the way to emerging
and future requirements of the OIS. Furthermore, idiosyncratic semantic entities for
a particular cancer could enable the completeness of coverage of the OIS to be assessed.

Initially the medical literature catalogue (MEDLINE) produced by the National Library of Medicine in the USA, which is available on-line through the PubMed portal3 ,
was accessed to assess the magnitude of the available data that could be assessed. A
search was undertaken on 18th May 2006 with the general pattern “Xxxxx”[MeSH
Major Topic] AND 200Y/MM[pdat]. Multiple searches were undertaken substituting different values. Firstly, “Xxxxx ” was substituted with NEOPLASM, Radiotherapy or Medical Informatics. Then 200Y was substituted with 2004, 2005 or 2006.
Finally MM which represented the month in numerical format (01-12) was substituted
with 01 (where 01 = January, 02 = February, etc). The average number of published
manuscripts per month were 5584 (NEOPLASM), 184 (Radiotherapy) and 669 (Med3

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
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ical Informatics).

The results of these searches are graphed in Figure 1. This small analysis indicates
that to avoid non-representative periods, a minimum 6 month lag is required from the
publication of a manuscript for the catalogue to become complete, and that the month
of February contains a similar or greater number of manuscripts as other months.
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Figure 4.1 Selecting the Sample

An initial trial of semantic entity coding established the expectation that an average of 6-8 unique entities will be discovered in each article, and that a total of 900-1200
entities might be reasonable sample. With this assumption in mind, the first month of
the research, February 2006 was selected and a PubMed search (‘‘Radiotherapy’’
[MESH Major Topic] AND 2006/02[pdat]) was undertaken. This search produced
167 results [21/2/2011]. In addition to, and including these results, a search was undertaken of the specialist Radiation Oncology, and general Oncology literature where
all articles were selected for review (Table 4.1 & 4.2). In addition, the popular general
medical literature was screened for articles relating to Radiation Oncology (Table 4.3).

The literature utilised excluded articles that were devoid of patient data, as these
reports were not germane to the problems of clinical knowledge structure definition.
In addition reviews and basic science articles that addressed issues such as onco-
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genes using in vitro methods without patient selection were excluded. The sample
of manuscripts remaining after filtering numbered 121 and is listed in Appendix C
(Radiation Oncology Literature Corpus).

Table 4.1: Specialist Radiation Oncology journals
Journals reviewed
Australasian Radiology
International Journal of Radiation Oncology, Biology, Physics
Radiotherapy and Oncology
Clinical Oncology (R Coll Radiol)
Radiation Research
British Journal of Cancer

pISSN
0004-8461
0360-3016
0167-8140
0936-6555
0033-7587
0007-0920

Table 4.2: General Oncology journals
Journals reviewed
Journal of Clinical Oncology
Cancer
Annals of Oncology
International Journal of Cancer
Cancer Research
Cancer Treatment and Research

4.3.3.3

pISSN
0732-183X
0008-543X
0923-7534
0020-7136
0008-5472
0927-3042

The Advantage of a Manual Method

As with all empirical investigations, researchers should be careful to provide a definition that ensures the reproducibility of the methodology and results. In the future it
is hoped that the use of automated technologies, such as automated content analysis
and Natural Language Processing, could be applied to this end, as has occurred in
literature and radiology reports [33, 50, 66, 154].
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Table 4.3: General medical journals
Journals reviewed
British Medical Journal
The Lancet
New England Journal of Medicine
Medical Journal of Australia
Australian and New Zealand Journal of Medicine
Australian and New Zealand Journal of Surgery

pISSN
0007-1447
0140-6736
0028-4793
0025-729X
0004-8291
0004-8682

In these endeavours, the accuracy of current data extraction technique has not been
shown to be mature enough to replace a manual method. It is therefore unavoidable
that initially the domain expert is required for content analysis. The manual analysis
will then take on the status of the ‘gold standard’ against which to benchmark the
ability of any software approaches.

4.3.3.4

External Validity

The external validity of this methodology and approach resides in the breadth of its
sample, and its ability to be repeated. Clinical data needs evolve quickly [47], so the
ability to be re-used at intervals will ascertain the inevitable changing data needs of
the oncology community.

Just as asking clinicians how they work and what they want in a GUI interface can
and should inform the design and construction process of the software, the emerging
data needs of the profession expressed in the literature can forewarn software providers
of the need to alter their software to meet new challenges.

Chapter 5
Results
5.1

Collection of Semantic Entities

The journals listed were accessed for the relevant months, and the relevant articles
printed. While reading, the semantic entities discovered were highlighted in the text
and recorded on a grading sheet (Appendix D – Data Collection Sheet). Where implicit semantic entities were detected, the same process was followed.

A list of semantic entities discovered in the surveyed articles is provided (Appendix
E – Semantic entities discovered from manuscript corpus). In addition to explicit and
implicit semantic entities discovered, associated semantic entities which were not found
were added later. For example, while entities relating to demographics are present
(Date of Birth, Race, Gender at Birth), other entities such as Place of Birth,
Mother and Father which are suggested by the entities found, were not discovered.
Given that manuscripts are usually summaries of patient groups, the absence of such
identifiers is expected. Appendix E does not include these suggested entities, but they
are included in Appendix I and following where the entity list is manipulated. All the
semantic entities were entered into a spreadsheet.
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Metrics of Semantic Entities

The data collection found 3290 instances of 768 discrete semantic entities in 109 clinically relevant manuscripts. Metrics describing these semantic entities are provided in
Table 5.1.
Table 5.1: Frequency of occurrence of semantic entities
Frequency of
occurrence

Individual
semantic
entities (n)

Total Number
of occurrences
(sum)

% of semantic entities

% of
rences

1–5
6 – 10
11 – 15
16 – 20
21 – 25
26 – 30
31 – 35
36 – 40
41 – 45
46 – 50
51 – 55
56 – 60
61 – 65
66 – 70
71 – 75
76 – 80
81 – 85
86 – 90
TOTAL

641
55
28
10
9
4
3
4
4
3
2
2
1
1
0
0
0
1
768

1005
418
368
183
205
111
99
150
171
145
102
113
65
70
0
0
0
86
3290

83.46
7.16
3.65
1.30
1.17
0.52
0.39
0.52
0.52
0.39
0.26
0.26
0.13
0.13
0.00
0.00
0.00
0.13
100.0

30.55
12.71
11.19
5.56
6.23
3.37
3.01
4.56
5.20
4.41
3.10
3.43
1.98
2.13
0.00
0.00
0.00
2.61
100.0

occur-

The first graph (Figure 5.1) demonstrates the incidence of semantic entities as a
proportion of entities and of occurrences.
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Figure 5.1 Proportions of Semantic Entities (all)

A second graph (Figure 5.2) is provided to better view the detail by excluding the
large number of entities in the 1-5 occurrence band.

Figure 5.2 Proportions of Semantic Entities (> 6)
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Published manuscripts contain many semantic entities. The most frequent entity was Diagnosis in 86 of the 109 manuscripts (n=86, 78.9%). There were only
4 entities that were used in more than 50% of the manuscripts – Date of Birth
(n=70, 64.2%), Histology (n=65, 59.6%), Surgery Decision (n=56, 51.4%), and
Radiation Decision (n=57, 52.3%). Other frequent entities included Stage N (n=36),
Prescription DrugName (n=37), Immunotherapy Decision (n=37), Stage T (n=41),
Radiation Prescription Technique (n=40), Stage Grouping (n=49), Chemotherapy Decision (n=44), Histopathological Confirmation (n=44), Stage M (n=42),
Surgery Procedure (n=47), Radiation Prescription TotalDose (n=49), Gender at Birth (n=51), and Date of Death (n=51). These 17 most common items
provided 27.4% (902/3290) of the total number of instances.

Analysis of the frequency of appearance of semantic entities revealed that the infrequent items were numerous, and that the frequent items were few in number. The
entities which appeared on only 1-5 occasions were numerous (83.46% of the total
number of semantic entities) but infrequent (30.55% of the total number of instances)
were described as uncommon. However the entities which appeared on 6 or more occasions were uncommon (16.54% of the total number of semantic entities) but frequently
seen (69.48% of the total number of instances) and so were described as common. In
fact of the 768 entity total, there were 458 different entities appearing just once, but
these comprise only 13.9% (458/3290) of the total instances found. The difference is
clear (Figure 5.3).

As will be described later, many semantic entities are related. Where radiotherapy
is described in a manuscript, a single term may be used, e.g., Radiation Decision
(57), and Radiation Prescription Technique (40), and Prescription TotalDose
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(49), however if a manuscript describes one of these, the others can all be implied since
a radiotherapy technique, by virtue of the expert domain imperatives, will also have
a total dose and a therapy decision. When all radiation-related entities are grouped,
75 manuscripts (68.8%) included at least one radiation term. The listing of terms in
Appendix E reveals that the entities found at least 4 times are all used in routine
clinical practice.

Figure 5.3 Frequency of Common and Uncommon entities

Inferred semantic entities were common. The commonest inferred entity was date
of event which was used to construct all outcome measures relating to time. When
an entity such as ‘event-free survival’ (proportion of patients reaching a fixed interval without a recurrence event) is common, it is calculated within the KaplanMeier statistic [87] using the Date of Diagnosis and Date of Local Recurrence,
Regional Recurrence, Distant Recurrence or Death. The manuscript will rarely
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list all four dates as the calculation method is well known and widely used.

5.3

Organising the Semantic Entities

The listing provided in Appendix E is of little use. The list describes a small portion of
the items that could be required in an OIS. It is likely that the next month will see the
same pattern with the same group of a small number of entities often repeated, and a
plethora of once-used items. The implications for OIS software design and assessment
are that the common elements must be handled well, while the infrequent elements
can be handled with a functionality that is infinitely expansible. Discovering whether
any OIS can store all these individual items is less important than seeing the items
properly stored.

If the semantic entities collected reflect a domain-specific knowledge structure, an
adequate OIS should address the knowledge structure. While the specialist medical
vocabulary has not been described, neither has the knowledge structure.

There are many ways that semantic entities could be grouped, perhaps as many
ways as there are domain experts. However, groupings should be comfortable, match
existing categories and offer some hope of agreement among experts. The grouping
should be deliberate and reasonable during construction, since agreement among domain experts is more important than a close proximity metric.

Radiation Oncology as an expert domain has a well defined work flow pattern [107],
which also extends into clinical trials and clinical guidelines, such that semantic entities
are not randomly distributed in the work flow and have an upstream and downstream
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dependence. This has already been demonstrated earlier using the domain specific
entity, Radiation Field Size Width.

The benefit of organisation of entities in line with the work flow used will lead to
a reduction in the barriers to orchestration of work flow [34]. This grouping according
to clinical activity may provide unforeseen benefits in cost management after business
process modeling [6], and also permit improved re-use of data from work flow [75].

The entered data elements were grouped to reflect their order of collection within
the clinical work flow. While this grouping may not be optimal, it is based on a tangible organisation model, and so should be less controversial and also easy to reproduce.

Based on the work flow orchestration described elsewhere [107, 105], the following
areas are separated:

1. REGISTRATION
(a) SPECIFICATION OF ANY ORGANISATION PROVIDING HEALTHCARE
i. all elements describing organisational entities involved in care provision.
This may be a specific departmental site, an academic or professional
organisation, as well as economic entities, and local, regional and national Ethics and Trial infrastructure
(b) DEMOGRAPHICS OF PATIENT
i. demographic items collected as part of the Registration process
ii. patient’s characteristics that permit comparison with populations, in-
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cluding race, age, income, mobility, educational attainment, home ownership, employment status, and location
2. CONSULTATION
(a) INDIVIDUAL CHARACTERISTICS OF PATIENT
items discovered or measured at any part of the clinical process that define
an individual’s milieu. These may pre-date or post-date the malignant
diagnosis
i. BIOLOGICAL MILIEU
A. measurement of biological variables (anatomical, physiological, endocrinological, genetic, genomic)
B. factors that may have proven or unproven significance in affecting
therapy selection and efficacy
ii. PSYCHOLOGICAL MILIEU
A. measurement of psychological parameters purported to reflect a
patient’s state of mind and quality of life
(b) CLINICAL HISTORY OF CANCER
i. the information gained by asking specific questions, either of the patient or of other people who know the person to give suitable historical
information (symptoms)
ii. the information gained by suitable physical examination of the patient
by a physician (signs)
iii. the search for factors already established to have significance in disease
outcome, therapy selection and efficacy (prognostic factors)
(c) INVESTIGATION OF CANCER
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i. information gained by imaging, or analysis of tissue and fluid samples
for tumour markers which was prompted by the clinical history disclosed to a physician
(d) DIAGNOSIS & STAGING OF CANCER
i. collation of the clinical history and application of standardized coding to define the nature and extent of the patient’s disease including
histopathology (including cytology and immunohistochemistry), laterality, and tumour grade.
(e) DECISIONS REGARDING TREATMENT OF CANCER
i. specification of the intent of treatment
ii. specification of the modalities of therapy to be applied
iii. indication of inclusion in a formal trial or use of published guideline
3. THERAPY
(a) SPECIFIC PARAMETERS OF THERAPIES USED
i. details that describe the conduct of the therapies used
A. preparation for delivery of the therapy
B. delivery of the therapy
(b) SIDE EFFECTS OF THERAPIES USED
i. subsequent additional Clinical History (i.e., signs and symptoms) that
specifically result from the administered therapies
4. FOLLOW UP
(a) OUTCOMES OF CANCER TREATMENTS
i. descriptions of the time course of a patient’s disease
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ii. descriptions of the time course of a patient’s late side effects
When looking at the data predating but associated with the original cancer diagnosis, there will be symptoms described by the patient, signs elicited by the doctor as
well as subsequent imaging and laboratory tests which inform the diagnosis. Previous
work has already demonstrated that these logical links between the diagnosis and prediagnosis findings can be utilised for decision making [123].

Formal validated classification of semantic entities and their groupings is preferred
and should be undertaken within a validation framework. The issue of physiological
factors within the Physiological Milieu of the patient should match already developed
knowledge structures. Matching the anatomical names and organisation to an ontology such as the Foundational Model of Anatomy makes sense. In much the same way
that all oncologists could expect a harmony between an Ontology of Surgical Oncology
and this Ontology of Radiation Oncology.

The attempts to devise Medical Ontologies encompassing all medicine have proved
cumbersome that has dulled their usefulness [121]. The medical expert domain does
have well recognised silos where idiosyncratic knowledge structures reside. A process
that addresses these silos but has an underlying structure to integrate these efforts is
needed.

5.4. Clinical Knowledge Markup Language (CKML)
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Clinical Knowledge Markup Language (CKML)

5.4.1

Re-factoring the Semantic Entity Groups

The semantic entities were grouped according to the framework presented in Section 5.3. It is evident that there is overlap between some groups such as Biological/Psychological Factors and Clinical History. The symptoms of cancer before diagnosis may lead to psychological distress which only later may be imputed to the
cancer. Similarly, a patient may complete treatment, be physically normal yet still
remain anxious thinking about whether the cancer may return.

The unstructured grouping of semantic entities is listed according to frequency in
Appendix E. This listing of semantic entities, with added additional terms that were
obvious additions within the broadly grouped semantic entities, was then organised
into the oncology work flow. This organisation is not exhaustive, rather it demonstrates what can be achieved.

The work flow within the Radiotherapy component was matched to that described
by Ford et al [64], and the subsequent personal communication that followed (Appendix
F – Johns Hopkins Hospital Radiotherapy Work flow). In that work flow there are
five action points for radiation oncologists:
1. Deciding to treat
This action point is firmly based on the completion of activities directed to
specify the disease type and extent. Until the specification is deemed complete,
no decision is reached or recommendation provided, and while options may be
discussed, no decision on the recommendation can be reached.
2. Obtaining consent
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This represents a flexure point in the medical management of the patient. Once
informed of issues relating to prognosis with and without treatment and a recommendation is formulated, the patient needs to select their treatment and inform
the clinician that they consent to the treatment.
3. Specifying the radiation prescription
The radiation prescription contains details of the site being treated, the dose
to be delivered, the beam type and energy to be used, the number of fractions
over which to deliver the dose, the prescription point (i.e., the 3D point inside
the patient which will get that absolute dose), the patient position, numbers of
days per week to be treated. These parameters can be specified as part of the
DICOM protocols.
4. Drawing the volumes and contours on a planning CT scan
The radiation plan utilises a CT scan on which the oncologist draws contours
to highlight normal anatomy which is at risk of radiation damage, and volumes
which delineate the areas at risk from the cancer. These are then expanded to
give some idea of the likely movement which will occur during treatment. The
radiation therapist (also called a “dosimetrist”) undertakes an iterative process
of placing radiation portals to aim at the structures defined by the oncologist,
altering beam numbers, intensity, beam energy and beam modifiers until a plan
is achieved that meets the oncologists expressed parameters of dose to the areas
at risk of cancer and the areas sensitive to radiation. The review process to
determine acceptability of a radiation plan requires that the oncologist look at
the structures previously drawn, and then to overlay predicted dose delivery. A
plan is acceptable where dose to the cancer volumes is high enough, and dose to
the critical contours is low enough. These parameters can be specified as part of
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the DICOM protocols.
5. Accepting a completed radiation plan
The radiation beam parameters used in the approved radiation plan are then
transferred to the Record & Verify system for use when the patient is treated.
These parameters can be specified as part of the DICOM protocols. These decision points are highlighted in pink. The other work flow actions are undertaken
by clerical staff, radiation therapists, radiation physicists and radiation nurses.

5.4.2

Developing an XML specification

The grouped semantic entities are further sub-grouped according to commonality.
Much of this commonality knowledge resides in the expert domain and has not been
quantified academically. As the eventual aim is to have medical knowledge in an interchangeable format, the semantic entities were converted into a permissive format.

The Standard Generalised Markup Language (SGML) has been developed for such
a purpose of describing the structure present in information within human readable
format. There are several specifications relating to special circumstances derived from
SGML including hypertext markup language (HTML), extensible markup language
(XML), and even a specifically designed medical markup language (MML) [16]. The
purpose of all SGML-based specifications is preparation for computational processing.
The XML specification is particularly useful for ad hoc description of structured data.
Specifying the semantic entities in an XML format is a necessary step in preparing the
semantic entities for general use. Wide scale deployment would require the description
of an XML Namespace and detailed dictionary, but this is outside the scope of this
work.
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The XML terms are derived locally without reference to any Standardised Nomenclature, although SNOMED-CT or the UMLS would be possible reference sources
[10, 144, 115, 122, 148], the accumulation of multiple terms makes correct choice difficult. Many of the terms used in the Radiotherapy section will have a pre-existing
DICOM-RT tag name, but no attempt is made to correlate these in this work. Likewise the taxonomy of terms relating to Histopathology are only referenced as these
are already organised in SNOMED1 and elsewhere [32]. Similarly the classifications of
malignant diseases within ICD102 , of late radiation effects (LENT/SOMA)3 , of cancer therapy side effects (NCI CTCAE v4)4 and the organisation of anatomical terms
within the Foundational Model of Anatomy [85] can be re-used.

Radiation Oncology departments utilise the DICOM-RT format to save radiation
plans. The DICOM–RT nomenclature [19, 20, 18, 17, 21, 23, 22] describes the nonmedical facets of radiation therapy and its delivery and recording. The only entries
from the medical domain experts recorded in the DICOM-RT files are the radiation
prescription and radiation target volumes provided by the radiation oncologist. The
DICOM-RT nomenclature was not derived from the Radiation Oncology expert domain but rather from domain experts from Radiation Therapy, Radiation Dosimetry
and Radiation Physics. The DICOM and XML formats are interchangeable which
raises the possibility of storing a cancer patient’s medical data inside a DICOM container. However, at present, few DICOM-RT files contain the patient’s medical data
in a structured format.

The hand-crafted XML Specification described in the following sections is called
1

http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html
http://www.who.int/classifications/icd/en/
3
LENT SOMA tables. Radiother Oncol 1995;35:1760
4
http://evs.nci.nih.gov/ftp1/CTCAE/About.html
2
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a “Clinical Knowledge Markup Language” (CKML). The new title is necessitated by
the imposition of the XML specification back into the expert domain to demonstrate
its usefulness and applicability. As some efforts have shown that general statistical
prediction of survival in cancer is inferior to specifically designed artificial neural nets
[2], the specification of cancer cases in a semantically sound structure might lead to
even greater success. The specification can produce high quality medical information
[12] which also removes the need to undertake data mining through natural language
processing. Even when analysing histopathology reports from cancer cases, the less
than perfect accuracy of multiple language processing approaches does not meet the
criteria for outcome reports [49]. Specification of reports and letters directly into
structured formats will be more accurate than any post-processing techniques. Many
authors point to the possibilities that arise if the medical knowledge present in free
text were actually formally structured[32].

The basic XML structure for semantic entities is listed in Appendix I (The CKML
superstructure).

5.4.3

Producing an Ontology from the XML Specification

While the XML specification derived provides “annotated text with important information about objects and their structures, thus concepts for the ontology to build”
[29], the definition of concepts, properties and relationships in a formal ontology is
outside the Radiation Oncology expert domain and outside the scope of this thesis.

Instead the XML specification in Appendix I which covers the commonly used
concepts and relationships in the field is used to demonstrate that this simplified view
has applicability within the domain [29] as a clinical knowledge markup language.

5.5. Evaluation of CKML and future applications
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Evaluation of CKML and future applications

Whether clinical data is specified in plain text or an XML schema is not a trivial
issue for informaticians or clinicians. There are reports of substantial academic energy expended trying to manipulate plain clinical text into useful schemata [103, 53].
Clinical data specified into XML formats can be used for many things [3], including
the important integration of routine clinical data with genomic, proteomic, lipidomic
or metabolomic bioinformatic data [13]. Furthermore, when coding is undertaken directly in electronic systems, it is usually very accurate [147].

If the Clinical Knowledge Markup Language (CKML) described in Appendix I has
any relevance to the expert domain, it will be applicable to the requirements of several domain specific knowledge areas relating to the clinical management of patients.
Discovering these knowledge areas occupies a significant focus for informatics energy
attempting to extract knowledge structures and ontologies from plain text.

The development of clinical knowledge in the Radiation Oncology expert domain
occurs in discrete steps:
• Specific application of current knowledge to an oncology patient (Routine Clinical Work). Current knowledge is deficient, and so arising from the management
of routine patients are clinical questions that seek to improve patient outcomes.
These clinical questions become new research questions which are answered using
the paradigm of the clinical trial.
• Systematic regimented accrual of patient information in the setting of a comparison of therapies to answer clinical questions (Clinical Trials)
• Reporting of the conclusions of clinical trials (Clinical Trial Reporting)
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• Generalized application of knowledge to the oncological population (Clinical
Guidelines)
• Specific application of ‘new’ current knowledge to an oncology patient (Routine
Clinical Work). The new current knowledge is less deficient, and so arising
from the management of routine patients are new clinical questions that seek
to improve patient outcomes. The use of newly discovered knowledge ‘closes
the loop’ in an iterative cycle of knowledge generation to produce a continually
changing knowledge domain.
This iterative loops describes the usual pattern of knowledge advancement. Examination of current data is a fundamental component that directs clinical trial activity.
Retrospective review of current data can point to where clinical trials are not needed,
or where the clinical trial budget is best applied. Advancement by serendipitous breakthrough is less common.

If the CKML is a correct representation of the clinical knowledge of the expert
domain, it should be able to function adequately with little modification in these four
settings, both in the development of software [4] and the use of that software. This
could drive data entry directly into ontological frameworks and facilitate re-use.

Achieving the interchangeability of natural language and structured text has been
difficult. While informaticians are able to manipulate and re-use structured text, clinicians are resistant to moving away from natural language. CKML could be demonstrated to be relevant by taking plain oncological text and using natural language
processing techniques to generate structured text consistent with the format. While
this approach does not disturb the domain expert’s work flow, prior work indicates
that inaccurate structured text will be produced. However, the resultant structured
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text remains obscure to the domain expert who is unfamiliar with the format of structured text and so reliable checking may be unachievable.

An alternate approach is to record data directly into the CKML format, from
which can be produced plain text that the domain expert can validate as correct. The
validity of CKML as a domain knowledge representation would then be demonstrated
to the informatician. The domain expert may also see the value of entry of data into
sympathetically structured text.

Studies to demonstrate the validity of this approach are not within the scope of this
thesis. Initially the ability of CKML to store knowledge from clinical settings should
be demonstrated. The remainder of this chapter will address this issue within a specific
oncological circumstance using the CKML structure shown in Appendix I. Within the
CKML structure is the requirement to select either <Trial>, <Report>, <Patient>
or <Guideline> depending on the item to be represented. The Clinical Trial Protocol
and Report differ in the addition of a trial outcome section along with summary items
which include counts detailing numbers of patients included and randomised, as well
as numbers receiving treatment and the characteristics of the randomised groups.

5.5.1

Oropharyngeal Cancer

The preceding discussion that predicts that a specification such as CKML has relevance
in describing radiation oncology knowledge structures and advantages in translating
its use to normal clinical practice can be demonstrated with an example. For this purpose, one disease site was chosen from within the interest area of the researcher, from
which was selected a patient, a relevant trial, the relevant trial’s published manuscript
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and current guidelines to illustrate the commonality of markup structure.

Cancers of the Head and Neck (H&N) region are not particularly numerous but well
recognised as requiring complex treatment in the form of combinations of radiotherapy, chemotherapy, immunotherapy and surgery. The patients who suffer this disease
are often quite unhealthy and unwell. Within the H&N region there are areas like
the oral cavity and oropharynx which have several sub-sites with very similar natural
history and treatment paradigms.

The base of tongue is a sub-site of the oropharynx and has been chosen as the index
site. A patient who was diagnosed with and treated for a locally advanced squamous
cell carcinoma of the base of tongue was chosen. Although written permission had
already been provided to re-use of anonymous data, a personal approach met with
agreement to use the clinical data. A search was also undertaken for an Australian
clinical trial protocol for which this patient would have been eligible. The TransTasman Radiation Oncology Group (TROG) had such a trial, called “HeadSTART”
and designated TROG02.02, which enrolled patients similar to the clinical case. Furthermore, this trial has matured and was reported in mid-2010, so the clinical trial
report was available. Lastly, a search was made for clinical guidelines recommending treatment for locally advanced oropharyngeal cancers. Three such guidelines were
found originating from the USA (National Comprehensive Cancer Network - NCCN),
Canada (British Columbia Cancer Agency - BCCA) and the UK (Scottish Intercollegiate Guideline Network - SIGN).

All of these documents are provided in the following appendices - the TROG02.02
clinical trial protocol (Appendix L), the TROG02.02 report published in the Journal of
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Clinical Oncology in 2010 (Appendix M), and the relevant guidelines from the NCCN
(Appendix Q), SIGN (Appendix P) and the BCCA (Appendix O).

5.5.2

CKML subset for Routine Clinical Data

For the purposes of defining a clinical record in the CKML structure, the clinical
record of the patient was accessed and specific entities were entered into the CKML
structure. A summary of the patient’s clinical history is provided in Appendix J,
with the relevant semantic entities in bold for comparison with the CKML produced.
All unused elements, such as <Trial>, were removed. Items that are appropriate as
instances are also included. The original clinical data has not been provided but is
available on request.

It is clear from the CKML structure imposed on the clinical data that the criteria
describing the patient, the treatment and the outcome are now explicit. The implications of a knowledge structure based firmly in work flow was appreciated early, and
further investigations were undertaken to determine the viability of these implications.
It was appreciated that software processes such as agents could determine whether the
patient was eligible for a clinical trial or guideline by searching for relevant parameters.
For example, any circumstance where the patient’s clinical record contains the data,
<ICD0>C01</ICD0>, it is possible to query to discover whether there exist trial protocols, trial reports or guidelines applicable to the disease “C01” categorised according
to ICD-10 classification. However natural language terms such as tongue, BOT, or
posterior tongue might not be accurately appreciated as “base of tongue” which is a
well defined anatomical subdivision of the tongue and distinct from lateral tongue.
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Since contextual searching within the CKML is feasible, there are now many further
uses for the data. During the course of the thesis, several applications of knowledge
structured in a CKML format have been explored and published, and are described
below. Many other applications exist.

5.5.2.1

Relevance of Routine Clinical Data to Clinical Trials

The trial, report and guideline are all tools used to aid the domain expert in either
the application of existing knowledge, or the discovery of new knowledge. The trial
seeks to discover new knowledge but can only do so by including patients with specific
inclusion criteria and without specific exclusion criteria which are derived from the
cancer description or facets of the patient’s condition (e.g., <BiologicalMilieu> or
<Demographics> (see Appendix L – Section 4: SELECTION OF PATIENTS).

Trials seek to maintain a homogeneous sample population. However, detecting eligible patients matching these long lists of eligibility criteria is problematic. The use
of a software agent that compares the patient’s data with the selection criteria could
increase the accrual rate of patients into trials through accurate identification [107].
These software agents provide optimal efficiency when dealing with a formalised structure that describes the patient data, rather than plain text requiring natural language
processing.

5.5.2.2

Relevance of Routine Clinical Data to detect Co-Incident Clinical
Processes

Once a treatment or trial has been selected for a patient, the knowledge specification
will contain a description of the clinical treatment processes that have been selected.

5.5. Evaluation of CKML and future applications

90

Given that other medical expert domains might use a similar structure to prescribe
therapy, this information is then available for the detection of other co-incident, and
clashing clinical processes planned for the patient that may be already ongoing or
planned [75]. Detection of conflicts between different treatment regimes can reduce
the scope for medical misadventure.

5.5.2.3

Relevance of Routine Clinical Data to Treatment Scheduling

The decision to treat requires detailed knowledge of the patient’s clinical data. At the
point when this is defined, even if outside the oncology department, the treatment to
be deployed as part of the treatment plan can be predicted from a detailed guideline
similar to those provided by the NCCN (Appendix Q). Since the treatment requires
radiotherapy, an appointment with a radiation oncologist is necessary, as are appointments for simulation and treatment. This is predictable from the normal radiotherapy
work flow (Appendix F). Planning these component results in a schedule. Using techniques such as support-based distributed optimisation (SBDO), it is possible to use
agents which access the knowledge structure to improve the efficiency of scheduling
[35], perhaps even balance oncology workload across regions.

5.5.2.4

Relevance of Routine Clinical Data to Argumentation and Clinical
Decision Support

The inclusion of patients into clinical trials, and the application of trial results and
guidelines to a patient’s management requires a decision making process resembling
formal Argumentation. The patient’s clinical parameters form the arguments which
can be used to establish an acceptable treatment approach for a patient [45].
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When all the possible knowledge sources - clinical trials, reports and guidelines are
presented in the same formal structure, the clinical decision making process can be
augmented as once again the patient characteristics serve as the base against which
to select the relevant available trials, published reports and guidelines. The selected
reports and guidelines can serve to inform the clinician about the best reported and
recommended treatments, and likely outcomes. The recommended trials present the
clinician with options for consideration if they believe that therapy outcomes can be
improved with respect to cure or side effects. The end of the process of Argumentation is to present the clinician with the results of the automated decision making.
The identification and incorporation of experience and other parameters that modify
decision making become possible once the knowledge application has been explicitly
argued.

The rapid application of trials would also permit more rapid accumulation of patients. More patients would allow oncological knowledge to advance faster (faster
accrual of required numbers, more trials in different homogeneous groups) and with
greater certainty (large trials with more numbers become feasible).

This use has already been investigated and proposed, and from an informatics perspective is already achievable. The formal knowledge structures are lacking.

5.5.3

CKML subset for Clinical Trial Protocols

The clinical trial process has several components. There are front-loaded components
outside of the clinical work flow that deal with the development and production of
the clinical trial protocol, the introduction and coordination of the trial in a clinical
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environment, and the monitoring of accrued data. There are back-loaded components
outside the clinical work flow that are responsible for the collation, analysis and reporting of the trial results. The actual trial however is a normal but constrained
treatment delivery process operating within the normal clinic environment to match
the specifications of the trial protocol [11, 107].

This subset of CKML describes the trial protocol specifying the inclusion and exclusion criteria, the randomised therapies to be applied and the outcomes which will
be measured and calculated. This CKML trial protocol specification can be automatically matched to the CKML patient description thereby permitting the determination
of whether the patient is eligible for the trial protocol and therefore possible inclusion
in the specified trial. A comparison of the two specifications should reveal that the
patient specification has a discrete value, while the trial specification may have a range
of acceptable values.

A patient enters a clinical trial when they satisfy the inclusion criteria and possess none of the exclusion criteria used for sample selection within the trial protocol,
and provide informed consent. After randomisation, a pre-determined treatment with
constrained parameters not open to alteration by treating clinicians is prescribed and
administered. The follow up intervals and medical assessments undertaken are specified. At each point, required clinical data is entered onto and submitted by Case
Report Forms (CRFs).

An example of a Clinical Trial Protocol is provided in Appendix K. The unused
elements are removed. The position of the inclusion and exclusion criteria mirrors
their position in the patient’s record. In particular there is a specification of inclu-
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sion/exclusion criteria in <Demographics>, <BiologicalMilieu>, <Diagnosis> and
<Stage> to name the more frequently used. The treatments to be used are also
specified in the same way as the clinical record, which allows the selected treatment
approach to be templated into the patient’s treatment record, including follow up assessments.

5.5.4

CKML subset for Clinical Trial Report

The abstract is a plain text mechanism for providing a synopsis of a lengthy literature
report so that the reader can establish relevance without having to needlessly read all
of the text. There are few rules governing its construction and structure with subsequent effects of retrieval [118]. The abstract has been the subject of natural language
processing techniques exploring easier ways to establishing ontologies than asking the
domain expert [30].

The Clinical Trial Protocol and the Clinical Trial Report are closely related when
confined to the clinical processes and outcomes defined. The difference relates to numbers of patients, and trial outcomes (levels of side effects, survival rates). The need
to quantify these outcomes were the raison d’etre for the trial (resulting in the generation of the Clinical Trial Protocol) and the conclusion of the trial (resulting in the
generation of the Clinical Trial Report).

While the desire to use natural language processing (NLP) and ontologies to extract
knowledge [37] is laudable, if the Clinical Trial Protocol is specified in an ontologybased framework like CKML by the domain expert, the generation of the Clinical Trial
Report only requires the addition of outcome and survival rates by the domain expert
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as they relate to randomised arms and the treated group. Essentially the Clinical Trial
Protocol specification is reused. If a plain language summary is required, this could
be automatically generated. However the use of the abstract is a way of assessing
whether the trial details are applicable to a particular case.

The CKML specification for a case can be used as a filter for trial reports, looking
for those applicable to a specific patient in essence determining if the patient could
have entered the trial subsequently reported. The Clinical Trial Report can be reused
to match to future patients, which would inform clinicians of evidence appropriate to
the present patient, hopefully improving clinical decision making [142].

The Clinical Trial Protocol provided in Appendix K includes the material reported
in the Clinical Trial Report that resulted from the protocol used . This process has
the advantage that the clinical specification of the treatment that produced the results
published is included in the Trial Report. In addition, since the selection criteria for
patients entering the trial remain intact, the report can continue to function as a
selector of patients. In this case all of the reported outcomes (toxicities and outcomes)
of both arms are available for the decision process of treatment selection.

5.5.5

CKML subset for Clinical Guidelines

Field and Lohr defined the clinical guidelines [110] as
“systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”
(page 38)
Patients can be assessed to see if they ‘fit’ the guideline (e.g., a prostate cancer treatment guideline has no applicability to a female patient; an asthma management guide-
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line has no applicability to a patient with pneumonia)with the guideline representing
the preferred clinical management strategy in a well defined group of patients. While
the systematic extraction of guidelines may have a work flow [127], the guideline itself
has to match clinical work flows. If the specification of the guideline does not match
the clinical work flow, it cannot be implemented.

The matching of patient to appropriate Clinical Guideline therefore mirrors the
patient to Clinical Trial Report matching described above. Clinical Guidelines are
most useful for describing treatment to patients who are ‘uncomplicated’ with respect
to the guideline selection criteria. At the boundaries of selection, more variability will
be expected (e.g., in a guideline that recommends treatment for breast cancers of size
2-5 cm, it is the tumours slightly more than 2 cm and slightly less than 5 cm for which
the guideline will not be followed, rather than for tumours for 3.5 cm).

There are several bodies that have a tradition for publishing best practice guidelines. The National Comprehensive Cancer Network (NCCN) in the USA, the Scottish
Intercollegiate Guideline Network (SIGN) in the UK and the British Columbia Cancer
Agency (BCCA) have published guidelines for over a decade. Their approaches to
guidelines are different, and so as a result their guidelines vary.

As a large clinical organisation working from several sites, the BCCA publishes
their guidelines which dictate the organisation’s approach to cancer management. As
such, their guidelines describe a local unified common approach to the defined problem. The BCCA is the sole cancer treatment organisation for British Columbia. They
publish their guidelines for the benefit of local referrers and patients.

5.5. Evaluation of CKML and future applications

96

The NCCN is a consortium of academic centres which seek to advise the rest of the
USA on what they consider is standard and non-experimental treatment. Guidelines
from the USA are usually characterised by presenting the range of options acceptable
in a particular circumstance, and the oropharyngeal cancer example is no different.

The SIGN is a professional collaboration that seeks to educate decision making.
Clinicians are advised about the evidence of what works and how robust that evidence
is. The authors do not address the nature and details of actions by clinicians, only
the evidence to be considered in making treatment decisions.

When translating a guideline into CKML, the Clinical Guideline is, surprisingly,
briefer than the Clinical Trial Report. Since guidelines are applied generally to a patient population, there are few of the inclusion and exclusion criteria seen with Clinical
Trial Protocols. There is the implicit assumption that if a patient will die as the result
of a particular treatment (e.g., chemotherapy in the very elderly patient), the clinician
will not pursue it. Furthermore many of the recommendations for treatment are more
of a generic statement about approach - “We advise an organ sparing approach, so radiotherapy is preferred to surgery”. Lastly, since Clinical Guidelines recommend best
practice treatment, the inclusion of outcome data is not required. Indeed, because the
characteristics of the general patient population will differ from the highly selected
sample included in the trial, the outcome of guideline-based treatment will be worse.

5.5.6

Comparison of CKML subsets

Each CKML instance describes an aspect of medical knowledge and is useful for
comparison. It is possible to identify the different scenarios because Clinical Trial
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Protocol, Clinical Trial Report and Clinical Guideline have no need for patient identifiers and can use their own unique tag. The CKML for Routine Clinical Work
has no need to identify a trial arm (<TrialArm>) or a guideline (<GuidelineID>),
although for the present patient, a clinical guideline may be used to determine treatment (<GuidelineEligibility>).

Entities within the specification may be an instance (<Patient>) or a range (e.g.,
<Trial>). In the Routine Clinical Work subset, an element such as <Morphology> will
have a single instance for each patient (e.g., Mr LOLLIPOP has a SQUAMOUS CELL
CARCINOMA of the base of tongue). However another clinical trial for lung cancer
might include patients with ‘non-small cell lung cancer’, an entity that includes SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA, and LARGE CELL CARCINOMA among others [84]. Similarly, a prior clinical trial publication may have demonstrated that 50 Gy/25 Fx has an equivalent outcome for 42.5 Gy/16 Fx for early stage
breast cancer [151], and so a range of acceptable fractionation schemes would be included in any applicable Clinical Guideline.

The domain expert, when seeking to manage an individual patient, looks for applicable clinical reports. The automated comparison of the patient’s specific parameter
value with the range that describes the patient group included in a trial or guideline
will permit the domain expert to quickly determine whether a patient does or does
not fit the profile of a clinical guideline (that is, whether the data is applicable), and
also what data elements are missing.

Chapter 6
Conclusion
The research undertaken by a radiation oncology domain expert has been successful
in producing a description of a radiation oncology knowledge structure. The basis of
this work has been demonstrated in the merging of semantic entities into a structured
work flow to provide a useful knowledge structure with several application formats.
The merged knowledge structure was formalised into an XML format, called Clinical
Knowledge Markup Language (CKML). It was demonstrated that the CKML specification can describe a real clinical case of oropharynx cancer, a real clinical cancer trial
for oropharynx cancer patients, the published manuscript of that trial and current
guidelines for the management of oropharynx cancer patients. While the knowledge
structure is not a formal ontology, it provides a positive step in building the bridge
between the domain experts and formal ontologists.

This thesis has described the iterative and dependent nature of knowledge development, acquisition and deployment seen in clinical work, trials, trial reports and
guidelines in Radiation Oncology. This development uses clinical understanding developed from routine clinical work to drive the investigation of new knowledge through
to the formal clinical trial structure. The new knowledge discovered during a clinical
98

99

trial is distributed as clinical trial reports through the peer reviewed processes of the
published literature. A catalogued and abstracted version of this report is made available in repositories such as MedLINE, even though the usefulness of this abstract is
limited. Finally the knowledge accumulated from multiple clinical trial reports comes
to rest in conclusions that summarise the current best treatment as clinical guidelines.
The entities that describe the population samples used in summarising this knowledge
can be compared and then used to inform decision making in an individual patient.

The research used a modified Content Analysis process to establish the semantic entities used in producing manuscripts for publication. The objective text corpus
analysed consisted of clinically oriented manuscripts drawn from a single month of
published manuscripts dealing with radiation oncology. These semantic entities could
be separated into the ‘few & frequent’ group and the ‘many & seldom’ group. The
’few & frequent’ group included several facets of patients and tumours, and the normal
clinical work flow in Radiation Oncology.

The usual methods for discovery and acquisition of medical knowledge in the expert domain is dependent on a clear, widely used and well established work flow.
Medical knowledge is both a prerequisite for some work flow components, for example
simulation or treatment, but it also is gathered from and arises from the work flow,
for example, consultation and simulation. When the semantic entities are allocated to
their usual position in the work flow, a hierarchy is revealed. This hierarchy was developed into a handcrafted XML-based ‘Clinical Knowledge Markup Language’ (CKML)
devised and deployed into each of the knowledge development areas.

The research provides a positive contribution to the field by demonstrating the
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usefulness of the published expert domain literature in discovering semantic entities
rather than just processing words. Furthermore the use of the clinical work flow as
the organising principle for knowledge structure is novel. While it has been attempted
in the past in a limited way, the interdependence of data used in the areas of clinical
work, clinical trial structure, trial reporting and clinical guidelines has been demonstrated in a way that is understandable to the domain expert.

6.1

Future Research

There are several possibilities that arise from the CKML for future development. The
development of a domain specific knowledge structure grounded in the domain specific
work flow enables the utilisation of technologies such as Business Process Modelling
Notation and Execution to supplement and constrain knowledge discovery and elucidation. This overlap of knowledge structure and work flow can permit the construction
of an electronic environment where the components of knowledge, the semantic entities, are captured at the right place by the right person within the work flow.

Furthermore, the expression of the domain specific knowledge into a mark up format permits the automated reuse of the knowledge in many areas of clinical practice,
work flow process, knowledge application and new knowledge discovery. Softwarebased agents, mixed-initiative argumentation, support-based distributed optimisation
and automated detection of interactions between co-incident clinical processes are some
of the areas that have been formally investigated. Other areas such as automated clinical risk analysis using anatomical ontologies are possible areas of further application.
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Validating the CKML structure

This work requires research to determine the veracity of the knowledge structures
presented. These structures should be validated by other domain experts in Radiation
Oncology to demonstrate that the CKML, or similar mark up, can actually be used
for documentation of patient data, clinical trial protocols, clinical trial reports and
clinical guidelines. The paradigm of constructing plain text outputs from CKML
instances, and then asking domain experts whether the original documents reflect the
same knowledge as the plain text output, will be more useful than natural language
processing of free text.

6.1.2

Developing a User Interface based on the CKML structure

The problems of data entry must eventually be addressed in graphical user interface
research. Presenting the views for data entry clearly in a user interface sympathetic to
the knowledge structure and work flow may enable clinicians to translate their knowledge directly into a useful data structure with a level of configurability which ensures
that complete data is collected with the least work.

6.1.3

Use of the CKML Structure in Clinical Knowledge Discovery

The translation of CKML into an XLST schema and submission as a formal template
in the XML Namespace will permit research to demonstrate that it is possible to output clinical data from any OIS for the purposes of knowledge sharing and aggregation.
This will allow the assessment of the OIS to establish whether a complete CKML speci-

6.1. Future Research

102

fication can be written from OIS contents, so that the capability of posting anonymous
CKML entries describing individual patients online can permit the collation of large
scale data sets.

6.1.4

Use of the CKML Structure in Clinical Trial and Guideline infrastructures

The structure of CKML has relevance to those who build, develop and extend OISs.
Several lines of research can be followed to extend and define this role. Research is
required to:
• enable the trial specifications found in Clinical trial clearing houses (e.g., CancerTrials.gov) to be made available for routine clinical use in matching patients
with available clinical trials without leaving the OIS and to demonstrate that
this IT based approach improves trial recruitment.
• demonstrate to these clearing houses that production of trial protocols in the
CKML enhances use.
• demonstrate that summaries of relevant clinical trials held in clinical data repositories such as MedLINE can be made available to clinicians in real time as they
deal with new patients. It is likely that this research will be based on Natural Language Processing used to analyse and structure previously published
abstracts in MedLINE into the CKML structure

6.1.5

Storage repositories for CKML Structures

The optimal place for the storage of the populated CKML description of a patient
is yet to be described. The utility of placing this data inside a separate database,
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or stored inside a DICOM container with the radiation plan images has not been
addressed in research.

6.1.6

Developing Agents that use CKML structures

The purpose of a standardised knowledge structure is to be able to deploy and reapply knowledge in appropriate circumstances. In Radiation Oncology, it is typical
when consulting a patient that the clinician wishes to apply previous knowledge in
determining how to manage the current patient. Agents that check for important data
and prompt for missing data to assist with clinical decision making will be a benefit.

6.2

Need for Collaboration

The cooperation of domain experts in knowledge engineering and medicine is problematic. Both require a decade to achieve their status and the individuals who might be
considered to be active experts in both domains are rare. The situation is not helped
by academic Informatics groups that produce papers and projects that are devoid of
any substantive medical influence.

The advice that I would give to publishers of Medical Informatics journals is to
reject Informatics articles that purport to provide a system that assists clinicians yet
have no relevant clinicians in their authorship. Pure Informatics manuscripts can
be devoid of clinical domain experts, but manuscripts describing Applied Informatics
must include clinical domain experts.

I urge my clinical colleagues to point trainees to look at the academic area of Informatics. The area is interesting and significant. I urge my Informatics colleagues
to engage clinicians until they have established meaningful academic relationships.
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Without this engagement, Medical Informatics will remain irrelevant to clinicians who
are the end users.

Finally, the structures described by domain experts need to be validated by ontology domain experts, translated into their specific ontological schema and once again
verified by radiation oncology domain experts using natural language output statements that verify the purity of the translation. The translation from the ontologynaive language of a domain expert into a formal ontology is necessary to enable the
production of oncology information systems that will allow routine clinical knowledge
about patients to be used to improve the management of oncology patients.
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Cosmesis_BreastSymmetry
Cosmesis_CatheterPuckering
cough
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Cox2_StainingIntensity
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CranialNerveFunction
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DesmoplasticReaction
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Drug_ApplicationToSite
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PacksPerDay
Pain
ParenteralFeeding_Method
Patient
PAX3/EKHR_translocation
PAX7/EKHR_translocation
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PemetrexedLevel
PemetrexedProteinBindingLevel
PerineuralInfiltration
PeripheralNeuropathy
PeritonealWashingStatus
PET_classification
PET_F18_misonidazole
PET_interpretation
PET_result
Physician
PIG3_promoterPCR
Place_Of_Death
Plan_Algorithm
Plan_Field_Reference_Image
Plan_GeometricField
Plan_GeometricField_AnatomyBorders
Plan_MaximumDose
Plan_Number
Plan_Planning_Protocol_Name
Plan_Planning_System
Plan_ReferenceVolume
Plan_ReferenceVolume_Dose
Plan_ReferenceVolume_height
Plan_ReferenceVolume_length
Plan_ReferenceVolume_volume
Plan_ReferenceVolume_width
Plan_Specification
Plan_VolumeCTVx_PrescriptionIsodose
Plan_VolumeGTV
Plan_VolumeGTV_author
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Plan_VolumeGTV_author_timetaken
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PointA_definition
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Prescription_BED
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Prescription_D90\
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Prescription_MinimumTargetDose
ProstateVolume_Method
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Protocol_Sponsor
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PSADT
PTHrP_Serum_Level
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PulmonaryFunctionTest
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1
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1
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1
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1
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1
Radiotherapy_TreatmentPosition
1
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1
Recurrence_DistantGrade
1
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1
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1
RecursivePartitioningAnalysis_Class
1
Regime_Guideline
1
RenalDialysis
1
RenalFunction
1
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1
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1
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1
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1
Retinal_Assessment
1
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1
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1
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1
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1
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1
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1
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1
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1
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Skin
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1
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1
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1
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1
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1
SkinBiopsy_Histology
1
SkinBiopsy_Site
1
Sleep_Insomnia
1
SoftTissueFibrosis
1
spasm
1
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1
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1
StageM_histopathology
1
StageM_Site_Symptoms
1
StageM_Volume
1
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1
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1
StageN_Number
1
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1
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1
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1
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1
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1
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StageT_Ulceration
Stain
StereotacticeHeadFrame
SuccinylDehydrogenaseComplexSubunitA
Surgery_InpatientDays
Surgery_PreAnaestheticEvaluation
Synuclein
TAp73-IHC
TATAbindingprotein
TetanusToxoidAb
Thickness_AnterirorPosterior
Thyroid_T3_level
Thyroid_T4_level
Thyroid_TSH_level
ThyroidFunction
TimeSinceQuit
TissueFactor_serum_level
TissueFactor_tissue_level
YKL-40_serum
ΔNp73-IHC
Topoisomerase Iia Ab_level
TP73-mRNA
Tracheostomy
Transfusion
TrigeminalNeuralgia
TUNEL_assay
UbiquitinC
Urethra_prostatic_length
UrinaryToxicity
Uterus_Size
Vagina
vaginal_atrophy
VaginovesicalFistula
VascularInvasion
VEGF_serum_level
VEGF-A_LI
VEGFR2_LI
ViableTumour
VisualAcuity
VisualEvokedPotentials
VisualFieldDeficit
Vomiting
weight loss
Xerostomia
YearsOfSmoking

Appendix F
Johns Hopkins Hospital
Radiotherapy Workflow
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Appendix G
A Selection of ICD-10-PCS list of
procedures
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Beam Radiation of
Right Breast using
Electrons
Beam Radiation of
Right Breast using
Electrons, Intraoperative

Male
Reproductive
System
Ear,
Nose,
Mouth
and
Throat

Radiation
Oncology

Breast

Breast

Radiation
Oncology

Radiation
Oncology

Radiation
Oncology

Male
Reproductive
System

Radiation
Oncology

Low Dose Rate (LDR)
Brachytherapy
of
Prostate using Iridium
192 (Ir-192)
Beam Radiation of
Prostate using Photons
1 - 10 MeV
Stereotactic
Gamma
Beam Radiosurgery of
Nasopharynx

Body System

Section

Preferred Name

Radia-

Beam
tion

Beam
tion
Radia-

Radia-

Stereotactic
Radiosurgery

Beam
tion

Brachytherapy

Root Type

Breast, Right

Breast, Right

Nasopharynx

Prostate

Prostate

Body Part

Electrons

Stereotactic
Gamma
Beam Radiosurgery
Electrons

Photons 1 10 MeV

Low Dose
Rate
(LDR)

Modality
Qualifier

-

-

-

-

Iridium
192
(Ir-192)

Isotope

None

None

None

None

-

Qualifier
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Radiation Oncology Terms used in the ICD10 PCS

Appendix H
Listing and Individual Critique of
the ACGT Master Ontology
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The following is a listing of all the items from the "Advancing
Clinico-Genomic Trials on Cancer" (ACGT) Master Ontology (MO).
A selection of criticisms are present as footnotes to establish
that this ontology is incomplete and inconsistent. Most of the
terms used in the ontology are undefined.
_______________________________________________________________
entity
continuant
dependent_continuant
generically_dependent_continuant
acgt:InformationObject
acgt:Comment
acgt:Design
acgt:PharmacotherapyRegime
acgt:ChemotherapyRegime
acgt:CWSChemotherapyRegime
acgt:HITChemotherapyRegime
acgt:SIOP2001ChemotherapyRegime
acgt:TherapyPlan
acgt:Document
acgt:ConsentForm
acgt:HospitalConsentForm
acgt:PatientConsentForm
acgt:DataProcessingPatientConsentForm
acgt:CRF
acgt:Diagnosis
acgt:PatientLetter
acgt:Protocol
acgt:ClinicalStudyProtocol
acgt:PrimaryClinicalStudyProtocol
acgt:SecondaryClinicalStudyProtocol
acgt:ClinicalTrialProtocol
acgt:Questionnaire
acgt:CardiacQuestionnaire
acgt:ParentQuestionnaire
acgt:PathologyQuestionnaire
acgt:PatientQuestionnaire
acgt:QualityOfLifeQuestionnaire
acgt:SocioEconomicQuestionnaire
acgt:Identifier
acgt:Address
acgt:AddressPart
acgt:CountryName
acgt:BirthCountryName
acgt:HouseNumber
acgt:PlaceName
acgt:CityName
acgt:BirthCityName
acgt:PostalCode
acgt:StreetName
acgt:ClinicalStudyIdentifier
acgt:ClinicalTrialIdentifier
acgt:CranialNerveNumber
acgt:CRFNumber
acgt:EMailAddress
acgt:FaxNumber

181

acgt:ICDClass
acgt:ICDOClass
acgt:InstitutionIdentifier
acgt:HospitalIdentifier
acgt:JournalNumber
acgt:LegalGuardianIdentifier
acgt:ParentIdentifier
acgt:MedicalExpertIdentifier
acgt:Name
acgt:FirstName
acgt:FullName
acgt:LastName
acgt:MaidenName
acgt:PatientIdentifier
acgt:ClinicalStudyPatientNumber
acgt:ClinicalTrialPatientNumber
acgt:EU-RHABIdentificationNumber
acgt:GPOH-PID
acgt:IMBEIIdentifier
acgt:RegistrationNumber
acgt:RegistryIdentifier
acgt:TelephoneNumber
acgt:Image
acgt:MedicalImage
acgt:Proposition
acgt:DeclarativeProposition
acgt:Publication
acgt:InvestigatorNewsletter
acgt:Website
specifically_dependent_continuant
quality
acgt:CertaintyLevel
acgt:AbsoluteCertainty
acgt:LowCertainty
acgt:CompletenessLevel
acgt:Complete
acgt:Incomplete
acgt:FeasibilityLevel
acgt:Feasible
acgt:Unfeasible
acgt:FieldOfVision
acgt:CanonicalFieldOfVision
acgt:PathologicalFieldOfVision
acgt:FunctionalOrStructural
acgt:Functional
acgt:Structural
acgt:Gender
acgt:AmbiguousGender
acgt:Female
acgt:Male
acgt:GrossMotorSkills
acgt:Intactness
acgt:Damaged
acgt:Intact
acgt:Lateness
acgt:Laterality
acgt:Bilateral
acgt:Midline
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acgt:Systemic
acgt:Unilateral
acgt:Left
acgt:Right
acgt:Magnitude
acgt:AbsoluteNeutrophilCount
acgt:Age
acgt:BinaryStatus
acgt:BodyMassIndex
acgt:CatecholaminLevel
acgt:IncreasedCatecholaminLevel
acgt:NormalCatecholaminLevel
acgt:Dose
acgt:AbsorbedRadiationDose
acgt:CumulativeDose
acgt:ErythropoietinLevel
acgt:HeartRate
acgt:LVEF
acgt:LVSF
acgt:Maximum
acgt:MethotrexatLevel
acgt:Minimum
acgt:NumberOfBloodCells
acgt:NumberOfGranularLeucocytes
acgt:NumberOfLeucocytes
acgt:NumberOfPlatelets
acgt:NumberOfCycles
acgt:NumberOfLatenessDays
acgt:NumberOfLymphNodes
acgt:NumberOfStemCells
NumberOfStemCellsX10ToThe4CD3:kg
NumberOfStemCellsX10ToThe6CD34:kg
NumberOfStemCellsX10ToThe8ANC:kg
acgt:NumberOfTumors
acgt:MultipleTumors
acgt:SingleTumor
acgt:pCRRate
acgt:PerformanceRating
acgt:CardioPerformanceRating
acgt:CardioPerformanceClassI
acgt:CardioPerformanceClassII
acgt:CardioPerformanceClassIII
acgt:CardioPerformanceClassIV
acgt:ECOGPerformanceRating
acgt:ECOG0
acgt:ECOG1
acgt:ECOG2
acgt:ECOG3
acgt:ECOG4
acgt:ECOG5
acgt:GeneralHealthRating
acgt:BedriddenState
acgt:ConsiderablyReducedActivityState
acgt:IntensiveCareRequiredState
acgt:MinorImpairmentState
acgt:NormalActivityState
acgt:KarnofskyRating
acgt:KarnofskyScore0
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acgt:KarnofskyScore10
acgt:KarnofskyScore100
acgt:KarnofskyScore20
acgt:KarnofskyScore30
acgt:KarnofskyScore40
acgt:KarnofskyScore50
acgt:KarnofskyScore60
acgt:KarnofskyScore70
acgt:KarnofskyScore80
acgt:KarnofskyScore90
acgt:LanskyRating
acgt:LanskyScore0
acgt:LanskyScore10
acgt:LanskyScore100
acgt:LanskyScore20
acgt:LanskyScore30
acgt:LanskyScore40
acgt:LanskyScore50
acgt:LanskyScore60
acgt:LanskyScore70
acgt:LanskyScore80
acgt:LanskyScore90
acgt:PhysicalMagnitude
acgt:Density
acgt:ALPLevel
acgt:ALTCount
acgt:ANCount
acgt:ASTCount
acgt:HemoglobinConcentration
acgt:PlateletCount
acgt:SerumCreatinineConcentration
acgt:TotalBilirubin
acgt:TotalRBC
acgt:WBCCount
acgt:Energy
acgt:Frequency
acgt:PulseRepetitionFrequency
acgt:Length
acgt:Breadth
acgt:Circumference
acgt:Depth
acgt:Diameter
acgt:Height
acgt:Thickness
acgt:Width
acgt:Pressure
acgt:BloodPressure
acgt:DiastolicBloodPressure
acgt:PathologicalDiastolicBloodPressure
acgt:SystolicBloodPressure
acgt:IntracranialPressure
acgt:SurfaceSize
acgt:BodySurfaceArea
acgt:Volume
acgt:ESV
acgt:Weight
acgt:PregnancyStatus
acgt:RadiationFraction
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acgt:RFSDays
acgt:StressLevel
acgt:EndSystolicWallStressLevel
acgt:ToxicityLevel
acgt:CommonToxicityCriteriaGrade
acgt:AnemiaGrade
acgt:AnemiaGrade0
acgt:AnemiaGrade1
acgt:AnemiaGrade2
acgt:AnemiaGrade3
acgt:AnemiaGrade4
acgt:ArrhythmiaGrade
acgt:ArrhythmiaGrade0
acgt:ArrhythmiaGrade1
acgt:ArrhythmiaGrade2
acgt:ArrhythmiaGrade3
acgt:ArrhythmiaGrade4
acgt:BilirubinGrade
acgt:BilirubinGrade0
acgt:BilirubinGrade1
acgt:BilirubinGrade2
acgt:BilirubinGrade3
acgt:BilirubinGrade4
acgt:CentralNeurotoxicityGrade
acgt:CentralNeurotoxicityGrade0
acgt:CentralNeurotoxicityGrade1
acgt:CentralNeurotoxicityGrade2
acgt:CentralNeurotoxicityGrade3
acgt:CentralNeurotoxicityGrade4
acgt:CreatinineClearanceGrade
acgt:CreatinineClearanceGrade0
acgt:CreatinineClearanceGrade1
acgt:CreatinineClearanceGrade2
acgt:CreatinineClearanceGrade3
acgt:CreatinineClearanceGrade4
acgt:CreatinineGrade
acgt:CreatinineGrade0
acgt:CreatinineGrade1
acgt:CreatinineGrade2
acgt:CreatinineGrade3
acgt:CreatinineGrade4
acgt:DiarrheaGrade
acgt:DiarrheaGrade0
acgt:DiarrheaGrade1
acgt:DiarrheaGrade2
acgt:DiarrheaGrade3
acgt:DiarrheaGrade4
acgt:FeverGrade
acgt:FeverGrade0
acgt:FeverGrade1
acgt:FeverGrade2
acgt:FeverGrade3
acgt:FeverGrade4
acgt:GranularLeucocyteGrade
acgt:GranularLeucocyteGrade0
acgt:GranularLeucocyteGrade1
acgt:GranularLeucocyteGrade2
acgt:GranularLeucocyteGrade3
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acgt:GranularLeucocyteGrade4
acgt:GranulocytopeniaGrade
acgt:GranulocytopeniaGrade0
acgt:GranulocytopeniaGrade1
acgt:GranulocytopeniaGrade2
acgt:GranulocytopeniaGrade3
acgt:GranulocytopeniaGrade4
acgt:HeartFunctionGrade
acgt:HeartFunctionGrade0
acgt:HeartFunctionGrade1
acgt:HeartFunctionGrade2
acgt:HeartFunctionGrade3
acgt:HeartFunctionGrade4
acgt:HematuriaGrade
acgt:HematuriaGrade0
acgt:HematuriaGrade1
acgt:HematuriaGrade2
acgt:HematuriaGrade3
acgt:HematuriaGrade4
acgt:HemoglobinGrade
acgt:HemoglobinGrade0
acgt:HemoglobinGrade1
acgt:HemoglobinGrade2
acgt:HemoglobinGrade3
acgt:HemoglobinGrade4
acgt:HemorrhageGrade
acgt:HemorrhageGrade0
acgt:HemorrhageGrade1
acgt:HemorrhageGrade2
acgt:HemorrhageGrade3
acgt:HemorrhageGrade4
acgt:InfectionGrade
acgt:InfectionGrade0
acgt:InfectionGrade1
acgt:InfectionGrade2
acgt:InfectionGrade3
acgt:InfectionGrade4
acgt:LeucocyteGrade
acgt:LeucocyteGrade0
acgt:LeucocyteGrade1
acgt:LeucocyteGrade2
acgt:LeucocyteGrade3
acgt:LeucocyteGrade4
acgt:LeukopeniaGrade
acgt:LeukopeniaGrade0
acgt:LeukopeniaGrade1
acgt:LeukopeniaGrade2
acgt:LeukopeniaGrade3
acgt:LeukopeniaGrade4
acgt:LVSFGrade
acgt:LVSFGrade0
acgt:LVSFGrade1
acgt:LVSFGrade2
acgt:LVSFGrade3
acgt:LVSFGrade4
acgt:PeripheralNeurotoxicityGrade
acgt:PeripheralNeurotoxicityGrade0
acgt:PeripheralNeurotoxicityGrade1
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acgt:PeripheralNeurotoxicityGrade2
acgt:PeripheralNeurotoxicityGrade3
acgt:PeripheralNeurotoxicityGrade4
acgt:PlateletGrade
acgt:PlateletGrade0
acgt:PlateletGrade1
acgt:PlateletGrade2
acgt:PlateletGrade3
acgt:PlateletGrade4
acgt:ProteinuriaGrade
acgt:ProteinuriaGrade0
acgt:ProteinuriaGrade1
acgt:ProteinuriaGrade2
acgt:ProteinuriaGrade3
acgt:ProteinuriaGrade4
acgt:SkinResponseGrade
acgt:SkinResponseGrade0
acgt:SkinResponseGrade1
acgt:SkinResponseGrade2
acgt:SkinResponseGrade3
acgt:SkinResponseGrade4
acgt:StomatitsGrade
acgt:StomatitisGrade0
acgt:StomatitisGrade1
acgt:StomatitisGrade2
acgt:StomatitisGrade3
acgt:StomatitisGrade4
acgt:ThrombocytopeniaGrade
acgt:ThrombocytopeniaGrade0
acgt:ThrombocytopeniaGrade1
acgt:ThrombocytopeniaGrade2
acgt:ThrombocytopeniaGrade3
acgt:ThrombocytopeniaGrade4
acgt:VomitingGrade
acgt:VomitingGrade0
acgt:VomitingGrade1
acgt:VomitingGrade2
acgt:VomitingGrade3
acgt:VomitingGrade4
SGOT:SGPTGrade
SGOT:SGPTGrade0
SGOT:SGPTGrade1
SGOT:SGPTGrade2
SGOT:SGPTGrade3
SGOT:SGPTGrade4
acgt:Malfunction
acgt:Malignancy
acgt:NephroblastomaSpread
acgt:InfrahepaticNephroblastomaSpread
acgt:IntracardiacNephroblastomaSpread
acgt:RetrohepaticNephroblastomaSpread
acgt:SuprahepaticNephroblastomaSpread
acgt:Normality
acgt:Abnormal
acgt:Normal
acgt:PatientPosition
acgt:pCRStatus
acgt:ProcessOrigin
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acgt:Accidental
acgt:NonAccidental
acgt:Radicality
acgt:Regionality
acgt:Extraregional
acgt:Regional
acgt:Suspiciousness
acgt:Suspicious
acgt:Unsuspicious
acgt:TherapyAim
acgt:Toxicity
acgt:CardioToxicity
acgt:Hematotoxicity
acgt:HepatoToxicity
acgt:Nephrotoxicity
acgt:Neurotoxicity
acgt:CentralNeurotoxicity
acgt:PeripheralNeurotoxicity
acgt:Ototoxicity
acgt:TumorClass
acgt:DifferentiationClass
acgt:AJCDifferentiation
acgt:G1
acgt:G2
acgt:G3
acgt:G4
acgt:GX
acgt:BloomRichardsonDifferentiation
acgt:BRGrade1
acgt:BRGrade2
acgt:BRGrade3
acgt:FuhrmanNuclearGrade
acgt:FuhrmanGradeI
acgt:FuhrmanGradeII
acgt:FuhrmanGradeIII
acgt:FuhrmanGradeIV
acgt:GleasonDifferentiation
acgt:GleasonGrade10
acgt:GleasonGrade2
acgt:GleasonGrade3
acgt:GleasonGrade4
acgt:GleasonGrade5
acgt:GleasonGrade6
acgt:GleasonGrade7
acgt:GleasonGrade8
acgt:GleasonGrade9
acgt:ERStatus
acgt:ERNegative
acgt:ERPositive
acgt:GenomicType
acgt:HistologicalType
acgt:NodalStatus
acgt:NodalStatusNegative
acgt:N0
acgt:NodalStatusPositive
acgt:PRStatus
acgt:TumorStage
acgt:MammaryCarcinomaClass
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acgt:ClinicalClassTNM
acgt:MClass
acgt:M0
acgt:M1
acgt:MX
acgt:NClass
acgt:N0
acgt:NodalStatusNegative
acgt:N1
acgt:N2
acgt:N2a
acgt:N2b
acgt:N3
acgt:N3a
acgt:N3b
acgt:N3c
acgt:NX
acgt:TClass
acgt:T0
acgt:T1
acgt:T1a
acgt:T1b
acgt:T1c
acgt:T1mic
acgt:T2
acgt:T3
acgt:T4
acgt:T4a
acgt:T4b
acgt:T4c
acgt:T4d
acgt:Tis
acgt:TisDCIS
acgt:TisLCIS
acgt:TisPaget
acgt:TX
acgt:PathologicClasspTNM
acgt:pMClass
acgt:pM0
acgt:pM1
acgt:pMX
acgt:pNClass
acgt:pN0
acgt:pCRStatus
acgt:pN1
acgt:pN1a
acgt:pN1b
acgt:pN1c
acgt:pN1mi
acgt:pN2
acgt:pN2a
acgt:pN2b
acgt:pN3
acgt:pN3a
acgt:pN3b
acgt:pN3c
acgt:pNX
acgt:pTClass
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acgt:pT0
acgt:pT1
acgt:pT1a
acgt:pT1b
acgt:pT1c
acgt:pT1mic
acgt:pT2
acgt:pT3
acgt:pT4
acgt:pT4a
acgt:pT4b
acgt:pT4c
acgt:pT4d
acgt:pTis
acgt:pTisDCIS
acgt:pTisLCIS
acgt:pTisPaget
acgt:pTX
acgt:RClass
acgt:R0
acgt:R1
acgt:R2
acgt:RX
acgt:WilmsTumorStage
acgt:WilmsTumorStageI
acgt:WilmsTumorStageII
acgt:WilmsTumorStageIII
acgt:WilmsTumorStageIV
acgt:WilmsTumorStageV
acgt:TumorHomogeneity
acgt:CysticTumor
acgt:HomogenousTumor
acgt:InhomogenousTumor
acgt:TumorSituation
acgt:LocallyAdvancedSituation
acgt:TwinType
acgt:TwinCount
acgt:TriPletOrMultiPlet
acgt:TwoPlet
acgt:TwinGeneticType
acgt:BiZygotic
acgt:MonoZygotic
acgt:VisualAcuity
acgt:CanonicalVisualAcuity
acgt:PathologicalVisualAcuity
acgt:VitalityLevel
acgt:Avital
acgt:Vital
realizable_entity
disposition
acgt:Disease
acgt:InfectiousDisease
acgt:BacterialInfection
acgt:ViralInfection
acgt:ChronicViralInfection
acgt:NonInfectiousDisease
acgt:Alcoholism
acgt:Allergy
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acgt:HematologicalDisease
acgt:Coagulopathy
acgt:HematologicalMalignancy
acgt:Hypertonia
acgt:Neuropathy
acgt:MotorNeuropathy
acgt:SensoryNeuropathy
acgt:Neutropenia
acgt:SIOPRelevantHistory
acgt:Syndrome
acgt:Aniridia
acgt:BuddChiariSyndrome
acgt:Drash
acgt:HemiHypertrophy
acgt:Perlman
acgt:RhabdoidTumorPredispositionSyndrom
acgt:StuartBrasSyndrome
acgt:WAGR
acgt:WiedemannBeckwithEMG
acgt:SystemicNonInfectiousDisease
acgt:Tabagism
function
role
acgt:AdministrativeRole
acgt:Director
acgt:LegalGuardianRole
acgt:Patient
acgt:ProtocolPatient
acgt:ResponsibleITPerson
acgt:StudyNurse
acgt:CancerTreatment
acgt:Complication
acgt:LateComplication
acgt:NeurologicalComplication
acgt:ContrastMedium
acgt:Criterion
acgt:EligibilityCriterion
acgt:ExclusionCriterion
acgt:InclusionCriterion
acgt:Drug
acgt:AnalgeticDrug
acgt:AntibioticDrug
acgt:AntimycoticDrug
acgt:Betablocker
acgt:ChemotherapyDrug
acgt:AntiTumorAntibiotic
acgt:AromataseInhibitor
acgt:Cytostatic
acgt:SERM
acgt:Diuretic
acgt:HighCeilingLoopDiuretic
acgt:OsmoticDiuretic
acgt:PotassiumSparingDiuretic
acgt:HormoneTherapyDrug
acgt:GnRHAnalog
acgt:LHRHAnalog
acgt:ImmunotherapyDrug
acgt:EmergencySurgeryRole
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acgt:ExtrapyramidalMotorSystem
acgt:Hormone
acgt:HematologicalGrowthFactor
acgt:Implant
acgt:Marker
acgt:BiologicalMarker
acgt:TumorMarker
acgt:BreastCancerTumorMarker
acgt:MeasurementUnit
acgt:FrequencyUnit
acgt:LinearUnit
acgt:MassUnit
acgt:PressureUnit
acgt:SurfaceUnit
acgt:VolumeUnit
acgt:MirrorBlock
acgt:Nadir
acgt:ProfessionalRole
acgt:Jurist
acgt:Lawyer
acgt:MedicalPractitioner
acgt:Dermatologist
acgt:GeneralPractitioner
acgt:Gynecologist
acgt:Internist
acgt:Haematooncologist
acgt:Otorinolaryngologist
acgt:Paediatrician
acgt:PaediatricOncologist
acgt:Pathologist
acgt:LocalPathologist
acgt:ReferencePathologist
acgt:Radiologist
acgt:LocalRadiologist
acgt:ReferenceRadiologist
acgt:Radiotherapist
acgt:LocalRadiotherapist
acgt:ReferenceRadiotherapist
acgt:Surgeon
acgt:GeneralSurgeon
acgt:HeartSurgeon
acgt:NeuroSurgeon
acgt:OrthopaedicSurgeon
acgt:PaediatricSurgeon
acgt:ThoracicSurgeon
acgt:VascularSurgeon
acgt:Urologist
acgt:Nurse
acgt:Paramedic
acgt:Philosopher
acgt:Scientist
acgt:Biologist
acgt:Geneticist
acgt:MolecularBiologist
acgt:ComputerScientist
acgt:Ontologist
acgt:Mathematician
acgt:Physicist
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acgt:Statistician
acgt:Prothesis
acgt:ProtocolDeviationRole
acgt:RadiotherapyRiskOrgan
acgt:Reason
acgt:ReasonForPatientEnrollment
acgt:ReasonOfAdmission
acgt:ReasonOfTherapyTermination
acgt:RelativeRole
acgt:OffspringRole
acgt:ParentRole
acgt:FatherRole
acgt:MotherRole
acgt:ProgenitorRole
acgt:SiblingRole
acgt:SecondaryTumor
acgt:SecondaryBenignTumor
acgt:SecondaryMalignTumor
acgt:Symptom
acgt:GeneralizedSymptom
acgt:SpecificSymptom
acgt:AlimentarySystemSymptom
acgt:CardiovascularSystemSymptom
acgt:CardiacSymptom
acgt:VascularSymptom
acgt:DeepFascialSystemSymptom
acgt:EndocrineSystemSymptom
acgt:GenitalSystemSymptom
acgt:FemaleGenitalSystemSymptom
acgt:MaleGenitalSystemSymptom
acgt:HemolymphoidSystemSymptom
acgt:CoagulationDisorder
acgt:IntergumentarySystemSymptom
acgt:MusculoskeletalSystemSymptom
acgt:NervousSystemSymptom
acgt:RespiratorySystemSymptom
acgt:UrinarySystemSymptom
acgt:Therapy
acgt:FurtherTherapy
acgt:HighDoseTherapy
acgt:PreTherapy
acgt:PrimaryTherapy
acgt:ForeignPrimaryTherapy
acgt:NationalPrimaryTherapy
acgt:SalvageTherapy
acgt:SecondLookSurgicalProcess
acgt:SupportingTherapy
acgt:AdjuvantTherapy
acgt:AdjuvantChemotherapy
acgt:NeoadjuvantTherapy
acgt:NeoadjuvantChemotherapy
acgt:WindowTherapy
acgt:Transplant
independent_continuant
material_entity
fiat_object_part
acgt:PortionOfSoftTissue
acgt:ResectionLine
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acgt:SubstanceSample
acgt:BloodPlasmaSample
acgt:BloodSample
acgt:PeripheralBloodSample
acgt:BloodSerumSample
acgt:CerebrospinalLiquidSample
acgt:HistologicalSample
acgt:TissueSample
acgt:TumorSample
acgt:ProgenitorCellSample
acgt:BoneMarrowProgenitorCellSample
acgt:PerpheralProgenitorCellSample
acgt:StemCellSample
acgt:PeripheralBloodStemCellSample
acgt:TumorDNASample
acgt:TumorRNASample
acgt:UrineSample
object
acgt:BiologicalIndependentContinuant
acgt:ExtraOrganismalIndependenContinuant
acgt:Population
acgt:PopulationSubgroup
acgt:Organism
acgt:HumanBeing
acgt:FemaleHumanBeing
acgt:MaleHumanBeing
acgt:OrganismalIndependentContinuant
acgt:ImmaterialOrganismalIndependentContinuant
acgt:OrganismalSpace
acgt:CanonicalOrganismalSpace
acgt:CanonicalAnatomicalCavity
acgt:SubdivisionOfCavityOfOrganSystemSubdivision
acgt:AnteriorCranialFossa
acgt:MiddleCranialFossa
acgt:PathologicalOrganismalSpace
acgt:Abscess
acgt:OrganismalSurface
acgt:CanonicalOrganismalSurface
acgt:PathologicalOrganismalSurface
acgt:MaterialOrganismalIndependentContinuant
acgt:CanonicalMaterialOrganismalIndependentContinuant
acgt:AnatomicalSet
acgt:AnatomicalStructure
acgt:AcellularAnatomicalStructure
acgt:AnatomicalCluster
acgt:BiologicalMacromolecule
acgt:Body
acgt:CardinalBodyPart
acgt:CardinalCellPart
acgt:CardinalOrganPart
acgt:CardinalTissuePart
acgt:Cell
acgt:Organ
acgt:OrganSystem
acgt:OrganSystemSubdivision
acgt:PortionOfTissue
acgt:SubdivisionOfCardinalBodyPart
acgt:LimbSegment
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acgt:SubdivisionOfBodyProper
acgt:Neck
acgt:SubdivisionOfTrunk
acgt:SubdivisionOfTrunkProper
acgt:Abdomen
acgt:Perineum
acgt:SubdivisionOfAbdomen
acgt:SubdivisionOfThorax
acgt:Thorax
acgt:Trunk
acgt:SubdivisionOfHead
acgt:Face
acgt:VariantAnatomicalStructure
acgt:BodySubstance
acgt:Blood
acgt:MetabolismByproduct
acgt:Bilirubin
acgt:Creatinine
acgt:Urine
acgt:PleuralEffusion
acgt:Pus
acgt:Serum
acgt:PathologicalFormation
acgt:Granuloma
acgt:Lesion
acgt:IntestinalLesion
acgt:LiverLesion
acgt:SpleenLesion
acgt:VascularLesion
acgt:Neoplasm
acgt:BenignNeoplasm
acgt:Adenoma
acgt:CysticNephroma
acgt:MesoblasticNephroma
acgt:MalignNeoplasm1
acgt:Carcinoma
acgt:MammaryCarcinoma
acgt:InvasiveMammaryCarcinoma
acgt:ColloidCarcinoma
1

acgt:MalignNeoplasm has multiple suboptions including acgt:PrimaryTumour,
acgt:Carcinoma, acgt:Sarcoma and acgt:NeuroendocrineTumour.
However acgt:Carcinoma is an instance of a acgt:PrimaryTumour.

The division of acgt:MalignantNeoplasm into acgt:PrimaryTumour should follow a different division as shown below:
acgt:MalignNeoplasm
acgt:PrimaryTumor
acgt:Carcinoma
acgt:Sarcoma
acgt:DysontogeneticTumor
acgt:HaematooncologicalTumor
acgt:NeuroendocrineTumor
acgt:MixedTumor
acgt:Metastasis
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acgt:InflammatoryCarcinoma
acgt:InvasiveDuctalCarcinoma
acgt:ComedoCarcinoma
acgt:MixedCarcinoma
acgt:SchirrousCarcinoma
acgt:InvasiveLobularCarcinoma
acgt:MedullaryCarcinoma
acgt:TubularCarcinoma
acgt:NonInvasiveMammaryCarcinoma
acgt:DCIS
acgt:LCIS
acgt:PagetNippleTumor
acgt:RenalCellCarcinoma
acgt:ChromophobeRenalCarcinoma
acgt:ClearCellCarcinoma
acgt:PapillaryRenalCellCarcinoma
acgt:DysontogeneticTumor
acgt:Nephroblastoma
acgt:HighRiskNephroblastoma
acgt:DiffuseAnaplasticNephroblastoma
acgt:HighRiskBlastemaRichNephroblastoma
acgt:IntermediateRiskNephroblastoma
acgt:EpithelialNephroblastoma
acgt:FocalAnaplasticNephroblastoma
acgt:IntermediateRiskBlastemaRichNephroblastoma
acgt:MixedNephroblastoma
acgt:RegressiveTypeNephroblastoma
acgt:StromaRichNephroblastoma
acgt:LowRiskNephroblastoma
acgt:CompletelyNecroticNephroblastoma
acgt:CysticPartiallyDifferentiatedNephroblastoma
acgt:RhabdoidTumor
acgt:MRT
acgt:RTK
AT:RT
acgt:HaematooncologicalTumor
acgt:Metastasis2
acgt:SecondaryMetastasis
acgt:MixedTumor
acgt:NeuroendocrineTumor
acgt:PrimaryTumor
acgt:ExtrarenalPrimaryTumor
acgt:HaematooncologicalTumor3
acgt:Sarcoma
acgt:ClearCellTumor
acgt:PrimitiveNeuroectodermalTumor
acgt:SemiMalignNeoplasm
acgt:Nephroblastomatosis
2

acgt:Metastasis has a single suboption called acgt:SecondaryMetastasis. This is a tautology or nonsensical. Metastases are also called ‘secondaries’, and the concept of a ‘primary’ metastasis is foreign.
3
acgt:HaematooncologicalTumor
occurs
in
two
places,
firstly
as
a
suboption
for
acgt:MalignNeoplasm,
and
secondly
here
as
a
suboption
below acgt:PrimaryTumor. It is unclear why acgt:Carcinoma or acgt:MammaryCarcinoma do not
also qualify as acgt:MalignNeoplasm and acgt:PrimaryTumor, which is most certainly applicable
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acgt:Thrombus
acgt:TumorCapsule
acgt:TumorCell
acgt:UrogenitalMalformation
acgt:ChemicalSubstance
acgt:Cobalt-60
acgt:PharmaceuticalSubstance
acgt:Actinomycin-D
acgt:Anthracycline
acgt:Adriamycin
acgt:Daunorubicin
acgt:Doxorubicin
acgt:Epirubicin
acgt:Idarubicin
acgt:Rubex
acgt:Arimidex
acgt:Carboplatin
acgt:Cyclophosfamide
acgt:DigitalisGlycoside
acgt:Docetaxel
acgt:Etoposide
acgt:Furosemide
acgt:Herceptin
acgt:Ifosfamide
acgt:Lomustine
acgt:Mannitol
acgt:Methotrexat
acgt:Spironolactone
acgt:Tamoxifen
acgt:Taxotere
acgt:Temozolomide
acgt:Thiazide
acgt:Hydrochlorothiazide
acgt:Trofosfamide
acgt:Vincristine
acgt:Zoladex
acgt:Electron
acgt:Institution
acgt:BioBankingOrganization
acgt:Company
acgt:InsuranceCompany
acgt:ITCompany
acgt:PharmaceuticalCompany
acgt:EthicsCommittee
acgt:FundingInstitution
acgt:Hospital
acgt:GeneralHospital
acgt:NationalHospital
acgt:SpecializedHospital
acgt:PaediatricHospital
acgt:RadiooncologicalHospital
acgt:UniversityHospital
acgt:Institute
acgt:EthicsInstitute
acgt:ITInstitute
acgt:ResearchInstitute
acgt:Laboratory
acgt:StudyCommittee
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acgt:Quantum
acgt:TechnicalObject
acgt:BiopsyNeedle
acgt:DigitalFile
acgt:HearingDevice
acgt:ImplantObject
acgt:LinearParticleAccelerator
acgt:Mask
acgt:PlasterFrame
acgt:ProthesisObject
acgt:VenaCavaProthesisObject
acgt:VacuumCushion
object_aggregate
acgt:Microarray
acgt:AntibodyMicroarray
acgt:DNAMicroarray
acgt:ProteinMicroarray
acgt:TissueMicroarray
acgt:TransfectionMicroarray
object_boundary
site
spatial_region
snap:one_dimensional_region
snap:three_dimensional_region4
acgt:RadiationField
snap:two_dimensional_region5
acgt:Isodose
snap:zero_dimensional_region
occurrent
processual_entity
acgt:StateOfAffairs
acgt:AdhesionIleus
acgt:Alopecia
acgt:Anemia
acgt:Arrhythmia
acgt:Arthralgia
acgt:Asthenia
acgt:Ataxia
acgt:CardiacArrest
acgt:CardiacMurmur
acgt:Fever
acgt:Glomerulopathy
acgt:HearingLoss6
acgt:HearingLoss16To30dB
acgt:HearingLoss31To60dB
acgt:HearingLossGreater60dB
4

snap:three˙dimensional˙region has a single suboption, acgt:RadiationField, which is a 2D structure presented as a field aperture. The relevant snap:three˙dimensional˙region would be
acgt:IrradiatedVolume which already has a standardised definition courtesy of the International Commission on Radiation Units (ICRU).
5
snap:two˙dimensional˙region has a single suboption called acgt:Isodose. This is ambiguous as acgt:Isodose can be considered a 3D structure with a volume in mLs, that is the volume receiving 95% of the reference dose that should cover the entire target volume.
6
acgt:HearingLoss while this option characterises dB loss levels it should also include laterality (right/left) as occurs with acgt:Hemiparesis
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acgt:HearingLossLess15dB
acgt:Hematuria
acgt:Hemiparesis
acgt:LeftHemiparesis
acgt:RightHemiparesis
acgt:Hypertension
acgt:Hypotension
acgt:ImmuneDeficiency
acgt:LostToFollowUp
acgt:Monoparesis
acgt:Myalgia
acgt:Nausea
acgt:Papilledema
acgt:Paraparesis
acgt:Paraplegia
acgt:CompleteParaplegia
acgt:IncompleteParaplegia
acgt:Proteinuria
acgt:PulmonaryEdema
acgt:SensoryDisturbance
acgt:SkinEdema
acgt:Tetraparesis
acgt:Thrombosis
acgt:HepaticVeinOcclusion
acgt:Tubulopathy
acgt:Unconsiousness
acgt:Coma
acgt:Somnolence
acgt:Stupor
fiat_process_part
acgt:Cycle
acgt:CardiacCycle
acgt:MenstrualCycle
acgt:TreatmentCycle
acgt:PharmacotherapyCycle
acgt:ChemotherapyCycle
acgt:DocetaxelCycle
acgt:EpirubicinCycle
process
acgt:IntentionalProcess
acgt:AdministrativeProcess
acgt:CareProcess
acgt:NursingCare
acgt:ParenteralFeeding
acgt:PsychosocialCare
acgt:MedicalProcess
acgt:DiagnosticProcess
acgt:Audiometry
acgt:Autopsy
acgt:Biopsy
acgt:BiopsyWithIncision
acgt:BiopsyWithoutIncision
acgt:ConeBiopsy
acgt:CoreNeedleBiopsy
acgt:SuctionAssistedCoreBiopsy
acgt:EndoscopicBiopsy
acgt:FineNeedleBiopsy
acgt:PunchBiopsy
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acgt:SurfaceBiopsy
acgt:TrucutBiopsy
acgt:BloodPressureMeasuringProcess
acgt:CellCounting
acgt:TumorCellCounting
acgt:CerebrospinalLiquidPuncture
acgt:LumbarCerebrospinalFluidPuncture
acgt:VentricularCerebrospinalFluidPuncture
acgt:ClinicalExamination
acgt:CytogeneticExamination
acgt:CytologicalExamination
acgt:ECG
acgt:HematologicalBiochemicalTest
acgt:AlkalinePhosphataseTest
acgt:ANC
acgt:CountingPlatelets
acgt:CountingRedBloodCells
acgt:EPOLevelTest
acgt:HbTest
acgt:SerumCreatinineTest
acgt:TotalBilirubinTest
acgt:TransaminaseBiochemistry
acgt:TroponinTest
acgt:WBC
acgt:HistologicalExamination7
acgt:DCISHistologicalAssessment
acgt:ERHistologicalAssessment
acgt:HistopathologicTypeAssessment
acgt:InvasiveDuctalCarcinomaAssessment
acgt:InvasiveLobularCarcinomaAssessment
acgt:LCISHistologicalAssessment
acgt:PRHistologicalAssessment
acgt:Imaging8
acgt:Computertomography
acgt:MagneticResonanceImaging
acgt:NuclearImaging
acgt:MUGAScan
acgt:RoentgenologicalImaging
acgt:ReferenceRoentgenologicalImaging
acgt:Scintigraphy
acgt:BoneScintigraphy
acgt:Ultrasound
acgt:Echocardiography
acgt:ImmunohistochemicalExamination
acgt:Inking
acgt:MacropathologicalExamination
acgt:MalignancyRelatedDiagnosticProcess
acgt:MicropathologicalExamination
7

acgt:HistologicalExamination
has
a
number
of
suboptions
which
all
relate to BREAST cancer only. The acgt:HistologicalExamination
of other cancers such as prostate
brain
oesophagus
lung
and pancreas are not included. Even within the setting of acgt:HistologicalExamination of breast cancers there is no acgt:TumourGradeAssessment or acgt:TumourLymphaticInvasionAssessment.
8
acgt:Imaging has a wide range of suboptions
however the subsuboptions are not comprehensive. For example there is no acgt:PETScan. Furthermore, acgt:Scintigraphy does not include acgt:ThyroidScan, acgt:GalliumScan or acgt:sestamibiScan. There are even more.
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acgt:MoleculargeneticExamination
acgt:NeurologicalExamination
acgt:OphtalmologicalDiagnosticProcess
acgt:PregnancyTest
acgt:PrenatalDiagnosticProcess
acgt:ProphylacticCheckUp
acgt:Screening
acgt:SputumExam
acgt:Surveillance
acgt:TumorClassAssessment
acgt:NodalStatusAssessment
acgt:TumorGradeAssessment
acgt:UrineExam
acgt:TherapeuticProcess
acgt:DoseModulation
acgt:DoseIncrease
acgt:DoseReduction
acgt:Drainage
acgt:LiquorDrainage
acgt:VentriculoAtrialLiquorDrainage
acgt:VentriculoPeritonealLiquorDrainage
acgt:GeneTherapy
acgt:InducedAbortion
acgt:Infusion
acgt:Overdosage
acgt:Pharmacotherapy9
acgt:AntiarrhythmicPharmacotherapy
acgt:Chemotherapy10
acgt:ABVDChemo
acgt:ACChemo
acgt:BEPChemo
acgt:C-VAMPChemo
acgt:CAFChemo
acgt:CapecitabineDocetaxelChemo
acgt:CarboplatinEtoposideChemo
acgt:CAVChemo
acgt:ChlVPPChemo
acgt:CHOPChemo
acgt:CisplatinFluorouracilChemo
acgt:CMFChemo
acgt:DeGramontChemo
acgt:DHAPandARDHAPChemo
acgt:DocetaxelCisplatinChemo
acgt:DoxorubicinIfosfamideChemo
acgt:E-CMFChemo
acgt:ECChemo
acgt:ECFChemo
acgt:ECXChemo
acgt:EEXChemo
9

acgt:Pharmacotherapy has a number of suboptions which do not include small molecule therapies (erlotinib etc) or the monoclonal antibodies (trastuzumab etc).
10
It is debatable whether the options listed under acgt:Chemotherapy represent correct knowledge enbgineering. acgt:ABVDChemo is actually a combination four drugs each with their own dosing and scheduling which can vary from institution to institution. There is even no guarantee that the acgt:ABVDChemo of two oncologists in the Illawarra Cancer Care Centre will be identical.
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acgt:ELFChemo
acgt:ESHAPandR-ESHAPChemo
acgt:EtoposideCisplatinChemo
acgt:FECChemo
acgt:GemCapChemo
acgt:GemCarboChemo
acgt:GemicitabineCisplatinChemo
acgt:GemTaxolChemo
acgt:ICEChemo
acgt:IrinotecanWithDeGramontChemo
acgt:MayoChemo
acgt:MICChemo
acgt:MMChemo
acgt:MMMChemo
acgt:MTXChemo
acgt:MVPChemo
acgt:OralMaintainanceChemo
acgt:TEOralMaintainanceChemo
acgt:TIOralMaintainanceChemo
acgt:TMZOralMaintainanceChemo
acgt:Oxaliplatin5FUChemo
acgt:PaclitaxelCarboplatinChemo
acgt:PCVChemo
acgt:PemetrexedCisplatinChemo
acgt:PMitCEBOChemo
acgt:TACChemo
acgt:TandemChemotherapy
acgt:VADChemo
acgt:VAPEC-BChemo
acgt:VCDChemo
acgt:VDChemo
acgt:VinorelbineCarboplatinChemo
acgt:VinorelbineCisplatinChemo
acgt:w-VDChemo
acgt:HormonalTreatment
acgt:HRT
acgt:ERT
acgt:LHRHAnalogTreatment
acgt:Immunotherapy
acgt:SupportivePharmacotherapy
acgt:Physiotherapy
acgt:Purging
acgt:CD34SelectionPurging
acgt:Radiotherapy11
acgt:Brachytherapy
acgt:Teletherapy
acgt:BathIrradiation
11

acgt:Radiotherapy
This section is grossly incomplete. There is no commonality in the concepts of acgt:Brachytherapy and acgt:BoostIrradiation. The former is a method of delivering dose using radioactive implants, while the latter relates to a method called ‘‘shrinking field technique’’ where the radiation dose is escalated in the area of highest risk through any delivery
method.
acgt:BathIrradiation
is
not
a
generally
accepted
term.
Finally both acgt:MultipleFieldIrradiation and acgt:OpposingFieldIrradiation describe radiation beam arrangements and since acgt:OpposingFieldIrradiation uses TWO fields, it is an example of acgt:MultipleFieldIrradiation.
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acgt:BoostIrradiation
acgt:MultipleFieldIrradiation
acgt:OpposingFieldIrradiation
acgt:StemCellHarvesting
acgt:FirstStemCellHarvesting
acgt:StemCellMobilisation
acgt:ChemoPlusHGFStemCellMobilisation
acgt:ChemoStemCellMobilisation
acgt:HGFStemCellMobilisation
acgt:SurgicalProcedure
acgt:SurgicalApproach
acgt:CardiopulmonaryBypass
acgt:EpigastricTransverseIncision
acgt:LongitudinalIncision
acgt:ThoracoAbdominalApproach
acgt:TransversalApproach
acgt:SurgicalOperation
acgt:Amputation
acgt:EmergencySurgery
acgt:LymphNodeDissection12
acgt:AxillaryNodeDissection
acgt:ReconstructiveBreastSurgery
acgt:Resection
acgt:BreastResection
acgt:Adenomastectomy
acgt:Mastopexy
acgt:Lumpectomy
acgt:Mastectomy
acgt:PartialMastectomy
acgt:Quadrantectomy
acgt:SegmentalMastectomy
acgt:PateyMastectomy
acgt:TotalMastectomy
acgt:MaddenMastectomy
acgt:SkinSparingTotalMastectomy
acgt:SubcutaneousMastectomy
acgt:Hysterectomy
acgt:PartialHysterectomy
acgt:TotalHysterectomy
acgt:Lobectomy
acgt:Metastasectomy
acgt:Nephrectomy
acgt:PartialNephrectomy
acgt:Enucleation
acgt:StandardPartialNephrectomy
acgt:WedgeResection
acgt:TotalNephrectomy
acgt:Ovariectomy
acgt:BilateralOvariectomy
acgt:UnilateralOvariectomy
12

acgt:LymphNodeDissection
has
a
single
suboption,
acgt:AxillaryNodeDissection.
There
is
the
possibility
of
lymph
node
dissection
in
any
of
the
nodal
bearing
areas of the body, e.g., acgt:PelvicNodeDissection, acgt:ParaAorticDissection,
acgt:MediastinalNodeDissection, acgt:HilarNodeDissection, acgt:CervicalNodeDissection,
acgt:PortaHepatisNodeDissection.
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acgt:Pneumonectomy
acgt:TumorResection
acgt:PartialTumorResection
acgt:SubtotalTumorResection
acgt:TotalTumorResection13
acgt:ExcisionalBiopsy
acgt:Transplantation
acgt:SurgicalSuture
acgt:Transfusion
acgt:ErythrocyteTransfusion
acgt:ThrombocyteTransfusion
acgt:MolecularBiologyTechnique
acgt:DNAReplication
acgt:PCR
acgt:Immunostaining
acgt:ELISA
acgt:FlowCytometry
acgt:ICC
acgt:IHC
acgt:ImmunoEM
acgt:WesternBlotting
acgt:MicroarrayHybridization
acgt:ResearchProcess14
acgt:Experiment
acgt:MicroarrayExperiment
acgt:Suicide
acgt:NaturalProcess
acgt:IonizingRadiation
acgt:OrganismalProcess
acgt:Adhesion
acgt:PathologicalAdhesion
acgt:PlateletAdhesion
acgt:Bleeding15
acgt:CerebralHemorrhage
acgt:SkinHemorrhage
acgt:Bulging
acgt:CerebralSeizure
acgt:CharacterChange
acgt:ChromosomeAberration
acgt:ConvulsiveSeizure
acgt:Coughing
acgt:CreatinineClearance
acgt:Deglutition
13

acgt:TotalTumourResection has one suboption, acgt:ExcisionalBiopsy which is not an example of total tumour resection. A biopsy, by its very nature, is not an attempt at complete tumour resection. It is at best a acgt:PartialTumourResection.
14
acgt:ResearchProcess has the suboptions, acgt:Experiment and acgt:MicroArrayExperiment.
This
is
only
one
type
of
research
process
that
might
be
undertaken
in
an
oncological
setting.
More
prevalent
would
be
a
subsuboption like acgt:ClinicalExperiment further characterised with the subsubsuboption acgt:RandomisedClinicalExperiment. This area might also be expanded to include the concepts of the various Phase I-III designations.
15
acgt:Bleeding has the suboptions of acgt:CranialBleeding and acgt:SkinBleeding. Bleeding can occur in all organs which are supplied by blood, therefore the pattern, acgt:[Organ]Bleeding, should be used with organ name substitution
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acgt:Desquamtation
acgt:Diarrhea
acgt:DiseaseProcess
acgt:InfectiousDiseaseProcess
acgt:BacterialInfectionProcess
acgt:ViralInfectionProcess16
acgt:ChronicViralInfectionProcess
acgt:NonInfectiousDiseaseProcess
acgt:AlcoholismProcess
acgt:HematologicalDiseaseProcess
acgt:CoagulopathyProcess
acgt:HematologicalMalignancyProcess
acgt:LeukemiaProcess
acgt:HypertoniaProcess
acgt:NeuropathyProcess17
acgt:MotorNeuropathyProcess
acgt:SensoryNeuropathyProcess
acgt:NeutropeniaProcess
acgt:SIOPRelevantHistoryProcess
acgt:SyndromeProcess18
acgt:AniridiaProcess
acgt:BuddChiariSyndromeProcess
acgt:DrashProcess
acgt:HemiHypertrophyProcess
acgt:PerlmanProcess
acgt:RhabdoidTumorPredispositionSyndromProcess
acgt:StuartBrasSyndromeProcess
acgt:WAGRProcess
acgt:WiedemannBeckwithEMGProcess
acgt:SystemicNonInfectiousDiseaseProcess
acgt:TabagismProcess
acgt:Dyspnea
acgt:Enanthema
acgt:Engraftment
acgt:Epitheliolysis
acgt:ErythemaDevelopment
acgt:Fibrosis
acgt:GeneExpression
acgt:GeneticMutation19
acgt:GeneticDelationMutation
acgt:Headache
acgt:Hearing
acgt:HeartFunctioning
acgt:Hernia20
16

acgt:ViralInfectionProcess has one suboption, acgt:ChronicViralInfectionProcess.
There should also be an acgt:AcuteViralInfectionProcess option.
17
acgt:NeuropathyProcess has the suboptions of acgt:MotorNeuropathyProcess and
acgt:SensoryNeuropathyProcess which is incomplete. There should also be
acgt:AutonomicNeuropathyProcess
18
acgt:SyndromeProcess lists formally recognised eponomous medical patterns, however the list is very limited as there are many more syndromic names.
19
acgt:GeneticMutation has a suboption, acgt:GeneticDelationMutation, which is mispelt (acgt:GeneticDeletionMutation), but should include other mutational mechanisms like acgt:GeneticSubstitutionMutation and acgt:GeneticInsertionMutation.
20
acgt:Hernia has the suboption of acgt:DiaphragmaticHernia but this is poorly organ-
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acgt:DiaphragmaticHernia
acgt:IncisionalHernia
acgt:Immunoreaction
acgt:Infection21
acgt:WoundInfection
acgt:Infiltration
acgt:Inflammation22
acgt:Stomatitis
acgt:IntentionTremor
acgt:Invagination
acgt:KidneyFunctioning
acgt:Labor
acgt:Lactation
acgt:Life
acgt:Menopause
acgt:Menstruation
acgt:Metabolism
acgt:Metaplasia
acgt:Anaplasia
acgt:PathologicalAnaplasia
acgt:DiffuseAnaplasia
acgt:FocalAnaplasia
acgt:MultifocalAnaplasia
acgt:PhysiologicalAnaplasia
acgt:Misscarriage
acgt:MotoricCoordination
acgt:Mucositis
acgt:Necrosis
acgt:Infarction23
acgt:IntestinalInfarction
acgt:NeuroendocrinologicalProcess
acgt:NeuropsychologicalProcess
acgt:NightSweating
acgt:Nystagmus
acgt:Obstruction24
acgt:VenaCavaObstruction
acgt:OrganismalEpilation
acgt:Osteochondritits
acgt:Otitis
ised. The suboption, acgt:AnatomicHernia, should be expanded with subsuboptions including acgt:DiaphragmaticHernia, acgt:InguinalHernia and acgt:FemoralHernia, among others.
21
acgt:Infection
has
a
single
suboption
acgt:WoundInfection.
However should there also be acgt:SpontaneousInfection for infections that do not occur at a wound site.
22
acgt:Inflammation has a single suboption - acgt:Stomatitis. Other inflammations should be included e.g., acgt:Dermatitis, acgt:Mucositis, acgt:Oesophagitis
acgt:Nephritis, and more.
23
acgt:Infarction or death of tissue has a single suboption (acgt:IntestinalInfarction) but none for
the more common acgt:CardiacInfarction and acgs:LungInfarction. Other organs could also be included.
24
acgt:Obstruction has a single sub-option - acgt:VenaCavaObstruction. Other obstructions such as acgt:IntestinalObstruction, acgt:UretericObstruction
acgt:LymphaticObstruction, acgt:TrachealObstruction, acgt:OesophagealObstruction,
acgt:GastricObstruction, acgt:BiliaryTreeObstruction, acgt:CSFObstruction are not included.
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acgt:ExternalOtitis
acgt:MedialOtitis
acgt:Parturition
acgt:Pigmentation
acgt:Pregnancy
acgt:RelapseFreeSurvival
acgt:Rupture
acgt:MajorRupture
acgt:MinorRupture
acgt:Sepsis
acgt:Sight
acgt:SkinResponse
acgt:Teleangiectasia
acgt:TubulesFunctioning
acgt:TumorDevelopment
acgt:TumorProgress
acgt:TumorRegression
acgt:TumorRelapse25
acgt:LocalTumorRelapse
acgt:TumorRemission
acgt:CompleteTumorRemission
acgt:PartialTumorRemission
acgt:TumorStagnation
acgt:Ulceration
acgt:VegetativeFunctioning
acgt:Vomiting
acgt:WoundDehiscence
process_aggregate
acgt:RegularCheckup
acgt:ChildhoodRegularCheckup
acgt:PrenatalCheckUp
process_boundary
acgt:ProcessEnd
acgt:Death
acgt:MeasuringProcessEnd
acgt:EndOfConcentrationMeasuringProcess
acgt:EndOfDensityMeasuringProcess
acgt:EndOfFrequencyMeasuringProcess
acgt:EndOfPressureMeasuringProcess
acgt:EndOfBloodPressureMeasuringProcess
acgt:EndOfCranialPressureMeasuringProcess26
acgt:EndOfRoomPressureMeasuringProcess
acgt:EndOfTirePressureMeasuringProcess
acgt:EndOfWeightMeasuringProcess
acgt:RecordingProcessEnd
acgt:EndOfFrequencyRecordingProcess
acgt:EndOfPressureRecordingProcess
acgt:EndOfBloodPressureRecordingProcess
acgt:EndOfRoomPressureRecordingProcess
acgt:EndOfTirePressureRecordingProcess
acgt:EndOfWeightRecordingProcess
25

acgt:TumorRelapse has a single sub-option called acgt:LocalTumorRelapse excluding equivalent categories like acgt:RegionalTumorRelapse and acgt:DistantTumorRelapse.
26
acgt:EndOfCranialPressureMeasuringProcess
has
no
corresponding
entity to start the cranial pressure measuring process; there should be an entry called acgt:StartOfCranialPressureMeasuringProcess.
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acgt:ProcessStart
acgt:Birth
acgt:MeasuringProcessStart
acgt:StartOfDensityMeasuringProcess
acgt:StartOfFrequencyMeasuringProcess
acgt:StartOfLengthMeasuringProcess
acgt:StartOfPressureMeasuringProcess
acgt:StartOfBloodPressureMeasuringProcess
acgt:StartOfRoomPressureMeasuringProcess
acgt:StartOfTirePressureMeasuringProcess
acgt:StartOfTemperatureMeasuringProcess
acgt:RecordingProcessStart
acgt:StartOfDensityRecordingProcess
acgt:StartOfFrequencyRecordingProcess
acgt:StartOfPressureRecordingProcess
acgt:StartOfBloodPressureRecordingProcess
acgt:StartOfRoomPressureRecordingProcess
acgt:StartOfTirePressureRecordingProcess
acgt:StartOfTemperatureRecordingProcess
acgt:StartOfPatientTemperatureRecordingProcess
acgt:StartOfRoomTemperatureRecordingProcess
acgt:StartOfSampleTemperatureRecordingProcess
processual_context
spatiotemporal_region
connected_spatiotemporal_region
spatiotemporal_instant
spatiotemporal_interval
scattered_spatiotemporal_region
temporal_region
connected_temporal_region
temporal_instant
temporal_interval
acgt:Day
acgt:Hour
acgt:Minute
acgt:Month
acgt:Second
acgt:Week
acgt:Year
scattered_temporal_region
owl:AllDisjointClasses
owl:AsymmetricProperty
owl:IrreflexiveProperty

Appendix I
The CKML superstructure used in
the following appendices for
Routine Clinical Work, Clinical
Trial Protocol, Clinical Trial
Report and Clinical Guideline
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The Clinical Knowledge Markup Language can be use to provide the work flow
oriented structure to the knowledge contained in Routine Clinical Work, a Clinical
Trial Protocol, the subsequent Clinical Trial Report in the literature and a Clinical
Practice Guideline.

<Organisation>
** REGISTRATION
<Department>
<Doctor>
<Trial> | <Guideline> | <Patient> | <Report>
** CONSULTATION
<BiologicalMilieu>
<PsychologicalMilieu>
<Diagnosis>
<Cancer>
<CancerDiagnosisDate>
<CancerSymptoms>
<CancerSigns>
<CancerPrognosis>
<CancerImaging>
<CancerMarkers>
<CancerDiagnosis>
<Histopathology>
<Cytology>
<CancerStage>
<TrialEligibility>
<GuidelineEligibility>
<TreatmentIntent>
<TrialArm>
<TrialArmName>
<TrialArmSummary>
<Therapy>
** TREATMENT PREPARATION
** TREATMENT DELIVERY
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<Surgery>
<Radiotherapy>
<Chemotherapy>
** FOLLOW UP
<CancerOutcome>
<PsychologicalMilieu>
<CancerResponse>
<CancerLocalRecurrence>
<CancerRegionalRecurrence>
<CancerDistantRecurrence>
<CancerDeath>
<TrialOutcome>
<LateSideEffects>

Appendix J
A CKML subset for use in a
Routine Clinical Work with
example
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J.1. The Clinical History
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The patient data reported here is anonymous and is derived from the chart of a
patient treated locally. The names and dates pertaining to the patient have been
changed. The patient whose data is displayed has granted permission to use this data,
firstly in the form of a departmental release to use data for research purposes which is
held in the clinical record, as well as a subsequent verbal confirmation in 2011 before
thesis submission.

J.1

The Clinical History

The following clinical history may require input from a domain expert to assert that
it is a consistent account of a patient’s cancer journey. If the reader finds the domain
specific terms unfamiliar, a brief reading of this text by a radiation oncologist will
confirm that it is intelligible.
The patient was treated at the Illawarra Cancer Care Centre by Dr
Alexis Andrew Miller. The patient, LARRY LOLLIPOP was a male
born on 15/03/1949 in Wollongong. His hospital ID is 99999999. He
is a causasian with tertiary qualifications, and an income of $100,000150,000 per year earned in a professional job. He is a property owner.

He was a well man. His creatinine clearance was measured as 80 mLs/min
using the Cockcroft-Gault algorithm. He has normal peripheral nerve
motor function, normal peripheral nerve sensory function and normal auditory function with no auditory function loss. He takes no medical drugs.
He is not smoking. He ceased smoking in 1994 before which he was smoking cigarettes at 1 packet per day for 20 years. He drinks wine every
days at the rate of 4 drinks per day and 28 drinks per week. He had
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a performance status of 0 on 02/04/2009, and a performance status of
0 on 17/10/2011. Actuarial estimates give him 35 years of remaining life.

He was diagnosed with a colon cancer (C18.7) on 03/03/1998 which
was an adenocarcinoma (8140/3) with moderate differentiation (G2).
Immunohistochemistry was positive for CK7. The tumour was staged
at Stage IIa. Pathologic staging revealed a T3 (3.0 CM) local tumour
with N0 (0/9) nodes. Image-based staging revealed no metastases (M0).
The intent of treatment was cure and primary surgery was undertaken for
the purposes of locoregional control using a sigmoid colectomy which
achieved an R0 resection and no complications. He received no radiotherapy and no chemotherapy after the operation. When assesed on 10/05/1998,
no measurable disease was found, in particular the primary had a CR
and the nodes had a CR. There was no evidence of local recurrence on
06/11/2011, no evidence of regional recurrence on 06/11/2011 and no
evidence of distant recurrence on 06/11/2011. When last seen on 06/11/2011
he was alive.

He was disagnosed with a base of tongue cancer (C01) on 06/03/2009
with symptoms of right otalgia, dysphagia, neck swelling and no weight
loss and signs of an exophytic tongue base lesion crossing midline and
extending down to the vallecula with a right level II/III firm mobile
node and a left level II firm mobile node. A CT scan was undertaken of
the Head & Neck because of symptoms. A FDG-PET was undertaken
on 11/03/2009 which reported “An FDG PET scan was performed
from vertex to proximal femora with a low dose non-contrast CT scan
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for attenuation correction and localisation. SCAN FINDINGS: The
known primary lesion in the right tongue base demonstrates intense
FDG accumulation (maximum SUV = 8.9) with apparent extension
inferiorly to just above the level of the valleculla. Moderate to intense FDG uptake was demonstrated within several enlarged lymph
nodes in the right upper cervical regions (level II) with the most intense uptake localising to the largest lymph node measuring 27mm
in the right submandibular region and the 22 mm lymph node more
superiorly. Mildly increased FDG uptake was also seen in several level
II lymph nodes in the left upper cervical region. Tracer distribution
the remainder of the study was within physiologic limits (prominent
uptake was seen in the left tongue/tonsillar region most likely physiological). CONCLUSION: The known primary malignancy in the right
tongue base which appears to extend inferiorly to just above the level
of the valleculla is intensely metabolically active. There is evidence of
bilateral cervical (level II) lymph node metastases, much larger and
more intense on the right. No evidence of metabolically active disease
in the remainder of the study.” The maximum SUV was 8.9.

Histopathology was reported as a Basaloid squamous cell carcinoma
(8083/3 with poor differentiation (G3). Immunohistochemistry was positive for CK7. The tumour was staged at Stage IVa. Image-based staging
revealed a T4a tumour with a size of 55 mm, local tumour with infiltration of muscles of the tongue, and N2c with 2 nodes, one on the right
measuring 27mm in level II, and one on the left measuring 22mm in level
II. Image-based staging revealed a no metastases (M0).
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He was eligible for inclusion on trial TROG.02.02, and also for guidelines
NCCN H&N ADVANCED, BCCC OROPHARYNX, SIGN H&N and
ICCC ReScan Protocol. He was entered on the ICCC ReScan Protocol.

The intent of treatment was cure. The therapies to be used consisted of
no surgery¿, primary external beam radiotherapy, no brachytherapy, and
concurrent chemotherapy. Supportive therapy consisted of a prophylactic
PEG tube inserted on 02/04/2009 and removed on 22/07/2009.

The radiation prescription called for 70 GY in 35 FX treated 1 per day,
5 per week with BD compensation for treatment breaks, using photons
(6MV) with IMRT using non-coplanar beams. Radiation was prescribed
to a non-ICRU prescription point.

The patient underwent radiotherapy simulation in a supine position with
an immobilisation mask and bolus. Field imaging utilised digitally reconstructed radiographs and a simulation CT.

Target volumes for the IMRT technique consisted of a PTV7000 with
a prescription dose of 70GY/35FX which was a 3mm expansion of the
CTVp, which was based on the GTVp with a 5mm expansion, and a
3mm expansion of the CTVn, which was based on the GTVn with a 5mm
expansion.
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Target volumes for the IMRT technique consisted of a PTV6000 with
a prescription dose of 60GY/35FX which was a 3mm expansion of the
CTVp, which was based on the GTVp with a 5mm expansion, and a 3mm
expansion of the CTVn, which was based on the GTVn with a 5mm expansion, and a 3mm expansion of the CTVn0, which was based on the UNINVOLVED LYMPH NODES with a 5mm expansion. Planning contours
includes the spinal cord, right parotid gland, left parotid gland, right
submandibular gland, left submandibular gland, mucosa, and mandible.

During Radiotherapy Planning, PTV dose heterogeneity ranged between
-5% and +7%. For the spinal cord (SPINAL CORD), the Organ At Risk
dose constraint set to ¡45Gy, for the right parotid gland it was less than
a mean of 26Gy, for the left parotid gland it was less than a mean
of 26Gy, for the right submandibular gland it was less than a mean
of 26Gy, for the left submandibular gland it was less than a mean of
26Gy, for the mucosa it was as low as reasonably achievable, and for
the mandible it was as low as reasonably achievable.

The concurrent chemotherapy regime was Weekly Cisplatin given over
7 cycles that started with radiotherapy and lasted 1 week each. On
day 1 of the cycle, cisplatin at a dose of 40mg/m2 was administered intravenously as a 1 hour infusion starting 1 hour before radiotherapy,
supported with IV hydration of 500mL normal saline and an antiemetic
drug. During the chemotherapy he developed febrile neutropaenia, and
suffered a hospital admission from 20/05/2009 to 22/05/2009. He also
developed dehydration.
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Following the completion of treatment his response was assessed with a
FDG-PET on 10/08/2009 which reported CONCLUSION: The scan
findings suggest good partial metabolic response with mild uptake in
the anterior aspect of the primary tumour at the base of the tongue
and also mild uptake in residual upper cervical lymph nodes, suggestive of residual disease. No new focus of FDG-avid disease is seen.
There was no measurable disease, and according to RECIST criteria, the
primary response was scored as a CR, and the nodal response was scored
as a CR.

There was no local recurrence on 06/11/2011, no regional recurrence on
06/11/2011 and no distant recurrence on 06/11/2011. He was alive
on 06/11/2011. The late side effects suffered on 6/10/2011 consisted
of G1 late effects in the skin, G0 late effects in subcutaneous tissue, G2
late effects in mucosa, G0 late effects in the spinal cord, G0 late effects in
larynx, and G0 late effects in feeding.

J.2

The CKML coding of this Clinical History

Using the CKML structure described in Appendix I, the clinical history was translated
into the CKML structure. All unused criteria have been removed.

<Organisation>
<Department>ILLAWARRA CANCER CARE CENTRE
<Doctor>ALEXIS ANDREW MILLER</Doctor>
</Department>
<Patient>
<PatientID>
<LastName>LOLLIPOP</LastName> * a pseudonym
<FirstName>LARRY</FirstName>
<Gender>
<Male>YES</Male>
</Gender>
<UniqueID>99999999
<DateOfBirth>32/13/1949</DateOfBirth>
<PlaceOfBirth>WOLLONGONG</PlaceOfBirth>
</UniqueID>
</PatientID>
<Demographics>
<Race>CAUSACIAN</Race>
<Education>TERTIARY</Education>
<Income>100,000-150,000</Income>
<Employment>PROFESSIONAL</Employment>
<Housing>PROPERTY OWNER</Housing>
</Demographics>
<BiologicalMilieu>
<Physiology>
<RenalFunction>
<CreatinineClearance>80
<CreatinineClearanceAlgorithm>COCKCROFT-GAULT</CreatinineClearanceAlgorithm>
</CreatinineClearance>
</RenalFunction>
<PeripheralNerveFunction>
<PeripheralNerveMotorFunction>NORMAL</PeripheralNerveMotorFunction>
<PeripheralNerveSensoryFunction>NORMAL</PeripheralNerveSensoryFunction>
</PeripheralNerveFunction>
<AuditoryFunction>NORMAL
<AuditoryFunctionLoss>NONE</AuditoryFunctionLoss>
</AuditoryFunction>
<DrugUse>
<DrugUseMedical>NO</DrugUseMedical>
<DrugUsePersonal>
<Smoking>
<SmokingCurrent>NO</SmokingCurrent>
<SmokingPast>
<SmokingCessationDate>1994</SmokingCessationDate>
<SmokingDevice>CIGARETTE
<SmokingDevicePerDay>1 PKT</SmokingDevicePerDay>
<SmokingDevicePerDayDuration>20 YEARS</SmokingDevicePerDayDuration>
</SmokingDevice>
</SmokingPast>
</Smoking>
<Ethanol>
<EthanolCurrent>
<EthanolForm>WINE
<StandardDrinksPerWeekDay>4</StandardDrinksPerWeekDay>
<StandardDrinksPerWeek>28</StandardDrinksPerWeek>
</EthanolForm>
</EthanolCurrent>
</Ethanol>
</DrugUsePersonal>
</DrugUse>
</Physiology>
<PerformanceStatus>
<DateofAssessment>02/04/2009
<PerformanceStatusECOG>0</PerformanceStatusECOG>
</DateofAssessment>
<DateofAssessment>17/10/2011
<PerformanceStatusECOG>0</PerformanceStatusECOG>
</DateofAssessment>
</PerformanceStatus>
<ActuarialSurvival>35 YEARS</ActuarialSurvival>
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</BiologicalMilieu>
<Diagnosis>
<Cancer>
<CancerDiagnosis>
<ICD0>C18.7</ICD0>
<CancerDiagnosisDate>03/03/1998</CancerDiagnosisDate>
<Histopathology>
<Morphology>ADENOCARCINOMA
<ICD0Morphology>8140/3</ICD0Morphology>
</Morphology>
<Differentiation>G2</Differentiation>
<Immunohistochemistry>
<IHC-CK7>POSITIVE</IHC-CK7>
</Immunohistochemistry>
</Histopathology>
<CancerStage>
<Stage>IIa</Stage>
<T_Stage>T3
<T_stagebasis>PATHOLOGIC</T_stagebasis>
<T_size>3.0 CM</T_size>
</T_Stage>
<N_Stage>N0
<N_stagebasis>PATHOLOGIC</N_stagebasis>
<N_numberexamined>9</N_numberexamined>
<N_numberpositive>0</N_numberpositive>
</N_Stage>
<M_Stage>M0
<M_stagebasis>IMAGING</M_stagebasis>
</M_Stage>
</CancerStage>
<TreatmentIntent>CURE
<Therapy>
<Surgery>
<Importance>PRIMARY</Importance>
<SurgicalIndication>LOCOREGIONAL CONTROL
<SurgicalProcedure>SIGMOID COLECTOMY
<SurgicalComplications>NIL</SurgicalComplications>
<SurgicalResectionStatus>R0</SurgicalResectionStatus>
</SurgicalProcedure>
</SurgicalIndication>
</Surgery>
<Radiotherapy>
<ExternalBeam>
<Importance>NO</Importance>
</ExternalBeam>
</Radiotherapy>
<Chemotherapy>
<Importance>NO</Importance>
</Chemotherapy>
</Therapy>
<CancerOutcome>
<CancerResponse>
<DateofResponseMeasure>01/01/2009
<RECISTcriteria>
<MeasurableDisease>NO</MeasurableDisease>
<RECIST-Primary>CR</RECIST-Primary>
<RECIST-Nodal>CR</RECIST-Nodal>
</RECISTcriteria>
</DateofResponseMeasure>
</CancerResponse>
<CancerLocalRecurrence>NO
<CancerLocalRecurrenceDate>06/11/2011</CancerLocalRecurrenceDate>
</CancerLocalRecurrence>
<CancerRegionalRecurrence>NO
<CancerRegionalRecurrenceDate>06/11/2011</CancerRegionalRecurrenceDate>
</CancerRegionalRecurrence>
<CancerDistantRecurrence>NO
<CancerDistantRecurrenceDate>06/11/2011</CancerDistantRecurrenceDate>
</CancerDistantRecurrence>
<CancerDeath>NO
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<DateOfDeath>06/11/2011</DateOfDeath>
</CancerDeath>
</CancerOutcome>
</TreatmentIntent>
</CancerDiagnosis>
<CancerDiagnosis>
<ICD0>C01</ICD0>
<CancerDiagnosisDate>06/03/2009</CancerDiagnosisDate>
<CancerSymptoms>RIGHT OTALGIA; DYSPHAGIA; NECK SWELLING; NO WEIGHT LOSS</CancerSymptoms>
<CancerSigns>FIRM EXOPHYTIC TONGUE BASE LESION CROSSING MIDLINE AND DOWNTO VALLECULA;
RIGHT LEVEL II/III FIRM MOBILE NODE; LEFT LEVEL II FIRMMOBILE NODE </CancerSigns>
<CancerImaging>
<AnatomicalImaging>
<CTscan>
<CTscanRegion>HEAD and NECK</CTscanRegion>
<CTscanRegionReason>SYMPTOMS</CTscanRegionReason>
</CTscan>
</AnatomicalImaging>
<FunctionalImaging>
<FDG-PET>
<FDG-PETdate>11/03/2009</FDG-PETdate>
<FDG-PETreport>An FDG PET scan was performed from vertex to proximal femora with a low dose
non-contrast CT scan for attenuation correction and localisation. SCAN FINDINGS: The known
primary lesion in the right tongue base demonstrates intense FDG accumulation (maximum
SUV = 8.9) with apparent extension inferiorly to just above the level of the valleculla. Moderate to
intense FDG uptake was demonstrated within several enlarged lymph nodes in the right upper
cervical regions (level II) with the most intense uptake localising to the largest lymph node
measuring 27mm in the right submandibular region and the 22 mm lymph node more superiorly.
Mildly increased FDG uptake was also seen in several level II lymph nodes in the left upper cervical
region. Tracer distribution the remainder of the study was within physiologic limits (prominent
uptake was seen in the left tongue/tonsillar region most likely physiological). CONCLUSION: The
known primary malignancy in the right tongue base which appears to extend inferiorly to just above
the level of the valleculla is intensely metabolically active. There is evidence of bilateral cervical
(level II) lymph node metastases, much larger and more intense on the right. No evidence of
metabolically active disease in the remainder of the study.</FDG-PETreport>
<FDG-PETmaximumSUV>8.9</FDG-PETmaximumSUV>
</FDG-PET>
</FunctionalImaging>
</CancerImaging>
<Histopathology>
<Morphology>Basaloid squamous cell carcinoma
<ICD0Morphology>8083/3</ICD0Morphology>
</Morphology>
<Differentiation>G3</Differentiation>
<Immunohistochemistry>
<IHC-CK7>POSITIVE</IHC-CK7>
</Immunohistochemistry>
</Histopathology>
<CancerStage>
<Stage>IVa</Stage>
<T_Stage>T4a
<T_stagebasis>IMAGING</T_stagebasis>
<T_size>5.5cm</T_size>
<T_infiltration>muscles of tongue</T_infiltration>
</T_Stage>
<N_Stage>N2c
<N_stagebasis>IMAGING</N_stagebasis>
<N_numberpositive>2
<N_laterality>RIGHT
<N_maxsize>27MM</N_maxsize>
<N_necklevel>II</N_necklevel>
</N_laterality>
<N_laterality>LEFT
<N_maxsize>22MM</N_maxsize>
<N_necklevel>II</N_necklevel>
</N_laterality>
</N_numberpositive>
</N_Stage>
<M_Stage>M0
<M_stagebasis>IMAGING</M_stagebasis>
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</M_Stage>
</CancerStage>
<TreatmentIntent>CURE
<TrialEligibility>TROG.02.02</TrialEligibility>
<GuidelineEligibility>NCCN H and N ADVANCED</GuidelineEligibility>
<GuidelineEligibility>BCCC OROPHARYNX</GuidelineEligibility>
<GuidelineEligibility>SIGN H and N</GuidelineEligibility>
<GuidelineEligibility>ICCC ReScan Protocol
<GuidelineApplied>YES</GuidelineApplied>
</GuidelineEligibility>
<Therapy>
<Surgery>
<Importance>NO</Importance>
</Surgery>
<Radiotherapy>
<ExternalBeam>
<Importance>PRIMARY</Importance>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE
<RadiotherapyBreakCompensation>BD</RadiotherapyBreakCompensation>
</RadiationFractionsPerWeek>
<RadiationBeamParticle>PHOTONS
<RadiationBeamEnergy>6MV</RadiationBeamEnergy>
</RadiationBeamParticle>
<RadiationTechnique>IMRT
<RadiotherapyBeamArrangement>NONCOPLANAR
<RadiationPrescriptionPoint> NON-ICRU PRESCRIPTIONPOINT</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
</RadiationPrescription>
<RadiotherapySimulation>
<RadiotherapyPosition>SUPINE</RadiotherapyPosition>
<RadiotherapyImmobilisation>MASK</RadiotherapyImmobilisation>
<RadiotherapySurfaceAlteration>BOLUS</RadiotherapySurfaceAlteration>
<RadiotherapySimulationFieldImaging>SIMULATION DRR</RadiotherapySimulationFieldImaging>
<RadiotherapySimulationFieldImaging>SIMULATION CT</RadiotherapySimulationFieldImaging>
<TargetVolume>
<RadiationTechnique>IMRT
<PlanningVolumes>
<PlanningTreatmentVolume>PTV7000
<PTVPrescriptionDose>70GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0.3CM</PTVExplansion>
<ClinicalTargetVolume>CTVp
<GrossTumourVolume>GTVp</GrossTumourVolume>
<CTVExpansion>0.5CM</CTVExpansion>
</ClinicalTargetVolume>
<ClinicalTargetVolume>CTVn
<GrossTumourVolume>GTVn</GrossTumourVolume>
<CTVExpansion>0.5CM</CTVExpansion>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV6000
<PTVPrescriptionDose>60GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0.3CM</PTVExplansion>
<ClinicalTargetVolume>CTVp
<GrossTumourVolume>GTVp</GrossTumourVolume>
<CTVExpansion>0.5CM</CTVExpansion>
</ClinicalTargetVolume>
<ClinicalTargetVolume>CTVn
<GrossTumourVolume>GTVn</GrossTumourVolume>
<CTVExpansion>0.5CM</CTVExpansion>
</ClinicalTargetVolume>
<ClinicalTargetVolume>CTVn0
<GrossTumourVolume>UNINVOLVED LYMPH NODES</GrossTumourVolume>
<CTVExpansion>0.5CM</CTVExpansion>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
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</PlanningVolumes>
<PlanningContours>
<Anatomy>
<Organ>SPINAL_CORD</Organ>
<Organ>PAROTID_R</Organ>
<Organ>PAROTID_L</Organ>
<Organ>>SUBMAND_R</Organ>
<Organ>SUBMAND_L</Organ>
<Organ>MUCOSA</Organ>
<Organ>MANDIBLE</Organ>
</Anatomy>
</PlanningContours>
</RadiationTechnique>
</TargetVolume>
</RadiotherapySimulation>
<RadiotherapyPlanning>
<RadiotherapyPlanningPTVDoseHeterogeneity>-5%</RadiotherapyPlanningPTVDoseHeterogeneity>
<RadiotherapyPlanningPTVDoseHeterogeneity>+7%</RadiotherapyPlanningPTVDoseHeterogeneity>
<Anatomy>
<Organ>SPINAL_CORD
<RadiotherapyOARDoseConstraint>45GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>PAROTID_R
<RadiotherapyOARDoseConstraint>MEAN 26GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>PAROTID_L
<RadiotherapyOARDoseConstraint>MEAN 26GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>SUBMAND_R
<RadiotherapyOARDoseConstraint>MEAN 26GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>SUBMAND_L
<RadiotherapyOARDoseConstraint>MEAN 26GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>MUCOSA
<RadiotherapyOARDoseConstraint>ALARA</RadiotherapyOARDoseConstraint>
</Organ>
<Organ>MANDIBLE
<RadiotherapyOARDoseConstraint>ALARA</RadiotherapyOARDoseConstraint>
</Organ>
</Anatomy>
</RadiotherapyPlanning>
</ExternalBeam>
<Brachytherapy>
<Importance>NO</Importance>
</Brachytherapy>
<AcuteSideEffects>
<EnteralFeeding>YES</EnteralFeeding>
</AcuteSideEffects>
</Radiotherapy>
<Chemotherapy>
<Importance>CONCURRENT</Importance>
<ChemotherapyRegime>WEEKLY CISPLATIN
<ChemotherapyCycle>
<ChemotherapyCycleNumber>SEVEN</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>ONE WEEK
<ChemotherapyCycleDay>DAY 1</ChemotherapyCycleDay>
<ChemotherapyDrug>CISPLATIN</ChemotherapyDrug>
<ChemotherapyDrugDose>40MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>ONE HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVHYDRATION>500mL NORMALSALINE</IVHYDRATION>
<Drug>ANTIEMETIC</Drug>
</ChemotherapyDrugSupport>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
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<SideEffects>
<FebrileNeutropaenia>YES
<HospitalAdmission>YES
<HospitalAdmissionDate>20/05/2009</HospitalAdmissionDate>
<HospitalDischargeDate>22/05/2009</HospitalDischargeDate>
</HospitalAdmission>
</FebrileNeutropaenia>
<Dehydration>YES</Dehydration>
</SideEffects>
</Chemotherapy>
<SupportiveTherapy>
<PEGtube>
<PEGtubeInsertionIndication>PROPHYLACTIC</PEGtubeInsertionIndication>
<PEGtubeInsertionDate>02/04/2009</PEGtubeInsertionDate>
<PEGtubeRemovalDate>22/07/2009</PEGtubeRemovalDate>
</PEGtube>
</SupportiveTherapy>
</Therapy>
<CancerOutcome>
<CancerResponse>
<DateofResponseMeasure>
<FunctionalImaging>
<FDG-PET>
<FDG-PETdate>10/08/2009</FDG-PETdate>
<FDG-PETreport>CONCLUSION: The scan findings suggest good partial metabolic response
with mild uptake in the anterior aspect of the primary tumour at the base of the tongue and
also mild uptake in residual upper cervical lymph nodes, suggestive of residual disease. No
new focus of FDG-avid disease is seen.</FDG-PETreport>
</FDG-PET>
</FunctionalImaging>
<RECISTcriteria>
<MeasurableDisease>NO</MeasurableDisease>
<RECIST-Primary>CR</RECIST-Primary>
<RECIST-Nodal>CR</RECIST-Nodal>
</RECISTcriteria>
</DateofResponseMeasure>
</CancerResponse>
<CancerLocalRecurrence>NO
<CancerLocalRecurrenceDate>06/11/2011</CancerLocalRecurrenceDate>
</CancerLocalRecurrence>
<CancerRegionalRecurrence>NO
<CancerRegionalRecurrenceDate>06/11/2011</CancerRegionalRecurrenceDate>
</CancerRegionalRecurrence>
<CancerDistantRecurrence>NO
<CancerDistantRecurrenceDate>06/11/2011</CancerDistantRecurrenceDate>
</CancerDistantRecurrence>
<CancerDeath>NO
<DateOfDeath>06/11/2011</DateOfDeath>
</CancerDeath>
</CancerOutcome>
<LateSideEffects>
<DateofAssessment>6/10/2011
<LateEffectsSkin>G1</LateEffectsSkin>
<LateEffectsSubcutaneous>G0</LateEffectsSubcutaneous>
<LateEffectsMucosa>G2</LateEffectsMucosa>
<LateEffectsSpinalCord>G0</LateEffectsSpinalCord>
<LateEffectsLarynx>G0</LateEffectsLarynx>
<LateEffectsEnteralFeeding>G0</LateEffectsEnteralFeeding>
</DateofAssessment>
</LateSideEffects>
</TreatmentIntent>
</CancerDiagnosis>
</Cancer>
</Diagnosis>
</Patient>
</Organisation>
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Appendix K
A CKML subset for use in a
Clinical Trial Protocol with
example
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The “HeadSTART” trial was devised and executed under the auspices of the TransTasman Radiaition Oncology Group (TROG). The trial was also called by its TROG
designation “TROG02.02”. This trial has closed, and was a Phase III randomised trial
of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant
radiation and cisplatin in patients with advanced head and neck cancer. The trial
was undertaken to compare the efficacy and safety of standard treatment (concurrent
cisplatin chemotherapy with high dose radiotherapy) with a new agent, tirapazamine,
which had shown an affinity for hypoxic areas in some tumours and also been shown
to produce more radiation damage than normal in these areas. The trial sought to
demonstrate a difference in overall survival. This primary endpoint is most highly
prized as the patient group to be included cannot expect a great probability of cure
according to previous data. See the element ¡TrialPredictedSurvivalControl¿ below for
specific numbers.

Following are two documents. The first provides a handcrafted CKML instance of
the completed clinical trial protocol known as TROG.02.02. Only items that relate to
clinical management have been entered. Even so, the specification is lengthy.

The second item is the actual protocol document used in the CKML production.

<Organisation>
<Trial>
<TrialID>
<TrialName>TROG.02.02</TrialName>
<TrialSponsorOrganisation>TROG</TrialSponsorOrganisation>
<TrialSponsorCommercial>SANOFI-SYNTHELABO</TrialSponsorCommercial>
<TrialPrincipalInvestigator>LESTER PETERS</TrialPrincipalInvestigator>
<TrialTitle>Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus
concomitant radiation and cisplatin in patients with advanced head and neck cancer.</TrialTitle>
<OutcomeAnalysis>OVERALL SURVIVAL</OutcomeAnalysis>
<OutcomeAnalysis>TIME TO LOCOREGIONAL FAILURE</OutcomeAnalysis>
<OutcomeAnalysis>FAILURE FREE SURVIVAL</OutcomeAnalysis>
<OutcomeAnalysis>PATTERN OF INITIAL FAILURE SITE</OutcomeAnalysis>
<OutcomeAnalysis>SEVERE TREATMENT RELATED TOXICITY</OutcomeAnalysis>
<OutcomeAnalysis>UNACCEPTABLE LOCOREGIONAL TREATMENT OUTCOME </OutcomeAnalysis>
<OutcomeAnalysis>QUALITY O FLIFE</OutcomeAnalysis>
<OutcomeAnalysis>TOXICITY</OutcomeAnalysis>
<OutcomeAnalysis>INITIAL RESPONSE RATE</OutcomeAnalysis>
<OutcomeAnalysis>FINAL COMPLETE RESPONSE</OutcomeAnalysis>
<TrialPatients>550
<TrialPower>80%</TrialPower>
<TrialType1Error>0.05; 2-SIDED LOG RANK</TrialType1Error>
<TrialPredictedSurvivalControl>60% AT 2 YEARS</TrialPredictedSurvivalControl>
<TrialPredictedSurvivalControl>51% AT 3 YEARS</TrialPredictedSurvivalControl>
<TrialPredictedSurvivalExperimental>70% AT 2 YEARS</TrialPredictedSurvivalExperimental>
<TrialPredictedSurvivalExperimental>63% AT 3 YEARS</TrialPredictedSurvivalExperimental>
</TrialPatients>
<TrialCentres>80</TrialCentres>
</TrialID>
<InclusionCriteria>
<Demographics>
<Age>18 YEARS OR OLDER</Age>
</Demographics>
<BiologicalMilieu>
<Physiology>
<RenalFunction>
<CreatinineClearance>55mL/MIN OR MORE
<CreatinineClearanceAlgorithm>COCKCROFT-GAULT</CreatinineClearanceAlgorithm>
</CreatinineClearance>
</RenalFunction>
<HepaticFunction>
<SerumBilirubin>1.25xUPPERLIMITNORMAL LESS THAN</SerumBilirubin>
<SerumAST>5xUPPERLIMITNORMAL LESS THAN</SerumAST>
<SerumALT>5xUPPERLIMITNORMAL LESS THAN</SerumALT>
</HepaticFunction>
<BloodFunction>
<HematologicFunction>
<NeutrophilCountAbsolute>1.5x10^9/L OR MORE</NeutrophilCountAbsolute>
<PlateletCount>100X10^9/L OR MORE</PlateletCount>
<Haemoglobin>10g/dL OR MORE</Haemoglobin>
</HematologicFunction>
</BloodFunction>
<PerformanceStatusECOG>0;1;2</PerformanceStatusECOG>
<ActuarialSurvival>6 MONTHS</ActuarialSurvival>
<ReproductiveFunction>INFERTILE;CONTRACEPTION</ReproductiveFunction>
<TrialConsentDocument>
<TrialConsentDocumentSigned>YES</TrialConsentDocumentSigned>
</TrialConsentDocument>
</Physiology>
</BiologicalMilieu>
<PsychologicalMilieu>
<FollowUpReliability>YES
<FollowUpReliabilityDuration>4 YEARS OR MORE</FollowUpReliabilityDuration>
</FollowUpReliability>
</PsychologicalMilieu>
</InclusionCriteria>
<ExclusionCriteria>
<BiologicalMilieu>
<Anatomy>
<AnatomicalImaging>
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<PlainXR>
<PlainXRRegion>BONE</PlainXRRegion>
<PlainXRRegionReason>"BONE SYMPTOMS"</PlainXRRegionReason>
<PlainXRReport>METASTASIS</PlainXRReport>
</PlainXR>
<CTscan>
<CTscanRegion>CHEST</CTscanRegion>
<CTscanReport>METASTASIS</CTscanReport>
</CTscan>
<CTscan>
<CTscanRegion>LIVER</CTscanRegion>
<CTscanRegionReason>"ABNORMAL LIVER FUNCTION TEST"</CTscanRegionReason>
<CTscanReport>METASTASIS</CTscanReport>
</CTscan>
<USscan>
<USscanRegion>LIVER</USscanRegion>
<USscanRegionReason>"ABNORMAL LIVER FUNCTION TEST"</USscanRegionReason>
<USscanReport>METASTASIS</USscanReport>
</USscan>
</AnatomicalImaging>
<FunctionalImaging>
<Scintillography>BONE</Scintillography>
<ScintillographyReason>"BONE SYMPTOMS"</ScintillographyReason>
<ScintillographyReport>METASTASIS</ScintillographyReport>
</FunctionalImaging>
</Anatomy>
<Physiology>
<CardiacFunction>
<CardiacFunction1LitreFluidChallenge>FAIL</CardiacFunction1LitreFluidChallenge>
</CardiacFunction>
<PeripheralNerveFunction>
<PeripheralNerveSensoryFunction>
<PeripheralNerveSensoryFunctionLoss>G2 OR MORE</PeripheralNerveSensoryFunctionLoss>
</PeripheralNerveSensoryFunction>
</PeripheralNerveFunction>
<AuditoryFunction>
<Audiogram>dB loss</Audiogram>
<AuditoryFunctionLossAssessment>"CLINICALLY SIGNIFICANT"</AuditoryFunctionLossAssessment>
</AuditoryFunction>
<Size>
<Weight>
<DateofWeightMeasure>TODAY()-120DAYS</DateofWeightMeasure>
<EstimatedWeightChange>-20%</EstimatedWeightChange>
</Weight>
</Size>
<PhysiologicalState>PREGNANT</PhysiologicalState>
<BreastFunction>LACTATING</BreastFunction>
<BloodFunction>
<HematologicFunction>
<BoneMarrowFunction>
<BoneMarrowIrradation>30% OR MORE</BoneMarrowIrradation>
</BoneMarrowFunction>
</HematologicFunction>
</BloodFunction>
<MiscellaneousCondition>Prior experimental therapy for cancer within 30 days</MiscellaneousCondition>
</Physiology>
</BiologicalMilieu>
<PsychologicalMilieu>
<FollowUpReliability>YES
<FollowUpReliabilityDuration>4 YEARS LESS THAN</FollowUpReliabilityDuration>
</FollowUpReliability>
<TreatmentComplianceEstimate>POOR</TreatmentComplianceEstimate>
</PsychologicalMilieu>
</ExclusionCriteria>
<TrialSpecification>PHASE III</TrialSpecification>
<TrialSpecification>RANDOMISED
<TrialStratification>STAGE
<CancerStage>
<Stage>III
<TNMstage>T3N0M0</TNMstage>
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<TNMstage>T3N1M0</TNMstage>
</Stage>
<Stage>IV
<TNMstage>T4aN0M0</TNMstage>
<TNMstage>T4aN1M0</TNMstage>
<TNMstage>T1N2M0</TNMstage>
<TNMstage>T2N2M0</TNMstage>
<TNMstage>T3N2M0</TNMstage>
<TNMstage>T4aN2M0</TNMstage>
<TNMstage>T4bN1M0</TNMstage>
<TNMstage>T4bN2M0</TNMstage>
<TNMstage>T4bN3M0</TNMstage>
<TNMstage>T1N3M0</TNMstage>
<TNMstage>T2N3M0</TNMstage>
<TNMstage>T3N3M0</TNMstage>
<TNMstage>T4N3M0</TNMstage>
</Stage>
</CancerStage>
</TrialStratification>
<TrialStratification>
<CancerDiagnosis>
<ICD0>C01-C06</ICD0> * mouth
<ICD0>c09-C10</ICD0> * pharynx
<ICD0>C12-14</ICD0> * hypopharynx
<ICD0>C32</ICD0> * larynx
</CancerDiagnosis>
</TrialStratification>
<TrialStratification>
<HematologicFunction>
<Gender>FEMALE
<Haemoglobin>12.5g/dL OR MORE</Haemoglobin>
<Haemoglobin>12.4g/dL OR LESS</Haemoglobin>
</Gender>
<Gender>MALE
<Haemoglobin>13.5g/dL OR MORE</Haemoglobin>
<Haemoglobin>13.4g/dL OR LESS</Haemoglobin>
</Gender>
</HematologicFunction>
</TrialStratification>
</TrialSpecification>
<TrialSpecification>INTERNATIONAL</TrialSpecification>
<TrialSpecification>OPEN-LABEL</TrialSpecification>
<TrialSpecification>TWOARM</TrialSpecification>
<TrialSpecification>CONTROLLED</TrialSpecification>
<TrialSpecification>MULTICENTRE</TrialSpecification>
<TrialDocumentation>
<TrialConsentDocument>SIGNED DOCUMENT</TrialConsentDocument>
</TrialDocumentation>
<Diagnosis>
<Cancer>
<InclusionCriteria>
<CancerDiagnosis>
<ICD0>C01-C06;c09-C10;C12-14;C32</ICD0> * mouth, pharynx, hypopharynx and larynx
<ICD0>C01-C99
<DiagnosisDate>5 YEARS NOT LESS</DiagnosisDate>
</ICD0>
<ICD0>D06</ICD0>
<Histopathology>
<Morphology>SQUAMOUSCELLCARCINOMA</Morphology>
</Histopathology>
<Cytology>
<Morphology>SQUAMOUSCELLCARCINOMA</Morphology>
</Cytology>
<CancerStage>
<Stage>
<TNMstage>T3N0M0</TNMstage>
<TNMstage>T3N1M0</TNMstage>
<TNMstage>T4aN0M0</TNMstage>
<TNMstage>T4aN1M0</TNMstage>
<TNMstage>T1N2M0</TNMstage>
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<TNMstage>T2N2M0</TNMstage>
<TNMstage>T3N2M0</TNMstage>
<TNMstage>T4aN2M0</TNMstage>
<TNMstage>T4bN1M0</TNMstage>
<TNMstage>T4bN2M0</TNMstage>
<TNMstage>T4bN3M0</TNMstage>
<TNMstage>T1N3M0</TNMstage>
<TNMstage>T2N3M0</TNMstage>
<TNMstage>T3N3M0</TNMstage>
<TNMstage>T4N3M0</TNMstage>
</Stage>
</CancerStage>
</CancerDiagnosis>
</InclusionCriteria>
<ExclusionCriteria>
<CancerDiagnosis>
<ICD0>B20-B24</ICD0> *HIV infection
<ICD0>I20;I22-I52;J81</ICD0> *Acute & Chronic heart disease
<ICD0>I21 MORE THAN 6 MONTHS</ICD0> * Heart attack
<ICD0>J43-J44</ICD0>
<ICD0>F10;X65;Z72.1</ICD0>
<ICD0>"ACTIVE INFECTION"</ICD0>
<ICD0>"FEBRILE ILLNESS"</ICD0>
<CancerDiagnosisDate></CancerDiagnosisDate>
<ICD0>C01-C06;c09-C10;C12-14;C32 * mouth, pharynx, hypopharynx and larynx
<CancerLocalRecurrence>YES</CancerLocalRecurrence>
<CancerRegionalRecurrence>YES</CancerRegionalRecurrence>
<CancerDistantRecurrence>YES</CancerDistantRecurrence>
</ICD0>
<ICD0>C11;C30;C31</ICD0> * Cancers of Nose, Sinuses and Nasopharynx
<ICD0>C50</ICD0> *Cancer of breast
<ICD0>C61</ICD0> *Cancer of prostate
<ICD0>C43</ICD0> *Melanoma of skin
<CancerStage>
<Stage>
<TNMstage>T*N*M1</TNMstage>
<TNMstage>T1N0M0</TNMstage>
<TNMstage>T2N0M0</TNMstage>
<TNMstage>T1N1M0</TNMstage>
<TNMstage>T2N1M0</TNMstage>
</Stage>
</CancerStage>
</CancerDiagnosis>
</ExclusionCriteria>
<TrialArm>ONE
<TrialArmName>RADIOTHERAPY + CISPLATIN</TrialArmName>
<Therapy>
<Surgery>
<SurgicalIndication>OPTION1: RESIDUAL/PROGRESSIVE NECK MASS
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION2: INITIAL N2/N3 DISEASE
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION3: NO/RESOLVING NECK MASS
<SurgicalProcedure>NO OPERATION</SurgicalProcedure>
</SurgicalIndication>
</Surgery>
<Radiotherapy>
<ExternalBeam>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE
<RadiotherapyBreakCompensation>BD</RadiotherapyBreakCompensation>
</RadiationFractionsPerWeek>
<RadiationBeamParticle>ELECTRONS</RadiationBeamParticle>
<RadiationBeamParticle>PHOTONS
<RadiationBeamEnergy>4MV</RadiationBeamEnergy>
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</RadiationBeamParticle>
<RadiationTechnique>FIELD-BASED
<RadiotherapyBeamArrangement>PARALLEL OPPOSED
<RadiationPrescriptionPoint>MIDPOINTDOSE</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
<RadiotherapyBeamArrangement>ANTERIOR
<RadiationPrescriptionPoint>DEPTH 2CM</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<RadiotherapyBeamArrangement>NON-COPLANAR
<RadiationPrescriptionPoint>PRESCRIPTION POINT</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
</RadiationPrescription>
<RadiotherapySimulation>
<RadiotherapyPosition>SUPINE</RadiotherapyPosition>
<RadiotherapyImmobilisation>MASK</RadiotherapyImmobilisation>
<RadiotherapyImmobilisation>INTRAORAL DEVICE</RadiotherapyImmobilisation>
<RadiotherapySurfaceAlteration>NO BOLUS</RadiotherapySurfaceAlteration>
<RadiotherapySimulationFieldImaging>SIMULATION RADIOGRAPHS</RadiotherapySimulationFieldImaging>
<RadiotherapySimulationFieldImaging>SIMULATION CT</RadiotherapySimulationFieldImaging>
<TargetVolume>
<RadiationTechnique>FIELD-BASED
<RadiotherapyPhase>ONE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
<ClinicalTargetVolume>
<ClinicalTargetVolumeDosePrescription>50GY/25FX</ClinicalTargetVolumeDosePrescription>
<ClinicalTargetVolumeAnatomy>1st LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeAnatomy>2nd LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeMarginToFieldEdge>1CM</ClinicalTargetVolumeMarginToFieldEdge>
</ClinicalTargetVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>TWO
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>10GY/5FX</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>THREE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>1CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<PlanningVolumes>
<PlanningTreatmentVolume>PTV1
<PTVPrescriptionDose>50GY/25FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV1
<GrossTumourVolume>PRIMARY + INVOLVED LN + UNINVOLVED LN
<CTVExpansion>1.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV2
<PTVPrescriptionDose>70GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
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<ClinicalTargetVolume>CTV2
<GrossTumourVolume>PRIMARY + INVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV3
<PTVPrescriptionDose>60GY/30FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV3
<GrossTumourVolume>HIGH RISK UNINVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
</PlanningVolumes>
<PlanningContours>
<Anatomy>
<Organ>SPINALCORD</Organ>
<Organ>PAROTID_R</Organ>
<Organ>PAROTID_L</Organ>
</Anatomy>
</PlanningContours>
</RadiationTechnique>
</TargetVolume>
</RadiotherapySimulation>
<RadiotherapyPlanning>
<RadiotherapyPlanningPTVDoseHeterogeneity>-5%</RadiotherapyPlanningPTVDoseHeterogeneity>
<RadiotherapyPlanningPTVDoseHeterogeneity>+7%</RadiotherapyPlanningPTVDoseHeterogeneity>
<Anatomy>
<Organ>SPINALCORD
<RadiotherapyOARDoseConstraint>45GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
</Anatomy>
</RadiotherapyPlanning>
</ExternalBeam>
<Brachytherapy>
<Importance>NO</Importance>
</Brachytherapy>
</Radiotherapy>
<Chemotherapy>
<ChemotherapyRegime>CISPLATIN
<ChemotherapyCycle>
<ChemotherapyCycleNumber>THREE</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>THREE WEEKS
<ChemotherapyCycleDay>DAY 1</ChemotherapyCycleDay>
<ChemotherapyDrug>CISPLATIN</ChemotherapyDrug>
<ChemotherapyDrugDose>100MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>ONE HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<Drug>ANTIEMETIC</Drug>
</ChemotherapyDrugSupport>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
</Chemotherapy>
</Therapy>
</TrialArm>
<TrialArm>TWO
<TrialArmName>RADIOTHERAPY + CISPLATIN + TIRAPAZIMINE</TrialArmName>
<Therapy>
<Surgery>
<SurgicalIndication>OPTION1: RESIDUAL/PROGRESSIVE NECK MASS
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION2: INITIAL N2/N3 DISEASE
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<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION3: NO/RESOLVING NECK MASS
<SurgicalProcedure>NO OPERATION</SurgicalProcedure>
</SurgicalIndication>
</Surgery>
<Radiotherapy>
<ExternalBeam>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE
<RadiotherapyBreakCompensation>BD</RadiotherapyBreakCompensation>
</RadiationFractionsPerWeek>
<RadiationBeamParticle>ELECTRONS</RadiationBeamParticle>
<RadiationBeamParticle>PHOTONS
<RadiationBeamEnergy>4MV</RadiationBeamEnergy>
</RadiationBeamParticle>
<RadiationTechnique>FIELD-BASED
<RadiotherapyBeamArrangement>PARALLEL OPPOSED
<RadiationPrescriptionPoint>MIDPOINT DOSE</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
<RadiotherapyBeamArrangement>ANTERIOR
<RadiationPrescriptionPoint>DEPTH 2CM</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<RadiotherapyBeamArrangement>NON-COPLANAR
<RadiationPrescriptionPoint>PRESCRIPTION POINT</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
</RadiationPrescription>
<RadiotherapySimulation>
<RadiotherapyPosition>SUPINE</RadiotherapyPosition>
<RadiotherapyImmobilisation>MASK</RadiotherapyImmobilisation>
<RadiotherapyImmobilisation>INTRAORAL DEVICE</RadiotherapyImmobilisation>
<RadiotherapySurfaceAlteration>NO BOLUS</RadiotherapySurfaceAlteration>
<RadiotherapySimulationFieldImaging>SIMULATION RADIOGRAPHS</RadiotherapySimulationFieldImaging>
<RadiotherapySimulationFieldImaging>SIMULATION CT</RadiotherapySimulationFieldImaging>
<TargetVolume>
<RadiationTechnique>FIELD-BASED
<RadiotherapyPhase>ONE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
<ClinicalTargetVolume>
<ClinicalTargetVolumeDosePrescription>50GY/25FX</ClinicalTargetVolumeDosePrescription>
<ClinicalTargetVolumeAnatomy>1st LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeAnatomy>2nd LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeMarginToFieldEdge>1CM</ClinicalTargetVolumeMarginToFieldEdge>
</ClinicalTargetVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>TWO
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>10GY/5FX</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>THREE
<GrossTumourVolume>
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<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>1CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<PlanningVolumes>
<PlanningTreatmentVolume>PTV1
<PTVPrescriptionDose>50GY/25FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV1
<GrossTumourVolume>PRIMARY + INVOLVED LN + UNINVOLVED LN
<CTVExpansion>1.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV2
<PTVPrescriptionDose>70GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV2
<GrossTumourVolume>PRIMARY + INVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV3
<PTVPrescriptionDose>60GY/30FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV3
<GrossTumourVolume>HIGH RISK UNINVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
</PlanningVolumes>
<PlanningContours>
<Anatomy>
<Organ>SPINALCORD</Organ>
<Organ>PAROTID_R</Organ>
<Organ>PAROTID_L</Organ>
</Anatomy>
</PlanningContours>
</RadiationTechnique>
</TargetVolume>
</RadiotherapySimulation>
<RadiotherapyPlanning>
<RadiotherapyPlanningPTVDoseHeterogeneity>-5%</RadiotherapyPlanningPTVDoseHeterogeneity>
<RadiotherapyPlanningPTVDoseHeterogeneity>+7%</RadiotherapyPlanningPTVDoseHeterogeneity>
<Anatomy>
<Organ>SPINALCORD
<RadiotherapyOARDoseConstraint>45GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
</Anatomy>
</RadiotherapyPlanning>
</ExternalBeam>
<Brachytherapy>
<Importance>NO</Importance>
</Brachytherapy>
</Radiotherapy>
<Chemotherapy>
<ChemotherapyRegime>TIRAPAZAMINE + CISPLATION
<ChemotherapyCycle>
<ChemotherapyCycleNumber>THREE WEEKS</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>THREE WEEKS
<ChemotherapyCycleDay>DAY 1</ChemotherapyCycleDay>
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>290MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
-8-

<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-3 HOUR</ChemotherapyDrugDeliveryStart>
</ChemotherapyDrug>
<ChemotherapyDrug>CISPLATIN
<ChemotherapyDrugDose>75MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>ONE HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
<ChemotherapyRegime>TIRAPAZAMINE
<ChemotherapyCycle>
<ChemotherapyCycleNumber>TWO</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY DAY 5</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>ONE WEEKS
<ChemotherapyCycleDay>DAY 1
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
<ChemotherapyCycleDay>DAY 3
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
<ChemothersapyCycleDay>DAY 5
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
</ChemotherapyCycleDuration>
-9-

</ChemotherapyCycle>
</ChemotherapyRegime>
<SideEffects>
<TirapazamineSideEffects>MUSCLE CRAMPS; HEARING LOSS; ABNORMAL VISION;
NAUSEA; VOMITING; DIARRHOEA</TirapazamineSideEffects>
</SideEffects>
</Chemotherapy>
</Therapy>
</TrialArm>
</Cancer>
</Diagnosis>
</Trial>
</Organisation>
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Appendix L
The Trans-Tasman Radiation
Oncology Group (TROG)
”HeadSTART” Clinical Trial
protocol (TROG02.02)
This protocol was provided on request by Professor Lester Peters through the TROG
Trials Office.
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CLINICAL TRIAL SUMMARY
COMPOUND: SR259075

STUDY No.: EFC4690

TITLE

Phase III randomized trial of concomitant radiation,
cisplatin, and tirapazamine (SR259075) versus
concomitant radiation and cisplatin in patients with
advanced head and neck cancer

INVESTIGATOR / TRIAL LOCATION

Multicenter

STUDY OBJECTIVES

The trial will compare the efficacy and safety of
concomitant chemoradiation with tirapazamine,
cisplatin, and radiation versus cisplatin and radiation.
The primary endpoint is Overall Survival.
Secondary endpoints include, but are not limited to, the
following:
• Time to locoregional failure with date of
randomization as the start date.
• Failure-free survival. Failure is defined as death
due to any cause, locoregional failure or
development of distant metastasis.
• Patterns of failure as the initial site of failure at the
primary site, neck, distant sites or combinations of
these.
• Cumulative incidence of unacceptable locoregional
treatment outcome as a function of time. An
unacceptable outcome is defined as either
locoregional failure or severe late treatment-related
toxicity which may be any of the following: grade 4
skin, subcutaneous tissue, mucous membrane or
bone toxicity, grade 3 or 4 spinal cord toxicity,
grade 4 laryngeal toxicity requiring tracheostomy,
or the need for enteral feeding persisting beyond 12
months following completion of treatment.
• Change in QoL from baseline as assessed by
FACT-H&N scale in eligible patients at 6 months
post-treatment (see 6.1.2.7 QoL Evaluation).
• Toxicity and safety, determined through review of
adverse events, routine symptom assessment, and
laboratory determinations.
• Initial response rates defined as rates of CR , PR,
SD or PD eight weeks after completion of
chemoradiation therapy as described in Section
6.1.2.5.
• Final CR rate as defined in Section 6.1.2.5 (d).
Additional analysis will include correlation of efficacy
with baseline hypoxia measurements. Measurements
of hypoxia will include FAZA-PET (in selected sites)
and blood levels of chemical markers.

STUDY DESIGN

Phase III, open-label, 2-armed, randomized, controlled,
multicenter.
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STUDY POPULATION
Main selection criteria:

Subjects with previously untreated squamous cell
carcinoma of the oral cavity, oropharynx, hypopharynx,
or larynx, Stage III or Stage IV (excluding T1N1, T2N1
and metastatic disease). Subjects must have ambulatory
ECOG performance status ≤2 and adequate renal,
hepatic, and hematologic function.

Total expected number of patients:

550 evaluable subjects

Expected number of centers:

Between 50 and 80.

INVESTIGATIONAL PRODUCT(S)
Formulation(s):

250 ml of Tirapazamine will be supplied as a clear
yellow-orange liquid (0.7 mg/ml) in an isotonic citrate
buffer with a pH between 3.7 and 4.3 in 300 ml bottles.

Route(s) of administration:

Tirapazamine and cisplatin: Intravenous (IV)
Antiemetics: Oral (PO) and/or intravenous (IV)
Antidiarrheals: Oral (PO)

Dose regimen:

Radiotherapy: All patients will receive conventionally
fractionated radiation therapy with the macroscopic sites
of disease treated to 70 Gy in 35 fractions over 7 weeks.
Techniques using conformal techniques to deliver the
radiation can be used. Centers not using conformal
techniques have a one-time option of changing to such
techniques.
Cisplatin (Arm 1)
2
Cisplatin (100 mg/m , 1-hour infusion) immediately
before radiation therapy on Day 1 of weeks 1, 4, and 7
of radiotherapy.
Tirapazamine and cisplatin (Arm 2)
2
Tirapazamine (290 mg/m , two-hour infusion), followed
2
after 1 hour by cisplatin (75 mg/m , 1-hour infusion)
immediately before radiation therapy on Day 1 of weeks
1, 4, and 7 of radiotherapy.
2

Tirapazamine (160 mg/m , two-hour infusion) on days
1, 3, and 5 of weeks 2 and 3 of radiotherapy.
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The primary endpoint is overall survival.
Secondary efficacy endpoints: time to locoregional
failure, failure-free survival, patterns of failure,
cumulative incidence of unacceptable locoregional
treatment outcome, Quality of Life (QoL), toxicity and
safety, response rate and final CR rate.
Additional analyses will include correlation of baseline
hypoxia as assessed by FAZA-PET scans (in selected
centers) and tumor markers to outcome.

Safety Criteria:

Safety will be determined through review of adverse
events, routine symptom assessment, and laboratory
determinations.

ASSESSMENT SCHEDULE

See Flow Chart

STATISTICAL CONSIDERATIONS

The sample size of 275 per treatment arm will provide
at least 80% power under the following assumptions:
• Survival in the control arm is 60% at 2 years and
51% at 3 years. Beyond 3 years the mortality risk
(hazard rate) will be 0.05 death per patient per
year.
• The test population will experience a 31%
reduction in the risk of mortality, compared to the
controls. This would produce a survival rate of
70% at 2 years and 63% at 3 years. For patients
surviving beyond 3 years the mortality risk
(hazard rate) would be 0.0345 death per patient
per year.
• 1.5-year accrual period, with 2.5 years of followup after enrollment of the last patient.
• Type I error of 0.05 with 2-sided logrank test.
• Constant hazard rates in each treatment arm
during the periods 0 - 2 years, 2 – 3 years, and 3 +
years.
• Constant accrual rate.
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The cutoff date for the final survival analysis will be the
th
date of the 240 death. An interim analysis of survival
will be done at the time of the analysis of locoregional
failure. The level of the interim test will be determined
by the proportion of the expected 240 deaths that have
been observed, using an O’Brien – Fleming like alpha
spending function.
An analysis of time to locoregional failure will be done
with a two-sided logrank test when 150 patients have
reached this endpoint. The analysis of locoregional
failure has at least 85% power to detect a difference in
postulated locoregional failure rates of 40% in the
control arm versus 25% in the experimental arm with a
two-sided test at the 0.05 level. It is assumed that
among the patients who do experience locoregional
failure, the yearly event probability will be 0.7.
Treatment assignment will be done by centrally
stratifying for disease stage (III v IV), primary site
(oropharynx/larynx v hypopharynx/oral cavity),
hemoglobin (≥13.5 g/dL for men and ≥12.5 g/dL for
women v otherwise). A dynamic allocation method will
be used to avoid extreme imbalance of treatment
assignment within a single institution.
The stratified log rank test will be used to compare the
treatment groups for time-related parameters, such as
time to locoregional failure and failure free survival.
Categorical parameters, such as response rate, will be
evaluated using the chi-squared test.
Characteristics of subjects assigned to the 2 treatment
arms will be summarized. These include sex, race, age,
weight, height, performance status, histology, stage of
disease, measurable disease, time since diagnosis,
presence of other disease conditions, and clinical
laboratory tests.
The incidence of adverse events will be summarized by
type of event and toxicity grade.

DURATION OF STUDY PERIOD
(per subject)

The duration of study for an individual patient will
include a period for inclusion and treatment planning of
up to 1 month, a 7 week treatment period followed by a
minimum of 4 weeks of follow-up for chemotherapy
related toxicities after the last dose of study drug(s). All
subjects will be followed for disease status until
locoregional disease progression, death, or the study
cutoff date, whichever comes first. All subjects will be
followed for QoL until three years after completion of
therapy or study cut-off date. All subjects will be
followed for survival, radiation toxicity and further
therapy until death or the study cutoff date. The study
th
cutoff date is defined as the date of the 240 death.
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LIST OF ABBREVIATIONS
5HT: 5-hydroxytryptophan.
AE/ SAE: Adverse event/ Serious adverse event.
ALT: Alanine transaminase (SGPT).
APTT: activated partial thromboplastin time.
AST: aspartate aminotransferase. .
BP: blood pressure.
CI: Confidence interval.
CIB: Clinical investigator’s brochure.
CIS: Cisplatin.
CO-60: Cobalt 60.
CR: Complete Response.
CRF: clinical report form.
CT: Computed tomography.
DNA: Desoxyribonucleic acid.
FACT-H&N: Functional Assessment of Cancer Therapy – Head & Neck, version 4.
FAZA: Fluoro-azomycin-arabinoside.
FDG: Fluorodeoxyglucose.
G-CSF: Granulocyte colony stimulating factor.
GM-CSF: Granulocyte/macrophage colony stimulating factor.
GTV: Gross tumor volume.
Gy: Gray.
HF: Hyperfractionated.
HR: heart rate.
IEC: Independent Ehics Committee.
IRB: Institutional Review Board.
LD: longest diameter.
LRF: Locoregional failure.
m²: Square meters.
mg: Milligram.
MRI: Magnetic resonance imaging.
MV: Megavolt.
NCI: National Cancer Institute.
PD: Progressive disease.
PET: Positron emission tomography.
PR: Partial Response.
PTV: Planning target volume.
QARC: Quality Assurance Review Center.
QoL: Quality of life.
RECIST: Response Evaluation Criteria in Solid Tumors.
RT: Radiation therapy.
RTOG: Radiation Therapy Oncology Group.
SD: Stable disease.
SGOT: serum glutamate oxaloacetate transaminase. .
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T: temperature. .
TMC: Trial management committee.
TROG: Trans-Tasman Radiation Oncology Group.
ULN: Upper limit of normal.
WHO: World Health Organization.
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1. INTRODUCTION AND RATIONALE
1.1 Natural history of head and neck cancer
Head and neck cancer occurs with an annual incidence of approximately 40,000 cases in
the United States (1). Generally, about 30% of these patients will present with locally
confined (T1 or T2, Stage I or Stage II) lesions. The majority of patients will present with
locoregionally advanced disease (T3, T4, N1-N3, Stage III or IV). Metastatic spread to
distant organs at the time of diagnosis is seen clinically in few patients. Autopsy series,
however, have indicated a higher incidence of approximately 50% of patients with
micrometastatic spread (2,3). Due to the firm association of this disease with tobacco and
alcohol use, patients with head and neck cancer usually suffer from a variety of additional
diseases related to these risk factors, e.g., advanced arteriosclerosis, obstructive lung
disease and hepatic disease (4). Most importantly, they are at risk for second synchronous
or metachronous malignancies in the head and neck region as well as other organs,
predominantly the lung and esophagus (5).
1.2 Locoregionally advanced disease
For patients with locoregionally advanced disease (Stage III or IV), surgery and radiation
have traditionally been used in sequence. Despite this aggressive bimodality treatment
approach, cure is achieved in only a minority of patients (6). Most patients die of
locoregional persistence or recurrence of disease. The addition of chemotherapy to the
overall treatment plan has been studied intensively over the last 3 decades. Research
strategies, generally, have included the use of induction (neoadjuvant) or adjuvant
chemotherapy, as well as concomitant chemoradiotherapy. The primary goal of such
research is to improve local control and survival. Given the anatomic location of the
disease and the frequently aggressive surgical approaches used, the use of less extensive
surgery (and the preservation of organ function) is an important second treatment goal.
Recently reported randomized trials conducted to study the role of chemotherapy have
yielded the consistent finding that concurrent administration of chemotherapy (platinum
+/- 5-FU) and radiotherapy results in improved locoregional control and overall survival
compared to radiotherapy alone (7,8,9,10,11,12). Conversely, sequential (usually
neoadjuvant) chemotherapy has yielded only a marginal non-significant benefit (6). As of
2002, it is now widely accepted that combinations of cisplatin with radiation are the
standard of care for those patients with locally advanced disease in whom surgery cannot
be performed or for those patients who do not wish the radical surgery that is required
(13).
1.3 Hypoxia and head and neck cancer
Radiation kills dividing cells through the creation of double stranded DNA breaks. This
process is dependent on the presence of oxygen, which “fixes” free-radical-induced
lesions produced by ionizing radiation.
Hypoxia in tumors limits the potential of radiation therapy to kill tumor cells (14). This
has been found to happen not only in animal models but it also has been found to have an
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important clinical effect. This has been best demonstrated in head and neck cancer where
the disease is accessible to direct measurement of intratumor oxygen tension
(15,16,17,18). The presence of hypoxia was found to be a strong prognostic factor in
predicting the outcome of patients with advanced head and neck cancer after radiation
therapy.
1.4 Rationale for tirapazamine in advanced head and neck cancer
Tirapazamine is a bioreductively activated, hypoxia-selective antitumor agent of the
benzotriazine series. It is 35 to 450 times more cytotoxic (dependent on tumor cell line
studied) to hypoxic cells than to well-oxygenated cells (19,20,21,22). Tirapazamine is
bioactivated to a cytotoxic metabolite by electron transfer. This one-electron reduction
product, which is an oxidizing radical anion, causes extensive single- and double-strand
breaks in DNA. It may also accentuate DNA damage induced by radiation or
DNA-damaging cytotoxic agents by inhibiting DNA repair (23).
Tirapazamine also results in a marked potentiation of cisplatin cytotoxicity (24). This
may be the primary cause of anti-tumor efficacy, since in a number of models, the level of
cytotoxicity of tirapazamine alone is quite low while the combination of tirapazamine and
cisplatin increases the level of cell kill by many orders of magnitude.
The scientific rationale for and function of tirapazamine in oncology is supported by
previous human experience, particularly in non-small cell lung cancer. This experience
may be summarized as follows:
• In solid tumors, the combination of cisplatin and tirapazamine is efficacious compared
to cisplatin alone. [Phase II (25,26) and Phase III (CATAPULT I) (27) trials]
• In man, tirapazamine can be added to radiation regimens safely, and tirapazamine is
likely to contribute to the therapy of those tumors, where hypoxia has long been known
to limit the effectiveness of radiation. [DRI2938 (28), EFC3344, EFC3714 (29)]
The selection of tirapazamine for development in the treatment of head and neck cancer is
based on the observation that:
• It is a disease, which is known to be significantly hypoxic, and where hypoxia is known
to be a marker for poor prognosis after radiation therapy (15,16,17,18,23)
• It is a disease where both cisplatin and radiation therapy have an important role in
therapy, but where these active agents still do not cure a majority of selected patients.
Furthermore, no second chemotherapy agent has a clearly established role.
• It is a disease where local control has an important benefit for patients because of the
functional and cosmetic importance of the anatomical area.

19/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

1.4.1 Tirapazamine related toxicities
Based on the patients treated with tirapazamine plus cisplatin in 2 large randomized
Phase III trials in lung cancer, 5 toxicities have been observed where the tirapazamine arm
had significantly more events than the control arm (See the CIB for more details):
• Muscle cramps: Muscle cramps tend to occur early in the course of therapy. They are
associated with the administration of treatment (median =1 day from prior infusion),
and are typically of brief duration (median =2 days). Only 45% of patients
experiencing muscle cramps during the first cycle experienced a recurrence on
subsequent cycles. There was no tendency toward progressive worsening of muscle
cramps upon repeat exposure. Muscle cramps is not a dose related toxicity.
• Hearing loss: Two distinct patterns of hearing loss (early onset and late onset) were
observed in EFC2753, with some evidence to support distinct underlying pathogenesis.
In the tirapazamine plus cisplatin treatment arm, the time to first occurrence of hearing
loss was acute and most often occurred in the first few days of Cycle 1. This early
onset hearing loss (reported within 5 days or less after 1st infusion) was acute (median
occurrence =1 day from 1st infusion) and of short duration (median=1 day). For some
tirapazamine-treated subjects with early onset hearing loss, unscheduled audiograms
were performed early in the first treatment cycle. Analyses of these audiograms
revealed a distinct pattern of decreased hearing threshold across all frequencies, which
typically reversed at the subsequent examination (end of Cycle 2, per protocol).
Hearing loss is a dose related toxicity and the frequency of this event is lower using
2
doses lower than 390 mg /m as was used in the randomized trials. In addition, late
onset hearing loss (occurring more than 5 days after 1st infusion) was also identified.
The co-administration of tirapazamine did not appear to enhance the frequency or
severity of late onset-hearing loss that is associated with cisplatin.
• Abnormal vision: Visual adverse events were of interest during the conduct of
EFC2753 because preclinical toxicology findings had identified eye lesions in the dog
as a potential toxicity of tirapazamine. Because of these findings, visual adverse events
were of particular interest in this study. A more frequent incidence of varied visual
adverse events [blurred vision, decreased visual acuity, visual disturbance, etc.] were
reported in the tirapazamine plus cisplatin treatment arm [50 (23%) of 219 subjects in
the tirapazamine plus cisplatin treatment arm reported this event vs. 21 (10%) of
219 subjects in the cisplatin monotherapy treatment arm]. No evidence of late onset
cumulative toxicity of this event was observed. Specific visual tests (visual acuity and
color discrimination) were performed at 6-week intervals during the study to further
characterize vision changes. The incidence of objective abnormalities in visual acuity
and color discrimination was low overall, the same in both treatment arms, and did not
appear to be related to clinical adverse events. No evidence of visual toxicity of the
severity or frequency observed in the dog was seen in human subjects.
• Nausea/vomiting: Both nausea and vomiting were significantly more frequent in the
tirapazamine arm of EFC2753 (86% and 82% compared to 69% and 46% respectively
in the cisplatin monotherapy arm). No evidence of clinically significant late-onset
cumulative toxicity was apparent in either treatment arm. Nausea and vomiting
induced by tirapazamine, especially when given in combination with cisplatin or other
emetogenic agents, should be managed prophylactically with 5HT antagonists.
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• Diarrhea: Diarrhea was typically of abrupt onset (median <1 day from prior infusion),
and brief in duration (median <1 day), irrespective of grade and cycle of onset. Highgrade episodes were reported in the context of associated incontinence, presumably
related to the abrupt onset. Patients could be re-treated without necessarily
experiencing a recurrence of diarrhea or worsening in severity.
1.5 Clinical experience with tirapazamine for head and neck cancer
1.5.1 Radiotherapy and single-agent tirapazamine
A Phase II trial was done to determine the tolerability of radiation therapy and
concomitant tirapazamine in head and neck cancer (30). Thirty-nine patients with Stage
III or IV head and neck cancer were treated with conventional RT (70 Gy in 7 weeks)
and concurrent tirapazamine (159 mg/m2 intravenously 3 times per week for 12 doses).
32/39 (83%) received full 12 drug doses and 32/39 received full radiation. The most
frequent drug toxicities were muscle cramps and nausea/vomiting. Thirteen patients had
Grade 3 or Grade 4 drug related toxicities. No excessive RT-associated acute normal
tissue reactions were noted. With a median follow-up of 13 months, the 1-year and 2-year
local control rate (primary site only) was 64% and 59% respectively. The authors
concluded that the tirapazamine regimen was well tolerated, the toxicity with RT was
acceptable, and the disease control was encouraging.
1.5.2 Radiotherapy, cisplatin, and tirapazamine for head and neck cancer
1.5.2.1 The Peter MacCallum Phase I Trial
The maximally tolerated dose of tirapazamine when combined with cisplatin and radiation
in patients with T3-4 and/or N2-3 squamous cell carcinoma of the head and neck has been
investigated by Rischin et al (31).
The starting schedule was conventionally fractionated radiotherapy (70 Gy in 7 weeks),
2
2
with concomitant cisplatin 75 mg/m and tirapazamine 290 mg/m (prior to cisplatin) in
2
weeks 1, 4, and 7, and tirapazamine alone 160 mg/m 3 times a week in Weeks 2, 3, 5,
and 6. PET scans for tumor hypoxia (18F misonidazole) were performed prior to and
during radiotherapy. This regimen is schematically shown in Figure (1.5.2.1) 1 .
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Cis 75
TPZ 290 TPZ only X3

TPZ only X3

Cis
TPZ

Week 1

Week 3

Week 4

Week 2

TPZ only X3* TPZ only X3*

Week 5

Week 6

Cis
TPZ

Week 7

Standard Radiation- 70 Gy, 35 fractions, once daily
*The TPZ only weeks 5 and 6 are omitted in the Phase 2 recommended regimen.
Figure (1.5.2.1) 1 - RISCHIN/PETERS Concomittant chemotherapy radiotherapy regimen

Sixteen patients with predominantly oropharyngeal primaries, including 10 patients with
T4 or N3 disease were treated. Febrile neutropenia occurred towards the end of
radiotherapy in 3 out of 6 patients treated on the initial dose level. Another 10 patients
were treated with the same doses, but weeks 5 and 6 tirapazamine doses were omitted.
This resulted in less neutropenia, only 1 dose-limiting toxicity (febrile neutropenia), and
8 out of 10 patients completed treatment without any dose omissions. The acute radiation
toxicities were not obviously enhanced compared to chemoradiotherapy regimens using
concurrent platinum and 5-fluorouracil. Muscle cramps were troublesome in some
patients during the first 2 weeks of treatment. However, the cramps had generally
subsided and largely resolved by the third week of treatment, without any alteration to
chemotherapy doses and irrespective of the treatment given for the cramps. Transient skin
18
rashes due to tirapazamine were seen in 4 patients. F misonidazole scans detected
hypoxia in 14/15 patients at baseline with only 1 patient having detectable hypoxia at the
end of treatment. With a median follow-up of 2.2 years, the 2 year failure-free survival
rate is 69% (SE = 12%), the 2 year local progression-free rate is 88% (SE = 8%), and the
2 year overall survival rate is 75% (SE = 11%).
The authors concluded that dose-limiting toxicity was febrile neutropenia, which could be
overcome by omitting tirapazamine in weeks 5 and 6. The triple combination of
tirapazamine, cisplatin, and radiotherapy resulted in remarkably good and durable clinical
responses in patients with very advanced head and neck cancers.
1.5.2.2 The Stanford Experience
A second randomized Phase II trial comparing a cis/5FU/Radiation regimen to that of the
same regimen with TPZ added is in progress directed at organ preservation at Stanford
and the toxicities have been reported in an abstract (32). Tirapazamine 300-330 mg/m2
day (d) 1, 22, cisplatin 100 mg/m2 d1, 22 and fluorouracil 1000 mg/m2/d by continuous
infusion d1-5 & d22-26 are given initially, followed by the simultaneous administration of
radiotherapy and tirapazamine 160-260 mg/m2 d43, 45, 47, 71, 73, 75, and cisplatin
20 mg/m2 d43, 45, 47, 71, 73, 75, and fluorouracil 600 mg/m2/day by 96 hour continuous
infusion d43-46 & d71-74. At the time of the interim analysis, 23 patients have been
randomized to treatment with tirapazamine and 20 were evaluable for toxicity.
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Granulocytopenia was the most frequent toxicity during the induction chemotherapy.
Grade 3 or 4 granulocytopenia occurred in 8/16 patients treated at 300 mg/m2 and 4/4
2
treated at 390 mg/m . During simultaneous chemoradiation, 1/4, 3/12, and 2/4 patients
treated with 160mg/m2, 220 mg/m2, and 290 mg/m2 developed Grade 3 granulocytopenia.
The most common toxicity during simultaneous chemoradiation was mucositis, which
reached Grade 3 in 9/20 and Grade 4 in 2/20. Skin reactions, weight loss, fatigue, muscle
cramps and tinnitus, and other of mild toxicity were also seen. The authors concluded that
the overall toxicity is comparable to the same regimen without tirapazamine.
1.5.2.3 The TROG Randomized Phase II Trial
Following the interesting results of the Phase I trial, the TROG initiated a randomized
Phase II trial that was designed to select the experimental arm for their next Phase III
study.
The 2 arms were the CDDP/TPZ/XRT regimen developed in the Phase I trial and a
“chemoboost” regimen slightly modified from a protocol developed by Peters and
colleagues at the University of Texas` MD Anderson Cancer Center (33). The modified
regimen differed from the MD Anderson protocol by administration of cisplatin as a
weekly bolus rather than a continuous infusion and reduction of the 5FU dose from
2
2
400mg/m to 360 mg/m because of hematological toxicity. The “chemoboost” regimen
was piloted at the Peter MacCallum Cancer Institute in 28 patients with locally advanced
head and neck cancer including 14 patients with T4 and/or N3 disease (34). The overall
complete response rate was 71% (95% CI: 51%-67%). With a median potential followup time of 29 months, the 2 year failure-free survival rate was estimated to be 40% (CI:
21%-59%) and the 2 year overall survival rate was estimated to be 50% (CI: 29%-71%).
The initial site of relapse or progression was locoregional in 11 of the 16 patients who
failed.
The TROG randomized Phase II study has currently accrued over 100 of a target of
120 patients at 11 centers in Australia and New Zealand. An interim safety analysis was
performed on the first 63 patients (35). On the tirapazamine arm, Grade 3 neutropenia
occurred in 30% and Grade 4 neutropenia in 3% of patients. Twelve percent of patients
on this arm experienced an episode of febrile neutropenia. Thrombocytopenia of any
grade was uncommon in both arms, but 2 patients on the tirapazamine arm had grade 4
thrombocytopenia. There was no statistically significant difference in mucositis between
the 2 arms, but the radiation skin reaction was of longer duration in the “chemoboost" arm.
While the toxicities were significant, including hematological toxicities and some of the
known toxicities of tirapazamine, TROG has concluded that the regimen can be used in a
multicenter trial.
1.6 Rationale for study
The approach of using concurrent radiation, tirapazamine, and cisplatin appears promising
from the initial Phase I/II trials. This randomized Phase III trial will be a pivotal trial to
compare this regimen with a standard regimen that is currently used for head and neck
cancer.

23/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

1.6.1 Selection of a control arm
Most investigators today agree that a platin (cisplatin or carboplatin) is the most active
agent to add to radiation. However, no single platin-based regimen combined with
radiation therapy has emerged as an overall standard of care. Several recent randomized
trials, either in progress or planned, use 3 doses of cisplatin, 100 mg/m2 in weeks 1, 4, and
7 of standard radiation therapy (70 Gy in 35 fractions over 7 weeks). These include the
recently reported Intergroup Phase III trial for laryngeal cancer RTOG 91-11 (11), the
Intergroup trial for unresectable head and neck cancer (12) and the planned RTOG Phase
III trial (KK Ang personal communication) where this regimen will be the control arm.
1.6.2 Selection of endpoints
The study is powered for the primary endpoint of overall survival. An analysis of time to
locoregional failure (TLRF) is planned prior to the completion of follow-up for survival.
1.6.2.1 Overall survival
The goal of therapy in this protocol is to cure the patient. As such, overall survival is the
primary endpoint. With advanced head and neck cancer, uncontrolled locoregional
disease is the most common cause of death and it is therefore expected that improved
locoregional control should be associated with improved overall survival. However, it is
apparent that the survival gain to be expected from any realized improvement in
locoregional control is quantitatively less because of deaths from distant metastatic
disease, second cancers and intercurrent non-malignant medical conditions to which this
patient population is prone.
1.6.2.2 Locoregional failure
Squamous cell carcinoma of the head and neck is a disease that if locally uncontrolled
causes considerable morbidity and mortality. This is because the natural history of the
disease is usually of local progression and regional spread in advance of life-threatening
distant metastasis. A relatively small percentage of patients with head and neck cancer
will manifest distant metastases. This is particularly true for head and neck cancer
patients with early stage nodal disease. The vast majority of treatment failures involve a
component of loco-regional disease recurrence. Depending on the exact site of disease,
locally uncontrolled disease is associated with debilitating problems in eating, breathing
and speaking, pain, malodor, and in the case of advanced neck disease, tumor fungation.
Death usually results from inanition, aspiration pneumonia, or torrential hemorrhage.
Patients with locally uncontrolled head and neck cancer frequently become social outcasts
and in need of high level palliative care. Because uncontrolled disease exacts such a
heavy price, the general consensus within the head and neck community is that
loco-regional control is the single most important determinant of patient well-being. This
is intuitively obvious and has, therefore, not been the subject of formal QoL studies in
head and neck cancer. One study, however, on 40 patients without and 8 patients with
recurrent disease, reported, not surprisingly, that patients with recurrence scored badly in
all domains (36).
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An important concern with locoregional failure as an endpoint for clinical trials is the
potential subjectivity of the endpoint, which can cause bias, and irreproducibility of the
results. However, for head and neck cancer, recurrence of disease is generally not
clinically silent to careful examination or symptoms. The areas at risk for locoregional
failure are amenable to examination by direct inspection, fiberoptic endoscopy and
palpation of accessible primary sites and the neck. For this study, these examinations will
be done every 2 months the first year, every 3 months the second year and every 4 months
the third year or until study cut-off. If there is a suspicion of recurrence, CT /MRI will be
done as well as biopsy. Scheduled CT or MRIs will complement the clinical exams every
4 months for the first year and then every 6 months until the cut-off date. Using this
rigorous follow-up, bias of the observer can be minimized. Furthermore, when there is
recurrence of disease, it is usually rapidly progressive, and inter-observer differences
would not significantly alter time to locoregional failure.
1.6.2.3 Quality of life evaluation
Quality of life (QoL) is an important secondary outcome of this phase III trial. It is
possible that the primary hypothesis of improved overall survival may not be
demonstrated with statistical significance. Such an outcome could reasonably occur due
to dilution of a true treatment effect by high rates of intercurrent illness and non-cancer
deaths. In this event, improved locoregional control in the experimental arm combined
with improved QoL may constitute sufficient evidence of benefit for the experimental
treatment to be adopted as standard. In contrast, durably inferior QoL results in the
experimental arm would necessitate a careful examination of the risks and benefits before
adopting the experimental arm as standard treatment, even if a survival benefit of small
magnitude is shown.
1.6.2.3.1 Quality-of-life hypotheses
It is expected that baseline QoL scores will decline during treatment and recover
approximately to baseline by 6 months following completion of treatment in patients
achieving a complete response. Thereafter, the average QoL in both arms will decline
over time as more patients relapse and develop new symptoms. As pain is a dominant
symptom of recurrent head and neck cancer, pain scores would be expected to be
particularly sensitive to post-treatment relapse. The hypothesis to be tested is: the
difference between baseline scores and the current QoL and pain scores, measured after
the acute treatment toxicities have resolved, will be more positive in the experimental arm.
This is consistent with the importance of the other endpoints of survival and locoregional
failure, which are not acute endpoints.

25/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

2. STUDY OBJECTIVES
2.1 Primary
The trial will compare the efficacy and safety of concomitant chemoradiation with
tirapazamine, cisplatin, and radiation versus cisplatin and radiation. This trial is designed
with the primary endpoint of overall survival.
2.2 Secondary
Secondary endpoints include, but are not limited to, the following (See Section 6.1.2.6) :
• Time to locoregional failure.
• Failure-free survival.
• Patterns of failure.
• Cumulative incidence of unacceptable locoregional treatment outcome.
• Change in QoL from baseline.
• Toxicity and safety.
• Initial response rates at 2 months after completion of chemoradiation therapy.
• Final CR rate.
• Biological correlates of outcome eg hypoxia, tumor markers
3. STUDY DESIGN
3.1 Description of the protocol
This is a Phase III, multicenter, international, randomized open-label, 2-arm trial
comparing 2 chemotherapy regimens: cisplatin (control arm) versus cisplatin and
tirapazamine (experimental), each used with concomitant radiation in advanced head and
neck cancer. A two-stage sequential design will be used.
3.2 Interim analysis
An interim analysis of overall survival will be done at the time of the analysis of time to
locoregional failure. The cut-off date for these analyses is defined as the date of
150 locoregional failures, which is expected to be approximately 2.5 years after the start
of accrual. It is estimated that approximately 85% of total expected locoregional failures
during study will have occurred by the time of interim analysis. Interim analysis of
locoregional failure will be at the 0.05 level of significance. A final analysis of
locoregional failure will be conducted at the time of the primary analysis of overall
survival. The interim survival analysis will be adjusted for type I error as specified in
Section 10.7.1.2. The interim analysis will be performed by the trial statistician/s and
their report will be submitted to the Trial Management Committee and the Sponsor, who
will jointly be responsible for the trial decisions. Results of the interim analysis will also
be provided to the Independent Data and Safety Monitoring Committee.
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If at the time of interim analysis there is a statistically significant difference in overall
survival in either direction (using an • level as defined in section 10.7.1.2), study accrual
will be stopped, assuming the target sample size has not been reached. Patients already
entered will be followed up for completion of clinical/survival data for a certain period to
be determined by the Trial Management Committee. If the interim survival analysis is not
significant, patients will continue to be accrued and followed till the study cut-off date
defined in the protocol. Analysis of the locoregional failure endpoint will not form the
basis for stopping early.
3.3 Study committees
A Trial Management Committee (TMC) including members of the Trans-Tasman
Radiation Oncology Group (TROG) will supervise the conduct of the trial. Responsibility
for the trial will be jointly held by the TMC and the sponsor, Sanofi-Synthelabo Research.
There will be at least eight seats on the committee, the majority of whom shall be clinical
investigators. TROG membership will include the principal investigators and the
statistician. Sponsor representative will be limited to three members including a
statistician. The TMC will choose additional representatives from participating
clinicians.
An Independent Data and Safety Monitoring Committee (IDSMC) will meet periodically
to review the safety of the trial. The broad responsibility of the IDSMC will be to
independently monitor the conduct of the trial. Specifically it will monitor the trial’s
scientific integrity, ensure patient safety and monitor adverse effects.
3.4 Duration of study participation
The duration of the study participation will include for each patient a one month inclusion
and treatment planning period, followed by a 7 week treatment period, followed by a
minimum of 4 weeks of follow-up for chemotherapy related toxicities after the completion
of the study treatment. In addition, all patients will be followed for radiation toxicity until
death or study cut-off. All subjects will be followed for disease status until locoregional
progression, death, or the study cut-off date whichever comes first. All subjects will be
followed for QoL until three years after completion of therapy or study cut-off date. All
subjects will be followed for survival and further therapy until death or the study cut-off
date.
The LRF analysis will be performed when 150 patients reach the endpoint of locoregional
failure. The study cut-off date is defined as the date of the 240th death, which is expected
to occur approximately 2.5 years after the enrollment of the last patient. The estimated
time for accrual is 1.5 years, giving an estimated total duration of the trial of 4 years.
Additional follow-up may be recommended by the trial management committee to answer
significant clinical questions related to the objectives.
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4. SELECTION OF PATIENTS
4.1 Number of patients planned
This study plans to enroll 550 evaluable patients.
4.2 Inclusion criteria
a) Previously untreated squamous cell carcinoma of the oral cavity, oropharynx,
hypopharynx, or larynx, histologically or cytologically confirmed.
b) Stage III or IV disease (excluding T1N1, T2N1 and metastatic disease). (Appendix 1)
c) Age ≥18.
d) ECOG performance status ≤2. (Appendix 2)
e) Absolute neutrophil count ≥1.5 X 109/L, platelet count ≥100 X 109/L, and hemoglobin
≥10g/dL.
f) Serum bilirubin <1.25 times ULN and AST/ALT <5 times ULN. Calculated creatinine
clearance (Cockcroft-Gault) ≥55 mL/min. (Appendix 3)
g) Signed written consent.
h) Availability for follow-up for up to 4 years after treatment.
i) The patient is infertile or is aware of the risk of becoming pregnant or fathering
children and will use adequate contraception (oral contraception, intrauterine devices,
diaphragm and spermicide or male condom and spermicide) throughout therapy and for
at least 3 months after therapy.
j) Life expectancy greater than 6 months.
4.3 Exclusion criteria
a) Significant intercurrent illness that will interfere with the chemotherapy or radiation
therapy during the trial such as HIV infection, cardiac insufficiency, myocardial
infarction within 6 months, pulmonary compromise, active alcohol abuse, active
infection or febrile illness.
b) Primary cancers of the nasal and paranasal cavities and of the nasopharynx.
c) Distant metastases. (All patients will have had a chest CT; patients with abnormal liver
function tests to have abdominal ultrasound or CT; patients with bone symptoms to
have a bone scan and plain films.)
d) Symptomatic peripheral neuropathy ≥ grade 2.
e) Clinically significant sensori-neural hearing impairment which may be exacerbated by
cisplatin (Audiometric abnormalities without corresponding clinical deafness will not
be grounds for exclusion)
f) Significant cardiac disease resulting in an inability to tolerate the intravenous fluid load
as required for administration of cisplatin.
g) Weight loss greater than 20% of normal body weight in the 3 months preceding trial
entry.
h) High risk for poor compliance with therapy or follow-up as assessed by investigator.
i) Pregnant or lactating women.
j) Prior radiation therapy to greater than 30% of the bone marrow
k) Prior experimental therapy for cancer within 30 days of entering the trial.
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l) Prior radiation for head and neck cancer.
m) Prior chemotherapy for head and neck cancer.
n) Prior cisplatin chemotherapy.
o) Patients with prior cancers, except: those diagnosed more than five years ago with no
evidence of disease recurrence and clinical expectation of recurrence of less than 5%;
or successfully treated non-melanoma skin cancer; or carcinoma in situ of the cervix.
However, any patient with previous invasive breast cancer, prostate cancer or
melanoma is excluded.
5. TREATMENT
5.1 Radiotherapy
In both treatment arms radiotherapy will consist of a conventionally fractionated radical
course of treatment. The dose to sites of macroscopic disease identified clinically or
radiologically will be 70 Gy in 35 fractions over 7 weeks except for small volume nodal
disease (under 2 cm maximum diameter on CT) where 60 Gy in 30 fractions over 6 weeks
is sufficient. This is important in the lower neck to minimize the risk of brachial plexus
injury. Sites of potential subclinical involvement will receive 50 Gy in 5 weeks or its
biologic equivalent. Lymphatic pathways to be treated electively must include a minimum
of two echelons of uninvolved nodes eg a patient with T3NO oropharyngeal cancer would
require treatment of the upper and mid cervical nodes but not necessarily the
supraclavicular nodes. Patients with ipsilateral N2 or N3 disease must have the entire
opposite neck treated electively. Specifics of radiotherapy technique and reporting
requirements are described below.
Treatment may be planned using either standard (parallel-opposed) or 3D conformal
techniques. IMRT is not allowed on this study. An approved benchmark for either
standard or 3D planning must be on file at the Quality Assurance Review Center (QARC).
The benchmark material is available on the QARC website (www.QARC.org). Centers
wishing to use only standard planning must complete the standard planning benchmark.
Centers that have completed the 3D benchmark may use either planning method. To
avoid bias, all phases of the radiotherapy course for each patient must be planned before
randomization. If a site wishes to upgrade from standard planning to conformal planning,
a 3D benchmark must be completed and approved by QARC.
Only linear accelerator based treatments (photon energy 4 MV or greater or electrons) are
allowed on this study. Co-60 is not allowed.
5.1.1 Central radiation QA review
Diagnostic films and treatment plans will be reviewed centrally on all patients from each
center. The treatment plan for all phases and associated documentation as set out in
Section 5.1.12 must be submitted to QARC within a week of starting radiotherapy. After
treatment is completed on each patient, a summary of the treatment actually delivered
including port films for all phases must be provided and submitted to QARC within one
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month of the treatment completion. QARC will compare each treatment plan to the
treatment actually delivered to each patient.
5.1.2 Immobilization
Patients should be positioned supine and immobilized using either a thermoplastic mask or
a vacuum formed mask. An intraoral stent or tongue depressor should be used if this will
allow a greater amount of the tongue or oral cavity to be excluded from the treatment
volume.
5.1.3 Standard simulation
At simulation, relevant anatomical landmarks should be identified as appropriate.
For oral cavity tumors a radio-opaque seed to define the anterior margin of palpable
disease should be inserted.
On the simulation film the lateral projection of the primary tumor and nodal disease
should be marked by reconstructing the information available from clinical examination
and CT/MRI scans. Alternatively, all gross disease can be marked on the planning CT.
Fields should be shaped with custom blocks or multi-leaf collimators to achieve maximum
sparing of normal tissues while achieving adequate tumor coverage. A minimum field
margin of 2 cm around all gross disease and potential sites of subclinical involvement is
required for the first phase of treatment. A minimum field margin of 1 cm round gross
disease (as defined pre-treatment) is required for the boost. Skin fall-off should be
avoided anteriorly whenever possible. Except in patients who have had an open biopsy of
neck nodal disease, or in whom tumor is infiltrating the skin, no surface bolus should be
used.
5.1.4 Standard planning
All patients must have a planning CT for dose calculation and to verify coverage of gross
disease in the treatment volume. At a minimum, slices for isodose calculation must be
obtained at the central axis of the field, through the plane of maximum tumor bulk (if this
does not coincide with the central axis) and 1 cm inside the upper and lower margins of
the fields. In the plane of maximum tumor bulk the isodose distribution should be
overlaid on the CT image to confirm tumor coverage.
For the first phase of treatment (on cord) fields should be planned where possible to avoid
splitting any nodal disease. For the second phase, if the location of nodal disease permits,
oblique off cord fields are recommended to cover all gross disease. If this is not possible
abutting electron fields should be used to treat extensions of nodal disease posterior to the
mid-vertebral plane. The energy of the electron beam must be determined by the
thickness of nodal disease to ensure adequate coverage but at the same time avoiding too
high a dose to the spinal cord. In the event that immobilization is inadequate due to
weight loss or significant regression of the node(s) during treatment a second planning CT
scan is required.
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5.1.5 Standard dosimetry
The prescription point for parallel opposing fields is in the midplane of the central axis
(ICRU 50). Missing tissue compensation should be used if available to provide dose
homogeneity within the PTV. The dose variation within 1.5 cm of gross disease should
not exceed +7% and –5% of the prescription point dose. Where an electron beam abuts a
photon beam overlying gross disease a small volume hot spot of up to 120% is
permissible. For electron fields the dose will be specified as the peak dose (D max) with
energy chosen to deliver at least 90% to sites of gross disease. The nominal tumor dose to
gross disease as defined clinically or radiologically shall be 70 Gy except for small
volume nodal disease (under 2 cm diameter) where a minimum dose of 60 Gy shall be
specified. Sites of potential subclinical involvement shall be treated to 50 Gy. In the
lower neck this (subclinical disease) dose will be specified at a depth of 2 cm.
If the junction plane between lateral and anterior neck fields provides a margin of less than
1 cm below all gross nodal disease, the subclinical dose should be increased to 60 Gy
within a buffer zone adjacent to gross disease. Likewise clinically impalpable but
radiologically suspicious (not definitely involved) nodes should be boosted to 60 Gy. The
dose to the spinal cord shall not exceed 40 Gy from the direct beams and shall not exceed
45 Gy from all dose contributions. If the location of gross disease mandates a higher cord
dose to achieve adequate coverage of gross disease, a cord dose of up to 48 Gy is
permitted. Point doses to the spinal cord within the cone down volume must be
calculated.
5.1.6 Standard field verification
Portal films should be taken weekly. At least one portal film for each field (or hard copy
of real time portal images) must be submitted for QA audit.
5.1.7 Conformal planning
A planning CT covering the entire volume of interest is required with slice separation of
no more than 5 mm through sites of imageable disease and 10 mm elsewhere. The
planning CT should be fused with diagnostic images whenever possible. The gross tumor
volume (GTV ) must be marked on all slices where imageable disease is present. Two
planning target volumes (PTVs) must be marked: PTV1 to cover the GTV (primary and
involved nodal regions) and potential areas of local extension or lymphatic spread with a
minimum 1.5 cm margin, and PTV2 to cover the GTV (primary and involved lymph node
regions) with a minimum 0.5 cm margin in all planes. In cases where small volume neck
disease is present, a third PTV3 will be marked to cover this desease with a minimum 0.5
cm margin. Parotid and/or submandibular gland sparing techniques are encouraged to the
extent that coverage of the PTV is not compromised.
5.1.8 Conformal dosimetry
The dose to PTV1 will be 50 Gy, to the PTV2 70 Gy, and to PTV3 60 Gy all in 2 Gy
fractions. The dose variation within PTV2 and PTV3 should not exceed +7% and –5% of
the prescription point dose. The maximum spinal cord dose shall not exceed 45 Gy from
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all fields. If the location of gross disease mandates a higher cord dose to achieve adequate
coverage of gross disease, a cord dose of up to 48 Gy is permitted. Point doses to the
spinal cord must be calculated for all relevant fields. Composite isodose distributions and
dose volume histograms for PTV1, PTV2, PTV3 and the spinal cord shall be submitted.
5.1.9 Conformal treatment delivery verification
Isocenter verification on orthogonal films plus BEV and REV (Section 5.1.13) are
required.
5.1.10 Fractionation
For both arms of the trial, conventional once daily fractionation, 5 fractions per week are
specified. In the event of public holidays, missing treatment(s) should be made up in the
same way as for treatment interruptions (see below).
Every effort must be made to avoid protraction of treatment beyond 7 weeks. Treatment
interruptions should be avoided unless there is severe acute toxicity which cannot be
managed conservatively. In the event of a treatment interruption for any other reason, the
missing dose fraction(s) should be made up by treatment on a weekend or by giving a
second treatment on one or more of the remaining treatment days with a minimum 6-hour
interfraction interval provided that no more than 6 fractions are given in any one week.
The reason for any treatment interruption must be documented. Chemotherapy scheduling
will be adjusted to conform to any break in radiotherapy. (Section 5.2.1)
5.1.11 Dose calculation and reporting
Prescription point
The monitor units required to deliver the prescribed dose to the prescription point shall be
calculated and submitted.
Dose uniformity
For standard treatment plans the maximum and minimum doses within 1.5 cm of gross
disease shall be reported. For conformal plans, the maximum and minimum doses in the
PTV shall be calculated and reported as per ICRU 50. These may be extracted from
isodose distributions, calculated separately or derived from DVHs.
Reference point
The dose reference point calculated on this study is the isocenter. The total dose to this
point shall be calculated and reported.
Critical organs
The maximum dose to the spinal cord shall be calculated, recorded in the treatment
records, and submitted with the QA documentation. For patients treated with volumebased techniques, the appropriate dose volume histograms shall be submitted. This
includes the parotids for patients treated with parotid sparing techniques.
Isodose distribution
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An isodose plot of dose distribution in the central transverse plane through the target
volume shall be submitted. In addition, dose distributions 1 cm inside the upper and lower
margins of the fields shall also be submitted. The prescription point and the outlines of
the planning target volume and critical organs shall be shown. Isodose values must be
clearly labeled. The effects of shielding blocks shall be included and corrections for
heterogeneity shall be shown.
For volume based treatment planning, a hard copy isodose distribution for the total dose
plan in the axial, sagittal, and coronal planes, which includes the isocenter of the planning
target volume (PTV) must be submitted (central axis, two superior and two inferior
planes). These dose distributions must include the following:
A sufficient number of isodose contours should be shown to determine that the dose
distribution conforms to the protocol guidelines. These isodoses should be superimposed
over treatment planning CT or MR images. However, if such hard copy presents
difficulty, similar plots without the gray scale image are acceptable if enough critical
contours are identified to verify the dose distribution to target volumes and critical normal
structures. Specifically, include those volumes for which there are dose volume
histograms.
5.1.12 QA documentation
Note: Black and white copies of color documentation are not acceptable.
Within one week of the start of radiotherapy, the following data shall be submitted for
rapid review for patients using standard planning techniques:
• Copies of the planning CT and the diagnostic imaging utilized in defining the gross
target volume.
• Copies of simulator films and/or digitally reconstructed radiographs (DRRs) for each
field. It is required that the lateral projection of all gross disease be drawn on the
simulator films.
• Copies of verification (portal) films for each field.
• Photographs of the patient in the treatment position, with the fields marked on the skin
or on the immobilization device and visible in the photograph.
• The RT-1 Dosimetry Summary Form, one for each target volume.
• Copies of worksheets and/or printouts used for calculations of monitor settings to give
the prescribed dose, and doses to all normal structures.
• Copies of isodose distributions for all phases of treatment to demonstrate that the dose
variation is within specification. The treatment volumes and the prescription point
must be clearly shown.
If 3D-conformal treatment planning is utilized, submit the following for rapid review:
• Copies of the planning CT and the diagnostic imaging utilized in defining the gross
target volume.
• Digitally reconstructed radiographs of each treatment portal.

33/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

• RT-3D Dosimetry Summary Form, which includes a complete description of each
portal, including energy, gantry, couch and collimator position, wedge description (if
used), and equivalent field size.
• One set of orthogonal anterior/posterior and lateral films for isocenter localization for
each group of concurrently treated beams. If portals being submitted contain an
orthogonal set, this is sufficient.
• Photographs of the patient in the treatment position, with the fields marked on the skin
or on the immobilization device and visible in the photograph.
• BEVs of portals showing collimator, beam aperture, target volume and critical
structures.
• A room’s eye view (REV), i.e., a composite illustration of all the fields and their
angles, if available from your planning system. Otherwise submit an overview diagram
or illustration of the patient with all beams and their orientation indicated.
• Copies of the isodose distributions for the total dose plan in the axial, sagittal and
coronal planes, which includes the isocenter(s) of each planning target volume. The
target volume isocenter and the prescription point (if different) must be clearly
indicated.
• Dose volume histograms for the entire treatment course for PTV 2 and critical
structures within the treatment volume as required in 5.1.11.
Within one month of the completion of radiotherapy, the following data shall be
submitted.
• Copies of additional simulation and verification (portal) films for any field
modifications or re-planning done subsequent to the initial reporting of data for rapid
review.
• A copy of the patient's radiotherapy record including prescription, and the daily and
cumulative doses to all required areas and specified dose points.
• Copies of calculations and isodoses performed subsequent to the submission of the
rapid review data.
• An RT-1 Dosimetry Summary Form or RT-3D Dosimetry Summary Form if changes
have been made subsequent to submission of rapid review data.
• The RT-2 Radiotherapy Total Dose Record Form
These data should be forwarded to:
Quality Assurance Review Center
825 Chalkstone Avenue
Providence, Rhode Island 02908-4735
Questions regarding the dose calculations or documentation should be directed to:
Protocol Dosimetrist
Telephone 401-456-6500
FAX 401-456-6550
Email: physics@qarc.org
Definitions of Deviations in Protocol Performance:
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Prescription dose
Minor Deviation: The dose per fraction or total dose to the prescription point differs from
that in the protocol by between 6% and 10%. For the spinal cord, any dose greater than 48
and less than or equal to 50Gy.
Major Deviation: The dose per fraction or total dose to the prescription point differs from
that in the protocol by more than 10%. Any spinal cord dose greater then 50 Gy.
Dose uniformity
Minor Deviation: the variation of dose to areas of gross disease exceeds +7% or –5% of
the dose to the planning target volume.
Major deviation: Variation in dose to areas of gross disease exceeds +/- 20%.
Volume
Minor Deviation: Margins less than specified or unnecessary irradiation of normal tissue.
Major Deviation: Geographic miss of any part of the GTV
Treatment Prolongation
Minor Deviation: Greater than 7 weeks less than/equal to 8 weeks
Major Deviation: Greater than 8 weeks.
5.2 Chemotherapy
2
Arm 1 – Cisplatin 100 mg/m will be given as a 1-hour infusion immediately before
radiotherapy on day 1 of weeks 1, 4, and 7 of radiotherapy. Hydration will be required
with each dose of cisplatin with the standard hydration schedule used at each institution.
Standard antiemetic regimens for cisplatin should be used, which would generally include
a 5-HT3 antagonist and dexamethasone.

Arm 2 – Tirapazamine will be given at a dose of 290 mg/m2 via a 2 hour intravenous
infusion followed after a 1 hour interval by cisplatin 75 mg/m2 as a 1 hour infusion
immediately before radiotherapy on day 1 of weeks 1, 4, and 7.
Tirapazamine alone at a dose of 160 mg/m2 will be given as a 2 hour infusion on days 1, 3,
and 5 of weeks 2 and 3, with radiotherapy given not earlier than 30 minutes and not later
than 2 hours after the end of the infusion. Hydration will be required with each dose of
cisplatin with the standard hydration schedule used at each institution. A possible
schedule for hydration with cisplatin and tirapazamine is outlined in Appendix 4. For
cisplatin and tirapazamine doses, an antiemetic regimen including a 5-HT3 antagonist and
dexamethasone is required. The antiemetic regimen for delayed emesis should include
dexamethasone. In Weeks 2 and 3 a 5-HT3 antagonist and 4 mg dexamethasone
intravenously prior to each tirapazamine dose is generally adequate to control nausea and
vomiting. Diarrhea of short duration frequently occurs during or immediately following
the tirapazamine infusion, particularly after the higher dose given prior to cisplatin.
Treatment of muscle cramps is symptomatic with analgesics and muscle relaxants such as
benzodiazepines.
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For patients with a calculated body surface area >2.0 m but ≤2.2 m the Investigator may
2
2
cap the dose at 2.0 m . For patients with a calculated body surface area >2.2 m , the
2
Investigator must cap the dose at 2.2 m .
2
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5.2.1 Dose modification
The schedules for dose reductions are presented in the following tables:
Cisplatin (Arm1) or combined cisplatin/tirapazamine (Arm 2) in Weeks 4 and 7

On treatment day

On treatment day

On treatment day

Nadir

Hematological toxicity
9
Neutrophil ≥ 1.0 x 10 /L
And
9
Platelets ≥ 100 x 10 /L
Neutrophil ≥ 0.5 and <
9
1.0 x 10 /L
And/or
Platelets > 25 and < 100
9
x 10 /L

Cisplatin
Full
dose
scheduled

Tirapazamine
when Full dose when scheduled

1) Delay by up to 4
days.
2) AND then:
Administer the full
dose if Neutrophil
9
≥1.0 x 10 /L and/or
9
Platelets ≥100 x 10 /L
Or
Omit that dose if after
4 days any of those
counts remain under
those limits
and administer the
next planned dose
without dose reduction
9
1)
Delay by up to 4
Neutrophil < 0.5 x 10 /L
days
And/or
2) AND then:
Platelets < 25 x 109/L
Administer the dose
with 25 % dose
if
reduction
Neutrophils ≥1.0 x
9
10 /L and/or Platelets
9
≥100 x 10 /L
or
Omit that dose if after
4 days any of those
counts remain under
those limits
and administer the
next planned dose with
25% dose reduction
Neutrophil < 1 x 109/L Administer the next
associated with fever or dose with 25 % dose
infection or lasting ≥ 7 reduction if
Neutrophils ≥1.0 x
days
9
10 /L
And/or
and/or Platelets ≥100 x
Platelets < 25 x 109/L
9
10 /L
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1) Delay by up to 4 days.
2) AND then:
Administer the full dose if
9
Neutrophil ≥1.0 x 10 /L
and/or Platelets ≥100 x
9
10 /L
or
Omit that dose if after 4
days any of those counts
remain under those limits
and administer the next
planned dose without dose
reduction

1) Delay by up to 4 days
2) AND then:
Administer the full dose if
9
Neutrophils ≥1.0 x 10 /L
and/or Platelets ≥100 x
9
10 /L
or
Omit that dose if after 4
days any of those counts
remain under those limits
and administer the next
planned dose without dose
reduction
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as a full dose if
9
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and/or Platelets ≥100 x
9
10 /L
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If chemotherapy is delayed by up to 4 days in Week 4, then the Week 7 dose should be no
earlier than 20 days later.
Renal Toxicity
Creatinine Clearance calculated using
the Cockcroft Gault formula
> 50 mL/min
40-50 mL/min
< 40 mL/min

Peripheral neuropathy
(CTC)
> Grade 2
Ototoxicity
(CTC)
≥ Grade 2, not
acutely reversible
Acute reversible
hearing loss

Cisplatin
Tirapazamine
No modification
No modification
Administer it but reduce dose to No modification
2
50 mg/m (applies to both arms)
No modification
Omit that dose.

Cisplatin
Omit that dose.

Tirapazamine
No modification

Cisplatin
Tirapazamine
Omit AND restart if condition No modification
improves to <Grade 2
In case of hearing loss ≥Grade 2 the dose
should be reduced by 25% in Weeks 4 and 7
but not in Weeks 2 and 3 when a lower dose of
tirapazamine is administered.

No modification

Other non-hematological
a
toxicities
(CTC)

Cisplatin

Tirapazamine

Grade 0-2

No modification

No modification

Grade 3-4 (excluding

Hold chemotherapy until symptoms improve to ≤Grade 2.

If

nausea/vomiting, alopecia and acute symptoms persist >2 weeks contact Medical Monitor or withdraw
radiation related toxicities)
a

patient. Restart if Grade < 2. Subsequent doses may be reduced

by 25% at the discretion of the Investigator.
If the toxicity is clearly due to one of the chemotherapy drugs, then only the dose of that drug should
be reduced.

Tirapazamine toxicity
The dose limiting toxicity in the Phase I trial has been neutropenia, which only occurred in
the last 2-3 weeks of treatment. Muscle cramps, diarrhea, and rashes do not generally
require dose reductions or omission of doses. Cramps and skin rashes do not appear to be
dose related. Cramps are most troublesome in the first 2 weeks, and then appear to
subside despite continuing treatment with tirapazamine. Tirapazamine doses may be
reduced by 25% following severe tirapazamine related toxicity, at the discretion of the
Investigator. Hearing loss after tirapazamine has generally been seen at doses higher than
are being used in this trial. If acute reversible hearing loss (> Grade 2) occurs, then a 25%
dose reduction of tirapazamine would be required for weeks 4 and 7, but not in weeks 2
and 3 when a lower dose of tirapazamine is administered.
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Nausea and vomiting predominantly occur following combined tirapazamine/cisplatin
doses, and in general should not result in a dose reduction. Grade 3 or 4 non-hematologic
toxicity (apart from toxicities mentioned above) that is due to the chemotherapy may
require a dose delay for cisplatin/tirapazamine doses or a dose omission for tirapazamine
alone doses. Subsequent doses may be reduced by 25% at the discretion of the
Investigator.
Delays
• If radiotherapy is interrupted then chemotherapy will also be delayed. When
radiotherapy is reintroduced, chemotherapy should not be given on days when two
fractions of radiation are given.
• Combined cisplatin and tirapazamine doses on the experimental arm may be delayed
for up to 4 days if required (longer if radiotherapy has also been delayed). If severe
chemotherapy toxicity persists for more than 2 weeks the chemotherapy drug related to
that toxicity should be definitively discontinued.
• If cisplatin has been terminated due to toxicity, tirapazamine may still be given in
weeks 4 and 7. Tirapazamine alone doses in weeks 2 and 3 that cannot be given on the
scheduled day due to toxicity will be omitted rather than delayed, unless radiotherapy
had to be delayed as well.
• If radiotherapy is interrupted, missed doses of radiotherapy should be made up. If
chemotherapy is delayed or ceased due to toxicity then radiotherapy should continue to
be given according to protocol.
• No chemotherapy will be administered after completion of radiotherapy.
Chemotherapy toxicity will be graded according to the Common Toxicity Criteria (CTC
Version 2.0 Publish Date: April 30, 1999) (Appendix 7).
5.2.2 Management of neutropenia
The dose limiting toxicity in the Phase I trial has been neutropenia, which only occurred in
the last 2-3 weeks of treatment. Preliminary analysis of the first 50 patients in the
randomized phase II trial showed that 30% percent of the patients on the tirapazamine arm
had Grade 3 neutropenia and 3 % had grade 4 neutropenia. 12% of the patients on the
tirapazamine arm had febrile neutropenia. Although the neutropenia is often mild, it
occurs when the acute mucous membrane and skin toxicities are at a maximum and when
the patients are at a high risk of aspiration pneumonia. During the period when the
patients are at greatest risk of febrile neutropenia (weeks 5-7) patients on both arms should
check their temperatures twice a day and notify their physician of temperatures greater
than 38°C. Patients who develop febrile neutropenia must be managed carefully and
aggressively with fever work-up including blood cultures and chest x-ray and intravenous
antibiotics.
5.3 Post-chemoradiation neck surgery
Two months following completion of chemoradiotherapy, patients will have an evaluation
described under assessments (6.1).
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Provided there has been a complete response at the primary site, there are 3 management
strategies for residual resectable neck masses that can be adopted on this trial. Each
institution must elect at the outset which of these 3 policies it wishes to adopt for this trial,
and consistently apply the policy. The 3 policy options are:
1) If there is a residual mass in the neck either clinically or radiologically, a planned
selective neck dissection will be performed.
2) If the neck mass is regressing, it will be kept under surveillance at monthly intervals
up to a further 6 months (8 months following end of treatment) with surgery being
allowed at any time if the mass ceases regressing.
3) Planned neck dissection will be undertaken in all patients with baseline N2 (> 3 cm) or
N3 disease irrespective of response in the neck, provided there has been a CR at the
primary site. If bilateral neck dissections are planned, they should be done as separate
procedures. Institutions adopting this option must declare if they will use policy 1 or 2
for residual neck masses from nodes initially ≤ 3 cm.
With policies 1 and 2, no neck dissection will take place if there has been a clinical and
radiological CR in the neck at the 2-month evaluation. Regardless of the policy adopted
for the management of the neck, any surgical intervention requires that residual nodal
disease be deemed completely resectable.
Patients who are thought to be in clinical CR at the primary site but have a minor residual
imaging abnormality will be assumed to be in CR for the purposes of deciding about neck
surgery. When there is considerable edema at the 2-month evaluation, e.g. laryngeal
cancer, that makes the clinical and imaging determination of CR at the primary site
difficult, sites that have adopted policies 1 and 3, may revert to policy 2 for these patients.
This will allow more time to clarify the response at the primary site prior to any neck
dissection.
5.4 Investigational product
Tirapazamine will be supplied by Sanofi-Synthelabo. 250ml of Tirapazamine will be
supplied as a clear yellow-orange liquid (0.7 mg/ml) in an isotonic citrate buffer with a pH
between 3.7 and 4.3 in 300 ml bottles. Tirapazamine is supplied in solution form that will
not need dilution. The total dose of tirapazamine for each subject scheduled to receive
this drug should be transferred from the supplied bottles into a chemotherapy bag/bottle
and must be administered via infusion pump for the stated time interval. Tirapazamine
will not be administered with a diluent unless specifically stated.
The dose of tirapazamine (TPZ) will be calculated as follows:

BSA ( m 2 ) x TPZ dose (mg / m 2 )
= TPZ volume ( mL)
0.7 mg / mL
Thus, for a subject with a BSA (body surface area) = 1.85 m2 treated at a tirapazamine
dose of 290 mg/m2, the volume of tirapazamine to be administered would be 766 ml. The
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volumes of the bottles may fluctuate slightly. However, when the entire bottle containing
the expected 250 ml of solution is planned to be used, one can assume the volume is
correct and the actual volume does not need to be measured. The possible excess is less
than 3.5%. Note that the subject's weight and BSA must be re-evaluated prior to each
treatment cycle, with corresponding adjustment of dose as appropriate.
Information on expiration dates of tirapazamine will be supplied on a lot-by-lot basis. The
Sponsor will notify the Investigator of any lots that are about to expire, and replacement
supplies will be shipped. All cancer chemotherapeutic agents should be handled with
utmost care during preparation and administration. To avoid any form of physical contact
with the drug by the health care provider, gowns, gloves, and masks should be worn when
appropriate. As a parenteral agent, tirapazamine should be prepared in a vertical-flow
biologic safety cabinet. Refer to hospital guidelines for any additional precautions that
may apply.
Cisplatin will be handled in accordance with standard procedures for these cytotoxics at
the institution.
5.5 Method of assigning patients to treatment group
Randomization will only be done after all phases of radiation planning have been
completed. At sites where PET-FDG scans are being performed prior to treatment, the
results must be reviewed before randomization. Randomization should take place as close
as possible but not more than 2 weeks prior to the anticipated start of treatment.
Treatment assignment will be done centrally, by stratifying for disease stage (III v IV),
primary site (oropharynx/larynx v hypopharynx/oral cavity), and hemoglobin (≥13.5 g/dL
for men and ≥12.5 g/dL for women v otherwise). A dynamic allocation method will be
used to avoid extreme imbalance of treatment assignment within an institution.
5.6 Packaging and labeling
250mL of tirapazamine 0.7 mg/mL solution is supplied in 300mL bottles.
Tirapazamine bottles are individually labelled with a booklet label, with text in all
languages of the participating countries, and a separate label containing variable
information (product batch number).
Four bottles are packaged in a labelled and sealed outer box, with a foam insert to hold the
bottles in place, and either an absorbent pad (placed under the bottles) or absorbent sachets
(placed alongside) in case of breakage. Each outer box is sealed in a polythene bag.
Outer cartons are labelled with booklet labels, a label “4x” to indicate that 4 bottles are in
the carton and a label which details batch number and expiry date.
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5.7 Storage conditions
Information on expiration dates of tirapazamine will be supplied on a lot-by-lot basis. The
Sponsor will notify the Investigator of any lots that are about to expire, and replacement
supplies will be shipped.
Tirapazamine must be stored between 15°C and 30°C in the light proof packaging
provided. During administration to subjects Tirapazamine must be protected from light,
though it is not necessary to protect infusion lines. As an investigational agent,
tirapazamine must be kept in a secure area and may be supplied only to subjects treated
under the direction of the Investigator and in accordance with this protocol.
Cisplatin will be stored in accordance with standard procedures for these cytotoxics at the
institution.
5.8 Responsibilities for investigational product
The Investigator, the Hospital Pharmacist, or other personnel allowed to store and
dispense Investigational Product will be responsible for ensuring that the Investigational
Product used in the study is securely maintained as specified by the Sponsor and in
accordance with the applicable regulatory requirements.
All Investigational Product shall be dispensed in accordance with the Investigator's
prescription and it is the Investigator's responsibility to ensure that an accurate record of
Investigational Product issued and returned is maintained.
Under no circumstances will the Investigator supply Investigational Product to a third
party, allow the Investigational Product to be used other than as directed by this protocol,
or dispose of Investigational Product in any other manner.
5.9 Retrieval and/or destruction of investigational product
• All partially used treatments should be destroyed at the site. A detailed treatment log
of the destroyed supplies will be established with the Investigator (or the pharmacist)
and countersigned by the Investigator and the Monitoring Team.
• At the end of the trial or upon for expiration.
• The Investigator will destroy the unused Investigational Product after written
authorization by the Sponsor or Sponsor's representative.
5.10 Concomitant therapy
5.10.1 Not permitted concomitant therapy
Concomitant therapy with agents known to have anticancer activity (including systemic
retinoids) is not permitted during the treatment phase of the study. Erythropoietin is not
allowed while the patient is on study.
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Subjects may not participate in any other protocols using investigational treatment(s) or
procedure(s) while participating in the treatment phase of this trial, except those that may
be directly related to this trial and approved by the Trial Management Committee.
5.10.2 Permitted concomitant therapy
Medications used for the treatment of pre-existing illnesses or new symptoms and
illnesses are permitted unless they are not permitted (refer to the Section 5.10.1). G-CSF
and GM-CSF are allowed for use during or after an episode of febrile neutropenia, but
their use must be recorded. However, G-CSF or GM-CSF must stop 24 hours before any
chemotherapy is administered. G-CSF should not be used prophylactically. The
unexpected finding has been reported that G-CSF had a negative impact on local control
and survival in a study that first randomized patients to receiving either hyper fractionated
(HF) accelerated radiochemotherapy or hyper-fractionated accelerated radiotherapy in
advanced H&N cancer followed by a second randomization to evaluate the prophylactic
use of G-CSF.
6. OUTCOME ASSESSMENT
6.1 Efficacy
6.1.1 Clinical assessment methods
The secondary endpoints require the determination of disease status at the end of the
treatment phase and sequentially thereafter. It is highly important to have objective
definitions and measures of clinical status since there is a concern that bias can be
introduced with the proposed definition of loco-regional failure.
Clinical follow-up examinations will be performed by members of a qualified head and
neck cancer team nominated by each institution. Physical examination will include direct
inspection and palpation of accessible sites and fiberoptic endoscopy. The neck will be
examined by palpation. Imaging will be done at defined times (specified below) or at any
time there is clinical suspicion of recurrence or progression. Biopsy or cytological
confirmation of recurrent disease should be obtained whenever possible.
Imaging (CT or MRI depending on which was done prior to treatment) of primary site and
neck will be performed at 2 months after treatment and prior to any surgery. Patients with
a clinical and radiological CR in the neck will not undergo neck dissection, unless the
treating center has adopted a policy of routine neck dissection in all patients with baseline
N2 (>3 cm) or N3 disease (Section 5.3). Radiological CR requires that any residual nodal
tissue is <1cm in maximum diameter and of homogeneous (non-necrotic) appearance. For
centers with PET capability, there must be no residual metabolic activity on 18F-FDG
scanning.
Following the 2-month assessment, patients will be reviewed for disease status and
toxicity assessments at least every 2 months the first year, every 3 months the second year
and every 4 months the third year. Imaging will be repeated every 4 months for the first
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year and then every 6 months or until study cut-off. Please see flow chart for other
assessments.
6.1.2 Criteria of efficacy
6.1.2.1 Primary criteria
The trial will compare the efficacy and safety of concomitant chemoradiation with
tirapazamine, cisplatin, and radiation versus cisplatin and radiation. The primary endpoint
will be overall survival.
6.1.2.2 Secondary criteria
Secondary endpoints include the following:
• Time to locoregional failure with date of randomization as the start date. Locoregional
failure is defined in this study as the presence of persistent progressive or recurrent
disease above the clavicles (see Section 6.1.2.6).
• Failure-free survival. Failure is defined as death due to any cause, locoregional failure
or development of distant metastasis.
• Patterns of failure as the initial site of failure at the primary site, neck, distant sites or
combinations of these.
• Cumulative incidence of unacceptable locoregional treatment outcome as a function of
time. An unacceptable outcome is defined as either locoregional failure or severe late
(>90 days from the start of treatment) treatment-related toxicity which may be any of
the following: grade 4 skin, subcutaneous tissue, mucous membrane or bone toxicity,
grade 3 or 4 spinal cord toxicity, grade 4 laryngeal toxicity requiring tracheostomy, or
the need for enteral feeding persisting beyond 12 months following completion of
treatment.
• Change in QoL from baseline as assessed by FACT-H&N scale in eligible patients at 6
months post-treatment (see 6.1.2.7 QoL Evaluation).
• Toxicity and safety, determined through review of adverse events, routine symptom
assessment, and laboratory determinations.
• Initial response rates defined as rates of CR, PR, SD or PD 2 months after completion
of chemoradiation therapy as described in Section 6.1.2.5.
• Final CR rate as defined in Section 6.1.2.5 (d).
Additional analysis to include correlation of efficacy with baseline hypoxia measurements
including F-AZA-PET (at selected sites) and blood levels of chemical markers for hypoxia
as directed by the Trial Management Committee. For example, correlation of hypoxia has
been studied with the serum markers, osteopontin (37) and PAI-1. Unstained slides of
tumor biopsies will be collected for immunohistochemical analysis for prognostic markers
such as Ki-67, HIF1α and p53.
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6.1.2.3 Measurement of response
The initial response will be determined after all protocol treatment has been finished,
whether or not all of the planned treatment is achieved. This evaluation will be performed
8 weeks after completion of chemoradiation therapy.
The RECIST (Response Evaluation Criteria in Solid Tumors) criteria, as modified below,
will be followed for assessment of tumor response (38). These criteria are a revised
version of the World Health Organization (WHO) criteria originally published in 1979.
The RECIST criteria were developed by a consensus group (including the WHO, NCI
Canada, NCI U.S., cooperative oncology groups and industry). The RECIST criteria
require confirmation of responses with a second study. This trial does not conform to the
usual chemotherapy trial with repeated doses of chemotherapy where confirmation makes
sense. In this trial, response will only be measured after a discrete period of concomitant
therapy. A confirmatory study after the concomitant therapy would not be appropriate
since the initial assessment will occur 8 weeks after the completion of chemoradiotherapy.
6.1.2.4 Definition of measurable/non-measurable disease
The following definitions of measurable and non-measurable disease will be used:
• Measurable disease: lesions that can accurately be measured in at least one dimension
as ≥2.0 cm with conventional techniques or as ≥1.0 cm with spiral CT scan. The
longest diameter (LD ) will be recorded.
• Non-measurable disease: all other lesions, including those with a longest diameter <2.0
cm with conventional techniques or as <1.0 cm with spiral CT scan.
6.1.2.5 Definition of response
Responses will be recorded separately for the primary site and the neck.
6.1.2.5.1 Primary site
RECIST criteria will be modified to take into account clinical (which must include
fiberoptic examination for sites not amenable to direct inspection) and radiologic findings.
• Complete Response (CR): Complete disappearance of the primary tumor. A CR
requires that there is no evidence of disease (other than an equivocal imaging
abnormality at the primary site) by both clinical and radiologic criteria.
• Partial Response (PR): Decrease by 30% or greater in the LD of the primary lesion in
reference to the baseline LD by both clinical and radiological criteria; or decrease by
30% or greater in the LD of the primary lesion by radiologic criteria associated with
definite regression by fiberoptic endoscopy in sites not amenable to direct clinical
measurement; or decrease by 30% or greater in the LD of the primary lesion by direct
clinical measurement in a lesion that is not measurable radiologically; or definite
regression by fiberoptic endoscopy in a lesion that is not measurable either clinically or
radiologically.
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• Stable disease (SD): Failure to observe CR or PR as described above, in the absence of
progressive disease.
• Progressive Disease (PD): At least a 20% increase in the LD of the primary lesion
measured clinically or radiologically in reference to the smallest LD recorded since
initiation of treatment; or definite evidence of progression by clinical (including
fiberoptic) examination for non-measurable lesions
6.1.2.5.2 Neck nodal disease
When assessing initial disease status, nodes which are not palpable but which may be
noted on CT/MRI scans with diameters of < 1 cm should not be considered a site of
disease unless there is other evidence of involvement e.g., necrotic center.
• Complete Response (CR): Complete disappearance of all tumor lesions. When
assessing the response of initially involved nodes, all of which regress completely
clinically but persist on CT/MRI with a diameter < 1 cm and without central necrosis, a
CR should be scored.
• Partial Response (PR): Decrease by 30% or greater in the sum of LD of all nodal
lesions in reference to the baseline sum LD, both clinically and radiologically. No
nodal lesions should have progressed and no new nodal lesions should have appeared.
• Stable disease (SD): Failure to observe CR or PR as described above, in the absence of
any progressive or new lesions.
• Progressive Disease (PD): At least a 20% increase in the sum of LD of all nodal lesions
in reference to the smallest sum LD recorded, either clinically or radiologically, since
initiation of treatment and/or the appearance of any new nodal lesions.
6.1.2.5.3 Initial response assessment
Response to treatment (CR, PR, SD, or PD) will be assessed only at 8 weeks posttreatment, prior to any neck dissection. Subsequent evaluations will be based solely on
whether or not locoregional failure has occurred.
Patients who are clinically in CR but have a residual imaging abnormality at the primary
site will be classified as ‘response pending’. Documentation of stable imaging appearance
on 2 consecutive CTs at least 4 months apart without any clinical evidence of recurrence
will result in classification of their response at 8 weeks as CR.
6.1.2.5.4 Final complete response rate
It is recognized that response rates in the neck at 8 weeks will underestimate the true
pathologic CR rate. This will be estimated retrospectively as the proportion of patients
who ever achieve CR without surgery or have negative pathology at planned neck
dissection with primary disease controlled.
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6.1.2.6 Definition of locoregional failure
Locoregional failure is defined for this study as the occurrence of persistent, progressive,
or recurrent disease above the clavicles. Patients with persistent primary disease at the
two-month post-treatment assessment will be regarded as having failed at the time of that
assessment. Because a planned neck dissection for persistent (but not progressive)
resectable nodal masses is part of the treatment “package”, pathologic evidence of residual
tumor in the neck dissection specimen will not be regarded as a locoregional failure.
Patients with residual neck masses who do not undergo neck surgery will be deemed as
having failed only at the time of progression. Patients who undergo neck dissection for
residual disease, which is found to be unresectable, will be deemed to fail at the time of
surgery. Date of progression or recurrence is defined as the date of a measurable event,
either clinical, radiological or pathological. Clinically or radiologically manifest tumor
recurrence should be confirmed by biopsy or cytology whenever possible.
Patients with a clinical CR at the primary site who have a residual imaging abnormality at
the primary site will undergo further imaging 4 months later and will be deemed to have
locoregional failure in the primary site only if the imaging abnormality progresses. Some
patients with laryngeal primaries may be unassessable at the 2-month post-treatment
evaluation because of edema of the larynx. Such patients should be continued to be
followed clinically and radiographically. These patients will be classified as locoregional
failure only if and when progression is documented. In the absence of a target lesion
biopsy is not recommended. For unusual clinical scenarios not covered above, a ruling of
the occurrence of locoregional failure will be submitted to the principal investigators who
will make a decision without knowing the treatment arm.
Patients with distant metastasis will continued to be followed for locoregional failure

status.
Second primary cancers
A newly diagnosed cancer arising in any site involved by or adjacent to the index cancer
must be designated as a local recurrence (e.g. epiglottis and base of tongue). A second
primary neoplasm can only be declared when the second lesion is in a non-adjacent
subsite (e.g., soft palate and glottic larynx) or is contralateral to an index cancer, which did
not approach the midline (e.g., right and left tonsil).
6.1.2.7 Quality-of-life evaluation
To maximize the ability of a questionnaire to discriminate between groups of patients and
to respond to changes in QoL between patients, it is necessary to choose a disease-specific
instrument that measures the concerns of patients with head and neck cancer (39). To
maximize the reliability and internal validity of the QoL results, participants must
complete their own questionnaires without family input. To maximize the validity and
generalization of QoL results, all eligible patients should participate in the QoL
component of the study. Thus, the questionnaire must be available in the multiple
languages in use at the participating centres. For QoL results to be interpretable, a
standard questionnaire with known validity and reliability must be used.
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QoL assessment is mandatory in all patients, excluding only those who meet the following
criteria:
1) Inability to comprehend at least one of the following languages: (English, Dutch,
French, German, Italian, Norwegian, Spanish, Swedish, Portuguese, Hungarian,
Russian, Chinese, Polish)
2) Inability to comprehend QoL questions due to cognitive or psychiatric deficits.
3) In blind or illiterate patients the FACT-H&N should be administered verbally.
Whenever possible, all QoL assessments should take place during the scheduled clinic
visits, and prior to the physician's assessment.
6.1.2.7.1 FACT-H&N Quality-of-life questionnaire
For this study, the FACT-H&N has been chosen. The FACT-H&N, developed by Dr.
David Cella and colleagues in the United States (40), comprises a core questionnaire
called FACT-G, and a disease-specific subscale. It was designed for descriptive,
discriminative and evaluative use (41). The core questionnaire and head and neck
modules have been tested for reliability and validity (41, 42, 43). Clinical trials have
shown improvements in scores with time from treatment, which is a preliminary indicator
of responsiveness (43, 44, 45)The minimal important difference, a measure of the clinical
significance of a small change in questionnaire scores over time, has been measured and
corresponds to a 5-10% difference in score (46). Patients typically complete the
questionnaire in 10-15 minutes (47).
The FACT instruments are self-administered multi-item indices using category-rating
scales. FACT-G consists of 27 questions in 4 domains: physical (7 questions),
social/family (7 questions), emotional (6 questions), and functional (7 questions). The
38-item FACT-H&N also includes an 11-item head and neck cancer specific subscale.
Each response is rated from 0-4 on a Likert index, considering the past 7 days.
Items H&N8 and H&N9 are currently not scored. For all other items, scores are
calculated separately for each domain. Scores range from 0 to 28 for physical, social, and
functional domains and from 0 to 24 for the emotional dimension. An unweighted
summary score is calculated for the FACT-G and the total FACT-H&N. The maximum
score of 144 (27 + 9 = 36 items scored between 0 and 4) reflects the best possible quality
of life. Because pain is often a dominant symptom of recurrent head and neck cancer,
item GP4 of FACT-G (I have pain) will also be analyzed as a single item pain index.
Analgesic use will therefore also be assessed at the time of each QoL assessment.
6.1.2.7.2 Timing of assessment
Quality of life and pain will be assessed at the following time points: at baseline (prior to
treatment), 2 months post treatment, 6 months post-treatment, 12 months post-treatment,
24 months post-treatment and 36 months post-treatment.
6.2 Safety
Toxicity and safety will be determined through review of adverse events, routine symptom
assessment, and laboratory determinations.
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6.3 Pharmacokinetics
Not applicable.
7. PATIENT SAFETY
7.1 Adverse events monitoring
Definitions:
An Adverse Event is any untoward medical occurrence in a patient or clinical
investigation patient administered a pharmaceutical product and which does not
necessarily have to have a causal relationship with this treatment.
A Serious Adverse Event is any untoward medical occurrence that at any dose:
• Results in death or
• Is life-threatening or
Note: The term "life-threatening" in the definition of "serious" refers to an event in which the patient was
at risk of death at the time of the event; it does not refer to an event, which hypothetically might
have caused death if it were more severe.

•
•
•
•

Requires in-patient hospitalization or prolongation of existing hospitalization or
Results in persistent or significant disability/incapacity or
Is a congenital anomaly/birth defect.
Is a medically important event

Medical and scientific judgment should be exercised in deciding whether expedited
reporting is appropriate in other situations, such as important medical events that may not
be immediately life-threatening or result in death or hospitalization but may jeopardize the
patient or may require intervention to prevent one of the other outcomes listed in the
definition above.
These should also usually be considered serious.
Note: Examples of such events are intensive treatment in an emergency room or at home for allergic
bronchospasm, blood dyscrasias, convulsions or symptomatic ALT increase * 10 ULN that do not
result in hospitalization, or development of drug dependency or drug abuse.

Adverse Events
All Adverse Events regardless of seriousness or relationship to study drug, including those
occurring during the wash-out period (where applicable), are to be recorded on the
corresponding page(s) included in the Case Report Form. Whenever possible, symptoms
should be grouped as a single syndrome or diagnosis. The Investigator should specify the
date of onset, maximal intensity, action taken with respect to study drug, corrective
therapy given, outcome and his/her opinion as to whether there is a reasonable possibility
that the Adverse Event was caused by the study drug.
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Serious Adverse Events
In the case of a Serious Adverse Event the Investigator must immediately:
• SEND (within 1 working day, preferably by fax) the signed and dated corresponding
page(s) in the Case Report Form to the representative of the Monitoring Team whose
name and address and fax number appear on the protocol;
• ATTACH the photocopy of all examinations carried out and the dates on which these
examinations were performed. For laboratory results, include the laboratory normal
ranges.
Follow-up
• The Investigator should take all appropriate measures to ensure the safety of the
patients, notably he/she should follow up on the outcome of any Adverse Events
(clinical signs, laboratory values or other, etc.) until the return to normal or until
consolidation of the patient conditions.
• In the case of any Serious Adverse Event, the patient must be followed up until clinical
recovery is complete and laboratory results have returned to normal, or until
progression has been stabilized. This may imply that follow-up will continue after the
patient has left the study and that additional investigations may be requested by the
Monitoring Team.
• In case of any Serious Adverse Event brought to the attention of the Investigator at any
time after cessation of study treatment and considered by him/her caused by the study
drug with a reasonable possibility, this should be reported to the Monitoring Team.
Grading adverse events:
Acute radiation and all chemotherapy toxicities will be graded using CTC Version 2.0
(Appendix 7). In the case of toxicities within the irradiated volume occurring from the 2month follow-up visit onwards, the RTOG Late Radiation Toxicity scale (Appendix 8),
modified to include pharyngeal toxicity and ototoxicity, will be used. An exception
relates to acute mucositis, which must be graded according to the CTC criteria until it has
resolved to grade 1.
7.2 Laboratory tests monitoring
See Study Procedures (Section 9) the tests needed.
7.3 Safety instruction
The following events, should they meet the criteria of seriousness, are not to be considered
as SAE:
• any non fatal event secondary to documented cancer progression. These events are
collected elsewhere in the CRF since they do not impact the endpoints of the study.
The cases of death related to cancer progression are reported as SAEs as usual.
• any event that is included in the cancer management such as hospitalization for
insertion of a central venous catheter device or an enteral feeding tube.

50/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

8. PATIENT WITHDRAWAL
8.1 Criteria for withdrawal from treatment
Protocol treatment should be discontinued if it is considered to be in the best interest of
the patient. Reasons for treatment discontinuation include:
1) Patient request
2) Patient non-compliance with the protocol
3) Life threatening or other unacceptable drug-related toxicity
4) Progressive disease
5) Physician decision in view of patient’s other medical conditions.
When treatment is discontinued, the reason(s) for discontinuation should be documented
in the patient’s medical record and CRF, and follow-up should be maintained and
reported. When discontinued from protocol treatment, patients will still be followed as
defined in the protocol.
8.2 Withdrawal from study
The patients may withdraw from the study if they decide to do so, at any time and
irrespective of reason, or this may be the Investigator’s decision.
8.3 Withdrawal from follow-up
For patients considered lost to follow-up, the CRF must be filled in up to the last visit
performed. The Investigator should make every effort to re-contact and to identify the
reason why the patient failed to attend the visit and to determine his/her health status.
8.4 Consequence
Patients who have been withdrawn from the study cannot be re-included in the study.
Their inclusion and treatment number must not be re-used.
9. STUDY PROCEDURES
9.1 Screening and baseline procedures
Baseline evaluations including radiological exams and fiberoptic endoscopy must be
performed not longer than four weeks prior to initiation of treatment. Baseline evaluations
must include:
• A detailed medical and surgical history, including age, gender, ethnic origin,
medication list, performance status
• The cancer history of the patient including: cancer diagnosis (site and histopathology),
current status, prior chemotherapy, prior cancer surgery, prior radiation.
• A complete physical examination including fiberoptic endoscopy carried out by one of
the investigators. PE must include: body systems described on the CRF, height,
weight, BSA, vital signs (BP/HR/T)
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• Biopsy if not already performed
• Mandatory radiologic assessment (head and neck CT or MRI and chest CT)
• Consultation from radiation and medical oncology (required) and surgery
(recommended).
• Further diagnostic procedures as clinically indicated e.g. panendoscopy.
• Laboratory screening including:
Hematology: hemoglobin, WBC with differential count, absolute Neutrophil count
(ANC), and platelets
Biochemistry: sodium, potassium, chloride, bicarbonate, calcium, magnesium,
urea, glucose, creatinine, total protein, albumin, SGOT (AST), SGPT (ALT),
alkaline phosphatase, and total bilirubin
Creatinine clearance
Serum Pregnancy Test: women of childbearing potential are required to have a
serum beta-HCG pregnancy test.
• Audiogram
• Baseline QoL measurements
An extra plasma/serum sample will be collected for hypoxia marker studies. When
available, unstained slides of the tumor biopsy should be collected. Please send 10 slides
when available but a minimum of 2.
At selected sites with PET scanning capabilities, baseline FDG-PET scan and F-AZA-PET
scanning will be done for metabolic activity and hypoxia determination.
Instruction for extra sample collection for hypoxia and biological markers:
•

Blood sample will be drawn before study treatment administration, during the study
treatment period (week 5 or 6), at 2 months and 8 months following completion of the
treatment. Blood samples will be collected on Becton-Dickinson 5 ml EDTA tubes.
• Immediately after sample collection, the tubes will be centrifuged at 1500 g for 10
minutes at room temperature. The plasma will be collected with sterile pipettes,
transferred into properly labelled polypropylene tubes (Sarstedt 60.558 Polypropylene
screw-cap 5ml tube) and deep-frozen at -20°C.
• The day of sampling must be recorded in the CRF.
• One properly labelled, freeze-resistant, box will be provided per centre for storage
plasma aliquots at -20°C.
• Labeling:
The tubes will be identified with pre-printed stickers. Each sticker will bear the following:
- Protocol number: EFC4690
- Drug code: SR259075
- Sample number: P0 to Pn
- Subject number
- Centre n°:
The following will be printed on the label affixed to the freeze-resistant box.
- Protocol number: EFC 4690
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- Drug code: SR259075
- "Plasma sample"
- Subject number
- Centre n°:
Shipment of the samples:
At the end of the study, or before if required, the samples bearing the mention "To be kept
at -20°C on carbon ice packs. Biological samples" will be sent to:
Barbara Knight
Sanofi-Synthelabo Research
9 Great Valley Parkway
Malvern, PA 19355 - U.S.A.
Phone:
1.610.889-6071 or (610)889-6056 (to leave message)
Fax: 1.610.889-6356
Email: barbara.knight@sanofi-synthelabo.com
Contact Mrs. Knight prior to shipment with date of shipment and airbill number. No
sample should be sent later in the week than Tuesday after 4 PM and not on the event of
any public holiday.
Unstained slides from pre-treatment tumor biopsy (when available) should be labelled and
sent with the submission form to:
Barbara Knight
Sanofi-Synthelabo Research
9 Great Valley Parkway
Malvern, PA 19355 - U.S.A.
Phone:
1.610.889-6071 or (610)889-6056 (to leave message)
Fax: 1.610.889-6356
Email: barbara.knight@sanofi-synthelabo.com
9.2 Inclusion procedure
During the screening process, it will be determined if patients qualify for the study by the
inclusion and exclusion criteria. If significant clinical changes occur prior to the initiation
of therapy, a reassessment should occur.
All patient with their own teeth require a dental evaluation.
9.3 Description by type of visit
9.3.1 Concomitant chemoradiation therapy period
Please see flow chart for details of assessments. Concurrent chemotherapy and radiation
is frequently associated with significant acute severe toxicity that requires as standard of
care frequent follow-up during treatment and immediate post-treatment period.
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Biochemistry assessment will be done weeks 1, 4 and 7. Weekly hematology assessments
will be done. In weeks 5-7 hematology assessment will be done twice weekly.
Hematology assessment will include: hemoglobin, WBC, absolute neutrophil count
(ANC), and platelets. Biochemistry assessment will include sodium, potassium, chloride,
bicarbonate, calcium, magnesium, urea, glucose, creatinine, total protein, albumin, SGOT
(AST), SGPT (ALT) , alkaline phosphatase, and total bilirubin. Toxicity assessment will
be performed weekly.
Toxicity assessment will be done at two weeks after radiation is completed. Patients with
severe acute toxicities will require weekly follow-up.
9.3.2 Four-weeks follow-up visit
The patient will have a follow-up visit 4 weeks after the last radiation therapy. Please see
flow chart for details of assessments.
9.3.3 Follow-up visits
Following the 2-month assessment, patients will be reviewed for disease status and
toxicity assessments at least every 2 months the first year, every 3 months the second year
and every 4 months the third year. Imaging will be repeated every 4 months for the first
year and then every 6 months. Please see flow chart for other assessments.
9.4 Definition of source data
Source data is defined as all information in original records of clinical findings,
observations, or other activities of the clinical trial necessary for the reconstruction and
evaluation of the trial. Source data are contained in source documents. Source documents
are the original documents, data and records. Source documents include but are not
limited to hospital records, clinical and office charts, laboratory notes and reports
radiologic films and reports, memoranda, subject’s quality of life assessments, and
pharmacy dispensing records.
10. STATISTICAL CONSIDERATIONS
10.1 Statistical and analytical plans
This protocol contains a general description of the statistical design and of the analyses
that will be done to compare Arms 1 (cisplatin + radiotherapy) and 2 (cisplatin +
tirapazamine + radiotherapy) for the primary endpoint of overall survival. Methods are
also described for the analysis of secondary efficacy endpoints and safety.
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10.2 Determination of sample size
The sample size of 275 per treatment arm will provide at least 80% power for the survival
comparison under the following assumptions:
• Survival in the control arm is 60% at 2 years and 51% at 3 years. Beyond 3 years,the
mortality risk (hazard rate) will be 0.05 death per patient per year.
• The test population will experience a 31% reduction in the risk of mortality, compared
to the controls. This would produce a survival rate of 70% at 2 years and 63% at
3 years. For patients surviving beyond 3 years the mortality risk would be
0.0345 atients per year.
• 1.5 year accrual period, with 2.5 years of follow-up after enrollment of the last patient
• Type I error of 0.05 with 2-sided log rank test
• Constant hazard rates in each treatment arm during the periods 0 - 2 years, 2 – 3 years,
and 3 + years.
• Constant accrual rate
The control arm specifications and the difference this trial is powered to detect are based
on a review of similar trials in this disease (Section 1.5)
The cutoff date for patients included in the final survival analysis is planned to be the date
of the 240th death.
An analysis of time to locoregional failure will be done with a two-sided logrank test
when 150 patients have reached this endpoint. The logrank test will be stratified for the
factors disease stage (III v IV), primary site (oropharynx/larynx v hypopharynx/oral
cavity), and hemoglobin (≥13.5 g/dL for men or ≥12.5 g/dL for women v otherwise). The
analysis of locoregional failure has at least 85% power to detect a difference in postulated
locoregional failure rates of 40% in the control arm versus 25% in the experimental arm
with a two-sided test at the 0.05 level. It is assumed that among the patients who do
experience locoregional failure, the yearly event probability will be 0.7. Under trial
assumptions the analysis of locoregional failure will occur approximately 2.5 years after
the start of the study.
10.3 Study patient description
All randomized patients with previously untreated squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx or larynx will be considered in the intent-to-treat
population.
All patients who receive at least one dose of the assigned study treatment will be included
in the safety analysis.
10.3.1 Disposition of patients
The numbers of patients who are randomized will be shown by treatment arm. The
number of post-randomization discontinuations will be displayed by treatment arm and
reason for stopping treatment. Follow-up status after discontinuation will be summarized.
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10.3.2 Protocol deviations
Listings of patients with identified protocol deviations will be provided. Major protocol
deviations include, but are not limited to,
• Violation of inclusion/exclusion criteria.
• Receipt of chemotherapy or radiotherapy regimens not specified in the protocol.
• Failure to follow dose modification procedure in the protocol.
• Receipt of concomitant anti-cancer treatment prohibited by the protocol.
• Missing data in key efficacy or safety parameters.
10.4 Data analysis considerations
10.4.1 Dataset analyzed
10.4.1.1 Treatment group considered for statistical analysis
Two treatment groups are in this study: Cisplatin + Radiotherapy (Arm 1) versus Cisplatin
+ Tirapazamine + Radiotherapy (Arm 2).
10.4.1.2 Populations to be analyzed
Primary statistical analysis will be done following intent to treat principles (see
Section 10.3.).
All patients who receive assigned study treatment will be included in the safety analysis.
10.4.2 General Statistical Approach
The log rank test, stratified for the factors of disease stage (III v IV), primary site
(oropharynx/larynx v hypopharynx/oral cavity), and hemoglobin (≥13.5 g/dL for men or
≥12.5 g/dL for women v otherwise) will be used to compare the treatment groups for timerelated parameters, such as survival, time to locoregional failure and failure free survival.
Categorical parameters, such as response rate, will be evaluated using the chi-squared test.
Repeated measurement data, like QoL will be compared by change from the baseline at
fixed time points. The primary QoL outcome will be a comparison of change from
baseline in FACT H&N score at the 6-month assessment between control and
experimental groups using Student’s t-test.
Characteristics of subjects assigned to the two treatment arms will be summarized. These
include sex, race, age, weight, height, performance status, histology, stage of disease, and
measurable disease by RECIST criteria, time since diagnosis, presence of other disease
conditions, and clinical laboratory tests.
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10.4.3 General conventions
10.4.3.1 General rules for data handling of missing, unused or inconsistency data
In general there will be no imputation of missing data. In the time to event analyses
missing data due to reasons other than the defined event will be considered censored. For
the repeatedly measured variables, the amount of missing data will be described for each
treatment arm.
10.4.3.2 Other specific conventions
N/A
10.5 Demographic and baseline characteristics
Demographic and baseline characteristics will be summarized by treatment arm.
Continuous variables (such as age, weight, etc.) will be summarized using the mean,
standard deviation, minimum, and maximum. Qualitative characteristics (such as race,
disease stage, etc.) will be summarized by counts and percents.
10.5.1 Patient demographic characteristics, medical history and diagnoses
Patient demographic characteristics include country, age, weight, sex, race, and
performance status. Medical history will include all information collected in the relevant
CRF. Diagnosis information will include primary site, disease stage, and laboratory tests.
10.5.2 Previous medications
Patients should not receive any prior treatment for the indicated disease before entering
the study. The numbers of patients violating this criterion will be displayed.
10.5.3 Baseline efficacy/activity data
Baseline QoL data will be summarized by treatment arm.
10.5.4 Baseline safety parameters
Baseline laboratory data will be summarized by treatment arm.
10.6 Study drug and concomitant therapy
10.6.1 Study treatment
Exposure to tirapazamine, cisplatin and radiation will be summarized for each treatment
arm.
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10.6.1.1 Extent of exposure
The number of cycles administered, total cumulative dose, duration of dosing, and dose
intensity for cisplatin and tirapazamine will be summarized by treatment arm.
10.6.1.2 Measurement of treatment compliance
N/A
10.6.2 Concomitant medication/therapy
Concomitant medications will be coded to drug class, and the percentage of patients using
drugs from each class will be summarized by treatment arm.
10.7 Efficacy / activity analysis
10.7.1 Primary efficacy variable(s)
10.7.1.1 Description of the primary variable(s)
Overall survival measured from the date of randomization to the date of death from any
cause will be the primary endpoint. Overall survival will be censored by the cutoff date or
the date of last follow-up for patients lost to follow-up.
Time to locoregional failure measured from the date of randomization to the date of
locoregional failure is a secondary endpoint. Locoregional failure is defined as the
presence of persistent, progressive or recurrent disease above the clavicle (see
Section 6.1.2.6) Time to locoregional failure will be censored by the cutoff date, the date
of last follow-up for patients lost to follow-up, or death.
Safety will be assessed through review of adverse events, routine symptom assessment,
and laboratory determinations.
10.7.1.2 Primary analysis
The log rank test, stratifying for the factors disease stage (III v IV), primary site
(oropharynx/larynx v hypopharynx/oral cavity), and hemoglobin (≥13.5 g/dL for men or
≥12.5 g/dL for women v otherwise), will be used for the primary analysis of overall
survival. The cut-off date for patients included in the final analysis will be the date of the
240th death.
Analysis of time to locoregional failure will be done when 150 events have been observed,
and results for this parameter may be reported prior to completion of follow-up for
survival. Testing will use the stratified logrank test, will be two-sided, and will be done at
the 0.05 level.
An interim analysis of survival will be done at the same time as the analysis of time to
locoregional failure, using a two-sided logrank test, stratifying for the factors disease stage
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(III v IV), primary site (oropharynx/larynx v hypopharynx/oral cavity), and hemoglobin
(≥13.5 g/dL for men or ≥12.5 g/dL for women v otherwise).
The interim test for overall survival will be done at a level determined by the O’Brien –
Fleming alpha spending function [2 – 2 x Φ(Z0.975/sqrt(t*)), where Φ is the cumulative
distribution function for the standard normal, and t* is the proportion of deaths out of 240
that will be observed at the cutoff date for the locoregional failure analysis.] (48). This
spending function requires highly significant early differences in order to stop early and
requires minimal adjustment of the level of the final test.
10.7.1.2.1 Handling of dropouts or missing data
Patients who are lost to follow up before reaching the primary endpoint will be censored
in the primary analysis.
10.7.1.2.2 Data transformation before analysis, if any
Not applicable.
10.7.1.2.3 Main statistical model and adjustment for covariates
Not applicable.
10.7.1.2.4 Multiple comparisons/multiplicity
Analyses of overall survival will include an interim test conducted at the time of the
analysis of locoregional failure. The level of this test will depend upon the proportion of
the expected number of 240 deaths that have been observed (Section 10.7.1.2). Using an
alpha-spending approach, the level of the final statistical test will be adjusted
appropriately to maintain an overall type I error of 0.05.
10.7.1.3 Other Analyses for primary variable(s)
Not applicable.
10.7.2 Secondary / other efficacy variables
10.7.2.1 Description of secondary variables
Secondary endpoints include, but are not limited to, the following:
• Time to locoregional failure with date of randomization as the start date. Locoregional
failure is defined as the presence of persistent, progressive, or recurrent disease above
the clavicles (Section 6.1.2.6.)
• Failure-free survival. Failure is defined as death due to any cause, locoregional failure
or development of metastatic disease. Failure-free survival will be censored by the
cutoff date or the date of last follow-up for patients lost to follow-up.
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• Patterns of failure as the initial site of failure at the primary site, neck, distant sites or
combinations of these.
• Cumulative incidence of unacceptable locoregional treatment outcome as a function of
time. An unacceptable outcome is defined as either locoregional failure or severe late
(>90 days from the start of treatment) treatment-related toxicity which may be any of
the following: grade 4 skin, subcutaneous tissue, mucous membrane or bone toxicity,
grade 3 or 4 spinal cord toxicity, grade 4 laryngeal toxicity requiring tracheostomy, or
the need for enteral feeding persisting for 12 months or more following completion of
treatment. The date of unacceptable outcome based on enteral feeding will be recorded
as 12 months after completion of treatment. Death will be a competing event and the
cut-off date or date of last follow-up for patients lost to follow-up will be censoring
events.
• Change in QoL from baseline as assessed by FACT-H&N scale in eligible patients at 6
months post-treatment (see 6.1.2.7 QoL Evaluation).
• Toxicity and safety, determined by through review of adverse events, routine symptom
assessment, and laboratory determinations.
• Initial response rates defined as rates of CR, PR , SD or PD 2 months after completion
of chemoradiation therapy which is described in (Section 6.1.2.5).
• Final CR rate as defined in section 6.1.2.5 (d)
• Additional analysis to include correlation of efficacy with baseline hypoxia
measurements including F-AZA-PET (at selected sites) and blood levels of chemical
markers for hypoxia as directed by the Trial Management Committee. For example,
correlation of hypoxia has been studied with the serum markers, osteopontin and PAI1. Unstained slides of tumor biopsies will be collected for immunohistochemical
analysis for prognostic markers such as Ki-67, HIF1α and p53.
10.7.2.2 Statistical analysis of secondary variables
Approaches as described in (Section 10.4.2) will be used to analyze secondary parameters.
10.8 Safety analysis
Safety analysis will include all patients who receive at least one day of treatment. Patients
who receive cisplatin but not tirapazamine will be included in the cisplatin arm1. Any
patient receiving tirapazamine will be included in the cisplatin + tirapazamine arm 2.
Safety analyses for patients receiving only radiotherapy will be presented separately.
10.8.1 Adverse events
10.8.1.1 Definitions
Adverse events are recorded by episode. For each occurrence of an AE, the onset date,
resolution date, maximum grade, and action taken are recorded.
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10.8.1.2 Treatment-emergent adverse events
An AE is considered treatment emergent if the onset date is on or after the first day of the
first cycle of study treatment. Treatment-emergent adverse events are summarized by
body system and preferred term, showing the incidence and maximum grade by patient
and by cycle for each treatment arm.
10.8.1.3 Deaths and serious adverse events
All deaths and the causes of death will be listed by treatment arm. Serious adverse events
will be summarized and compared by treatment arm.
10.8.1.4 Adverse events leading to treatment discontinuation
Adverse events leading to treatment discontinuation will be listed, and the numbers of
patients discontinuing due to an adverse event will be compared between the two
treatment groups.
10.8.2 Clinical laboratory evaluations
Clinical laboratory data will be graded according to the NCI common toxicity criteria
version 2.0 (April 30, 1999). The numbers of patients with any abnormality and with
grade 3,4 abnormalities will be compared between the treatment arms.
10.8.3 Vital signs
A listing of vital signs will be created with abnormal values flagged.
11. ETHICAL AND REGULATORY STANDARDS
11.1 Ethical principles
This trial complies with the principles laid down by the 18th World Medical Assembly
(Helsinki, 1964) and all applicable amendments laid down by the World Medical
Assemblies, and the ICH, GCP guideline.
11.2 Laws and regulations
This protocol also complies with the laws and regulations of the country(ies) in which the
study is performed, as well as any applicable guidelines.
11.3 Informed consent
The Investigator, (according to applicable regulatory requirements), or a person
designated by the Investigator, should fully inform the patient of all pertinent aspects of
the clinical trial including the written information giving approval / favorable opinion by
the Ethics Committee (IRB /IEC ).

61/114

CPR-EFC4690-EN-E01

SANOFI-SYNTHELABO

Prior to a patient’s participation in the clinical trial, the Informed Consent Form should be
signed and personally dated by the patient or by the patient’s legally acceptable
representative, and by the person who conducted the informed consent discussion.
The Informed Consent Form used by the Investigator for obtaining the patient's informed
consent must be reviewed and approved by the Sponsor prior to submission to the
appropriate Ethics Committee (IRB/IEC) for approval / favorable opinion.
11.4 Institutional Review Board/Independent Ethics Committee (IRB/IEC)
The Investigator must submit this protocol to the appropriate Ethics Committee
(IRB/IEC), and is required to forward to the Sponsor a copy of the written and dated
approval / favorable opinion signed by the Chairman with Ethics Committee (IRB/IEC)
composition.
The study (study number, Protocol title and version number), the documents reviewed
(protocol, Informed Consent Form, Investigator’s Brochure, etc.) and the date of the
review should be clearly stated on the written (IRB/IEC) approval / favorable opinion.
Investigational Product will not be released at the study site and the trial will not start until
a copy of this written and dated approval / favorable opinion has been received by the
Sponsor.
During the clinical trial, any amendment or modification to the protocol should be sent to
the Ethics Committee (IRB/IEC). It should also be informed of any event likely to affect
the safety of patients or the continued conduct of the study, in particular any change in
safety and all updates to the Investigator’s Brochure will be sent to the Ethics Committee
(IRB/IEC).
If requested, a progress report is sent to the Ethics Committee (IRB/IEC) annually and a
summary of the trial’s outcome at the end of the clinical trial.
12. STUDY MONITORING
12.1 Responsibilities of the Investigator(s)
The Investigator(s) undertake(s) to perform the study in accordance with this protocol,
Good Clinical Practice and the applicable regulatory requirements.
The Investigator is required to ensure compliance with the Investigational Product
schedule, visit schedule and procedures required by the protocol. The Investigator agrees
to provide all information requested in the Case Report Form in an accurate and legible
manner according to the instructions provided and to ensure direct access to source
documents to Sponsor representatives.
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12.2 Responsibilities of the Sponsor
The Sponsor of this study is responsible to Health Authorities for taking all reasonable
steps to ensure the proper conduct of the study as regards ethics, protocol compliance,
integrity and validity of the data recorded on the Case Report Forms. Thus, the main duty
of the Monitoring Team is to help the Investigator and the Sponsor maintain a high level
of ethical, scientific, technical and regulatory quality in all aspects of the study.
At regular intervals during the study, the centre will be contacted, through site visits,
letters or telephone calls, by a representative of the Monitoring Team to review study
progress, Investigator and patient compliance to protocol requirements and any emergent
problems. During monitoring visits, the following points will be scrutinized with the
Investigator: patient informed consent, patient recruitment and follow-up, study drug
allocation, patient compliance with the Investigational Product, Investigational Product
accountability, concomitant therapy use, Adverse Event documentation and reporting, and
quality of data. Sections of Case Report Forms may be collected on a visit-by-visit basis.
12.3 Source document requirements
According to the guidelines on Good Clinical Practice, the Monitoring Team must check
the Case Report Form entries against the source documents, except for the pre-identified
source data directly recorded in the Case Report Form. The Informed Consent Form will
include a statement by which the patient allows the Sponsor’s duly authorized personnel,
the Ethics Committee (IRB/IEC), and the regulatory authorities to have direct access to
source data which supports the data on the Case Report Forms (e.g. patient's medical file,
appointment books, original laboratory records, etc.). These personnel, bound by
professional secrecy, will not disclose any personal identity or personal medical
information.
12.4 Use and completion of Case Report Forms (CRFs) and additional request
It is the responsibility of the Investigator to maintain adequate and accurate CRFs
designed by the Sponsor to record all observations and other data pertinent to the clinical
investigation. All CRFs should be completed in their entirety in a neat, legible manner to
ensure accurate interpretation of data; a black ballpoint pen should be used to ensure the
clarity of reproduced copy of all CRFs.
Should a correction be made, the information to be modified must not be overwritten. The
corrected information will be transcribed by the authorized person next to the previous
value, initialed and dated.
The computerized handling of the data by the Sponsor after receipt of the CRFs may
generate additional requests [Discrepancy Resolution Form (DRF)] to which the
Investigator is obliged to respond by confirming or modifying the data questioned. The
requests with their responses will be appended to the CRFs held by the Investigator and
the Sponsor.
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13. ADMINISTRATIVE RULES
13.1 Curriculum vitae
An updated copy of the curriculum vitae limited to the experience, qualification and
training for each Investigator and Sub-Investigator (and completed FDA 1572 form and
Financial Disclosure Form study under an IND) will be provided to the Sponsor prior to
the beginning of the study.
13.2 Record retention in study sites(s)
The Investigator must maintain all study documentation, and take measures to prevent
accidental or premature destruction of these documents.
The Investigator must retain the study documentation until at least two years after the last
approval of the marketing application, or if the application is not approved, at least two
years after the formal discontinuation of clinical development of the Investigational
Product.
However, applicable regulatory requirements should be taken into account in case of a
longer period required.
A study site must notify the Sponsor before destroying any data or records.
14. CONFIDENTIALITY
All materials, information (oral or written) and unpublished documentation provided to
the Investigators (or any company/institution acting on their behalf), inclusive of this
protocol, the patient Case Report Forms and the Investigator's Brochure, are the exclusive
property of the Sponsor and may not be given or disclosed, either in part or in whole, by
the Investigator or by any person under his/her authority to any third party without the
prior express consent of the Sponsor.
However, the submission of this protocol and other necessary documentation to the Ethics
Committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same
obligation of confidentiality.
The Investigator shall consider all information, results, discoveries, records accumulated,
acquired, or deduced in the course of the study, other than that information to be disclosed
by law, as confidential and shall not disclose any such results, discoveries, records to any
third party without the Sponsor’s prior written consent.
15. OWNERSHIP OF DATA AND USE OF THE STUDY RESULTS
The Sponsor retains exclusive ownership of all data, results, reports, findings, discoveries
and any other information collected during this study. Therefore, the Sponsor reserves the
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right to use the data from the present study, either in the form of Case Report Forms (or
copies of these), or in the form of a report, with or without comments and with or without
analysis, in order to submit them to the Health Authorities of any country.
Furthermore, in the event that the study generates patentable results, the Investigator (or
entity acting on his/her behalf according to local requirements) shall refrain from filing
patent application(s) on such results, which will be filed by the Sponsor or its designees in
its own name and at its expense.
16. INSURANCE COMPENSATION
The Sponsor certifies that it has taken out a liability insurance policy which covers the
liability of the Investigator and his/her coworkers and which is in accordance with local
laws and requirements. Specific statements will be contained in an appendix where
needed.
An insurance certificate will be provided to the Investigator in countries requiring this
document.
17. SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES
For the purpose of ensuring compliance with the protocol, Good Clinical Practice and
applicable regulatory requirements, the Investigator should permit auditing by the Sponsor
and inspection by applicable regulatory authorities.
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her
study records for review, being understood that this personnel is bound by professional
secrecy, and as such will not disclose any personal identity or personal medical
information.
As soon as the Investigator is notified of a future inspection by the authorities, he will
inform the Sponsor and authorize the Sponsor to participate at this inspection.
The confidentiality of the data verified and the anonymity of the patients should be
respected during these inspections.
18. PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE
CLOSEOUT OF A CENTRE
18.1 Premature discontinuation of the study
The Trial Management Committee (TMC) may discontinue the study if information on the
Investigational Product causes doubt as to the benefit/risk ratio, or if a demonstrably
superior treatment becomes available.
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18.1.1 Early stopping rules
If, after accrual of 50 patients on each arm of the study, there are 5 or more treatmentrelated deaths on either arm, accrual will be suspended pending detailed review of the
data. If no apparent correctable causes are found, then the TMC will consider early
termination of the trial. (This rule is based on specifying 3% as the maximum acceptable
treatment-related death rate in this group of patients, and determining that if 3% is the true
rate, then the probability of observing 5 or more deaths is ≤0.05)
The overall toxicity data will be periodically reviewed by the Independent Data and Safety
Monitoring Committee, which may recommend to the TMC suspension of the trial at any
time.
18.2 Premature closeout of a centre
The TMC may closeout a centre if the Center’s conduct of the trial is not in accordance
with the procedures defined in the approved protocol or trial agreement (e.g., low rate of
recruiting, protocol deviations, or failure to ensure the quality of the data collected).
An Investigator may withdraw at any time in which case he/she must notify the Sponsor of
his/her decision and give the reason in writing.
In all cases, Ethics Committee(s) (IRB/IEC) and Health Authorities should be informed.
19. CLINICAL STUDY REPORT
The Sponsor will be responsible for preparing a Clinical Study Report.
20. PUBLICATIONS
It is the policy of the Sponsor to encourage the presentation and/or publication of the
results of their studies, using only clean, checked and validated data in order to ensure the
accuracy of the results.
The analysis for publication will be performed by the TROG statistician in collaboration
with the trial statistician. The manuscript[s] for any publication[s] will be written by
TROG personnel with appropriate contributions by Sanofi-Synthelabo [but with no right
of veto] and collaborating clinical investigators. The Trial Management Committee will
be overall responsible for presentations and/or publications. The Trial Management
Committee must send a copy of the manuscript or abstract to the Sponsor for review at
least forty-five (45) days before submission, and, if necessary, delay publication or
communication for a limited time, not to exceed 90 days, in order to protect the
confidentiality or proprietary nature of any information contained therein.
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Authorship of publications will be guided by the Vancouver Agreement (49). The
Sponsor may request that the Sponsor’s name and/or names of one or several of its
employees appear or not appear in such publications.
All study participants (Investigators and Committee members) give full authority to the
Trial Management Committee for primary presentation and/or primary publication of
results. No other publication is allowed before the primary publication. Any subsequent
presentation or publication by a study participant must be approved by the Trial
Management Committee and make reference to the study and the primary publication.
21. PROTOCOL AMENDMENTS
All appendices attached hereto and referred to herein are made part of this protocol.
No changes or amendments to this protocol may be made by the Investigator or by the
Sponsor after the protocol has been agreed to and signed by both parties unless such
change(s) or amendment(s) has/have been fully discussed and agreed upon by the
Investigator and the Sponsor. Any change agreed upon will be recorded in writing, the
written amendment will be signed by the Investigator and by the Sponsor and the signed
amendment will be filed with this protocol.
Amendments are required to be approved by the Trial management committee and the
TROG Scientific Committee. Any amendment to the protocol requires written approval /
favorable opinion by the Ethics Committee (IRB/IEC) prior to its implementation, unless
there are overriding safety reasons.
In some instances, an amendment may require a change to the Informed Consent Form.
The Investigator must receive an IRB/IEC approval / favorable opinion concerning the
revised Informed Consent Form prior to implementation of the change.
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The Trans-Tasman Radiation Oncology Group’s ”HeadSTART” trial protocol comparing Radiotherapy with Cis-platinum with Radiotherapy with Cis-platinum and
Tirapazamine is provided in Appendix L. The trial has been completed and was
published in the Journal of Clinical Oncology in 2010.

1

The following pages of this Appendix consist of the handcrafted CKML specification for this report. The specification is consists of the previous trial protocol with
additional elements added to detail numbers of patients included and randomised, as
well as numbers receiving treatment and the characteristics of the randomised groups
(see TrialArmSummary tags). Towards the end of the specification, the outcome
of the trial is inserted in the sections headed by the tags OutcomeAnalysis, MultivariateAnalysis, CancerOutcome and TrialOutcome.

The second document is a copy of the trial report so that numbers can be compared
and verified.

1

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous
Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the TransTasman Radiation Oncology Group
Danny Rischin, Lester J. Peters, Brian O‘Sullivan, Jordi Giralt, Richard Fisher, Kally Yuen, Andy
Trotti, Jacques Bernier, Jean Bourhis, Jolie Ringash, Michael Henke, and Lizbeth Kenny
J Clin Oncol 28:2989-2995 2010

<Organisation>
<Report>
<TrialID>
<TrialName>TROG.02.02</TrialName>
<TrialSponsorOrganisation>TROG</TrialSponsorOrganisation>
<TrialSponsorCommercial>SANOFI-SYNTHELABO</TrialSponsorCommercial>
<TrialPrincipalInvestigator>LESTER PETERS</TrialPrincipalInvestigator>
<TrialTitle>Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus
concomitant radiation and cisplatin in patients with advanced head and neck cancer.</TrialTitle>
<OutcomeAnalysis>OVERALL SURVIVAL</OutcomeAnalysis>
<OutcomeAnalysis>TIME TO LOCOREGIONAL FAILURE</OutcomeAnalysis>
<OutcomeAnalysis>FAILURE FREE SURVIVAL</OutcomeAnalysis>
<OutcomeAnalysis>PATTERN OF INITIAL FAILURE SITE</OutcomeAnalysis>
<OutcomeAnalysis>SEVERE TREATMENT RELATED TOXICITY</OutcomeAnalysis>
<OutcomeAnalysis>UNACCEPTABLE LOCOREGIONAL TREATMENT OUTCOME </OutcomeAnalysis>
<OutcomeAnalysis>QUALITY OF LIFE</OutcomeAnalysis>
<OutcomeAnalysis>TOXICITY</OutcomeAnalysis>
<OutcomeAnalysis>INITIAL RESPONSE RATE</OutcomeAnalysis>
<OutcomeAnalysis>FINAL COMPLETE RESPONSE</OutcomeAnalysis>
<TrialPatients>550
<TrialPower>80%</TrialPower>
<TrialType1Error>0.05; 2-SIDED LOG RANK</TrialType1Error>
<TrialPredictedSurvivalControl>60% AT 2 YEARS</TrialPredictedSurvivalControl>
<TrialPredictedSurvivalControl>51% AT 3 YEARS</TrialPredictedSurvivalControl>
<TrialPredictedSurvivalExperimental>70% AT 2 YEARS</TrialPredictedSurvivalExperimental>
<TrialPredictedSurvivalExperimental>63% AT 3 YEARS</TrialPredictedSurvivalExperimental>
</TrialPatients>
<TrialCentres>80</TrialCentres>
</TrialID>
<InclusionCriteria>
<Demographics>
<Age>18 YEARS OR OLDER</Age>
</Demographics>
<BiologicalMilieu>
<Physiology>
<RenalFunction>
<CreatinineClearance>55mL/MIN OR MORE
<CreatinineClearanceAlgorithm>COCKCROFT-GAULT</CreatinineClearanceAlgorithm>
</CreatinineClearance>
</RenalFunction>
<HepaticFunction>
<SerumBilirubin>1.25xUPPERLIMITNORMAL LESS THAN</SerumBilirubin>
<SerumAST>5xUPPERLIMITNORMAL LESS THAN</SerumAST>
<SerumALT>5xUPPERLIMITNORMAL LESS THAN</SerumALT>
</HepaticFunction>
<BloodFunction>
<HematologicFunction>
<NeutrophilCountAbsolute>1.5x10^9/L OR MORE</NeutrophilCountAbsolute>
<PlateletCount>100X10^9/L OR MORE</PlateletCount>
<Haemoglobin>10g/dL OR MORE</Haemoglobin>
</HematologicFunction>
</BloodFunction>
<PerformanceStatusECOG>0;1;2</PerformanceStatusECOG>
<ActuarialSurvival>6 MONTHS</ActuarialSurvival>
<ReproductiveFunction>INFERTILE;CONTRACEPTION</ReproductiveFunction>
<TrialConsentDocument>
<TrialConsentDocumentSigned>YES</TrialConsentDocumentSigned>
</TrialConsentDocument>
</Physiology>
</BiologicalMilieu>
<PsychologicalMilieu>
<FollowUpReliability>YES
<FollowUpReliabilityDuration>4 YEARS OR MORE</FollowUpReliabilityDuration>
</FollowUpReliability>
</PsychologicalMilieu>
</InclusionCriteria>
<ExclusionCriteria>
<BiologicalMilieu>
<Anatomy>
<AnatomicalImaging>
-1-

<PlainXR>
<PlainXRRegion>BONE</PlainXRRegion>
<PlainXRRegionReason>"BONE SYMPTOMS"</PlainXRRegionReason>
<PlainXRReport>METASTASIS</PlainXRReport>
</PlainXR>
<CTscan>
<CTscanRegion>CHEST</CTscanRegion>
<CTscanReport>METASTASIS</CTscanReport>
</CTscan>
<CTscan>
<CTscanRegion>LIVER</CTscanRegion>
<CTscanRegionReason>"ABNORMAL LIVER FUNCTION TEST"</CTscanRegionReason>
<CTscanReport>METASTASIS</CTscanReport>
</CTscan>
<USscan>
<USscanRegion>LIVER</USscanRegion>
<USscanRegionReason>"ABNORMAL LIVER FUNCTION TEST"</USscanRegionReason>
<USscanReport>METASTASIS</USscanReport>
</USscan>
</AnatomicalImaging>
<FunctionalImaging>
<Scintillography>BONE</Scintillography>
<ScintillographyReason>"BONE SYMPTOMS"</ScintillographyReason>
<ScintillographyReport>METASTASIS</ScintillographyReport>
</FunctionalImaging>
</Anatomy>
<Physiology>
<CardiacFunction>
<CardiacFunction1LitreFluidChallenge>FAIL</CardiacFunction1LitreFluidChallenge>
</CardiacFunction>
<PeripheralNerveFunction>
<PeripheralNerveSensoryFunction>
<PeripheralNerveSensoryFunctionLoss>G2 OR MORE</PeripheralNerveSensoryFunctionLoss>
</PeripheralNerveSensoryFunction>
</PeripheralNerveFunction>
<AuditoryFunction>
<Audiogram>dB loss</Audiogram>
<AuditoryFunctionLossAssessment>"CLINICALLY SIGNIFICANT"</AuditoryFunctionLossAssessment>
</AuditoryFunction>
<Size>
<Weight>
<DateofWeightMeasure>TODAY()-120DAYS</DateofWeightMeasure>
<EstimatedWeightChange>-20%</EstimatedWeightChange>
</Weight>
</Size>
<PhysiologicalState>PREGNANT</PhysiologicalState>
<BreastFunction>LACTATING</BreastFunction>
<BloodFunction>
<HematologicFunction>
<BoneMarrowFunction>
<BoneMarrowIrradation>30% OR MORE</BoneMarrowIrradation>
</BoneMarrowFunction>
</HematologicFunction>
</BloodFunction>
<MiscellaneousCondition>Prior experimental therapy for cancer within 30 days</MiscellaneousCondition>
</Physiology>
</BiologicalMilieu>
<PsychologicalMilieu>
<FollowUpReliability>YES
<FollowUpReliabilityDuration>4 YEARS LESS THAN</FollowUpReliabilityDuration>
</FollowUpReliability>
<TreatmentComplianceEstimate>POOR</TreatmentComplianceEstimate>
</PsychologicalMilieu>
</ExclusionCriteria>
<TrialSpecification>PHASE III</TrialSpecification>
<TrialSpecification>RANDOMISED
<TrialStratification>STAGE
<CancerStage>
<Stage>III
<TNMstage>T3N0M0</TNMstage>
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<TNMstage>T3N1M0</TNMstage>
</Stage>
<Stage>IV
<TNMstage>T4aN0M0</TNMstage>
<TNMstage>T4aN1M0</TNMstage>
<TNMstage>T1N2M0</TNMstage>
<TNMstage>T2N2M0</TNMstage>
<TNMstage>T3N2M0</TNMstage>
<TNMstage>T4aN2M0</TNMstage>
<TNMstage>T4bN1M0</TNMstage>
<TNMstage>T4bN2M0</TNMstage>
<TNMstage>T4bN3M0</TNMstage>
<TNMstage>T1N3M0</TNMstage>
<TNMstage>T2N3M0</TNMstage>
<TNMstage>T3N3M0</TNMstage>
<TNMstage>T4N3M0</TNMstage>
</Stage>
</CancerStage>
</TrialStratification>
<TrialStratification>
<CancerDiagnosis>
<ICD0>C01-C06</ICD0> * mouth
<ICD0>c09-C10</ICD0> * pharynx
<ICD0>C12-14</ICD0> * hypopharynx
<ICD0>C32</ICD0> * larynx
</CancerDiagnosis>
</TrialStratification>
<TrialStratification>
<HematologicFunction>
<Gender>FEMALE
<Haemoglobin>12.5g/dL OR MORE</Haemoglobin>
<Haemoglobin>12.4g/dL OR LESS</Haemoglobin>
</Gender>
<Gender>MALE
<Haemoglobin>13.5g/dL OR MORE</Haemoglobin>
<Haemoglobin>13.4g/dL OR LESS</Haemoglobin>
</Gender>
</HematologicFunction>
</TrialStratification>
</TrialSpecification>
<TrialSpecification>INTERNATIONAL</TrialSpecification>
<TrialSpecification>OPEN-LABEL</TrialSpecification>
<TrialSpecification>TWOARM</TrialSpecification>
<TrialSpecification>CONTROLLED</TrialSpecification>
<TrialSpecification>MULTICENTRE</TrialSpecification>
<TrialDocumentation>
<TrialConsentDocument>SIGNED DOCUMENT</TrialConsentDocument>
</TrialDocumentation>
<Diagnosis>
<Cancer>
<InclusionCriteria>
<CancerDiagnosis>
<ICD0>C01-C06;c09-C10;C12-14;C32</ICD0> * mouth, pharynx, hypopharynx and larynx
<ICD0>C01-C99
<DiagnosisDate>5 YEARS NOT LESS</DiagnosisDate>
</ICD0>
<ICD0>D06</ICD0>
<Histopathology>
<Morphology>SQUAMOUSCELLCARCINOMA</Morphology>
</Histopathology>
<Cytology>
<Morphology>SQUAMOUSCELLCARCINOMA</Morphology>
</Cytology>
<CancerStage>
<Stage>
<TNMstage>T3N0M0</TNMstage>
<TNMstage>T3N1M0</TNMstage>
<TNMstage>T4aN0M0</TNMstage>
<TNMstage>T4aN1M0</TNMstage>
<TNMstage>T1N2M0</TNMstage>
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<TNMstage>T2N2M0</TNMstage>
<TNMstage>T3N2M0</TNMstage>
<TNMstage>T4aN2M0</TNMstage>
<TNMstage>T4bN1M0</TNMstage>
<TNMstage>T4bN2M0</TNMstage>
<TNMstage>T4bN3M0</TNMstage>
<TNMstage>T1N3M0</TNMstage>
<TNMstage>T2N3M0</TNMstage>
<TNMstage>T3N3M0</TNMstage>
<TNMstage>T4N3M0</TNMstage>
</Stage>
</CancerStage>
</CancerDiagnosis>
</InclusionCriteria>
<ExclusionCriteria>
<CancerDiagnosis>
<ICD0>B20-B24</ICD0> *HIV infection
<ICD0>I20;I22-I52;J81</ICD0> *Acute & Chronic heart disease
<ICD0>I21 MORE THAN 6 MONTHS</ICD0> * Heart attack
<ICD0>J43-J44</ICD0>
<ICD0>F10;X65;Z72.1</ICD0>
<ICD0>"ACTIVE INFECTION"</ICD0>
<ICD0>"FEBRILE ILLNESS"</ICD0>
<CancerDiagnosisDate></CancerDiagnosisDate>
<ICD0>C01-C06;c09-C10;C12-14;C32 * mouth, pharynx, hypopharynx and larynx
<CancerLocalRecurrence>YES</CancerLocalRecurrence>
<CancerRegionalRecurrence>YES</CancerRegionalRecurrence>
<CancerDistantRecurrence>YES</CancerDistantRecurrence>
</ICD0>
<ICD0>C11;C30;C31</ICD0> * Cancers of Nose, Sinuses and Nasopharynx
<ICD0>C50</ICD0> *Cancer of breast
<ICD0>C61</ICD0> *Cancer of prostate
<ICD0>C43</ICD0> *Melanoma of skin
<CancerStage>
<Stage>
<TNMstage>T*N*M1</TNMstage>
<TNMstage>T1N0M0</TNMstage>
<TNMstage>T2N0M0</TNMstage>
<TNMstage>T1N1M0</TNMstage>
<TNMstage>T2N1M0</TNMstage>
</Stage>
</CancerStage>
</CancerDiagnosis>
</ExclusionCriteria>
<TrialArm>ONE
<TrialArmName>RADIOTHERAPY + CISPLATIN</TrialArmName>
<TrialArmSummary>
<Gender>
<Male>378</Male>
<Female>50</Female>
</Gender>
<Age>
<AgeMedian>56</AgeMedian>
<AgeRange>23-80</AgeRange>
</Age>
<CountryOfResidence>
<RegionAUSTRALIANEWZEALAND>87</RegionAUSTRALIANEWZEALAND>
<RegionEASTERNEUROPE>46</RegionEASTERNEUROPE>
<RegionNORTHAMERICA>92</RegionNORTHAMERICA>
<RegionSOUTHAMERICA>49</RegionSOUTHAMERICA>
<RegionWESTERNEUROPE>154</RegionWESTERNEUROPE>
</CountryOfResidence>
<PerformanceStatusECOG>
<PerformanceStatusECOG0>265</PerformanceStatusECOG0>
<PerformanceStatusECOG1>150</PerformanceStatusECOG1>
<PerformanceStatusECOG2>13</PerformanceStatusECOG2>
</PerformanceStatusECOG>
<Diagnosis>
<CancerDiagnosis>
<ICD0_C01-C06>53</ICD0_C01-C06> * mouth
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<ICD0_C09-C10>228</ICD0_C09-C10> * pharynx
<ICD0_C12-14>70</ICD0_C12-14> * hypopharynx
<ICD0_C32>77</ICD0_C32> * larynx
<Stage>
<CancerStage>
<T1>13</T1>
<T2>61</T2>
<T3>149</T3>
<T4>205</T4>
<N0>65</N0>
<N1>40</N1>
<N2>275</N2>
<N3>48</N3>
</CancerStage>
</Stage>
</CancerDiagnosis>
</Diagnosis>
<HematologicFunction>
<HaemoglobinLESSTHAN10gperdL>122</HaemoglobinLESSTHAN10gperdL>
<HaemoglobinMORETHAN10gperdL>306</HaemoglobinMORETHAN10gperdL>
</HematologicFunction>
</TrialArmSummary>
<Therapy>426
<Surgery>
<SurgicalIndication>OPTION1: RESIDUAL/PROGRESSIVE NECK MASS
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION2: INITIAL N2/N3 DISEASE
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION3: NO/RESOLVING NECK MASS
<SurgicalProcedure>NO OPERATION</SurgicalProcedure>
</SurgicalIndication>
</Surgery>
<Radiotherapy>422
<ExternalBeam>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE
<RadiotherapyBreakCompensation>BD</RadiotherapyBreakCompensation>
</RadiationFractionsPerWeek>
<RadiationBeamParticle>ELECTRONS</RadiationBeamParticle>
<RadiationBeamParticle>PHOTONS
<RadiationBeamEnergy>4MV</RadiationBeamEnergy>
</RadiationBeamParticle>
<RadiationTechnique>FIELD-BASED
<RadiotherapyBeamArrangement>PARALLEL OPPOSED
<RadiationPrescriptionPoint>MIDPOINTDOSE</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
<RadiotherapyBeamArrangement>ANTERIOR
<RadiationPrescriptionPoint>DEPTH 2CM</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<RadiotherapyBeamArrangement>NON-COPLANAR
<RadiationPrescriptionPoint>PRESCRIPTION POINT</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
</RadiationPrescription>
<RadiotherapySimulation>
<RadiotherapyPosition>SUPINE</RadiotherapyPosition>
<RadiotherapyImmobilisation>MASK</RadiotherapyImmobilisation>
<RadiotherapyImmobilisation>INTRAORAL DEVICE</RadiotherapyImmobilisation>
<RadiotherapySurfaceAlteration>NO BOLUS</RadiotherapySurfaceAlteration>
<RadiotherapySimulationFieldImaging>SIMULATION RADIOGRAPHS</RadiotherapySimulationFieldImaging>
<RadiotherapySimulationFieldImaging>SIMULATION CT</RadiotherapySimulationFieldImaging>
<TargetVolume>
<RadiationTechnique>FIELD-BASED
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<RadiotherapyPhase>ONE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
<ClinicalTargetVolume>
<ClinicalTargetVolumeDosePrescription>50GY/25FX</ClinicalTargetVolumeDosePrescription>
<ClinicalTargetVolumeAnatomy>1st LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeAnatomy>2nd LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeMarginToFieldEdge>1CM</ClinicalTargetVolumeMarginToFieldEdge>
</ClinicalTargetVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>TWO
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>10GY/5FX</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>THREE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>1CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<PlanningVolumes>
<PlanningTreatmentVolume>PTV1
<PTVPrescriptionDose>50GY/25FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV1
<GrossTumourVolume>PRIMARY + INVOLVED LN + UNINVOLVED LN
<CTVExpansion>1.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV2
<PTVPrescriptionDose>70GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV2
<GrossTumourVolume>PRIMARY + INVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV3
<PTVPrescriptionDose>60GY/30FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV3
<GrossTumourVolume>HIGH RISK UNINVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
</PlanningVolumes>
<PlanningContours>
<Anatomy>
<Organ>SPINALCORD</Organ>
<Organ>PAROTID_R</Organ>
<Organ>PAROTID_L</Organ>
</Anatomy>
</PlanningContours>
</RadiationTechnique>
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</TargetVolume>
</RadiotherapySimulation>
<RadiotherapyPlanning>
<RadiotherapyPlanningPTVDoseHeterogeneity>-5%</RadiotherapyPlanningPTVDoseHeterogeneity>
<RadiotherapyPlanningPTVDoseHeterogeneity>+7%</RadiotherapyPlanningPTVDoseHeterogeneity>
<Anatomy>
<Organ>SPINALCORD
<RadiotherapyOARDoseConstraint>45GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
</Anatomy>
</RadiotherapyPlanning>
</ExternalBeam>
<Brachytherapy>
<Importance>NO</Importance>
</Brachytherapy>
<AcuteSideEffects>
<EnteralFeeding>65%</EnteralFeeding>
<Death>13</Death>
</AcuteSideEffects>
</Radiotherapy>
<Chemotherapy>423
<ChemotherapyRegime>CISPLATIN
<ChemotherapyCycle>
<ChemotherapyCycleNumber>THREE</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>THREE WEEKS
<ChemotherapyCycleDay>DAY 1</ChemotherapyCycleDay>
<ChemotherapyDrug>CISPLATIN</ChemotherapyDrug>
<ChemotherapyDrugDose>100MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>ONE HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<Drug>ANTIEMETIC</Drug>
</ChemotherapyDrugSupport>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
</Chemotherapy>
</Therapy>
</TrialArm>
<TrialArm>TWO
<TrialArmName>RADIOTHERAPY + CISPLATIN + TIRAPAZIMINE</TrialArmName>
<TrialArmSummary>
<Gender>
<Male>367</Male>
<Female>58</Female>
</Gender>
<Age>
<AgeMedian>57</AgeMedian>
<AgeRange>23-77</AgeRange>
</Age>
<CountryOfResidence>
<RegionAUSTRALIANEWZEALAND>86</RegionAUSTRALIANEWZEALAND>
<RegionEASTERNEUROPE>50</RegionEASTERNEUROPE>
<RegionNORTHAMERICA>80</RegionNORTHAMERICA>
<RegionSOUTHAMERICA>47</RegionSOUTHAMERICA>
<RegionWESTERNEUROPE>162</RegionWESTERNEUROPE>
</CountryOfResidence>
<PerformanceStatusECOG>
<PerformanceStatusECOG0>260</PerformanceStatusECOG0>
<PerformanceStatusECOG1>153</PerformanceStatusECOG1>
<PerformanceStatusECOG2>12</PerformanceStatusECOG2>
</PerformanceStatusECOG>
<Diagnosis>
<CancerDiagnosis>
<ICD0_C01-C06>56</ICD0_C01-C06> * mouth
<ICD0_C09-C10>237</ICD0_C09-C10> * pharynx
<ICD0_C12-14>61</ICD0_C12-14> * hypopharynx
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<ICD0_C32>71</ICD0_C32> * larynx
<Stage>
<CancerStage>
<T1>16</T1>
<T2>57</T2>
<T3>159</T3>
<T4>193</T4>
<N0>60</N0>
<N1>53</N1>
<N2>264</N2>
<N3>48</N3>
</CancerStage>
</Stage>
</CancerDiagnosis>
</Diagnosis>
<HematologicFunction>
<HaemoglobinLESSTHAN10gperdL>118</HaemoglobinLESSTHAN10gperdL>
<HaemoglobinMORETHAN10gperdL>307</HaemoglobinMORETHAN10gperdL>
</HematologicFunction>
</TrialArmSummary>
<Therapy>430
<Surgery>
<SurgicalIndication>OPTION1: RESIDUAL/PROGRESSIVE NECK MASS
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION2: INITIAL N2/N3 DISEASE
<SurgicalProcedure>NECK DISSECTION</SurgicalProcedure>
</SurgicalIndication>
<SurgicalIndication>OPTION3: NO/RESOLVING NECK MASS
<SurgicalProcedure>NO OPERATION</SurgicalProcedure>
</SurgicalIndication>
</Surgery>
<Radiotherapy>423
<ExternalBeam>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE
<RadiotherapyBreakCompensation>BD</RadiotherapyBreakCompensation>
</RadiationFractionsPerWeek>
<RadiationBeamParticle>ELECTRONS</RadiationBeamParticle>
<RadiationBeamParticle>PHOTONS
<RadiationBeamEnergy>4MV</RadiationBeamEnergy>
</RadiationBeamParticle>
<RadiationTechnique>FIELD-BASED
<RadiotherapyBeamArrangement>PARALLEL OPPOSED
<RadiationPrescriptionPoint>MIDPOINT DOSE</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
<RadiotherapyBeamArrangement>ANTERIOR
<RadiationPrescriptionPoint>DEPTH 2CM</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<RadiotherapyBeamArrangement>NON-COPLANAR
<RadiationPrescriptionPoint>PRESCRIPTION POINT</RadiationPrescriptionPoint>
</RadiotherapyBeamArrangement>
</RadiationTechnique>
</RadiationPrescription>
<RadiotherapySimulation>
<RadiotherapyPosition>SUPINE</RadiotherapyPosition>
<RadiotherapyImmobilisation>MASK</RadiotherapyImmobilisation>
<RadiotherapyImmobilisation>INTRAORAL DEVICE</RadiotherapyImmobilisation>
<RadiotherapySurfaceAlteration>NO BOLUS</RadiotherapySurfaceAlteration>
<RadiotherapySimulationFieldImaging>SIMULATION RADIOGRAPHS</RadiotherapySimulationFieldImaging>
<RadiotherapySimulationFieldImaging>SIMULATION CT</RadiotherapySimulationFieldImaging>
<TargetVolume>
<RadiationTechnique>FIELD-BASED
<RadiotherapyPhase>ONE
<GrossTumourVolume>
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<GrossTumourVolumeMORETHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>50GY/25FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolume>
<ClinicalTargetVolume>
<ClinicalTargetVolumeDosePrescription>50GY/25FX</ClinicalTargetVolumeDosePrescription>
<ClinicalTargetVolumeAnatomy>1st LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeAnatomy>2nd LEVEL UNINVOLVED LN</ClinicalTargetVolumeAnatomy>
<ClinicalTargetVolumeMarginToFieldEdge>1CM</ClinicalTargetVolumeMarginToFieldEdge>
</ClinicalTargetVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>TWO
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>2CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeMORETHAN2cm>
<GrossTumourVolumeLESSTHAN2cm>10GY/5FX</GrossTumourVolumeLESSTHAN2cm>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
<RadiotherapyPhase>THREE
<GrossTumourVolume>
<GrossTumourVolumeMORETHAN2cm>10GY/5FX
<GrossTumourVolumeMarginToFieldEdge>1CM</GrossTumourVolumeMarginToFieldEdge>
</GrossTumourVolumeMORETHAN2cm>
</GrossTumourVolume>
</RadiotherapyPhase>
</RadiationTechnique>
<RadiationTechnique>3DCONFORMAL
<PlanningVolumes>
<PlanningTreatmentVolume>PTV1
<PTVPrescriptionDose>50GY/25FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV1
<GrossTumourVolume>PRIMARY + INVOLVED LN + UNINVOLVED LN
<CTVExpansion>1.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV2
<PTVPrescriptionDose>70GY/35FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV2
<GrossTumourVolume>PRIMARY + INVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
<PlanningTreatmentVolume>PTV3
<PTVPrescriptionDose>60GY/30FX</PTVPrescriptionDose>
<PTVExplansion>0CM</PTVExplansion>
<ClinicalTargetVolume>CTV3
<GrossTumourVolume>HIGH RISK UNINVOLVED LN
<CTVExpansion>0.5CM</CTVExpansion>
</GrossTumourVolume>
</ClinicalTargetVolume>
</PlanningTreatmentVolume>
</PlanningVolumes>
<PlanningContours>
<Anatomy>
<Organ>SPINALCORD</Organ>
<Organ>PAROTID_R</Organ>
<Organ>PAROTID_L</Organ>
</Anatomy>
</PlanningContours>
</RadiationTechnique>
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</TargetVolume>
</RadiotherapySimulation>
<RadiotherapyPlanning>
<RadiotherapyPlanningPTVDoseHeterogeneity>-5%</RadiotherapyPlanningPTVDoseHeterogeneity>
<RadiotherapyPlanningPTVDoseHeterogeneity>+7%</RadiotherapyPlanningPTVDoseHeterogeneity>
<Anatomy>
<Organ>SPINALCORD
<RadiotherapyOARDoseConstraint>45GY LESS THAN</RadiotherapyOARDoseConstraint>
</Organ>
</Anatomy>
</RadiotherapyPlanning>
</ExternalBeam>
<Brachytherapy>
<Importance>NO</Importance>
</Brachytherapy>
</Radiotherapy>
<Chemotherapy>433
<ChemotherapyRegime>TIRAPAZAMINE + CISPLATION
<ChemotherapyCycle>
<ChemotherapyCycleNumber>THREE WEEKS</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>THREE WEEKS
<ChemotherapyCycleDay>DAY 1</ChemotherapyCycleDay>
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>290MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-3 HOUR</ChemotherapyDrugDeliveryStart>
</ChemotherapyDrug>
<ChemotherapyDrug>CISPLATIN
<ChemotherapyDrugDose>75MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>ONE HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
<ChemotherapyRegime>TIRAPAZAMINE
<ChemotherapyCycle>
<ChemotherapyCycleNumber>TWO</ChemotherapyCycleNumber>
<ChemotherapyStartEvent>RADIOTHERAPY DAY 5</ChemotherapyStartEvent>
<ChemotherapyCycleDuration>ONE WEEKS
<ChemotherapyCycleDay>DAY 1
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
<ChemotherapyCycleDay>DAY 3
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
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<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
<ChemothersapyCycleDay>DAY 5
<ChemotherapyDrug>TIRAPAZAMINE
<ChemotherapyDrugDose>160MG/M^2</ChemotherapyDrugDose>
<ChemotherapyDrugRoute>IV</ChemotherapyDrugRoute>
<ChemotherapyDrugDelivery>TWO HOUR INFUSION</ChemotherapyDrugDelivery>
<ChemotherapyDrugDeliveryStart>-1 HOUR</ChemotherapyDrugDeliveryStart>
<ChemotherapyDrugSupport>
<IVhydration>500mL NORMALSALINE</IVhydration>
<DrugEffect>ANTIEMETIC
<Drug>5HT3ANTAGONIST</Drug>
<Drug>DEXAMETHASONE</Drug>
</DrugEffect>
</ChemotherapyDrugSupport>
</ChemotherapyDrug>
</ChemotherapyCycleDay>
</ChemotherapyCycleDuration>
</ChemotherapyCycle>
</ChemotherapyRegime>
<SideEffects>
<TirapazamineSideEffects>MUSCLE CRAMPS; HEARING LOSS; ABNORMAL VISION;
NAUSEA; VOMITING; DIARRHOEA</TirapazamineSideEffects>
</SideEffects>
</Chemotherapy>
</Therapy>
</TrialArm>
<TrialOutcome>
<TrialPatients>861
<PatientsIneligible>
<Misdiagnosis>5</Misdiagnosis>
<EarlyWithdrawl>3</EarlyWithdrawl>
</PatientsIneligible>
<FollowUp>
<PatientLostToFollowUp>48</PatientLostToFollowUp>
<PatientFollowUpMeanDuration>27 MONTHS</PatientFollowUpMeanDuration>
<PatientFollowUpRange>22 - 45 MONTHS</PatientFollowUpRange>
</TrialPatients>
<CancerOutcome>
<OutcomeAnalysis>OVERALLSURVIVAL
<SurvivalDuration>2 YEAR</SurvivalDuration>
<TrialArm>ONE * (RADIATION + CISPLATIN)
<SurvivalRate>65.7%</SurvivalRate>
<ConfidenceInterval>61-70%</ConfidenceInterval>
</TrialArm>
<TrialArm>TWO * (RADIATION + TIRAPAZAMINE + CISPLATIN)
<SurvivalRate>66.2%</SurvivalRate>
<ConfidenceInterval>62-71%</ConfidenceInterval>
</TrialArm>
</OutcomeAnalysis>
<OutcomeAnalysis>FAILUREFREESURVIVAL
<SurvivalDuration>2 YEAR</SurvivalDuration>
<TrialArm>ONE
<SurvivalRate>57%</SurvivalRate>
<ConfidenceInterval>52-61%</ConfidenceInterval>
</TrialArm>
<TrialArm>TWO
<SurvivalRate>56%</SurvivalRate>
<ConfidenceInterval>51-61%</ConfidenceInterval>
</TrialArm>
<StatisticalDifference>
<pVALUE>0.96</pVALUE>
-11-

<HazardRatio>0.99</HazardRatio>
<ConfidenceInterval>0.81-1.21</ConfidenceInterval>
</StatisticalDifference>
</OutcomeAnalysis>
<OutcomeAnalysis>LOCOREGIONALFAILUREFREESURVIVAL
<SurvivalDuration>2 YEAR</SurvivalDuration>
<TrialArm>ONE
<SurvivalRate>74%</SurvivalRate>
<ConfidenceInterval>69-78%</ConfidenceInterval>
</TrialArm>
<TrialArm>TWO
<SurvivalRate>75%</SurvivalRate>
<ConfidenceInterval>70-79%</ConfidenceInterval>
</TrialArm>
<StatisticalDifference>
<pVALUE>0.44</pVALUE>
<HazardRatio>0.89</HazardRatio>
<ConfidenceInterval>0.68-1.17</ConfidenceInterval>
</StatisticalDifference>
</OutcomeAnalysis>
<OutcomeAnalysis>INITIALLOCOREGIONALFAILURE
<TrialArm>ONE
<FirstFailureSite>23%</FirstFailureSite>
</TrialArm>
<TrialArm>TWO
<FirstFailureSite>20%</FirstFailureSite>
</TrialArm>
</OutcomeAnalysis>
<OutcomeAnalysis>QUALITYOFLIFE
<SurvivalDuration>6 MONTHS</SurvivalDuration>
<TrialArm>ONE
<FACT-HNscorechange>-9.7</FACT-HNscorechange>
</TrialArm>
<TrialArm>TWO
<FACT-HNscorechange>-8.9</FACT-HNscorechange>
</TrialArm>
<StatisticalDifference>
<pVALUE>0.72</pVALUE>
</StatisticalDifference>
</OutcomeAnalysis>
<OutcomeAnalysis>
<PatientDeaths>318</PatientDeaths>
<PatientLocoRegionalFailure>203</PatientLocoRegionalFailure>
<PatientLocoRegionalDistantFailures>390</PatientLocoRegionalDistantFailures>
</OutcomeAnalysis>
<MultivariateAnalysis>TRIAL ARM
<TrialArm>ONE</TrialArm>
<TrialArm>TWO</TrialArm>
<StatisticalDifference>
<pVALUE>0.53</pVALUE>
<HazardRatio>1.07</HazardRatio>
<ConfidenceInterval>0.86-1.34</ConfidenceInterval>
</StatisticalDifference>
</MultivariateAnalysis>
<MultivariateAnalysis>PERFORMANCE STATUS
<PerformanceStatusECOG>0</PerformanceStatusECOG>
<PerformanceStatusECOG>1;2</PerformanceStatusECOG>
<StatisticalDifference>
<pVALUE>0.013</pVALUE>
<HazardRatio>0.75</HazardRatio>
<ConfidenceInterval>0.60-0.94</ConfidenceInterval>
</StatisticalDifference>
</MultivariateAnalysis>
<MultivariateAnalysis>SITE
<ICD0>C01-C06</ICD0> * mouth
<ICD0>C09-C10</ICD0> * pharynx
<ICD0>C12-14</ICD0> * hypopharynx
<ICD0>C32</ICD0> * larynx
<StatisticalDifference>
<pVALUE> LESS THAN 0.001</pVALUE>
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<HazardRatio>0.48</HazardRatio>
<ConfidenceInterval>0.38-0.60</ConfidenceInterval>
</StatisticalDifference>
</MultivariateAnalysis>
<MultivariateAnalysis>ANAEMIA
<Haemoglobin>10g/dL OR MORE</Haemoglobin>
<Haemoglobin>10g/dL LESS THAN</Haemoglobin>
<StatisticalDifference>
<pVALUE>LESS THAN 0.001</pVALUE>
<HazardRatio>0.57</HazardRatio>
<ConfidenceInterval>0.45-0.71</ConfidenceInterval>
</StatisticalDifference>
</MultivariateAnalysis>
<MultivariateAnalysis>STAGE
<CancerStage>III</CancerStage>
<CancerStage>IV</CancerStage>
<StatisticalDifference>
<pVALUE>0.12</pVALUE>
<HazardRatio>0.74</HazardRatio>
<ConfidenceInterval>0.51-1.08</ConfidenceInterval>
</StatisticalDifference>
</MultivariateAnalysis>
</CancerOutcome>
</TrialOutcome>
</TreatmentIntent>
</Cancer>
</Diagnosis>
</Report>
</Organisation>

-13-

Article below removed for copyright reasons.
Please refer to the citation:
Rischin, D. et al., 2010, ‘Tirapazamine, Cisplatin, and
radiation versus Cisplatin and radiation for advanced squamous
cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a
phase III trial of the Trans-Tasman Radiation Oncology Group’
Journal of Clinical Oncology, 28(18), pp. 2989-2995.
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There are several bodies that have a tradition for publishing best practice guidelines. The National Comprehensive Cancer Network (NCCN) in the USA, the Scottish
Intercollegiate Guideline Network (SIGN) in the UK and the British Columbia Cancer
Agency (BCCA) have published guidelines for over a decade. Their approaches to
guidelines are different.

The BCCA publishes their guidelines which dictate their approach to cancer management within their own service. As such, their guidelines describe a unified common
approach by a defined group of clinicians to the defined problem in a single institution.
The BCCA is the sole cancer treatment organisation for British Columbia. The BCCA
protocols are descriptions of practice in one institution.

The NCCN is a consortium of academic centres in the USA who seek to advise the
rest of the USA on what they consider is standard and non-experimental treatment.
Guidelines from the USA are usually characterised by presenting the range of options
acceptable in a particular circumstance. The NCCN protocols are descriptions of the
boundaries of acceptable practice for a large medical community.

The SIGN is a professional collaboration of Scottish clinicians that seeks to educate
decision making. Clinicians are advised about the evidence of what works and how
robust that evidence is. The SIGN protocols are descriptions of the evidence underlying medical practice anywhere.

These differences lead to guidelines with different styles. The patient described in
Appendix J has an locally advanced cancer of the base of tongue which is a specific
anatomical part of the oropharnyx. Described below is a paraphrase of each individual
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guideline which is then interpreted into CKML structure defined in Appendix I.

N.1. BCCA Guideline

N.1
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BCCA Guideline

The BCCA Guideline can be applied to cancers of the ”Base of the tongue (posterior
third of the tongue)”. It states that ”Advanced tumours T3 T4 N0 N1 N2 N3 should
be considered for a twice daily radiotherapy schedule or concurrent chemotherapy with
radiotherapy if the patient is fit.” Therefore when selecting management for a fit patient
with a locally advanced base of tongue cancer, this guideline advises that a single daily
radiotherapy schedule and concurrent chemotherapy is appropriate.

<Organisation>BCCA
<Guideline>
<GuidelineID>BCCA99</GuidelineID>
<GuidelineName>OROPHARYNX</GuidelineName>
<BiologicalMilieu>FIT<BiologicalMilieu>
<Diagnosis>
<Cancer>
<CancerDiagnosis>
<ICD0>Base of the tongue</ICD0>
<CancerStage>
<T_stage>T3; T4</T_stage>
<N_stage>N0; N1; N2; N3</N_stage>
<M_stage>M0</M_stage>
</CancerStage>
<Therapy>
<Surgery>NO</Surgery>
<Radiotherapy>YES</Radiotherapy>
<Chemotherapy>YES</Chemotherapy>
</Therapy>
</CancerDiagnosis>
</Cancer>
</Diagnosis>
</Guideline>
</Organisation>
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N.2. NCCN Guideline

N.2
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NCCN Guideline

The NCCN guideline (ORPH-1) is also applied to cancers of the oropharynx and
is more complicated. The relevant features that apply to the patient described in
Appendix J are boxed in blue. As this patient was staged as T4aN2cM0, the first
page clearly points to further management specified on page ORPH-4. This page
provides a selection of therapies which might be called ‘standard’ including the first
preferred option of “concurrent systemic therapy/RT cisplatin”. This selection is based
on Category 1 evidence1 . This completes the specification for the initial treatment.
The path of assessing the primary site and neck disease for a complete response was
folled with this patient. These observations being negative, the patient was observed.
The specification for the radiotherapy is provided in the page ORPH-A. This part
of the guideline calls for IMRT as the preferred technique and advised a particular
radiation dose to the visible cancer, and another to the at-risk areas (uninvolved nodal
stations).
The specification for the chemotherapy, i.e., concurrent cisplatin chemotherapy is
provided page CHEM-A, reveals that ”cisplatin alone” is an acceptable regime.

1

NCCN Categories of Evidence and Consensus
Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials)
and there is uniform NCCN consensus.
Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN
consensus.
Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN
consensus (but no major disagreement).
Category 3: The recommendation is based on any level of evidence but reflects major disagreement.
All recommendations are category 2A unless otherwise noted.

<Organisation>NCCN
<Guideline>
<GuidelineID>ORPH-1</GuidelineID>
<GuidelineName>CANCER OF THE OROPHARYNX</GuidelineName>
<GuidelineVersion>2.2011</GuidelineVersion>
<Diagnosis>
<Cancer>
<CancerDiagnosis>
<ICD0>OROPHARYNX</ICD0>
<CancerStage>
<T_stage>T1 ; T2; T3; T4a</T_stage>
<N_stage>N2; N3</N_stage>
<M_stage>M0</M_stage>
</CancerStage>
<Therapy>
<Surgery>
<Importance>NO</Importance>
<SurgicalIndication>UNRESECTABLE</SurgicalIndication>
</Surgery>
<Radiotherapy>
<ExternalBeam>
<RadiationPrescription>
<RadiationDose>70 GY</RadiationDose>
<RadiationFractions>35 FX</RadiationFractions>
<RadiationFractionsPerDay>ONE</RadiationFractionsPerDay>
<RadiationFractionsPerWeek>FIVE</RadiationFractionsPerWeek>
</RadiationPrescription>
<RadiationTechnique>IMRT
<PlanningVolumes>
<PlanningTreatmentVolume>
<PTVPrescriptionDose>70GY/35FX
<ClinicalTargetVolume>
<GrossTumourVolume>PRIMARY</GrossTumourVolume>
<GrossTumourVolume>GROSS ADENOPATHY</GrossTumourVolume>
</ClinicalTargetVolume>
</PTVPrescriptionDose>
<PTVPrescriptionDose>44-64GY/35FX
<ClinicalTargetVolume>
<GrossTumourVolume>UNINVOLVED NODAL STATIONS</GrossTumourVolume>
</ClinicalTargetVolume>
</PTVPrescriptionDose>
</PlanningTreatmentVolume>
</PlanningVolumes>
</RadiationTechnique>
</ExternalBeam>
</Radiotherapy>
<Chemotherapy>
<Importance>CONCURRENT</Importance>
<ChemotherapyRegime>CISPLATIN
<ChemotherapyCycle>
<ChemotherapyStartEvent>RADIOTHERAPY START</ChemotherapyStartEvent>
<ChemotherapyDrug>CISPLATIN</ChemotherapyDrug>
</ChemotherapyCycle>
</ChemotherapyRegime>
</Chemotherapy>
</Therapy>
</CancerDiagnosis>
</Cancer>
</Diagnosis>
</Guideline>
</Organisation>
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N.3. SIGN Guideline

N.3
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SIGN Guideline

The SIGN guideline is also applied to cancers of the oropharynx. Similarly to the
NCCN guideline, all stages of the disease are covered by the guideline. In the final
section (13.2.2), there are a series of statements with associated levels of recommnedation2

Appendix O
Clinical Practice Guideline for
advanced oropharynx cancer British Columbia Cancer Agency
(Canada)
This guideline is available on-line.1

1

http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/HeadnNeck/Management/
Oropharynx.htm
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Appendix P
Clinical Practice Guideline for
advanced oropharynx cancer Scottish Intercollegiate Guidelines
Network (UK)
The complete oropharynx cancer treatment guideline is available on-line

1

http://www.sign.ac.uk/pdf/sign90.pdf
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13 OROPHARYNGEAL CANCER

13

Oropharyngeal cancer
Oropharyngeal tumours may arise from the base of tongue, vallecula, tonsil and tonsillar fossa,
posterior wall and the inferior surface of the soft palate and uvula. The choice of therapeutic
option for patients with cancer of the oropharynx should be determined by the tumour’s site
and extent, the patient’s general condition and preference and availability of local expertise.
It is important to consider the treatment related morbidity, and likely cosmetic and functional
outcome of treatment as well as tumour control when making decisions about treatment.

13.1	Early oropharyngeal CANCER (STAGE I and II)
No RCTs were identified comparing surgical treatment with non-surgical treatment in early
oropharyngeal cancer.
There is no difference in local control, five-year cause specific and five-year absolute survival
when surgery with or without radiotherapy is compared to radiotherapy with or without neck
dissection in patients with tonsillar and base of tongue carcinoma.425 The risk of severe and fatal
complications is lower in patients treated with primary radiotherapy.425

3

No evidence comparing functional outcome following surgery or radiotherapy was identified.
There is no evidence to support the routine use of concurrent chemotherapy with radiotherapy
in early oropharyngeal cancer.
If appropriate expertise is available it may be possible to treat patients with small
oropharyngeal tumours with a combination of external beam radiotherapy and interstitial
brachytherapy.242,243,426
Although the incidence of occult metastases in the lymph nodes of the neck of patients with
oropharyngeal cancer is high (>50%),68,150-152 there is no randomised controlled evidence showing
that prophylactic treatment of the neck improves survival. Occult metastases predominate in
levels II, III and IV,150-152,154 although distribution varies with the anatomical site of the tumour
within the oropharynx. If the primary is in the base of tongue 17% of patients may have level V
nodal involvement, and 55% may have bilateral involved nodes.154 Only 3% of patients with
early carcinoma of the tonsil develop contralateral nodal metastases after ipsilateral radiation
to the primary tumour and neck.427

3

3

No RCTs comparing selective neck dissection to modified radical neck dissection in patients
with clinically N0 oropharyngeal cancers were identified.
Neck recurrence rates following selective procedures in patients with clinically N0 neck compare
favourably with those achieved by more extensive neck dissection.150,178,428 Radiotherapy and
surgery are equally effective for prophylactic treatment of patients with N0 neck.182,429


 Management of early oropharyngeal cancer should be individualised for each patient.
 Decisions regarding the choice of primary treatment modality should be made in
consultation with the patient and should take into account the anatomical location
of the tumour and availability of local expertise.

D

Patients with early oropharyngeal cancer may be treated by:
 primary resection, with reconstruction as appropriate, and neck dissection (selective
neck dissection encompassing nodal levels II-IV, or II-V if base of tongue)
 external beam radiotherapy encompassing the primary tumour and neck nodes
(levels II-IV, or levels II-V if base of tongue).

D
		

Patients with small accessible tumours may be treated by a combination of external
beam radiotherapy and brachytherapy in centres with appropriate expertise.

D
		

In patients with well-lateralised tumours prophylactic treatment of the ipsilateral neck
only is required.		

D
		

Bilateral treatment of the neck is recommended when the incidence of occult disease
in the contralateral neck is high (tumour is encroaching on base of tongue or soft palate).

3
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Radiotherapy delivered postoperatively to the primary site and/or neck in patients at high risk
of locoregional recurrence may improve locoregional control178,195,289-292 and survival289,292 (see
section 7.3).

3

The administration of cisplatin chemotherapy concurrently with postoperative irradiation results
in significantly better locoregional control307,308 and survival307 than with radiotherapy alone
particularly in those patients with extracapsular spread and/or positive surgical margins.

1++

D Postoperative radiotherapy should be considered for patients with clinical and
			pathological features that indicate a high risk of recurrence.
A
Administration of cisplatin chemotherapy concurrently with postoperative
			radiotherapy should be considered, particularly in patients with extracapsular spread
			and/or positive surgical margins.

13.2

Locally advanced oropharyngeal CANCER (Stage III and IV)
No good quality RCTs were identified comparing radiotherapy or chemoradiotherapy with
surgery and postoperative radiotherapy in patients with locally advanced head and neck
cancer.
Local control and overall survival are comparable in patients treated with primary radiotherapy
followed by neck dissection and those receiving primary surgery followed by postoperative
irradiation.425 The risk of severe and fatal complications is lower in patients treated by primary
radiotherapy.425

3

No evidence was identified comparing functional outcome in patients following either surgery
or radiotherapy.
If external beam radiotherapy is used as the primary modality of treatment, concurrent
administration of chemotherapy results in a 23% reduction in the risk of death at five years
when compared with radiotherapy alone.298

1++

Administration of cetuximab concurrently with radiotherapy in advanced oropharyngeal cancer
results in significantly improved locoregional control, progression-free survival compared with
radiotherapy alone (see section 8.2).226

1++

Accelerated radiotherapy or hyperfractionated radiotherapy with increased total dose results in
improved locoregional control compared with conventionally fractionated radiotherapy alone
(see section 6.3).

1++

There are no RCTs comparing surgery with radiotherapy (with or without chemotherapy) in
the treatment of patients with oropharyngeal cancer and node positive neck. In node positive
oropharyngeal cancer, levels II, III and IV are most commonly involved. Level V is positive
in 6-11% of patients.151,152,165,184 Levels I and V are only involved if there are positive nodes at
other levels.151,152

3

There is currently insufficient evidence to support the use of selective neck dissection in patients
with oropharyngeal cancer and advanced nodal disease.314
In patients with a small primary tumour, it is possible to resect advanced nodal disease prior
to treating the primary with definitive radiotherapy whilst delivering postoperative adjuvant
radiotherapy to the neck without compromising cancer control (see section 5.2.4).207,208,424

3

Nodal size predicts response to radiotherapy and it may be possible to treat a single node <3
cm with radiotherapy or chemoradiotherapy alone.196,198

3

Patients with N2 and N3 disease are better treated by a combination of surgery and
chemoradiotherapy (or radiotherapy in those unable to tolerate chemotherapy) rather than by
either modality alone (see sections 5.2.4 and 8.1).
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In patients with N2 or N3 oropharyngeal tumours with clinically detectable residual disease
after chemoradiotherapy, there is evidence of improved overall survival if a neck dissection is
performed.205 It is unclear from current evidence whether it is safe to omit neck dissection for
patients with N2 and N3 disease who have a complete clinical response to chemoradiotherapy.
After definitive radiotherapy it may be possible to dissect nodal levels II-IV only and omit levels
I and V if there is no clinical or radiological sign of residual disease at these levels.430
The administration of cisplatin chemotherapy concurrently with postoperative irradiation
results in significantly better locoregional control307,308 and survival307 than with radiotherapy
alone particularly in those patients with extracapsular nodal spread and/or positive surgical
margins.
 
			
			


D

3

1++

The decision regarding the choice of primary treatment modality in advanced
oropharyngeal cancer should be made in consultation with the patient and be
dependent on local expertise.
In patients where surgical resection is possible, the likelihood of obtaining adequate
surgical margins with acceptable morbidity, functional outcome and quality of life
must be taken into account.

Patients with advanced oropharyngeal cancer may be treated by:
 primary surgery (if a clear surgical margin can be obtained)
 an organ preservation approach.

13.2.1	Primary surgery


Resection of the primary tumour should be followed by reconstruction as necessary.

D
		

Patients treated by primary surgery who have a clinically node positive neck should
have a modified radical neck dissection.



 Ipsilateral neck dissection may be performed if the tumour is well lateralised.
 Prophylactic treatment of the contralateral neck should be considered, especially
when tumours encroach on the midline.

D
		

Postoperative chemoradiotherapy to the primary site and neck should be considered
for patients treated by primary surgery who show high risk pathological features.

A
Administration of cisplatin chemotherapy concurrently with postoperative radiotherapy
			should be considered, particularly in patients with extracapsular spread and/or
		
positive surgical margins.
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13.2.2

Organ preservation therapy
A

Radiotherapy should be administered with concurrent cisplatin chemotherapy.

D

The primary tumour and neck node levels (II-V) should be treated bilaterally.

A
In patients medically unsuitable for chemotherapy, concurrent administration of
			cetuximab with radiotherapy should be considered.
A
		

Where radiotherapy is being used as a single modality without concurrent chemotherapy
or cetuximab, a modified fractionation schedule should be considered.

D 
			
			

D
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Patients with N1 disease should be treated with chemoradiotherapy followed by
neck dissection where there is clinical evidence of residual disease following completion
of therapy.
Patients with N2 and N3 nodal disease should be treated with chemoradiotherapy
followed by planned neck dissection.

In patients with a small primary tumour, locally advanced nodal disease may be resected
prior to treating the primary with definitive chemoradiotherapy and the neck with
adjuvant chemoradiotherapy.
Salvage surgery should be available if an initial organ preservation approach is pursued.

Appendix Q
Clinical Practice Guideline for
advanced oropharynx cancer National Comprehensive Cancer
Network (USA)
The complete oropharynx cancer treatment guideline is available on-line after
registration with the NCCN.

1

1

http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
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See Treatment of Primary and Neck (ORPH-3)

See Treatment of Primary and Neck (ORPH-4)

See Treatment of Very Advanced
Head and Neck Cancer (ADV-1)

T3-4a, N0-1

Any T, N2-3

T4b, N any, or
unresectable nodal
disease

HPV testing should not change management decisions except in the context of a clinical trial.

Version 2.2011, 03/30/11 © National Comprehensive Cancer Network, Inc. 2011, All rights reserved. The NCCN Guidelines™ and this illustration may not be reproduced in any form without the express written permission of NCCN®.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

bAnatomical imaging is also recommended.

ORPH-1

See Treatment of Primary and Neck (ORPH-2)

T1-2, N0-1

CLINICAL STAGING

NCCN Guidelines Index
Head and NeckTable of Contents
Discussion

aImmunohistochemical staining for p16 is recommended. Although not used to guide treatment, HPV testing is valuable prognostically. The results of

Multidisciplinary consultation as indicated

· H&P including a complete head and neck
exam; mirror and fiberoptic examination
as clinically indicated
· Biopsy
· Tumor HPV testing suggested a
· Chest imaging
· CT with contrast and/or MRI with
contrast of primary and neck
· Consider PET-CTb for
stage III-IV disease
· Dental evaluation, including panorex as
indicated
· Nutrition, speech & swallowing
evaluation/therapy and audiogram as
indicated
· Examination under anesthesia with
endoscopy as indicated
· Preanesthesia studies

WORKUP

Base of tongue/tonsil/posterior pharyngeal wall/soft palate

NCCN Guidelines™ Version 2.2011
Cancer of the Oropharynx
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Excision of primary and bilateral
neck dissection d

N2c

dSee Principles of Surgery (SURG-A).
eSee Principles of Systemic Therapy (CHEM-A).

Positive

Adverse
features f

No adverse
features f

Other risk
features

Extracapsular
spread and/or
positive margin

Salvage surgery + neck
dissection as indicated d

Post-treatment
evaluation i

Negative

RTc
or
Consider
chemo/RTc,e

Chemo/RTc,e
(category 1)

Neck
dissection d

Observe

Neck
dissection d

Recurrent
or
Persistent
Disease
(See ADV-2)

Follow-up
(See FOLL-A)

ADJUVANT TREATMENT

NCCN Guidelines Index
Head and NeckTable of Contents
Discussion
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Note: All recommendations are category 2A unless otherwise indicated.
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ORPH-4

extracapsular nodal spread, positive margins, pT3 or pT4 primary, N2 or N3 nodal disease, nodal disease in levels IV or V, perineural invasion,
vascular embolism (See Discussion).
hSee Discussion on induction chemotherapy.
iSee Post Chemoradiation or RT Neck Evaluation (SURG-A 6 of 6).

fAdverse features:

Complete clinical
response of neck

Excision of primary, ipsilateral
or bilateral neck dissection d

Primary site:
residual tumor

Primary site:
Complete
clinical
response

Residual tumor
in neck

N1
N2a-b
N3

Multimodality clinical trials

or

Surgery: d
primary and
neck

or

Induction
chemotherapy e
followed by RT or
chemo/RT
(category 2B) h

or

Concurrent systemic
therapy/RTc,e cisplatin
(category 1) preferred

TREATMENT OF PRIMARY AND NECK

cSee Principles of Radiation Therapy (ORPH-A).

Any T, N2-3

CLINICAL
STAGING

Base of tongue/tonsil/posterior pharyngeal wall/soft palate
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Postoperative chemoradiation
· Concurrent single agent cisplatin at
100 mg/m2 every 3 wks x 3 doses is recommended. 3-5
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ORPH-A

concomitant chemotherapy for locally advanced head and neck cancer. N Engl J
Med 2004;350:1945-1952.
4Cooper JS, PajakTF, Forastiere AA, et al. Postoperative concurrent radiotherapy
and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
N Engl J Med 2004;350:1937-1944.
5Bernier J, Cooper JS, PajakTF, et al. Defining risk levels in locally advanced head
and neck cancers: A comparative analysis of concurrent postoperative radiation
plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck
2005;27:843-850.

3Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

conventional fractionation at 2.0 Gy per fraction to ³ 70 Gy in 7 wks with single
agent cisplatin given every 3 wks at 100 mg/m2 x 3 doses. Other fraction sizes
(eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of
cisplatin; altered fractionation with chemotherapy are efficacious, and there is no
consensus on the optimal approach. In general, the use of concurrent
chemoradiation carries a high toxicity burden; altered fractionation or multiagent
chemotherapy will likely further increase the toxicity burden. For any
chemoradiation approach, close attention should be paid to published reports for
the specific chemotherapy agent, dose, and schedule of administration.
Chemoradiation should be performed by an experienced team and should
include substantial supportive care.

2Based on published data, concurrent chemoradiation most commonly uses

1See Radiation Techniques (RAD-A) and Discussion.
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POSTOPERATIVE
RT
· Preferred interval between resection and postoperative RT
is £ 6 weeks.
· Primary: 60-66 Gy (2.0 Gy/fraction)
· Neck
> Involved nodal stations: 60-66 Gy (2.0 Gy/fraction)
> Uninvolved nodal stations: 44-64 Gy (1.6-2.0 Gy/fraction)

IMRT is a preferred technique for cancers of the oropharynx in order to minimize dose to critical structures.

Concurrent chemoradiation
· Conventional fractionation: 2
> Primary and gross adenopathy: ³ 70 Gy (2.0 Gy/fraction)
> Neck
Uninvolved nodal stations: 44-64 Gy (1.6-2.0 Gy/fraction)

DEFINITIVE
RT
· Conventional fractionation: 66-74 Gy
(2.0 Gy/fraction; daily Monday-Friday) in 7 weeks
· Altered fractionation:
> 6 fractions/week accelerated; 66-74 Gy to gross disease,
44-64 Gy to subclinical disease.
> Concomitant boost accelerated RT: 72 Gy/6 weeks
(1.8 Gy/fraction, large field; 1.5 Gy boost as second daily
fraction during last 12 treatment days)
> Hyperfractionation: 81.6 Gy/7 weeks
(1.2 Gy/fraction, twice daily)

PRINCIPLES OF RADIATION THERAPY1
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RAD-A

target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003;57(5):1480nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol
1491.
Biol Phys 2006;64(1):57-62. Epub 2005 Jun 2.
2Lee NY, de Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy 8Wu Q, Manning M, Schmidt-Ullrich R, Mohan R. The potential for sparing of parotids and
and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally
escalation of biologically effective dose with intensity-modulated radiation treatments of
advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66(4):966-974.
head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys
3Lee NY, O'Meara W, Chan K, et al. Concurrent chemotherapy and intensity-modulated
2000;46(1):195-205.
9Salama JK, Haddad RI, Kies MS, et al. Clinical Practice Recommendations for Radiotherapy
radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J
Radiat Oncol Biol Phys 2007;69(2):459-468. Epub 2007 May 9.
Planning following Induction Chemotherapy in Locoregionally Advanced Head and Neck
4Mohan R, Wu Q, Morris M, et al. “Simultaneous Integrated Boost” (SIB) IMRT of advanced Cancer. Int J Radiat Oncol Biol Phys. 75(3):725-733, 2009.
10Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and
head and neck squamous cell carcinomas—dosimetric analysis. Int J Radiat Oncol Biol
Phys 2001;51(3):180–181.
Oncology (ASTRO) and American College of Radiology (ACR) practice guidelines for
5Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of
intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys. 2009;73(1):9conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 14.
11IMRT Documentation Working Group, Holmes T, Das R, LowD, et al. American Society of
7 randomised controlled trial. Lancet 2003;362(9388):933-940.
6Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after intensityRadiation Oncology recommendations for documenting intensity-modulated radiation
therapy treatments. Int J Radiat Oncol Biol Phys. 2009;74(5):1311-1318.
modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys
2008;71(2):377-385. Epub 2007 Dec 31.

1Dogan N, King S, Emami B, et al. Assessment of different IMRT boost delivery methods on 7Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for

IMRT and Fractionation 10,11
A number of ways exist to integrate IMRT, target volume dosing, and fractionation. The Simultaneous Integrated Boost (SIB) technique uses
differential “dose painting” (66-74 Gy to gross disease; 50-60 Gy to subclinical disease) for each fraction of treatment throughout the entire
course of radiation. 4 SIB is commonly used in conventional (5 fractions/week) and the “6 fractions/week accelerated” schedule. 5 The Sequential
(SEQ) IMRT technique typically delivers the initial (lower dose) phase (weeks 1-5) followed by the high-dose boost volume phase (weeks 6-7)
using 2-3 separate dose plans, and is commonly applied in standard fractionation and hyperfractionation. The Concomitant Boost Accelerated
schedule may utilize a “Modified SEQ” dose plan by delivering the dose to the subclinical targets once a day for 6 weeks, and a separate boost
dose plan as a second daily fraction for the last 12 treatment days. 6

Intensity-Modulated Radiotherapy (IMRT)
IMRT has been shown to be useful in reducing long-term toxicity in oropharyngeal, paranasal sinus, and nasopharyngeal cancers by reducing the
dose to salivary glands, temporal lobes, auditory structures (including cochlea), and optic structures. The application of IMRT to other sites
(eg, oral cavity, larynx, hypopharynx, salivary glands) is evolving and may be used at the discretion of treating physicians.

Target delineation and optimal dose distribution require experience in head and neck imaging, and a thorough understanding of patterns of
disease spread. Standards for target definition, dose specification, fractionation (with and without concurrent chemotherapy), and normal tissue
constraints are still evolving. IMRT, 3D, and 2D conformal techniques may be used as appropriate depending on the stage, tumor location,
physician training/experience, and available physics support. Close interplay exists between radiation technology, techniques, fractionation, and
chemotherapy options resulting in a large number of combinations that may impact toxicity or tumor control. Close cooperation and
interdisciplinary management are critical to treatment planning and radiation targeting, especially in the postoperative setting or after induction
chemotherapy. 9

RADIATION TECHNIQUES 1-8
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Single agents
· Cisplatin
· Carboplatin
· Paclitaxel
· Docetaxel
· 5-FU
· Methotrexate
· Ifosfamide
· Bleomycin
· Gemcitabine23 (nasopharyngeal)
· Cetuximab (non-nasopharyngeal) 24
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Combination therapy
· Cisplatin or carboplatin + 5-FU + cetuximab (non-nasopharyngeal) 18
(category 1)
· Cisplatin or carboplatin + docetaxel 19 or paclitaxel 20
· Cisplatin/cetuximab (non-nasopharyngeal) 21
· Cisplatin + 5-FU20,22

Recurrent, Unresectable, or Metastatic (incurable)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

*Induction chemotherapy should only be done in a tertiary setting.

Induction*/Sequential chemotherapy
· Docetaxel/cisplatin/5-FU12-14
(category 1 if induction is chosen)
· Following induction, agents to be used with concurrent
chemoradiation typically include weekly platinums,
weekly taxanes, or cetuximab. 15

Postoperative Chemoradiation
· Cisplatin alone8-11 (category 1 for high risk)

Primary Systemic Therapy + concurrent RT
· Cisplatin alone1,2 (preferred) (category 1)
· Cetuximab 3 (category 1)
· 5-FU/hydroxyurea4
· Cisplatin/paclitaxel 4
· Cisplatin/infusional 5-FU5
· Carboplatin/infusional 5-FU6
· Carboplatin/paclitaxel 7 (category 2B)

Nasopharynx
Lip, Oral Cavity, Oropharynx, Hypopharynx, Glottic larynx,
Chemoradiation followed by adjuvant chemotherapy
Supraglottic larynx, Ethmoid Sinus, Maxillary Sinus, Occult Primary: · Cisplatin + RT followed by Cisplatin/5-FU16,17 (category 1)

Squamous Cell Cancers

The choice of chemotherapy should be individualized based on patient characteristics (performance status, goals of therapy).

PRINCIPLES OF SYSTEMIC THERAPY

NCCN Guidelines™ Version 2.2011
Head and Neck Cancers

Printed by Andrew Miller on 11/18/2011 8:58:36 PM. For personal use only. Not approved for distribution. Copyright © 2011 National Comprehensive Cancer Network, Inc., All Rights Reserved.

